Oncology Research Publications

Swami U, Monga V, Bossler AD, Zakharia Y, Milhem M (). Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. . Journal of Oncology.
Kessel A, McFarland TR, Sayegh N, Morton K, Sirohi D, Kohli M, Swami U, Nussenzveig R, Agarwal N, Maughan BL (). Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results. Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. (suppl 6; abstr 135). [Abstract]. 39.
Barata PC, Swami U, Kessel A, Jaeger E, Wesolowski S, Chipman J, Bilen MA, Heath EI, Nandagopal L, Vaena DA, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Agarwal N, Sartor OA (). Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients. Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 156). [Abstract]. 39.
Barata PC, Swami U, Kessel A, Jaeger E, Wesolowski S, Chipman J, Bilen MA, Heath EI, Nandagopal L, Vaena DA, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Agarwal N, Sartor OA (). Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients. (suppl 6; abstr 156). [Abstract]. 39.
Puri, S, Kerrigan, K (). Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC [Abstract]. 16(3, S344), P15.02.
Kerrigan K, Sinnott J, Haaland B, Puri S, Akerley W, Patel S (). Real World Survival Outcomes of Patients with Limited Stage Small Cell Lung Cancer (LS-SCLC) by Choice of Platinum Chemotherapy. Abstract submitted for 2021 World Conference on Lung Cancer (IASLC). September 8-14, 2021 [Abstract].
Li H, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Agarwal N, Maughan BL (). Combination therapy with avelumab (Ave) and cabozantinib (Cabo) in patients (pts) with newly diagnosed metastatic clear cell renal cell carcinoma (mccRCC). Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 334). [Abstract]. 39.
morra, a mescalankinl JonathanBeesleyqimrberghofereduau rkeemannkinl scanisiusnkinl thomasahearnnihgov andrulislunenfeldca hantoncuuciedu varndtdkfzde paulwlauergmailcom annelieaugustinssonmedluse freemalamailnihgov hbecherukede Fk-direktionuk-erlangende SBehrensdkfz-heidelbergde stigegilbojesenregionhdk mkh39medschlcamacuk hbrennerdkfzde brueningipa-dguvde Saundra Buys SaundraBuyshciutahedu BetteCaankporg danielecampaunipiit fcanziandkfz-heidelbergde estebancastelao17gmailcom jchang-claudedkfz-heidelbergde chanocksmailnihgov Ting-YuanChengRoswellParkorg christineclarkesydneyeduau grealous-hfno Sarah Colonna SarahColonnahscutahedu couchfergusmayoedu acoxshefacuk sscrosssheffieldacuk kamilaczenekise MaryDalyfcccedu jgd29camacuk doerkthilomh-hannoverde dossusliarcfr amd24medschlcamacuk MVDwekwestminsteracuk DMEcclessotonacuk ArifEkiciuk-erlangende nhahechanningharvardedu mikaelerikssonkise GarethEvanscmftnhsuk peterfaschingfaude henrikflygerregionhdk linfritschicurtineduau mgagomeduscedu jagsaenzyahoocom GrahamGilescancervicorgau mervigripppshpfi pascalguenelinsermfr melanieguenderthelmholtz-muenchende erichahnenuk-koelnde ChristopherHaimanmeduscedu NiclasHakanssonkise PerHallkise uhamanndkfz-heidelbergde HartStevenmayoedu jaanahartikainenueffi arndthartmannuk-erlangende weihekise mhooningerasmusmcnl reinerhoppeikp-stuttgartde jhopperunimelbeduau tonyhowellicsmanchesteracuk davidhunterndphoxacuk mythilysachchithananthansydneyeduau heatherthornepetermacorg ajagererasmusmcnl aniajpumedupl wolfgangjanniuniklinik-ulmde emjohnstanfordedu audreyjungdkfz-heidelbergde rkaaksdkfz-heidelbergde MachteldKeupersuzleuvenbe kitaharacmailnihgov koutrossmailnihgov pkrafthsphharvardedu vnkristensenmedisinuiono akurianstanfordedu jlaceycohorg dietherlambrechtskuleuvenvibbe Loiccchawaiiedu AnnikaLindblomkise robertlubenphpccamacuk lubinskipumedupl mjl81medschlcamacuk artomannermaaueffi mmanoochehridkfz-heidelbergde saramargolinsllse jmartenserasmusmcnl e8martinezhealthucsdedu mavrudismeduocgr kyriakimicingaccy RogerMilnecancervicorgau AnnaMarieMulliganuhnca taruamuranenhelsinkifi HeliNevanlinnahusfi williamnewmanmanchesteracuk sunefallgaardnielsenregionhdk boergenordestgaardregionhdk andyolshanuncedu hakanolssonmedluse nickorrqubacuk park-simontjoung-wonmh-hannoverde alpapatelcancerorg bernardpeisselistitutotumorimiit paolopeterlongoifomeu dijanamanuedumk kgraczyk91wppl rprenticfhcrcorg NPresneauwestminsteracuk BrigitteRackuniklinik-ulmde rennerttxtechnionacil rennerthedyclalitorgil vr264medschlcamacuk atocha10hotmailcom rroylanceuclacuk matthiasruebneruk-erlangende esaloustrosyahoogr elinorsawyerkclacuk ritaschmutzleruk-koelnde AndreasSchneeweissmeduni-heidelbergde ScottChristophermayoedu ms483medschlcamacuk smickotmk melissasoutheymonashedu jenniferstoneuwaeduau HaraldSurowyhhude AnthonySwerdlowicracuk rmt4001medcornelledu WJTappersotonacuk laurenterascancerorg mt146cumccolumbiaedu raemtollenaarlumcnl iantomlinsonigmmedacuk troesteruncedu theresetruonginsermfr vachoncelinemayoedu qw232medschlcamacuk amberwilcoxnihgov robertwinqvistoulufi AlicjaWolkkise aziogasuciedu hiltrudbrauchikp-stuttgartde montserratgarcia-closasnihgov pp10001medschlcamacuk dfe20medschlcamacuk GeorgiaTrenchqimrberghofereduau linetmexchangenihgov (6/28/2021). Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Res.
Sayegh N, Swami U, Barata PC, Lilly MB, Nussenzveig R, Hensel C, Bryce AH, Bilen MA, Heath EI, Nandagopal L, Garje R, Saylor PJ, Babiker HM, Vaena DA, Kohli M, Pal SK, Sartor O, Agarwal N (). Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA). Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. (suppl 6; abstr 256). [Abstract]. 39.
Rathkopf DE, Chi KN, Olmos D, Cheng HH, Agarwal N, Graff JN, Sandhu SK, Hayreh V, Lopez-Gitlitz A, Francis PSJ, Attard G (). AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr TPS176). [Abstract]. 39.
Reisinger R, Wesolowski S, Swami U, Barata PC, Hernandez EJ, Nussenzveig R, Lemmon G, Peterson B, Hensel C, Bilen MA, Heath EI, Nandagopal L, Saylor PJ, Babiker HM, Kohli M, Pal SK, Lilly MB, Yandell M, Sartor AO, Agarwal N (). Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA). Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 162). [Abstract]. 39.
Swami U, McFarland TR, Haaland B, Kessel A, Nussenzveig R, Sayegh N, Hahn AW, Rathi N, Sirohi D, Esther J, Li H, Kohli M, Maughan BL, Goldkorn A, Agarwal N (). Association of circulating tumor cells (CTC) with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort. Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. (suppl 6; abstr 59). [Abstract]. 39.
Zakharia Y, Reis R, Garje R, Swami U, Born JM, Brown JA, Nepple KG, Abuqayas B, Rajput M, Bellizzi A, Sieren JC, Rustum YM (). Phase I with expansion clinical trial of seleno-l-methionine (SLM) in combination with axitinib in patients with relapsed clear cell renal cell carcinoma (ccRCC): Bench to bedside. (suppl 6; abstr 322). [Abstract]. 39.
Barata PC, Swami U, Kessel A, Jaeger E, Wesolowski S, Chipman J, Bilen MA, Heath EI, Nandagopal L, Vaena DA, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Agarwal N, Sartor OA (). Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients. Proc Am Soc Clin Oncol, Abst 156. [Abstract].
De Bono JS, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Ozguroglu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, Hussain M (). Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Poster Presentation. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr 6100). [Abstract].
Loriot Y, Balar AV, Petrylak DP, Tagawa ST, Rezazadeh A, Flechon A, Jain R, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos PL, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P (). TROPHY-U-01 cohort 1 final results: A phase II study of sacituzamab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI). Proffered Paper. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr LBA24). [Abstract].
Eric D Johnson, MD Katerina Butler, PharmD and Sumati Gupta, MBBS (August 2021). Bone Health in Patients With Prostate Cancer: An Evidence-Based Algorithm. Federal Practitioner, (Special Issue), S20-S26.
Anna Morra mescalankinl JonathanBeesleyqimrberghofereduau rkeemannkinl scanisiusnkinl thomasahearnnihgov andrulislunenfeldca hantoncuuciedu varndtdkfzde paulwlauergmailcom annelieaugustinssonmedluse freemalamailnihgov hbecherukede Fk-direktionuk-erlangende SBehrensdkfz-heidelbergde stigegilbojesenregionhdk mkh39medschlcamacuk hbrennerdkfzde brueningipa-dguvde Saundra Buys SaundraBuyshciutahedu BetteCaankporg danielecampaunipiit fcanziandkfz-heidelbergde estebancastelao17gmailcom jchang-claudedkfz-heidelbergde chanocksmailnihgov Ting-YuanChengRoswellParkorg christineclarkesydneyeduau grealous-hfno Sarah Colonna SarahColonnahscutahedu couchfergusmayoedu acoxshefacuk sscrosssheffieldacuk kamilaczenekise MaryDalyfcccedu jgd29camacuk doerkthilomh-hannoverde dossusliarcfr amd24medschlcamacuk MVDwekwestminsteracuk DMEcclessotonacuk ArifEkiciuk-erlangende nhahechanningharvardedu mikaelerikssonkise GarethEvanscmftnhsuk peterfaschingfaude henrikflygerregionhdk linfritschicurtineduau mgagomeduscedu jagsaenzyahoocom GrahamGilescancervicorgau mervigripppshpfi pascalguenelinsermfr melanieguenderthelmholtz-muenchende erichahnenuk-koelnde ChristopherHaimanmeduscedu NiclasHakanssonkise PerHallkise uhamanndkfz-heidelbergde HartStevenmayoedu jaanahartikainenueffi arndthartmannuk-erlangende weihekise mhooningerasmusmcnl reinerhoppeikp-stuttgartde jhopperunimelbeduau tonyhowellicsmanchesteracuk davidhunterndphoxacuk mythilysachchithananthansydneyeduau heatherthornepetermacorg ajagererasmusmcnl aniajpumedupl wolfgangjanniuniklinik-ulmde emjohnstanfordedu audreyjungdkfz-heidelbergde rkaaksdkfz-heidelbergde MachteldKeupersuzleuvenbe kitaharacmailnihgov koutrossmailnihgov pkrafthsphharvardedu vnkristensenmedisinuiono akurianstanfordedu jlaceycohorg dietherlambrechtskuleuvenvibbe Loiccchawaiiedu AnnikaLindblomkise robertlubenphpccamacuk lubinskipumedupl mjl81medschlcamacuk artomannermaaueffi mmanoochehridkfz-heidelbergde saramargolinsllse jmartenserasmusmcnl e8martinezhealthucsdedu mavrudismeduocgr kyriakimicingaccy RogerMilnecancervicorgau AnnaMarieMulliganuhnca taruamuranenhelsinkifi HeliNevanlinnahusfi williamnewmanmanchesteracuk sunefallgaardnielsenregionhdk boergenordestgaardregionhdk andyolshanuncedu hakanolssonmedluse nickorrqubacuk park-simontjoung-wonmh-hannoverde alpapatelcancerorg bernardpeisselistitutotumorimiit paolopeterlongoifomeu dijanamanuedumk kgraczyk91wppl rprenticfhcrcorg NPresneauwestminsteracuk BrigitteRackuniklinik-ulmde rennerttxtechnionacil rennerthedyclalitorgil vr264medschlcamacuk atocha10hotmailcom rroylanceuclacuk matthiasruebneruk-erlangende esaloustrosyahoogr elinorsawyerkclacuk ritaschmutzleruk-koelnde AndreasSchneeweissmeduni-heidelbergde ScottChristophermayoedu ms483medschlcamacuk smickotmk melissasoutheymonashedu jenniferstoneuwaeduau HaraldSurowyhhude AnthonySwerdlowicracuk rmt4001medcornelledu WJTappersotonacuk laurenterascancerorg mt146cumccolumbiaedu raemtollenaarlumcnl iantomlinsonigmmedacuk troesteruncedu theresetruonginsermfr vachoncelinemayoedu qw232medschlcamacuk amberwilcoxnihgov robertwinqvistoulufi AlicjaWolkkise aziogasuciedu hiltrudbrauchikp-stuttgartde montserratgarcia-closasnihgov pp10001medschlcamacuk dfe20medschlcamacuk GeorgiaTrenchqimrberghofereduau linetmexchangenihgov (6/28/2021). Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Res.
Kerrigan, K (). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy. [Abstract]. 16(3 S122-123), OA09.05.
Chi KN, Chowdhury S, Bjartell A, Chung BH, de Santana Gomes AJP, Given R, Soto AJ, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Triantos S, Mundle S, McCarthy SA, Larsen JS, Sun Weili, Bevans K, Zhang K, Bandyopadhyay N, Agarwal N, For the TITAN Investigators (). Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. (suppl 6; abstr 11). [Abstract]. 39.
Li H, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Sirohi D, Agarwal N, Maughan BL (). Combination therapy with avelumab (Ave) and cabozantinib (Cabo) in patients (pts) with newly diagnosed metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol 39, (suppl 6; abstr 334). [Abstract]. 39.
Reisinger R, Wesolowski S, Swami U, Barata PC, Hernandez EJ, Nussenzveig R, Lemmon G, Peterson B, Hensel C, Bilen MA, Heath EI, Nandagopal L, Saylor PJ, Babiker HM, Kohli M, Pal SK, Lilly MB, Yandell M, Sartor AO, Agarwal N (). Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA). J Clin Oncol 39, (suppl 6; abstr 162). [Abstract]. 39.
Sayegh N, Swami U, Barata PC, Lilly MB, Nussenzveig R, Hensel C, Bryce AH, Bilen MA, Heath EI, Nandagopal L, Garje R, Saylor PJ, Babiker HM, Vaena DA, Kohli M, Pal SK, Sartor OA, Agarwal N (). Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA), (suppl 6; abstr 256). J Clin Oncol [Abstract]. 39.
Swami U, McFarland TR, Haaland B, Kessel A, Nussenzveig R, Sayegh N, Hahn AW, Rathi N, Sirohi D, Esther J, Li H, Kohli M, Maughan BL, Goldkorn A, Agarwal N (). Association of circulating tumor cells (CTC) with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort. Abst 59 [Abstract].
Kwan EM, Dai C, Fettke H, Hauser C, Bukczynska P, Ng N, Foroughi S, Graham LJK, Mahon KL, Tan W, Wang A, Zhao Z, Zheng T, Zhou K, Yu JJ, Du P, Horvath L, Jia S, Kohli M, Azad A (). Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts. Abst 159 [Abstract].
Reisinger R, Wesolowski S, Swami U, Barata PC, Hernandez EJ, Nussenzveig R, Lemmon G, Peterson B, Hensel C, Bilen MA, Heath EI, Nandagopal L, Saylor PJ, Babiker HM, Kohli M, Pal SK, Lilly MB, Yandell M, Sartor AO, Agarwal N (). Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA). Proc Am Soc Clin Oncol, Abst 162. [Abstract].
McFarland TR, Nussenzveig R, Swami U, Sayegh N, Kessel A, Sharma P, Li H, Kohli M, Maughan BL, Pal SK, Agarwal N (). Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations. J Clin Oncol 39, (suppl 6; abstr 166). [Abstract]. 39.
Kessel A, McFarland TR, Sayegh N, Morton K, Sirohi D, Kohli M, Swami U, Nussenzveig R, Agarwal N, Maughan BL (). Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results. (suppl 6; abstr 135). [Abstract]. 39.
Diab A, Hamid O, Thompson J, Ros W, Eskens F, Doi T, Hu-Lieskovan S, Klempner S, Ganguly B, Fleener C, Wang X, Jo T, Liao K, Salek-Ardakani S, Taylor C, Chou J, El-Khoueiry A (). A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers. Clin Cancer Res.
Kerrigan, K (). Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis. [Abstract]. 16(3), 89.05.
Zengin ZB, Weipert C, Hsu J, Salgia N, Hensel C, Maughan BL, Rathi N, Goel D, Agarwal N, Choueiri TK, Pal SK (). Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data. Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. (suppl 6; abstr 347). [Abstract]. 39.
Zengin ZB, Weipert C, Hsu J, Salgia N, Hensel C, Maughan BL, Rathi N, Goel D, Agarwal N, Choueiri TK, Pal SK (). llustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data. Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 347). [Abstract]. 39.
Freeman MM, Jaeger E, Zhu J, Phone A, Nussenzveig R, Caputo S, Ravindranathan D, Layton JL, Nandagopal L, Kessel A, Desai A, Koshkin VS, Basu A, Bilen MA, Swami U, Garcia JA, Agarwal A, Burgess EF, Sartor OA, Barata PC (). Multi-institutional evaluation of the clinical outcomes and genomic correlates of African Americans with metastatic castration-sensitive prostate cancer (mCSPC)(suppl 6; abstr 17). [Abstract]. 39.
Swami U, McFarland TR, Haaland B, Kessel A, Nussenzveig R, Sayegh N, Hahn AW, Rathi N, Sirohi D, Esther J, Li H, Kohli M, Maughan BL, Goldkorn A, Agarwal N (). Association of circulating tumor cells (CTC) with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort. (suppl 6; abstr 59). [Abstract]. 39.
McFarland TR, Nussenzveig R, Swami U, Sayegh N, Kessel A, Sharma P, Li H, Kohli M, Maughan BL, Pal SK, Agarwal N (). Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations. Proc Am Soc Clin Oncol, Abst 166. [Abstract].
Pal S, Tsao C, Suarez C, Kelly W, Pagliaro L, Vaishampayan UN, Loriot Y, Srinivas S, McGregor BA, Panneerselvam A, Curran D, Choueiri TK, Agarwal N (). Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study. Proffered Paper. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr 7020). [Abstract].
Grivas P, Sternberg CN, Agarwal N, Petrylak DP, Tagawa ST, Hong Q, Gladden A, Kanwal C, Goswami T, Loriot Y (). TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) and pembrolizumab (pempbro) in patients (pts) with progression or recurrence of metastatic urothelial cancer (mUC) after platinum (PLT)-based therapy. Poster Presentation. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr 796TiP). [Abstract].
Puri S, Naqash AR, Elliot A, Oliver T, Kerrigan K, Patel S, Seeber A, Kocher F, Uperty D, Mamdani H, Kulkarni A, Lopes G, Halmos B, Borghaei H, Akerley W, Liu S, Korn WM, Owonikoko T (). Real-world multi-omic characterization of small cell lung cancer subtypes reveals differential expression of clinically relevant biomarkers. Abstract accepted for 2021 ASCO Annual Meeting. [Abstract].
Rathi N, Maughan BL, Agarwal N, Swami U (). The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma, http://tcr.amegroups.com/article/view/30099. Translational Cancer Research.
Matsubara N, De Bono JS, Olmos D, Procopio G, Kawakami S, Uran Y, van Alphen RJ, Flechon A, Carducci MA, Choi YD, Hotte SJ, Korbenfeld EP, Kramer G, Agarwal N, Dearden S, Gresty C, Kang J, Poehlein CH, Harrington E, Hussain MHA (). Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study. Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. (suppl 6; abstr 27). [Abstract]. 39.
Makrakis D, Castellano D, de Kouchkovsky I, Park JJ, Bilen MA, Agarwal N, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson AA, Gatrell BA, Tripathi A, Bamias A, Rodriguez-Vida A, Liu S, McKay RR, Buznego LAA, Murgic J, Grivas P, Khaki AR (). Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 444). [Abstract]. 39.
Agarwal N, Azad A, Carles J, Chowdhury S, McGregor BA, Merseburger AS, Oudard S, Saad F, Soares A, Panneerselvam A, Wang F, Pal SK (). A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. (suppl 6; abstr TPS190). [Abstract]. 39.
Schmidt AL, Xie W, Gan CL, Wells C, Dudani S, Donskov F, Porta C, Suarez C, Szabados B, Wood L, Morales JMR, Tran B, Bjarnason GA, Yuasa T, Beuselinck B, Hansen AR, Agarwal N, Bakouny Z, Heng DYC, Choueiri TK (). The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC). Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. (suppl 6; abstr 339). [Abstract]. 39.
Graham J, Wells C, Dudani S, Gan CL, Donskov F, Lee JL, Kollmannsberger CK, Pal SK, Beuselinck B, Hansen AR, North SA, Bjarnason GA, Agarwal N, Kanesvaran R, Wood L, Hotte SJ, McKay RR, Choueiri TK, Hen DYC (). Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC). 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 316). [Abstract]. 39.
Zengin ZB, Weipert C, Hsu J, Salgia N, Saam J, Choueiri TK, Agarwal N, Pal S (). Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing. Proffered Paper. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr 7010). [Abstract].
McGregor BA, Agarwal N, Suarez C, Tsao C, Kelly W, Pagliaro L, Vaishampayan UN, Castellano D, Loriot Y, Werneke S, Curran D, Choueiri TK, Pal S (). Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study. Poster Presentation. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr 709P). [Abstract].
Agarwal N, Evans R, Abrams K, Dequen-OByrne P, McCrea C, Muston D, Gresty C, Ghate S, Fan L, Hettle R, Hawkins N (). Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study.Poster Presentation. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr 622P). [Abstract].
Kerrigan, K (). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers [Abstract]. 14(10), P1.01-35.
Kerrigan, K (). MA14.09 Real-World Survival of Relapsed Compared to De-Novo Stage IV Diagnosis of Advanced Non-Small Cell Lung Cancer [Abstract]. 14(10), S307-308.
Kerrigan, K (). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy. [Abstract]. 16(3, S199), FP05.01.
McFarland TR, Nussenzveig R, Swami U, Sayegh N, Kessel A, Sharma P, Li H, Kohli M, Maughan BL, Pal SK, Agarwal N (). Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations. Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. (suppl 6; abstr 166). [Abstract]. 39.
Li H, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Agarwal N, Maughan BL (). Combination therapy with avelumab (Ave) and cabozantinib (Cabo) in patients (pts) with newly diagnosed metastatic clear cell renal cell carcinoma (mccRCC). Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 334). [Abstract]. 39.
Freeman MM, Jaeger E, Zhu J, Phone A, Nussenzveig R, Caputo S, Ravindranathan D, Layton JL, Nandagopal L, Kessel A, Desai A, Koshkin VS, Basu A, Bilen MA, Swami U, Garcia JA, Agarwal N, Burgess EF, Sartor AO, Barata PC (). Multi-institutional evaluation of the clinical outcomes and genomic correlates of African Americans with metastatic castration-sensitive prostate cancer (mCSPC). 2021 Genitourinary Cancers Symposium, February 11-13, 2021. (suppl 6; abstr 17). [Abstract]. 39.
Kessel A, McFarland TR, Sayegh N, Morton K, Sirohi D, Kohli M, Swami U, Nussenzveig R, Agarwal N, Maughan BL (). Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results. Abst 135. [Abstract].
Foth M, Garrido-Laguna I, Kinsey CG (2021). Therapeutic Targeting of Autophagy in Pancreatic Cancer. Surg Oncol Clin N Am, 30(4), 709-718.
Dotan E, Walter LC, Browner IS, Clifton K, Cohen HJ, Extermann M, Gross C, Gupta S, Hollis G, Hubbard J, Jagsi R, Keating NL, Kessler E, Koll T, Korc-Grodzicki B, McKoy JM, Misra S, Moon D, OConnor T, Owusu C, Rosko A, Russell M, Sedrak M, Siddiqui F, Stella A, Stirewalt DL, Subbiah IM, Tew WP, Williams GR, Hollinger L, George GV, Sundar H (2021). NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021. J Natl Compr Canc Netw, 19(9), 1006-1019.
Iyengar S, Nevala-Plagemann C, Garrido-Laguna I (2021). Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. Ther Adv Med Oncol, 13, 17588359211045861.
Evans R, Hawkins N, Dequen-OByrne P, McCrea C, Muston D, Gresty C, Ghate SR, Fan L, Hettle R, Abrams KR, de Bono J, Hussain M, Agarwal N (2021). Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). (Epub ahead of print) Target Oncol.
Sayegh N, Swami U, Agarwal N (2021). Recent Advances in the Management of Metastatic Prostate Cancer. JCO Oncol Pract, OP2100206.
Sayegh N, Swami U, Agarwal N (2021). Recent Advances in the Management of Metastatic Prostate Cancer. JCO Oncol Pract, OP2100206.
Mundle R, Afenya E, Agarwal N (2021). The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature. Prostate Cancer Prostatic Dis, 24(3), 674-687.
Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK (2021). Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clin Cancer Res, 27(17), 4807-4813.
Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK (2021). Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clin Cancer Res, 27(17), 4807-4813.
Affolter KE, Hellwig S, Nix DA, Bronner MP, Thomas A, Fuertes CL, Hamil CL, Garrido-Laguna I, Scaife CL, Mulvihill SJ, Underhill HR (2021). Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma. Neoplasia, 23(9), 859-869.
Lin E, Hahn AW, Nussenzveig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, Agarwal N (2021). Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. Oncologist, 26(9), 751-760.
Swami U, Agarwal N (2021). Editorial Comment. J Urol, 101097JU000000000000212101.
Swami U, Agarwal N (2021). Editorial Comment. J Urol, 101097JU000000000000212101.
Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal N (2021). Radium-223 plus Enzalutamide versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. (Epub ahead of print) Oncologist.
Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal N (2021). Radium-223 plus Enzalutamide versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. (Epub ahead of print) Oncologist.
Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal N (2021). Radium-223 plus Enzalutamide versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. (Epub ahead of print) Oncologist.
Morra A, Escala-Garcia M, Beesley J, Keeman R, Canisius S, Ahearn TU, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Augustinsson A, Beane Freeman LE, Becher H, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brenner H, Brning T, Buys SS, Caan B, Campa D, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Cheng TD, Clarke CL, NBCS Collaborators, Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Drk T, Dossus L, Dunning AM, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Flyger H, Fritschi L, Gago-Dominguez M, Garca-Senz JA, Giles GG, Grip M, Gunel P, Gndert M, Hahnen E, Haiman CA, Hkansson N, Hall P, Hamann U, Hart SN, Hartikainen JM, Hartmann A, He W, Hooning MJ, Hoppe R, Hopper JL, Howell A, Hunter DJ, ABCTB Investigators, kConFab Investigators, Jager A, Jakubowska A, Janni W, John EM, Jung AY, Kaaks R, Keupers M, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kurian AW, Lacey JV, Lambrechts D, Le Marchand L, Lindblom A, Linet M, Luben RN, Lubiski J, Lush M, Mannermaa A, Manoochehri M, Margolin S, Martens JWM, Martinez ME, Mavroudis D, Michailidou K, Milne RL, Mulligan AM, Muranen TA, Nevanlinna H, Newman WG, Nielsen SF, Nordestgaard BG, Olshan AF, Olsson H, Orr N, Park-Simon TW, Patel AV, Peissel B, Peterlongo P, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Presneau N, Rack B, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Ruebner M, Saloustros E, Sawyer EJ, Schmutzler RK, Schneeweiss A, Scott C, Shah M, Smichkoska S, Southey MC, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Teras LR, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Truong T, Vachon CM, Wang Q, Hurson AN, Winqvist R, Wolk A, Ziogas A, Brauch H, Garca-Closas M, Pharoah PDP, Easton DF, Chenevix-Trench G, Schmidt MK (2021). Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Res, 23(1), 86.
Hutson TE, Michaelson MD, Kuzel TM, Agarwal N, Molina AM, Hsieh JJ, Vaishampayan UN, Xie R, Bapat U, Ye W, Jain RK, Fishman MN (2021). A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. Eur Urol, 80(2), 162-170.
Tripathi N, Agarwal N, Tripathi A (2021). Nature versus Nurture: Investigating Racial Disparity in Advanced Prostate Cancer. (Epub ahead of print) Oncologist.
Sayegh N, Agarwal N, Swami U (2021). Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations. Eur Urol Oncol, 4(4), 553-557.
Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Flchon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P (2021). TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol, 39(22), 2474-2485.
Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomki K, Andrulis IL, Arason A, Arnold N, Auber B, Azzollini J, Balmaa J, Barkardottir RB, Barrowdale D, Barwell J, Belotti M, Benitez J, Berthet P, Boonen SE, Borg, Bozsik A, Brady A, Brennan P, Brewer C, Brunet J, Bucalo A, Buys SS, Calds T, Caligo MA, Campbell I, Cassingham H, Lotte Christensen L, Cini G, Claes KBM, GEMO Study Collaborators, EMBRACE Collaborators, Cook J, Coppa A, Cortesi L, Damante G, Darder E, Davidson R, de la Hoya M, De Leeneer K, de Putter R, Del Valle J, Diez O, Chun Ding Y, Domchek SM, Donaldson A, Eason J, Eeles R, Engel C, Gareth Evans D, Feliubadal L, Fostira F, Frone M, Frost D, Gallagher D, Gehrig A, Giraud S, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gregory H, Gross E, Hahnen E, Hamann U, Hansen TVO, Hanson H, Hentschel J, Horvath J, KConFab Investigators, HEBON Investigators, Izatt L, Izquierdo A, James PA, Janavicius R, Birk Jensen U, Johannsson OT, John EM, Kramer G, Kroeldrup L, Kruse TA, Lautrup C, Lazaro C, Lesueur F, Lopez-Fernndez A, Mai PL, Manoukian S, Matrai Z, Matricardi L, Maxwell KN, Mebirouk N, Meindl A, Montagna M, Monteiro AN, Morrison PJ, Muranen TA, Murray A, Nathanson KL, Neuhausen SL, Nevanlinna H, Nguyen-Dumont T, Niederacher D, Olah E, Olopade OI, Palli D, Parsons MT, Sokilde Pedersen I, Peissel B, Perez-Segura P, Peterlongo P, Petersen AH, Pinto P, Porteous ME, Pottinger C, Angel Pujana M, Radice P, Ramser J, Rantala J, Robson M, Rogers MT, Rnlund K, Rump A, Mara Snchez de Abajo A, Shah PD, Sharif S, Side LE, Singer CF, Stadler Z, Steele L, Stoppa-Lyonnet D, Sutter C, Yen Tan Y, Teixeira MR, Teul A, Thull DL, Tischkowitz M, Toland AE, Tommasi S, Toss A, Trainer AH, Tripathi V, Valentini V, van Asperen CJ, Venturelli M, Viel A, Vijai J, Walker L, Wang-Gohrke S, Wappenschmidt B, Whaite A, Zanna I, Offit K, Thomassen M, Couch FJ, Schmutzler RK, Simard J, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L, Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (2021). Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. (Epub ahead of print) J Natl Cancer Inst.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, zgrolu M, Soto J, Merseburger AS, Uemura H, Ye D, Given R, Basch E, Miladinovic B, Lopez-Gitlitz A, Chi KN (2021). Reply by Authors. J Urol, 101097JU000000000000184103.
McFarland TR, Kessel A, Swami U, Agarwal N (2021). Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations. Am J Transl Res, 13(7), 7427-7439.
McFarland TR, Kessel A, Swami U, Agarwal N (2021). Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations. Am J Transl Res, 13(7), 7427-7439.
Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Jurez A, Merseburger AS, zgrolu M, Uemura H, Ye D, Brookman-May S, Mundle SD, McCarthy SA, Larsen JS, Sun W, Bevans KB, Zhang K, Bandyopadhyay N, Agarwal N (2021). Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol, 39(20), 2294-2303.
Costello BA, Bhavsar NA, Zakharia Y, Pal SK, Vaishampayan U, Jim H, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Mardekian J, Borham A, George DJ, Harrison MR (2021). A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. (Epub ahead of print) Clin Genitourin Cancer.
Martin DB, Stetson PD, Gilcrease GW, Stillman RC, Sugalski JM, Skinner J, Levy M (2021). Preferences in Oncology History Documentation Styles Among Clinical Practitioners. JCO Oncol Pract, OP2000756.
Choueiri TK, Zakharia Y, Pal S, Kocsis J, Pachynski R, Poprach A, Nixon AB, Liu Y, Starr M, Lyu J, Owzar K, deShazo M, Lara P, Geczi L, Ho TH, Walsh M, Adams B, Robertson L, Darif M, Theuer C, Agarwal N (2021). Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). Oncologist, 26(7), 560-e1103.
Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I (2021). Emerging Treatment Strategies in Pancreatic Cancer. Pancreas, 50(6), 773-787.
Harrison MR, Costello BA, Bhavsar NA, Vaishampayan U, Pal SK, Zakharia Y, Jim HSL, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Inman BA, Mardekian J, Borham A, George DJ (2021). Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer, 127(13), 2204-2212.
Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna I (2022). Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 50(6), 796-802.
Asare EA, Swami U, Stewart JH 4th (2021). Landmark Series on Disparities in Surgical Oncology: Melanoma. (Epub ahead of print) Ann Surg Oncol.
McKean W, Hu-Lieskovan S (2021). Combination Immunotherapy With IDO Inhibitors: Defining a Future Through Biomarker-Guided Patient Selection. . ASCO Daily News.
Lin E, Hahn AW, Nussenzveig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, Agarwal N (2021). Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. (Epub ahead of print) Oncologist.
Lin E, Hahn AW, Nussenzveig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, Agarwal N (2021). Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. (Epub ahead of print) Oncologist.
Lin E, Hahn AW, Nussenzveig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, Agarwal N (2021). Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. (Epub ahead of print) Oncologist.
Wang X, Haaland B, Hu-Lieskovan S, Colman H, Holmen SL (2021). First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer Reports.
Sayegh N, Agarwal N, Swami U (2021). Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations. Eur Urol Oncol.
Giannarini G, Agarwal N, Apolo AB, Briganti A, Grivas P, Gupta S, Kamat AM, Montorsi F, Rouprt M, Necchi A (2021). Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer. Eur Urol Oncol.
Gan HK, Millward M, Jalving M, Garrido-Laguna I, Lickliter JD, Schellens JHM, Lolkema MP, Van Herpen CLM, Hug B, Tang L, OConnor-Semmes R, Gagnon R, Ellis C, Ganji G, Matheny C, Drilon A (2021). A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. (Epub ahead of print) Oncologist.
Sun L, Du M, Kohli M, Huang CC, Chen X, Xu M, Shen H, Wang S, Wang L (2021). An Improved Detection of Circulating Tumor DNA in Extracellular Vesicles-Depleted Plasma. Front Oncol, 11, 691798.
Brundage J, Maughan BL (2021). New models for defining prostate cancer biology and patient prognosis. (Epub ahead of print) Asian J Androl.
Reisinger R, Santos VS, Nussenzveig R, Wesolowski S, Hernandez EJ, Henrie AR, Maughan BL, Swami U, Yandell M, Grivas P, Agarwal N (2021). Genomic predictors of response to PD-1 axis inhibitors in metastatic urothelial cancer (mUC) patients using machine learning analysis of tissue comprehensive genomic profiling (CGP). J Clin Oncol 39, (suppl 15; abstr 4542). [Abstract]. 39.
Swami U, McFarland TR, Haaland B, Kessel A, Nussenzveig R, Sayegh N, Hahn AW, Rathi N, Sirohi D, Esther J, Li Haoran, Kohli M, Maughan BL, Goldkorn A, Agarwal N (2021). Correlation of baseline circulating tumor cells (CTC) and associated genomic profile with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort. (suppl 15; abstr 5077). [Abstract]. 39.
Swami U, Hong A, El-Chaar NN, Nimke D, Ramaswamy K, Bell EJ, Sandin R, Agarwal N (2021). Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database. (suppl 15; abstr 5072). [Abstract]. 39.
Barata PC, Reisinger R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N (2021). Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA). (suppl 15; abstr 5058). [Abstract]. 39.
Florou V, Floudas CS, Maoz A, Naqash AR, Hildebrand G, Sokol E, Frampton GM, Puri S, Swami U, Wilky BA, Hosein PJ, Trent JC, Lopes G, Park W, Garrido-Laguna I (2021). Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB). (suppl 15; abstr 2599). [Abstract]. 39.
Agarwal N, Chowdhury S, Bjartell A, Chung BH, Gomes AJPS, Given R, Juarez A, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Brookman-May SD, Mundle S, McCarthy SA, Lefresne F, Dibaj S, Bevans KB, Chi KN (2021). Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). [Abstract]. 39.
Makrakis D, Talukder R, Carril L, de Kouchkovsky I, Park JJ, Bilen MA, McKay RR, Agarwal N, Zakharia Y, Devitt ME, Pinato DJ, Hoimes CJ, Gartrell BA, Tripathi A, Bamias A, Drakaki A, Murgic J, Lorenzo GD, Grivas P, Khaki AR (2021). Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history. [Abstract]. 39.
Barata PC, Reisinger R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N (2021). Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA). [Abstract]. 39.
Duarte C, Beuselinck B, Weise N, Dizman N, Collier K, Li H, Martinez N, Elias CR, Rose TL, Brugarolas J, Agarwal N, Mortazavi A, Pal SK, McKay RR, Hu J, Lam ET (2021). Treatment outcomes in renal cell carcinoma patients with metastases to the pancreas and other sites. [Abstract]. 39.
Reisinger R, Santos VS, Nussenzveig R, Wesolowski S, Hernandez EJ, Henrie AR, Maughan BL, Swami U, Yandell M, Grivas P, Agarwal N (2021). Genomic predictors of response to PD-1 axis inhibitors in metastatic urothelial cancer (mUC) patients using machine learning analysis of tissue comprehensive genomic profiling (CGP). [Abstract]. 39.
George DJ, Agarwal N, Rider JR, Li B, Shirali R, Sandin R, Hong A, Russell D, Ramaswamy K, Freedlan SJ (2021). Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings. [Abstract]. 39.
Agarwal NAzad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, Lin X, Niyazov A, Czibere A, Fizazi K (2021). TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC). [Abstract]. 39.
Agarwal N, Oudard S, Rodriguez JMMP, Schweizer MT, Flechon A, Gordoa TA, Nacerddine K, Lithio A, Johnston EL, Smith MR (2021). CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy [Abstract]. 39.
Agarwal N, Tangen C, Hussain MH, Gupta S, Plets M, Lara P, Harzstark A, Twardowski P, Paller CJ, Zylla DM, Zibelman MR, Levine EG, Roth BJ, Goldkorn RA, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM, Quinn DI (2021). SWOG S1216:A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691) [Abstract]. 39.
Swami U, McFarland TR, Haaland B, Kessel A, Nussenzveig R, Sayegh N, Hahn AW, Rathi N, Sirohi D, Esther J, Li Haoran, Kohli M, Maughan BL, Goldkorn A, Agarwal N (2021). Correlation of baseline circulating tumor cells (CTC) and associated genomic profile with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort. [Abstract]. 39.
Vaia Florou, Charalampos S Floudas, Asaf Maoz, Abdul Rafeh Naqash, Gregory Hildebrand, Ethan Sokol, Garrett M Frampton, Sonam Puri, Umang Swami, Breelyn A Wilky, Peter Joel Hosein, Jonathan C Trent, Gilberto Lopes, Wungki Park, Ignacio Garrido-Laguna (ASCO 2021). Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB). [Abstract]. 39(2021), (suppl 15: abstr 2599).
Amanda Gammon, Ambreen Khan, Joanne M Jeter (2021). Evaluation of cohort diversity in development and validation studies of hereditary cancer genetic risk assessment models. [Abstract].
Freedland SJ, Agarwal N, Ramaswamy K, Sandin R, Russell D, Hong A, Yang H, Gao W, Hagan K, George DJ (2021). Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis. [Abstract]. 39.
Swami U, Hong A, El-Chaar NN, Nimke D, Ramaswamy K, Bell EJ, Sandin R, Agarwal N (2021). Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database. [Abstract]. 39.
Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer RJ, Lee RJ, Jain RK, Davis NB, Appleman LJ, Goodman OB, Stadler WM, Gandhi SG, Geynisman DM, Mellado RIB, Figlin RA, Powles T, Akella LV, Orford KW, Escudier B (2021). CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies. [Abstract]. 39.
Kaphingst KA, Kohlmann W, Chambers RL, Goodman MS, Bradshaw R, Chan PA, Chavez-Yenter D, Colonna SV, Espinel WF, Everett JN, Gammon A, Goldberg ER, Gonzalez J, Hagerty KJ, Hess R, Kehoe K, Kessler C, Kimball KE, Loomis S, Martinez TR, Monahan R, Schiffman JD, Temares D, Tobik K, Wetter DW, Mann DM, Kawamoto K, Del Fiol G, Buys SS, Ginsburg O, BRIDGE research team (2021). Comparing models of delivery for cancer genetics services among patients receiving primary care who meet criteria for genetic evaluation in two healthcare systems: BRIDGE randomized controlled trial. BMC Health Serv Res, 21(1), 542.
Kaphingst KA, Kohlmann W, Chambers RL, Goodman MS, Bradshaw R, Chan PA, Chavez-Yenter D, Colonna SV, Espinel WF, Everett JN, Gammon A, Goldberg ER, Gonzalez J, Hagerty KJ, Hess R, Kehoe K, Kessler C, Kimball KE, Loomis S, Martinez TR, Monahan R, Schiffman JD, Temares D, Tobik K, Wetter DW, Mann DM, Kawamoto K, Del Fiol G, Buys SS, Ginsburg O, BRIDGE research team (2021). Comparing models of delivery for cancer genetics services among patients receiving primary care who meet criteria for genetic evaluation in two healthcare systems: BRIDGE randomized controlled trial. BMC Health Serv Res, 21(1), 542.
Okwundu N, Grossman D, Hu-Lieskovan S, Grossmann KF, Swami U (2021). The dark side of immunotherapy. [Review]. Annals of Translational Medicine.
Alexander S, Swami U, Kaur A, Gao Y, Fatima M, Ginn MM, Stein JE, Grivas P, Zakharia Y, Singh N (2020). Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. Ann Transl Med, 9(12), 1033.
Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY (2021). Correction: Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res, 27(11), 3265.
Zawit M, Swami U, Awada H, Arnouk J, Milhem M, Zakharia Y (2021). Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med, 9(12), 1038.
Grivas P, Agarwal N, Pal S, Kalebasty AR, Sridhar SS, Smith J, Devgan G, Sternberg CN, Bellmunt J (2021). Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer Treat Rev, 97, 102187.
Okwundu N, Grossman D, Hu-Lieskovan S, Grossmann KF, Swami U (2020). The dark side of immunotherapy. Ann Transl Med, 9(12), 1041.
MacInnis RJ, Knight JA, Chung WK, Milne RL, Whittemore AS, Buchsbaum R, Liao Y, Zeinomar N, Dite GS, Southey MC, Goldgar D, Giles GG, Kurian AW, kConFab Investigators, Andrulis IL, John EM, Daly MB, Buys SS, Phillips KA, Hopper JL, Terry MB (2020). Comparing 5-Year and Lifetime Risks of Breast Cancer using the Prospective Family Study Cohort. J Natl Cancer Inst, 113(6), 785-791.
Florou V, Puri S, Garrido-Laguna I, Wilky BA (2020). Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. Ann Transl Med, 9(12), 1035.
Swami U, Milhem M (2021). Cancer immunotherapy: recent advances and challenges. Ann Transl Med, 9(12), 1032.
Kalasekar SM, Garrido-Laguna I, Evason KJ (2021). Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma. Hepatology, 73(6), 2591-2593.
Bleicher J, McGuire LE, Robbins RB, Johnson JE, Fischbuch S, Gupta S, Beck AC, Cohan JN (2021). Preoperative Advance Care Planning for Older Adults Undergoing Major Abdominal Surgery. Am J Hosp Palliat Care, 10499091211020276.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, zgrolu M, Soto J, Merseburger AS, Uemura H, Ye D, Given R, Basch E, Miladinovic B, Lopez-Gitlitz A, Chi KN (2021). Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. J Urol, 101097JU0000000000001841.
Nath A, Cosgrove PA, Mirsafian H, Christie EL, Pflieger L, Copeland B, Majumdar S, Cristea MC, Han ES, Lee SJ, Wang EW, Fereday S, Traficante N, Salgia R, Werner T, Cohen AL, Moos P, Chang JT, Bowtell DDL, Bild AH (2021). Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat Commun, 12(1), 3039.
Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D, Chowdhury S (2021). Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). BMC Cancer, 21(1), 593.
Mooney K, Titchener K, Haaland B, Coombs LA, ONeil B, Nelson R, McPherson JP, Kirchhoff AC, Beck AC, Ward JH (2021). Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial. J Clin Oncol, JCO2003609.
Mooney K, Titchener K, Haaland B, Coombs LA, ONeil B, Nelson R, McPherson JP, Kirchhoff AC, Beck AC, Ward JH (2021). Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial. J Clin Oncol, JCO2003609.
Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G, Melanoma Research Foundation (2021). The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res, 27(10), 2678-2697.
Cannon-Albright LA, Teerlink CC, Stevens J, Huang FW, Sipeky C, Schleutker J, Hernandez R, Facelli J, Agarwal N, Trump DL (2021). A Rare Variant in ERF (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree. Cancers (Basel), 13(10).
Coignard J, Lush M, Beesley J, OMara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Biakowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Calds T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL, GEMO Study Collaborators, EMBRACE Collaborators, Colle JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Drk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, Garca-Closas M, Garca-Senz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulias V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Gonzlez-Neira A, Greene MH, Gunel P, Haeberle L, Hahnen E, Haiman CA, Hkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, Horcasitas DJ, Hulick PJ, Hunter DJ, Imyanitov EN, KConFab Investigators, HEBON Investigators, ABCTB Investigators, Jager A, Jakubowska A, James PA, Jensen UB, John EM, Jones ME, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khusnutdinova E, Kiiski JI, Ko YD, Kosma VM, Kraft P, Kurian AW, Laitman Y, Lambrechts D, Le Marchand L, Lester J, Lesueur F, Lindstrom T, Lopez-Fernndez A, Loud JT, Luccarini C, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Mebirouk N, Meindl A, Miller A, Milne RL, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Nielsen FC, OBrien KM, Olopade OI, Olson JE, Olsson H, Osorio A, Ottini L, Park-Simon TW, Parsons MT, Pedersen IS, Peshkin B, Peterlongo P, Peto J, Pharoah PDP, Phillips KA, Polley EC, Poppe B, Presneau N, Pujana MA, Punie K, Radice P, Rantala J, Rashid MU, Rennert G, Rennert HS, Robson M, Romero A, Rossing M, Saloustros E, Sandler DP, Santella R, Scheuner MT, Schmidt MK, Schmidt G, Scott C, Sharma P, Soucy P, Southey MC, Spinelli JJ, Steinsnyder Z, Stone J, Stoppa-Lyonnet D, Swerdlow A, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Teul A, Thull DL, Tischkowitz M, Toland AE, Torres D, Trainer AH, Truong T, Tung N, Vachon CM, Vega A, Vijai J, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wolk A, Yadav S, Yang XR, Yannoukakos D, Zheng W, Ziogas A, Zorn KK, Park SK, Thomassen M, Offit K, Schmutzler RK, Couch FJ, Simard J, Chenevix-Trench G, Easton DF, Andrieu N, Antoniou AC (2021). Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun (12(1), p. 2986). England.
Koh MY, Sayegh N, Agarwal N (2021). Seeing the forest for the trees-single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer. Cancer Cell, 39(5), 594-596.
Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. https://doi.org/10.1186/s12885-021-08242-4 [Abstract]. 21, 510.
Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510.
Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510.
Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510.
Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510.
Venkatachalam S, McFarland TR, Agarwal N, Swami U (2021). Immune Checkpoint Inhibitors in Prostate Cancer. Cancers (Basel), 13(9).
Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna I (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. J Natl Compr Canc Netw, 19(5), 478-482.
Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna I (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. J Natl Compr Canc Netw, 19(5), 478-482.
Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, ORegan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R (2021). NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw, 19(5), 484-493.
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group (2021). Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol (18(5), p. 320). England.
Wei M, Wang X, Zimmerman DN, Burt LM, Haaland B, Henry NL (2021). Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer. Breast Cancer Res Treat, 187(1), 287-294.
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group (2021). COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol, 18(5), 313-319.
Riaz IB, Siddiqi R, Islam M, He H, Riaz A, Asghar N, Naqvi SAA, Warner JL, Murad MH, Kohli M (2021). Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis. JCO Clin Cancer Inform, 5, 588-599.
Kessel A, Kohli M, Swami U (2021). Current management of metastatic castration-sensitive prostate cancer. Cancer Treat Res Commun, 28, 100384.
Azeem Khan M, Florou V, Swami U (2021). Immunotherapy and fatigue: what we know and what we don't know. Oncotarget (12(8), pp. 719-720). United States.
Maughan BL, Antonarakis ES (2021). Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. Expert Opin Pharmacother, 1-8.
Kwan EM, Dai C, Fettke H, Hauser C, Docanto MM, Bukczynska P, Ng N, Foroughi S, Graham LK, Mahon K, Tan W, Wang X, Zhao Z, Zheng T, Zhou K, Yu J, Du P, Horvath LG, Jia S, Kohli M, Azad AA (2021). Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, (5), 622-637.
Choi YH, Terry MB, Daly MB, MacInnis RJ, Hopper JL, Colonna S, Buys SS, Andrulis IL, John EM, Kurian AW, Briollais L (2022). Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncol, 7(4), 585-592.
Choi YH, Terry MB, Daly MB, MacInnis RJ, Hopper JL, Colonna S, Buys SS, Andrulis IL, John EM, Kurian AW, Briollais L (2022). Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncol, 7(4), 585-592.
Baron K, Moser JC, Patel S, Grossmann KF, Colonna SV, Hyngstrom JR (2020). Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. J Oncol Pharm Pract, 27(3), 555-559.
Rieth JM, Swami U, Mott SL, Zanaty M, Henry MD, Bossler AD, Greenlee JD, Zakharia Y, Vanneste M, Jennings B, Milhem MM (2021). Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy. Cancers (Basel), 13(7).
Lin HM, Huynh K, Kohli M, Tan W, Azad AA, Yeung N, Mahon KL, Mak B, Sutherland PD, Shepherd A, Mellett N, Docanto M, Giles C, Centenera MM, Butler LM, Meikle PJ, Horvath LG (2021). Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. (Epub ahead of print) Prostate Cancer Prostatic Dis.
Pfledderer CD, Gren LH, Metos J, Brusseau TA, OToole K, Buys SS, Daly MB, Frost CJ (2021). Mothers' Diet and Family Income Predict Daughters' Healthy Eating. Prev Chronic Dis, 18, E24.
Parikh M, Liu C, Wu CY, Evans CP, DallEra M, Robles D, Lara PN, Agarwal N, Gao AC, Pan CX (2021). Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Sci Rep, 11(1), 6377.
Palmbos PL, Daignault-Newton S, Tomlins SA, Agarwal N, Twardowski P, Morgans AK, Kelly WK, Arora VK, Antonarakis ES, Siddiqui J, Jacobson J, Davenport MS, Robinson DR, Chinnaiyan AM, Knudsen KE, Hussain M (2021). A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone Sensitive Prostate Cancer (mHSPC). (Epub ahead of print) Clin Cancer Res.
Bernard PS, Wooderchak-Donahue W, Wei M, Bray SM, Wood KC, Parikh B, McMillin GA (2021). Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast Cancer. Cancers (Basel), 13(6).
Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES (2021). An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. . Breast Cancer Res, 23(1).
Tay DL, Thompson C, Jones M, Gettens C, Cloyes KG, Reblin M, Thomas Hebdon MC, Beck AC, Mooney K, Ellington L (2021). "I Feel All Alone Out Here": Analysis of Audio Diaries of Bereaved Hospice Family Caregivers During the COVID-19 Pandemic. (Epub ahead of print) JHPN.
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA (2021). Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(3), 329-359.
Loaiza-Bonilla A, Benson AB 3rd, Grothey A, Karimi M, Klempner SJ, Lin D, Mahtani R, Soares HP (2021). Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. (Epub ahead of print) Oncologist.
Kerrigan K, Puri S, Sinnott J, Haaland B, Akerley W, Patel S (2021). Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis [Abstract]. 16(3), S690.
Kerrigan K, Chipman J, Jo YJ, Haaland B, Johnson E, Puri S, Varghese T, Akerley W, Patel S (2021). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy [Abstract]. 16(3), S57-S698.
Puri S, Patel S, Chalmers A, Kerrigan K, Loertscher E, George S, Boucher K, Akerley W (2021). Phase 1b Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCL [Abstract]. 16(3), S344.
Kerrigan K, Chan J, Vagher J, Kohlmann W, Naumer A, Anson J, Low S, Schiffman J, Maese L (2021). Lung Cancer in Li Fraumeni Syndrome. JCO Precision Oncology. Mar 2021. DOI: 10.1200/PO.20.00468. JCO Precis Oncol.
Neal J, Lim F, Felip E, Gentzler R, Patel S, Baranda J, Fang B, Squillante C, Simonelli M, Werneke S, Curran D, Aix SP (2021). Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021 [Abstract]. 16(3), S230-S231.
Fitzgerald L, Sinnott J, Trunk A, Chalmers A, Akerley W, Patel S (2021). Real World Outcomes of Advanced Non-Small Cell Lung Cancer (NSCLC) With Attention to Carboplatin Area Under the Curve (AUC) = 5 Versus 6 [Abstract]. 16(3), S238-S239.
Kerrigan K, Chipman J, Jo YJ, Haaland B, Johnson E, Puri S, Varghese T, Akerley W, Patel S (2021). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy. 2020 World Conference on Lung Cancer. [Abstract]. 16(3), S122-S123.
Swami U, Antonarakis ES, Agarwal N (2021). Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652-6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. [Letter to the editor]. Eur Urol, 79(3), e94-e95.
Sanchez A, Agarwal N (2021). Quantifying the Costs of Care Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated in the Veterans Health Administration. JAMA Netw Open, 4(3), e213816.
Swami U, Haaland B, Kessel A, Nussenzveig R, Maughan BL, Esther J, Sirohi D, Pal SK, Grivas P, Agarwal N (2020). Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma. J Urol, 205(3), 709-717.
Gulbahce HE, White S, Herget KA, Stoddard G, Camp NJ, Buys SS, Sweeney C (2020). 21-gene recurrence score testing utilization among older women from different races: A population-based study. J Geriatr Oncol, 12(2), 206-211.
Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, Sartor O, Mao S, Cao H, Fu W, Wang T, Abdallah R, Lim SJ, Bolejack V, Paller CJ, Carducci MA, Markowski MC, Eisenberger MA, Antonarakis ES (2021). TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol, JCO2002759.
Coignard J, Lush M, Beesley J, OMara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Biakowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Calds T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL, GEMO Study Collaborators, EMBRACE Collaborators, Colle JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Drk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, Garca-Closas M, Garca-Senz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulias V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Gonzlez-Neira A, Greene MH, Gunel P, Haeberle L, Hahnen E, Haiman CA, Hkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, Horcasitas DJ, Hulick PJ, Hunter DJ, Imyanitov EN, KConFab Investigators, HEBON Investigators, ABCTB Investigators, Jager A, Jakubowska A, James PA, Jensen UB, John EM, Jones ME, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khusnutdinova E, Kiiski JI, Ko YD, Kosma VM, Kraft P, Kurian AW, Laitman Y, Lambrechts D, Le Marchand L, Lester J, Lesueur F, Lindstrom T, Lopez-Fernndez A, Loud JT, Luccarini C, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Mebirouk N, Meindl A, Miller A, Milne RL, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Nielsen FC, OBrien KM, Olopade OI, Olson JE, Olsson H, Osorio A, Ottini L, Park-Simon TW, Parsons MT, Pedersen IS, Peshkin B, Peterlongo P, Peto J, Pharoah PDP, Phillips KA, Polley EC, Poppe B, Presneau N, Pujana MA, Punie K, Radice P, Rantala J, Rashid MU, Rennert G, Rennert HS, Robson M, Romero A, Rossing M, Saloustros E, Sandler DP, Santella R, Scheuner MT, Schmidt MK, Schmidt G, Scott C, Sharma P, Soucy P, Southey MC, Spinelli JJ, Steinsnyder Z, Stone J, Stoppa-Lyonnet D, Swerdlow A, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Teul A, Thull DL, Tischkowitz M, Toland AE, Torres D, Trainer AH, Truong T, Tung N, Vachon CM, Vega A, Vijai J, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wolk A, Yadav S, Yang XR, Yannoukakos D, Zheng W, Ziogas A, Zorn KK, Park SK, Thomassen M, Offit K, Schmutzler RK, Couch FJ, Simard J, Chenevix-Trench G, Easton DF, Andrieu N, Antoniou AC (2021). A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun, 12(1), 1078.
Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Frbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P (2021). Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. (Epub ahead of print) BJU Int.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, OMalley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM (2021). Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(2), 191-226.
Khan A, Cohen S, Weir C, Greenberg S (2020). Implementing innovative service delivery models in genetic counseling: a qualitative analysis of facilitators and barriers. J Genet Couns, 30(1), 319-328.
Parsons M, Lloyd S, Johnson S, Scaife C, Varghese T, Glasgow R, Garrido-Laguna I, Tao R (2020). Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Ann Surg Oncol, 28(2), 663-675.
Sena LA, Fountain J, Isaacsson Velho P, Lim SJ, Wang H, Nizialek E, Rathi N, Nussenzveig R, Maughan BL, Velez MG, Ashkar R, Larson AC, Pritchard CC, Adra N, Bryce AH, Agarwal N, Pardoll DM, Eshleman JR, Lotan TL, Antonarakis ES (2020). Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. Oncologist, 26(2), e270-e278.
Swami U, Grivas P, Pal SK, Agarwal N (2021). Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. Cancer Treat Res Commun, 27, 100325.
Swami U, Grivas P, Pal SK, Agarwal N (2021). Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. Cancer Treat Res Commun, 27, 100325.
Coletta AM, Rose NB, Johnson AF, Moxon DS, Trapp SK, Walker D, White S, Ulrich CM, Agarwal N, Oza S, Zingg RW, Hansen PA (2021). The impact of a hospital-based exercise oncology program on cancer treatment-related side effects among rural cancer survivors. (Epub ahead of print) Support Care Cancer.
Pokorny R, McPherson JP, Haaland B, Grossmann KF, Luckett C, Voorhies BN, Sageser DS, Wallentine J, Tolman Z, Hu-Lieskovan S, Swami U (2021). Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma. J Immunother Cancer.
Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM Jr, Agarwal N (2021). Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). (Epub ahead of print) Clin Cancer Res.
Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, Akerley W (2021). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. doi: https://doi.org/10.1016/j.cllc.2021.01.013 [Abstract].
Coletta AM, Sayegh N, Agarwal N (2021). Body composition and metastatic prostate cancer survivorship. Cancer Treat Res Commun, 27, 100322.
Hu-Lieskovan S, Malouf GG, Jacobs I, Chou J, Liu L, Johnson ML (2021). Addressing resistance to immune checkpoint inhibitor therapy - an urgent unmet need. [Review]. Future Oncol.
Patel SB, Tuan J (2021). A Community Perspective: Latest 340B Program’s Effect on Cancer Centers. https://dailynews.ascopubs.org/do/10.1200/ADN.21.200434/full/.
Morris BB, Wages NA, Grant PA, Stukenberg PT, Gentzler RD, Hall RD, Akerley WL, Varghese TK, Arnold SM, Williams TM, Coppola V, Jones DR, Auble DT, Mayo MW (2021). MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma. Front Oncol, 10, 585551.
Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Frbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P (2021). A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. (Epub ahead of print) Eur Urol Oncol.
Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, CGC, Karlan BY, Khan S, Klein C, Kohlmann W, CGC, Kurian AW, Laronga C, Litton JK, Mak JS, LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G, CGC, Senter-Jamieson L, CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA (2021). Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(1), 77-102.
Swami U, Antonarakis ES, Agarwal N (2021). Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652-6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. [Letter to the editor]. Eur Urol.
Welm BE, Vaklavas C, Welm AL (2021). Toward improved models of human cancer. 5(1).
Hahn AW, Bilen MA, Agarwal N (2021). Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement. JAMA Netw Open, 4(1), e2034652.
Sohal D, Duong MT, Chang R, Xue Y, Delman D, Garrido-Laguna I, Mulvihill SJ, Affolter K, Washington MK, Beg MS, Wang-Gillam A, Wade JL, Gandhi N, Ahmad SA, Lowy AM, Chiorean EG, Guthrie KA, Hochster HS, Philip PA, Beatty GL (2021). Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) in SWOG S1505. [Abstract]. 39(2021), (suppl 3; abstr 419).
Naqash AR, Kihn-Alarcon AJ, Stavraka C, Kerrigan K, Vareki M, Pinato DJ, Puri S (2021). The Role of Gut Microbiome in Modulating Response to Immune Checkpoint Inhibitor Therapy in Cancer. Ann Transl Med.
Parsons M, Lloyd S, Johnson SB, Scaife CL, Garrido-Laguna I, Tao R (2021). The implications of treatment delays in adjuvant therapy for cholangiocarcinoma patients. [Abstract]. 39(2021), (suppl 3: abstr 291).
Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, Akerley W (2021). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. Clin Lung Cancer.
Miotke L, Nevala-Plagemann CD, Ying J, Florou V, Haaland B, Garrido-Laguna I (2021). Real-world outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma. [Abstract]. 39(2021), (suppl 3: abstr 387).
Sohal D, Duong MT, Chang R, Xue Y, Delman D, Garrido-Laguna I, Mulvihill SJ, Affolter K, Washington MK, Beg MS, Wang-Gillam A, Wade JL, Gandhi N, Ahmad SA, Lowy AM, Chiorean EG, Guthrie KA, Hochster HS, Philip PA, Beatty GL (2021). Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) in SWOG S1505. [Abstract]. 39(2021), (suppl 3; abstr 419.
Pokorny R, McPherson JP, Haaland B, Grossmann KF, Luckett C, Voorhies BN, Sageser DS, Wallentine J, Tolman Z, Hu-Lieskovan S, Swami U (2020). Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma. J Immunother Cancer, 9(1).
Rathi N, McFarland TR, Nussenzveig R, Agarwal N, Swami U (2020). Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. (Epub ahead of print) Drugs.
Rathi N, McFarland TR, Nussenzveig R, Agarwal N, Swami U (2020). Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. (Epub ahead of print) Drugs.
McKay RR, McGregor BA, Xie W, Braun DA, Wei X, Kyriakopoulos CE, Zakharia Y, Maughan BL, Rose TL, Stadler WM, McDermott DF, Harshman LC, Choueiri TK (2020). Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). J Clin Oncol, 38(36), 4240-4248.
Watt GP, Sung J, Morris EA, Buys SS, Bradbury AR, Brooks JD, Conant EF, Weinstein SP, Kontos D, Woods M, Colonna SV, Liang X, Stein MA, Pike MC, Bernstein JL (2020). Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study. Breast Cancer Res, 22(1), 138.
Watt GP, Sung J, Morris EA, Buys SS, Bradbury AR, Brooks JD, Conant EF, Weinstein SP, Kontos D, Woods M, Colonna SV, Liang X, Stein MA, Pike MC, Bernstein JL (2020). Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study. Breast Cancer Res, 22(1), 138.
Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel JJB, Gupta S, Hanks BA, Janetzki S, Kleen TO, Koguchi Y, Lund AW, Maccalli C, Mahnke YD, Novosiadly RD, Selvan SR, Sims T, Zhao Y, Maecker HT (2020). SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. [Review]. J Immunother Cancer, 2(8).
Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel JJB, Gupta S, Hanks BA, Janetzki S, Kleen TO, Koguchi Y, Lund AW, Maccalli C, Mahnke YD, Novosiadly RD, Selvan SR, Sims T, Zhao Y, Maecker HT (2020). SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. J Immunother Cancer, 8(2).
Truong A, Yoo JH, Scherzer MT, Sanchez JMS, Dale KJ, Kinsey CG, Richards JR, Shin D, Ghazi PC, Onken MD, Blumer KJ, Odelberg SJ, McMahon M (2020). Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition. Clin Cancer Res, 26(23), 6374-6386.
Patell R, Midha S, Kimani S, Martin R, Neparidze N, Jaglal M, Freed J, Key NS (2020). Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States. [Letter to the editor]. Thromb Haemost, 120(12), 1725-1732.
Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel JJB, Gupta S, Hanks BA, Janetzki S, Kleen TO, Koguchi Y, Lund AW, Maccalli C, Mahnke YD, Novosiadly RD, Selvan SR, Sims T, Zhao Y, Maecker HT (2020). SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. J Immunother Cancer, 8(2).
Sena LA, Fountain J, Isaacsson Velho P, Lim SJ, Wang H, Nizialek E, Rathi N, Nussenzveig R, Maughan BL, Velez MG, Ashkar R, Larson AC, Pritchard CC, Adra N, Bryce AH, Agarwal N, Pardoll DM, Eshleman JR, Lotan TL, Antonarakis ES (2020). Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer. (Epub ahead of print) Oncologist.
Poran A, Scherer J, Bushway ME, Besada R, Balogh KN, Wanamaker A, Williams RG, Prabhakara J, Ott PA, Hu-Lieskovan S, Khondker ZS, Gaynor RB, Rooney MS, Srinivasan L (2020). Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. Cell Reports Medicine, 1(8).
Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA (2020). Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res, 1(26(21)), 5579-5587.
Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N (2020). Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol, 78(5), 652-656.
Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N (2020). Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol, 78(5), 652-656.
Tripathi A, Lin E, Xie W, Flaifel A, Steinharter JA, Stern Gatof EN, Bouchard G, Fleischer JH, Martinez-Chanza N, Gray C, Mantia C, Thompson L, Wei XX, Giannakis M, McGregor BA, Choueiri TK, Agarwal N, McDermott DF, Signoretti S, Harshman LC (2020). Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. J Immunother Cancer, 8(2).
Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG (2020). A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist, 25(11), e1655-e1662.
McDonald JA, Cherubin S, Goldberg M, Wei Y, Chung WK, Schwartz LA, Knight JA, Schooling CM, Santella RM, Bradbury AR, Buys SS, Andrulis IL, John EM, Daly MB, Terry MB (2020). Common Childhood Viruses and Pubertal Timing: The LEGACY Girls Study. (Epub ahead of print) Am J Epidemiol.
Meza L, Bergerot PG, Agarwal N, Pal SK (2020). Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe. PMID: 33121996. Annals of Oncology.
Swami U, Chennamadhavuni A, Borcherding N, Bossler AD, Mott SL, Garje R, Zakharia Y, Milhem M (2020). Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies. Antibiotics (Basel), 9(11).
Hwang JK, Agarwal N, Brugarolas J, Zhang T (2020). Checking the Hippo in sarcomatoid renal cell carcinoma with immunotherapy. (Epub ahead of print) Clin Cancer Res.
Cannon-Albright LA, Stevens J, Teerlink CC, Agarwal N (2020). The HOXB13 p.Gly84Glu variant observed in an extended five generation high-risk prostate cancer pedigree supports risk association for multiple cancer sites. Cancer Epidemiol, 69, 101834.
Swami U, Haaland B, Kessel A, Nussenzveig R, Maughan BL, Esther J, Sirohi D, Pal SK, Grivas P, Agarwal N (2020). Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum-Refractory Advanced Urothelial Carcinoma. J Urol, 101097JU0000000000001412.
Swami U, Haaland B, Kessel A, Nussenzveig R, Maughan BL, Esther J, Sirohi D, Pal SK, Grivas P, Agarwal N (2020). Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum-Refractory Advanced Urothelial Carcinoma. J Urol, 101097JU0000000000001412.
Knight JA, Kehm RD, Schwartz L, Frost CJ, Chung WK, Colonna S, Keegan THM, Goldberg M, Houghton LC, Hanna D, Glendon G, Daly MB, Buys SS, Andrulis IL, John EM, Bradbury AR, Terry MB (2020). Pre-Pubertal Internalizing Symptoms and Timing of Puberty Onset in Girls. (Epub ahead of print) Am J Epidemiol.
Knight JA, Kehm RD, Schwartz L, Frost CJ, Chung WK, Colonna S, Keegan THM, Goldberg M, Houghton LC, Hanna D, Glendon G, Daly MB, Buys SS, Andrulis IL, John EM, Bradbury AR, Terry MB (2020). Pre-Pubertal Internalizing Symptoms and Timing of Puberty Onset in Girls. (Epub ahead of print) Am J Epidemiol.
Ellis GK, Manda A, Topazian H, Stanley CC, Seguin R, Minnick CE, Tewete B, Mtangwanika A, Chawinga M, Chiyoyola S, Chikasema M, Salima A, Kimani S, Kasonkanji E, Mithi V, Kaimila B, Painschab MS, Gopal S, Westmoreland KD (2020). Feasibility of upfront mobile money transfers for transportation reimbursement to promote retention among patients receiving lymphoma treatment in Malawi. (Epub ahead of print) Int Health.
Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L (2020). A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 183(2), 347-362.
McComas K, Agarwal N, Bowen G, Maughan BL, Tward JD (2020). Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. Clin Genitourin Cancer, 18(5), e573-e584.
Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, Mavaddat N, Adlard J, Ahmed M, Aittomki K, Andrieu N, Andrulis IL, Arnold N, Arun BK, Azzollini J, Balmaa J, Barkardottir RB, Barrowdale D, Benitez J, Berthet P, Biakowska K, Blanco AM, Blok MJ, Bonanni B, Boonen SE, Borg, Bozsik A, Bradbury AR, Brennan P, Brewer C, Brunet J, Buys SS, Calds T, Caligo MA, Campbell I, Christensen LL, Chung WK, Claes KBM, Colas C, GEMO Study Collaborators, EMBRACE Collaborators, Collonge-Rame MA, Cook J, Daly MB, Davidson R, de la Hoya M, de Putter R, Delnatte C, Devilee P, Diez O, Ding YC, Domchek SM, Dorfling CM, Dumont M, Eeles R, Ejlertsen B, Engel C, Evans DG, Faivre L, Foretova L, Fostira F, Friedlander M, Friedman E, Frost D, Ganz PA, Garber J, Gehrig A, Gerdes AM, Gesta P, Giraud S, Glendon G, Godwin AK, Goldgar DE, Gonzlez-Neira A, Greene MH, Gschwantler-Kaulich D, Hahnen E, Hamann U, Hanson H, Hentschel J, Hogervorst FBL, Hooning MJ, Horvath J, Hu C, Hulick PJ, Imyanitov EN, kConFab Investigators, HEBON Investigators, GENEPSO Investigators, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James PA, Janavicius R, John EM, Joseph V, Karlan BY, Kast K, Koudijs M, Kruse TA, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Lesueur F, Liljegren A, Loud JT, Lubiski J, Mai PL, Manoukian S, Mari V, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Miller A, Montagna M, Mouret-Fourme E, Mukherjee S, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Nielsen FC, Nikitina-Zake L, Nogus C, Olah E, Olopade OI, Ong KR, OShaughnessy-Kirwan A, Osorio A, Ott CE, Papi L, Park SK, Parsons MT, Pedersen IS, Peissel B, Peixoto A, Peterlongo P, Pfeiler G, Phillips KA, Prajzendanc K, Pujana MA, Radice P, Ramser J, Ramus SJ, Rantala J, Rennert G, Risch HA, Robson M, Rnlund K, Salani R, Schuster H, Senter L, Shah PD, Sharma P, Side LE, Singer CF, Slavin TP, Soucy P, Southey MC, Spurdle AB, Steinemann D, Steinsnyder Z, Stoppa-Lyonnet D, Sutter C, Tan YY, Teixeira MR, Teo SH, Thull DL, Tischkowitz M, Tognazzo S, Toland AE, Trainer AH, Tung N, van Engelen K, van Rensburg EJ, Vega A, Vierstraete J, Wagner G, Walker L, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Yadav S, Yang X, Yannoukakos D, Zimbalatti D, Offit K, Thomassen M, Couch FJ, Schmutzler RK, Simard J, Easton DF, Chenevix-Trench G, Antoniou AC, Consortium of Investigators of Modifiers of BRCA and BRCA2 (2020). Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med, 22(10), 1653-1666.
Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde GP (2019). Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. Eur Urol Oncol, 3(5), 695-699.
Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC, from the Carcinoid Syndrome Control Collaborative (2020). Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas, 49(9), 1123-1130.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, zgrolu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J, PROfound Trial Investigators (2020). Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. (Epub ahead of print) N Engl J Med.
Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY (2020). Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res, 26(18), 4970-4982.
Tripathi A, McFarland T, Agarwal N (2020). PARP Inhibitors in Prostate Cancer: A Promise Delivered. Eur Urol Oncol.
Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD (2020). NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Netw, 18(9), 1160-1170.
Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol, 156(9), 1004-1011.
Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, Asrani K, Alshalalfa M, Antonarakis ES, Epstein JI, Joshu CE, Schaeffer EM, Mosquera JM, Lotan TL (2020). Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate, 80(12), 1012-1023.
Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol, 156(9), 1004-1011.
Kimani SM, Painschab MS, Horner MJ, Muchengeti M, Fedoriw Y, Shiels MS, Gopal S (2020). Epidemiology of haematological malignancies in people living with HIV. Lancet HIV, 7(9), e641-e651.
Bhowmick NA, Oft J, Dorff T, Pal S, Agarwal N, Figlin RA, Posadas EM, Freedland SJ, Gong J (2020). COVID-19 and androgen-targeted therapy for prostate cancer patients. Endocr Relat Cancer, 27(9), R281-R292.
Bhawal R, Oberg AL, Zhang S, Kohli M (2020). Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer. Cancers (Basel), 12(9).
Necchi A, Madison R, Pal SK, Ross JS, Agarwal N, Sonpavde G, Joshi M, Yin M, Miller VA, Grivas P, Chung JH, Ali SM (2020). Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. (Epub ahead of print) Eur Urol Focus.
Yung Lyou, Petros Grivas, Jonathan E Rosenberg, Jean Hoffman-Censits, David I Quinn, Daniel P Petrylak, Matthew Galsky, Ulka Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard Burris, Jessica Rearden, Ai Li, Hao Wang, Maribel Reyes, Susan Moran, Siamak Daneshmand, Dean Bajorin, Sumanta K Pal (2020). Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma PMID: 32847703 DOI: 10.1016/j.eururo.2020.08.002 Yung Lyou et al. Eur Urol.2020. Eur Urol 2020 Aug 23;S0302-2838(20)30616-3.doi: 10.1016/j.eururo.2020.08.002. Online ahead of print. . Eur Urol, 20(S0302).
Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, den Eertwegh AJMV, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Danielli R, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelv L, Hansen S, McHenry MB, Chen A, Logothetis C, CA184-043 Investigators (2020). Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. (Epub ahead of print) Eur Urol.
Swami U, Agarwal N (2020). Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer. Cancer Treat Res Commun, 25, 100205.
Swami U, Agarwal N (2020). Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer. Cancer Treat Res Commun, 25, 100205.
Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, Song Y, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM (2020). Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. Curr Med Res Opin, 1-11.
Swami U, Nussenzveig RH, Agarwal N (2020). Quest for Ideal Composite Biomarkers for Response to Immunotherapies. (Epub ahead of print) Clin Cancer Res.
Khaki AR, Agarwal N, Pal SK, Grivas P (2020). Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. Cancer.
Swami U, Nussenzveig RH, Agarwal N (2020). Quest for Ideal Composite Biomarkers for Response to Immunotherapies. (Epub ahead of print) Clin Cancer Res.
Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, OReilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru D (2020). Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol, JCO2001364.
Vaishnavi A, Scherzer MT, Kinsey CG, Parkman GL, Truong A, Ghazi P, Schuman S, Battistone B, Garrido-Laguna I, McMahon M (2019). Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Rep, 32(5), 107994.
Vaishnavi A, Scherzer MT, Kinsey CG, Parkman GL, Truong A, Ghazi P, Schuman S, Battistone B, Garrido-Laguna I, McMahon M (2019). Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Rep, 32(5), 107994.
Shilpa Gupta, Guru Sonpavde, Christopher J Weight, Bradley Alexander McGregor, Sumati Gupta, Benjamin Louis Maughan, Xiao X Wei, Ewan Gibb, Bharat Thyagarajan, David Johnson Einstein, Christopher B Dechet, William Thomas Lowrance, Paari J Murugan, Kerry L Kilbridge, Neeraj Agarwal, Elai Davicioni, Markus Eckstein, Matthew Mossanen, Mark A Preston, and Badrinath R Konety (2020). Pl Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. [Abstract]. 38(6_suppl), 439-439.
Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, Parisi G, Zaretsky JM, Garcia-Diaz A, Puig-Saus C, Cheung-Lau G, Wohlwender T, Krystofinski P, Vega-Crespo A, Lee CM, Mascaro P, Grasso CS, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Ribas A (2020). Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discov, 10(8), 1140-1157.
Fettke H, Kwan EM, Docanto MM, Bukczynska P, Ng N, Graham LK, Mahon K, Hauser C, Tan W, Wang XH, Zhao Z, Zheng T, Zhou K, Du P, Yu J, Huang Y, Jia S, Kohli M, Horvath LG, Azad AA (2020). Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer. Eur Urol, 78(2), 173-180.
Swami U, McFarland TR, Nussenzveig R, Agarwal N (2020). Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends Cancer, 6(8), 702-715.
Silvestri V, Leslie G, Barnes DR, CIMBA Group, Agnarsson BA, Aittomki K, Alducci E, Andrulis IL, Barkardottir RB, Barroso A, Barrowdale D, Benitez J, Bonanni B, Borg A, Buys SS, Calds T, Caligo MA, Capalbo C, Campbell I, Chung WK, Claes KBM, Colonna SV, Cortesi L, Couch FJ, de la Hoya M, Diez O, Ding YC, Domchek S, Easton DF, Ejlertsen B, Engel C, Evans DG, Feliubadal L, Foretova L, Fostira F, Gczi L, Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Hahnen E, Hogervorst FBL, Hopper JL, Hulick PJ, Isaacs C, Izquierdo A, James PA, Janavicius R, Jensen UB, John EM, Joseph V, Konstantopoulou I, Kurian AW, Kwong A, Landucci E, Lesueur F, Loud JT, Machackova E, Mai PL, Majidzadeh-A K, Manoukian S, Montagna M, Moserle L, Mulligan AM, Nathanson KL, Nevanlinna H, Ngeow J, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Osorio A, Papi L, Park SK, Pedersen IS, Perez-Segura P, Petersen AH, Pinto P, Porfirio B, Pujana MA, Radice P, Rantala J, Rashid MU, Rosenzweig B, Rossing M, Santamaria M, Schmutzler RK, Senter L, Simard J, Singer CF, Solano AR, Southey MC, Steele L, Steinsnyder Z, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Teo SH, Terry MB, Thomassen M, Toland AE, Torres-Esquius S, Tung N, van Asperen CJ, Vega A, Viel A, Vierstraete J, Wappenschmidt B, Weitzel JN, Wieme G, Yoon SY, Zorn KK, McGuffog L, Parsons MT, Hamann U, Greene MH, Kirk JA, Neuhausen SL, Rebbeck TR, Tischkowitz M, Chenevix-Trench G, Antoniou AC, Friedman E, Ottini L (2020). Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol, 6(8), 1218-1230.
Du M, Huang CC, Tan W, Kohli M, Wang L (2020). Multiplex Digital PCR to Detect Amplifications of Specific Androgen Receptor Loci in Cell-Free DNA for Prognosis of Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel), 12(8).
Sutherland N, Espinel W, Grotzke M, Colonna S (2020). Unanswered Questions: Hereditary breast and gynecological cancer risk assessment in transgender adolescents and young adults. J Genet Couns, 29(4), 625-633.
Silvestri V, Leslie G, Barnes DR, CIMBA Group, Agnarsson BA, Aittomki K, Alducci E, Andrulis IL, Barkardottir RB, Barroso A, Barrowdale D, Benitez J, Bonanni B, Borg A, Buys SS, Calds T, Caligo MA, Capalbo C, Campbell I, Chung WK, Claes KBM, Colonna SV, Cortesi L, Couch FJ, de la Hoya M, Diez O, Ding YC, Domchek S, Easton DF, Ejlertsen B, Engel C, Evans DG, Feliubadal L, Foretova L, Fostira F, Gczi L, Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Hahnen E, Hogervorst FBL, Hopper JL, Hulick PJ, Isaacs C, Izquierdo A, James PA, Janavicius R, Jensen UB, John EM, Joseph V, Konstantopoulou I, Kurian AW, Kwong A, Landucci E, Lesueur F, Loud JT, Machackova E, Mai PL, Majidzadeh-A K, Manoukian S, Montagna M, Moserle L, Mulligan AM, Nathanson KL, Nevanlinna H, Ngeow J, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Osorio A, Papi L, Park SK, Pedersen IS, Perez-Segura P, Petersen AH, Pinto P, Porfirio B, Pujana MA, Radice P, Rantala J, Rashid MU, Rosenzweig B, Rossing M, Santamaria M, Schmutzler RK, Senter L, Simard J, Singer CF, Solano AR, Southey MC, Steele L, Steinsnyder Z, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Teo SH, Terry MB, Thomassen M, Toland AE, Torres-Esquius S, Tung N, van Asperen CJ, Vega A, Viel A, Vierstraete J, Wappenschmidt B, Weitzel JN, Wieme G, Yoon SY, Zorn KK, McGuffog L, Parsons MT, Hamann U, Greene MH, Kirk JA, Neuhausen SL, Rebbeck TR, Tischkowitz M, Chenevix-Trench G, Antoniou AC, Friedman E, Ottini L (2020). Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol, 6(8), 1218-1230.
Lambert J, Marrel A, DAngelo SP, Burgess MA, Chmielowski B, Fazio N, Gambichler T, Grob JJ, Lebb C, Robert C, Russell J, Gzel G, Bharmal M (2020). Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. Patient, 13(4), 457-467.
Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O (2020). Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J Immunother Cancer, 8(2).
Chae YK, Hong F, Vaklavas C, Cheng HC, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, ODwyer PJ, Chen AP, Flaherty KT (2020). A Phase II Study of AZD4547 in Patients with Tumors harboring Aberrations in the FGFR Pathway: Results from the NCI-MATCH Trial (EAY131) Sub-protocol W. J Clin Oncol, 38(21), 2407-2417.
Ireland AS, Micinski AM, Kastner DW, Guo B, Wait SJ, Spainhower KB, Conley CC, Chen OS, Guthrie MR, Soltero D, Qiao Y, Huang X, Tarapcsk S, Devarakonda S, Chalishazar MD, Gertz J, Moser JC, Marth G, Puri S, Witt BL, Spike BT, Oliver TG (2020). MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. Cancer Cell, 38(1), 60-78.e12.
Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Sternberg CN, Bellmunt J, Baniel J, Niegisch G (2020). Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. (Epub ahead of print) Urol Oncol.
Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N (2020). Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. (Epub ahead of print) Eur Urol.
Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR (2020). North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas, 49(6), 723-728.
Armstrong JM, Martin CR, Dechet C, Morton K, Evans D, Ambrose J, Maughan BL, ONeil B, Lowrance W (2020). 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. Urol Oncol, 38(7), 636.e1-636.e6.
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hoffe S, Hubbard J, Hunt S, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gurski LA (2020). NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw, 18(7), 806-815.
Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol.
Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4.
Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4.
Florou V, Nevala-Plagemann C, Barber K, Mastroianni J, Cavalieri C, Garrido-Laguna I (June 2020). Immune checkpoint inhibition re-challenge after a planned treatment interruption in patients with pancreatic adenocarcinoma with mismatch repair deficient tumors. [Abstract]. Proceedings of the American Association for Cancer Research, June 2020.
Florou V, Nevala-Plagemann C, Mulvihill S, Garrido-Laguna I (June 2020). Pancreatic acinar carcinoma - a rare entity with a targetable BRAF V600E mutation. [Abstract]. Proceedings of the American Association for Cancer Research, June 2020.
Vaishnavi A, Scherzer M, Kinsey C, Garrido-Laguna I, McMahon M (2020). Combined TRKA and MEK1/2 Inhibition Forestalls the Onset of Acquired Resistance in a New Preclinical Model of NTRK1+ Pancreatic Cancer. [Abstract].
Channaoui N, Khan A, Wiesman C et al (2020). Summary report of the 2019 Diversity and Inclusion Task Force of the National Society of Genetic Counselors. J Genet Couns.
Swami U, McFarland TR, Nussenzveig R, Agarwal N (2020). Advanced Prostate Cancer: Treatment Advances and Future Directions. (Epub ahead of print) Trends Cancer.
Praful Ravi, Gregory Russell Pond, Leonidas Nikolaos Diamantopoulos, Rohit K Jain, William Paul Skelton, Sumati Gupta, Jonathan David Tward, Kathleen Olson, Parminder Singh, Camilla Marisa Grunewald, Guenter Niegisch, Jae-Lyun Lee, Andrea Gallina, Marco Bandini, Andrea Necchi, Matthew Mossanen, Bradley Alexander McGregor, Catherine Curran, Petros Grivas, and Guru Sonpavde (6/2020). Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration. [Abstract]. 38(15_suppl), 5043-5043.
Benjamin Louis Maughan, Andrew W Hahn, Roberto Nussenzveig, John Hoffman, Kathryn Morton, Sumati Gupta, Julia Anne Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth M Boucher, Benjamin Haaland, and Neeraj Agarwal (6/2020). Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints. [Abstract]. 38(6_suppl), 125-125.
Sergiusz Wesolowski Roberto Nussenzveig, Victor Sacristan Santos, John Esther, Divyam Goel, Umang Swami, Sumati Gupta, Benjamin Louis Maughan, Mark Yandell, Petros Grivas, and Neeraj Agarwal (6/2020). Genomic correlates of response to PD-1 axis inhibitors (IO) in metastatic urothelial cancer (mUC) using explainable artificial intelligence (AI). [Abstract]. 38(6_suppl), 570-570.
Lesli Ann Kiedrowski, Roby Antony Thomas, Nicholas J Vogelzang, Guru Sonpavde, Sumati Gupta, Theodore Stewart Gourdin, Bishoy Morris Faltas, Rebecca Nagy, Richard B Lanman, and Petros Grivas (6/2020). FGFR2/3 genomic alterations (GA) in cell-free (cf)DNA from patients (pts) with advanced urothelial carcinoma (aUC). [Abstract]. 38(6_suppl), 565-565.
Yung Lyou, Petros Grivas, Jonathan E Rosenberg, Jean H Hoffman-Censits, David I Quinn, Daniel Peter Petrylak, Matt D Galsky, Ulka N Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A Burris, Jessica Rearden, Yining Ye, Hao Wang, Susan Moran, Siamak Daneshmand, Dean F Bajorin, and Sumanta K Pal (06/2020). Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC). [Abstract]. 38(6_suppl), 576-576.
Benjamin Louis Maughan, Roberto Nussenzveig, Umang Swami, Sumati Gupta, and Neeraj Agarwal (06/2020). Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response. [Abstract]. 38(6_suppl), TPS267-TPS267.
Benjamin Louis Maughan, Andrew W Hahn, Roberto Nussenzveig, John Hoffman, Kathryn Morton, Sumati Gupta, Julia Anne Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth M Boucher, Benjamin Haaland, and Neeraj Agarwal (6/2020). Randomized phase II trial of radium-223 9RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints. [Abstract]. 38(6_suppl), 125-125.
Benjamin Louis Maughan, Alejandro Sanchez, Brock B ONeil, William Thomas LowranceChristopher B Dechet, Danel Joseph Albertson, Deepika Sirohi, Sumati Gupta, Umang Swami, and Neeraj Agarwal (6/2020). A phase 1b/II trial of perioperative intratumoral MVA-BN-brachyury (MVA) plus systemic PROSTVAC and atezolizumab (Atezo) for intermediate-risk and high-risk localized prostate cancer (AteoVax). [Abstract]. 38(6_suppl), TPS382-TPS382.
Petros Grivas, Yohann Loriot, Susan Feyerabend, Rafael Morales-Barrera, Min Yuen Teo, Nicholas J Vogelzang, Enrique Grande, Yousef Zakharia, Nabil Adra, Ajjai Shivaram Alva, Andrea Necchi, Sumati Gupta, Debra Hannah Josephs, Alejo Rodriguez-Vida, Sandy Srinivas, Kenton Wride, Daleen Thomas, Rachel Dusek, Dale L Nepert, and Simon Chowdhury (06/2020). Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial. [Abstract]. 38(6_suppl), 440-440.
Wells SM, Boothe D, Ager BJ, Tao R, Gilcrease GW 3rd, Lloyd S (2020). Analysis of Nonsurgical Treatment Options for Metastatic Rectal Cancer. Clin Colorectal Cancer, 19(2), 91-99.e1.
Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, Dang LH, Geynisman DM, Walling R, Alter RS, Kassar M, Wang J, Gupta S, Davis N, Picus J, Philips G, Quinn DI, Haines GK 3rd, Hahn NM, Zhao Q, Yu M, Pal SK (2020). Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. J Clin Oncol, 38(16), 1797-1806.
Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI, Petrylak DP, Galsky MD, Vaishampayan U, De Giorgi U, Gupta S, Burris HA, Soifer HS, Li G, Wang H, Dambkowski CL, Moran S, Daneshmand S, Rosenberg JE (2020). Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer, 126(11), 2597-2606.
Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M (2020). Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clin Cancer Res, 26(11), 2546-2555.
Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, OMara TA, Zhao N, Bolla MK, Dunning AM, Dennis J, Wang Q, Ful ZA, Aittomki K, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Arun BK, Auer PL, Azzollini J, Barrowdale D, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bialkowska K, Blanco A, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Bondavalli D, Borg A, Brauch H, Brenner H, Briceno I, Broeks A, Brucker SY, Brning T, Burwinkel B, Buys SS, Byers H, Calds T, Caligo MA, Calvello M, Campa D, Castelao JE, Chang-Claude J, Chanock SJ, Christiaens M, Christiansen H, Chung WK, Claes KBM, Clarke CL, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Diez O, Domchek SM, Drk T, Dwek M, Eccles DM, Ekici AB, Evans DG, Fasching PA, Figueroa J, Foretova L, Fostira F, Friedman E, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garca-Senz JA, Gaudet MM, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Gonzlez-Neira A, Greene MH, Gronwald J, Gunel P, Hberle L, Hahnen E, Haiman CA, Hake CR, Hall P, Hamann U, Harkness EF, Heemskerk-Gerritsen BAM, Hillemanns P, Hogervorst FBL, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huebner H, Hulick PJ, Imyanitov EN, kConFab Investigators, ABCTB Investigators, Isaacs C, Izatt L, Jager A, Jakimovska M, Jakubowska A, James P, Janavicius R, Janni W, John EM, Jones ME, Jung A, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khan S, Khusnutdinova E, Kitahara CM, Ko YD, Konstantopoulou I, Koppert LB, Koutros S, Kristensen VN, Laenkholm AV, Lambrechts D, Larsson SC, Laurent-Puig P, Lazaro C, Lazarova E, Lejbkowicz F, Leslie G, Lesueur F, Lindblom A, Lissowska J, Lo WY, Loud JT, Lubinski J, Lukomska A, MacInnis RJ, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Matricardi L, McGuffog L, McLean C, Mebirouk N, Meindl A, Menon U, Miller A, Mingazheva E, Montagna M, Mulligan AM, Mulot C, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen FC, Nikitina-Zake L, Nodora J, Offit K, Olah E, Olopade OI, Olsson H, Orr N, Papi L, Papp J, Park-Simon TW, Parsons MT, Peissel B, Peixoto A, Peshkin B, Peterlongo P, Peto J, Phillips KA, Piedmonte M, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Prokofyeva D, Rack B, Radice P, Ramus SJ, Rantala J, Rashid MU, Rennert G, Rennert HS, Risch HA, Romero A, Rookus MA, Rbner M, Rdiger T, Saloustros E, Sampson S, Sandler DP, Sawyer EJ, Scheuner MT, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schttker B, Schrmann P, Senter L, Sharma P, Sherman ME, Shu XO, Singer CF, Smichkoska S, Soucy P, Southey MC, Spinelli JJ, Stone J, Stoppa-Lyonnet D, EMBRACE Study, GEMO Study Collaborators, Swerdlow AJ, Szabo CI, Tamimi RM, Tapper WJ, Taylor JA, Teixeira MR, Terry M, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Torres D, Troester MA, Truong T, Tung N, Untch M, Vachon CM, van den Ouweland AMW, van der Kolk LE, van Veen EM, vanRensburg EJ, Vega A, Wappenschmidt B, Weinberg CR, Weitzel JN, Wildiers H, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zheng W, Zorn KK, Milne RL, Kraft P, Simard J, Pharoah PDP, Michailidou K, Antoniou AC, Schmidt MK, Chenevix-Trench G, Easton DF, Chatterjee N, Garca-Closas M (2020). Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet, 52(6), 572-581.
Lin E, Hahn AW, Nussenzveig R, Wesolowski S, Maughan BL, McFarland TR, Rathi N, Sartor AOO, Sonpavde G, Swami U, Kohli M, Rich TA, Yandell M, Agarwal N (2020). Genomic alterations associated with the progression from castration-sensitive to castration-resistant metastatic prostate cancer based on machine learning analysis of cell-free DNA genomic profile (suppl; abstr e17596). [Abstract]. 38.
Meric-Bernstam F, Calvo E, Moreno V, Chung HC, Park YH, Bang Y-J, Rosen LS, Mita MM, Garrido-Laguna I, Leung ACF, Dube H, Zhong W, Chen X, Dawaher R, Curigliano G (May 2020). A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF‑06804103) in patients with HER2-positive solid tumors. [Abstract]. 38(suppl; abstr 1039 American Society of Clinical Oncology Annual Meeting).
Swami U, Sinnott JA, Haaland B, Maughan BL, Rathi N, McFarland TR, Kohli M, Nussenzveig R, Pal SK, Agarwal N (2020). Overall survival (OS) with docetaxel (D) vs novel hormonal therapy (NHT) with abiraterone (A) or enzalutamide (E) after a prior NHT in patients (Pts) with metastatic prostate cancer (mPC): Results from a real-world dataset (suppl; abstr 5537). [Abstract]. 38.
Garrido-Laguna I, Dillon PM, Anthony SP, Janat-Amsbury M, Ashenbramer N, Warner SL, Mouritsen L, Wade ML, Whatcott C, Bearss D, Fu S (Mary 2020). A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑3654 administered daily for 28 days to patients with advanced solid tumors. [Abstract]. May 2020.
Neal JW, Lim FL, Felip E, Gentzler RD, Patel SB, Baranda J, Fang B, Squillante CM, Simonelli M, Werneke S, Curran D, Aix SP (2020). Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. (suppl) abstr 9610 [Abstract]. 38.
Pokorny R, McPherson JP, Grossmann KF, Luckett C, Voorhies BN, Sageser DS, Wallentine J, Tolman Z, Hu-Lieskovan S, Swami U (2020). Clinical outcomes with early-elective discontinuation of PD-1 inhibitors (PDi) at one year in patients (pts) with metastatic melanoma (MM) (suppl; abstr 10048). [Abstract]. 38.
Swami U, Haaland B, Maughan BL, Nussenzveig R, Esther J, Kessel A, Pal SK, Grivas P, Agarwal N (2020). Comparative effectiveness of second-line (2L) single-agent atezolizumab (A), nivolumab (N), and pembrolizumab (P) in patients (Pts) with locally advanced or metastatic urothelial cancer (aUC) who progressed on platinum-based systemic chemotherapy (plat-chemo): Results from a real-world dataset (suppl; abstr 5032). [Abstract]. 38.
Braithwaite M, Nevala-Plagemann CD, Baron K, Haaland B, Pappas LM, Garrido-Laguna I (May 2020). Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States. [Abstract]. 38(suppl; abstr 4030 American Society of Clinical Oncology Annual Meeting).
McGregor BA, Gordon M, Flippot R, Agarwal N, George S, Quinn DI, Rogalski M, Hawthorne T, Keler T, Choueiri TK (2020). Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. (Epub ahead of print) Invest New Drugs.
Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, Bakouny Z, Agarwal N, Zakharia Y, Costello BA, McKay RR, Narayan V, Alva A, McGregor BA, Gao X, McDermott DF, Choueiri TK (2020). Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. (Epub ahead of print) JAMA Oncol.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M (2020). Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med, 382(22), 2091-2102.
McKean W, Moser J, Rimm D, Hu-Lieskovan S (2020). Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. In ASCO Educational Book 40 (2020) (pp. e275-e291).
Rathi N, Maughan BL, Agarwal N, Swami U (2020). Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma. Cancer Manag Res, 12, 3741-3749.
Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, Philip S, Phillips C, Shane K, Martin A, Weinstein V, Pilarski R, Jeter J, Sweet K, Hatten B, Wurtmann EJ, Phippen S, Bro D, Schwartz MD (2018). Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. Transl Behav Med, 10(2), 337-346.
Rathi N, Maughan BL, Agarwal N, Swami U (2020). Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma. Cancer Manag Res, 12, 3741-3749.
Rathi N, Maughan BL, Agarwal N, Swami U (2020). Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma. Cancer Manag Res, 12, 3741-3749.
Baron K, Moser JC, Patel S, Grossmann KF, Colonna SV, Hyngstrom JR (2020). Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. J Oncol Pharm Pract, 1078155220924719.
Kim R, Sanoff H, Poklepovic A, Soares H, Kim J, Lyu J, Liu Y, Kim D (2020). A multi-institutional phase II trial of regorafenib in refractory advanced biliary tract cancer. Accepted. . Cancer.
Agarwal N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks J, Santos VS, Nachaegari G, Wang X, Boucher K, Haaland B, Maughan BL (2020). Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res, 26(9), 2104-2110.
Hanson HA, Leiser CL, ONeil B, Martin C, Gupta S, Smith KR, Dechet C, Lowrance WT, Madsen MJ, Camp NJ (2020). Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. Cancer Epidemiol Biomarkers Prev, 29(5), 918-926.
Agarwal N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks J, Santos VS, Nachaegari G, Wang X, Boucher K, Haaland B, Maughan BL (2020). Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res, 26(9), 2104-2110.
Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N (2019). Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. [Letter to the editor]. J Geriatr Oncol, 11(4), 724-726.
Kohli M, Tan W, Zheng T, Wang A, Montesinos C, Wong C, Du P, Jia S, Yadav S, Horvath LG, Mahon KL, Kwan EM, Fettke H, Yu J, Azad AA (2020). Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. EBioMedicine, 54, 102728.
Moser J, Hu-Lieskovan S (Apr 2020). Mechanisms of Resistance to PD-1 Checkpoint Blockade. [Review]. Drugs, 80(5), 459-465.
Moser JC, Wei G, Colonna SV, Grossmann KF, Patel S, Hyngstrom JR (2020). Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol, 59(4), 434-437.
Markham MJ, Wachter K, Agarwal N, Bertagnolli MM, Chang SM, Dale W, Diefenbach CSM, Rodriguez-Galindo C, George DJ, Gilligan TD, Harvey RD, Johnson ML, Kimple RJ, Knoll MA, LoConte N, Maki RG, Meisel JL, Meyerhardt JA, Pennell NA, Rocque GB, Sabel MS, Schilsky RL, Schneider BJ, Tap WD, Uzzo RG, Westin SN (2020). Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol, 38(10), 1081.
MacInnis RJ, Liao Y, Knight JA, Milne RL, Whittemore AS, Chung WK, Leoce N, Buchsbaum R, Zeinomar N, Dite GS, Southey MC, Goldgar D, Giles GG, McLachlan SA, Weideman PC, Nesci S, Friedlander ML, Glendon G, kConFab Investigators, Andrulis IL, John EM, Daly MB, Buys SS, Phillips KA, Hopper JL, Terry MB (2019). Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results. J Natl Cancer Inst, 112(4), 418-422.
Greenberg S, Slager S, Neil BO, Cooney K, Maughan B, Stopa N, Venne V, Zickmund S, Colonna S (2020). What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing. Prostate, 80(5), 441-450.
Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, Shannon KM, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SD (2020). NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J Natl Compr Canc Netw, 18(4), 380-391.
Maughan BL, Antonarakis ES (2020). Does sequencing order of antiandrogens in prostate cancer matter? Nat Rev Urol, 17(4), 197-198.
Kerrigan K, Patel SB, Haaland B, Ose D, Weinberg Chalmers A, Haydell T, Meropol NJ, Akerley W (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncol Pract, 16(4), e313-e323.
Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, ORegan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(4), 452-478.
Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I (2019). Response to Yang, Shi, Wang et al. [Letter to the editor]. J Natl Cancer Inst, 112(4), 428.
Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P (2020). Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol, JCO2000198.
Mobley EM, Swami U, Mott S, Ounda A, Milhem M, Monga V (2020). A Retrospective Analysis of Clinical Trial Accrual of Patients Presented in a Multidisciplinary Tumor Board at a Tertiary Health Care Center and Associated Barriers. Oncol Res Treat, 1-6.
Tward JD, ONeil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. (Epub ahead of print) Clin Genitourin Cancer.
Du M, Tian Y, Tan W, Wang L, Wang L, Kilari D, Huang CC, Wang L, Kohli M (2020). Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer. (Epub ahead of print) Prostate Cancer Prostatic Dis.
Puri S, Saltos A, Perez B, Le X, Gray JE (2020). Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Curr Oncol Rep, 22(4), 31.
Boyle JL, Hahn AW, Kapron AL, Kohlmann W, Greenberg SE, Parnell TJ, Teerlink CC, Maughan BL, Feng BJ, Cannon-Albright L, Agarwal N, Cooney KA (2020). Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer. JCO Precis Oncol, 4.
Boyle JL, Hahn AW, Kapron AL, Kohlmann W, Greenberg SE, Parnell TJ, Teerlink CC, Maughan BL, Feng BJ, Cannon-Albright L, Agarwal N, Cooney KA (2020). Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer. JCO Precis Oncol, 4.
McComas K, Agarwal N, Bowen G, Maughan BL, Tward JD (2020). Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. Clin Genitourin Cancer.
Barata P, Swami U, Agarwal N (2020). The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy. Expert Rev Anticancer Ther, 20(3), 147-150.
Gruhl JD, Garrido-Laguna I, Francis SR, Affolter K, Tao R, Lloyd S (2020). The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer. Cancer Med, 9(5), 1703-1711.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A (2020). Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(3), 329-354.
Barata P, Swami U, Agarwal N (2020). The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy. Expert Rev Anticancer Ther, 20(3), 147-150.
Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA, GENEPSO, Nogus C, Gauthier-Villars M, Caron O, Gesta P, Pujol P, Lortholary A, EMBRACE, Barrowdale D, Frost D, Evans DG, Izatt L, Adlard J, Eeles R, Brewer C, Tischkowitz M, Henderson A, Cook J, Eccles D, HEBON, van Engelen K, Mourits MJE, Ausems MGEM, Koppert LB, Hopper JL, John EM, Chung WK, Andrulis IL, Daly MB, Buys SS, kConFab Investigators, Benitez J, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Van Leeuwen FE, Arver B, Olsson H, Schmutzler RK, Engel C, Kast K, Phillips KA, Terry MB, Milne RL, Goldgar DE, Rookus MA, Andrieu N, Easton DF, IBCCS kConFab and BCFR (2020). Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (22(1), p. 25). England.
Smith LD, Liu Y, Zahid MU, Canady TD, Wang L, Kohli M, Cunningham BT, Smith AM (2020). High-Fidelity Single Molecule Quantification in a Flow Cytometer Using Multiparametric Optical Analysis. ACS Nano, 14(2), 2324-2335.
Nix DA, Hellwig S, Conley C, Thomas A, Fuertes CL, Hamil CL, Bhetariya PJ, Garrido-Laguna I, Marth GT, Bronner MP, Underhill HR (2020). The stochastic nature of errors in next-generation sequencing of circulating cell-free DNA. PLoS ONE, 15(2), e0229063.
Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A on behalf of the Translational Breast Cancer Research Consortium (2020). TBCRC 002: A phase II, randomized, open label trial of preoperative letrozole with or without bevacizumab in post-menopausal women with newly diagnosed stage II/III hormone receptor positive and HER2 negative breast cancer. Breast Cancer Res, 22(1).
Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, Song Y, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM (2020). Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma [Abstract]. 38.
Maughan BL, Sanchez A, ONeil BB, Lowrance WT, Dechet CB, Albertson DJ, Sirohi D, Gupta S, Swami U, Agarwal N (2020). A phase Ib/II trial of perioperative intratumoral MVA-BN-brachyury (MVA) plus systemic PROSTVAC and atezolizumab (Atezo) for intermediate-risk and high-risk localized prostate cancer (AtezoVax) [Abstract]. 38.
Wesolowski S, Nussenzveig R, Santos VS, Esther J, Goel D, Swami U, Gupta S, Maughan BL, Yandell M, Grivas P, Agarwal N (2020). Genomic correlates of response to PD-1 axis inhibitors (IO) in metastatic urothelial cancer (mUC) using explainable artificial intelligence (AI) [Abstract]. 38.
Swami U, Isaacsson Velho PI, Nussenzveig R, Santos VS, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N (2020). Impact of somatic SPOP (Speckle-Type POZ protein) mutation (mtSPOP) on response to systemic therapy and survival outcome in men with de novo metastatic castration-sensitive prostate cancer (d-mCSPC). [Abstract]. 38.
Maughan BL, Nussenzveig R, Swami U, Gupta S, Agarwal N (2020). Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response [Abstract]. 38.
Lin E, Wesolowski S, Nussenzveig R, McFarland TR, Swami U, Maughan BL, Yandell M, Agarwal N (2020). Identification of genomic alterations in signaling pathways associated with poor survival in newly diagnosed metastatic prostate cancer (mCSPC) using artificial intelligence (AI) [Abstract]. 38.
Esther J, Swami U, Chipman J, McFarland TR, Hahn AW, Sirohi D, Sharma P, Nussenzveig R, Agarwal N, Maughan BL (2020). Genomic alterations in visceral versus nonvisceral “metastatic” site tumor tissue in metastatic prostate cancer (mPC) [Abstract]. 38.
Hahn AW, Kessel A, McFarland TR, Swami U, Nussenzveig R, Esther J, Goel D, Sirohi D, Maughan BL, Agarwal N (2020). Response to systemic therapy and survival outcomes in de-novo (D1) metastatic castration-sensitive prostate cancer (mCSPC) versus mCSPC with prior local therapy (D0 [Abstract]. 38.
Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, DAmelio AM Jr, Ellis C, Ibrahim N, Yan L (2020). Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. (Epub ahead of print) Cancer Chemother Pharmacol.
Wong RL, Duong MT, Tangen CM, Agarwal N, Cheng HH, Vogelzang NJ, Hussain M, Thompson IM Jr, Quinn DI, Yu EY (2020). Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. (Epub ahead of print) Prostate Cancer Prostatic Dis.
Bandini M, Pederzoli F, Madison R, Briganti A, Ross JS, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Rosenberg JE, Bellmunt J, Pal SK, Galsky MD, Lucian R, Gallina A, Salonia A, Montorsi F, Ali SM, Chung JH, Necchi A (2020). Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. (Epub ahead of print) Clin Genitourin Cancer.
Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M (2020). Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. (Epub ahead of print) Clin Cancer Res.
Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol, 17(2), 108-123.
Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N (2019). A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. Oncologist, 25(2), 121-e213.
Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol, 17(2), 108-123.
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators (2019). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol, 21(2), 271-282.
Li H, Terry MB, Antoniou AC, Phillips KA, Kast K, Mooij TM, Engel C, Nogus C, Stoppa-Lyonnet D, Lasset C, Berthet P, Mari V, Caron O, GENEPSO study, Barrowdale D, Frost D, Brewer C, Evans DG, Izatt L, Side L, Walker L, Tischkowitz M, Rogers MT, Porteous ME, Snape K, EMBRACE study, Meijers-Heijboer HEJ, Gille JJP, Blok MJ, Hoogerbrugge N, HEBON Investigators, Daly MB, Andrulis IL, Buys SS, John EM, McLachlan SA, Friedlander M, kConFab Investigators, Tan YY, Osorio A, Caldes T, Jakubowska A, Simard J, Singer CF, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Arver B, Olsson H, Schmutzler RK, Hopper JL, Milne RL, Easton DF, Van Leeuwen FE, Rookus MA, Andrieu N, Goldgar DE (2019). Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiol Biomarkers Prev, 29(2), 368-378.
Patel VL, Busch EL, Friebel TM, Cronin A, Leslie G, McGuffog L, Adlard J, Agata S, Agnarsson BA, Ahmed M, Aittomki K, Alducci E, Andrulis IL, Arason A, Arnold N, Artioli G, Arver B, Auber B, Azzollini J, Balmaa J, Barkardottir RB, Barnes DR, Barroso A, Barrowdale D, Belotti M, Benitez J, Bertelsen B, Blok MJ, Bodrogi I, Bonadona V, Bonanni B, Bondavalli D, Boonen SE, Borde J, Borg A, Bradbury AR, Brady A, Brewer C, Brunet J, Buecher B, Buys SS, Cabezas-Camarero S, Calds T, Caliebe A, Caligo MA, Calvello M, Campbell IG, Carnevali I, Carrasco E, Chan TL, Chu ATW, Chung WK, Claes KBM, Collaborators GS, Collaborators E, Cook J, Cortesi L, Couch FJ, Daly MB, Damante G, Darder E, Davidson R, de la Hoya M, Puppa LD, Dennis J, Dez O, Ding YC, Ditsch N, Domchek SM, Donaldson A, Dworniczak B, Easton DF, Eccles DM, Eeles RA, Ehrencrona H, Ejlertsen B, Engel C, Evans DG, Faivre L, Faust U, Feliubadal L, Foretova L, Fostira F, Fountzilas G, Frost D, Garca-Barbern V, Garre P, Gauthier-Villars M, Gczi L, Gehrig A, Gerdes AM, Gesta P, Giannini G, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gutierrez-Barrera AM, Hahnen E, Hamann U, Hauke J, Herold N, Hogervorst FBL, Honisch E, Hopper JL, Hulick PJ, Investigators K, Investigators H, Izatt L, Jager A, James P, Janavicius R, Jensen UB, Jensen TD, Johannsson OT, John EM, Joseph V, Kang E, Kast K, Kiiski JI, Kim SW, Kim Z, Ko KP, Konstantopoulou I, Kramer G, Krogh L, Kruse TA, Kwong A, Larsen M, Lasset C, Lautrup C, Lazaro C, Lee J, Lee JW, Lee MH, Lemke J, Lesueur F, Liljegren A, Lindblom A, Llovet P, Lopez-Fernndez A, Lopez-Perolio I, Lorca V, Loud JT, Ma ESK, Mai PL, Manoukian S, Mari V, Martin L, Matricardi L, Mebirouk N, Medici V, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Miller C, Gomes DM, Montagna M, Mooij TM, Moserle L, Mouret-Fourme E, Mulligan AM, Nathanson KL, Navratilova M, Nevanlinna H, Niederacher D, Nielsen FCC, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Ong KR, Osorio A, Ott CE, Palli D, Park SK, Parsons MT, Pedersen IS, Peissel B, Peixoto A, Prez-Segura P, Peterlongo P, Petersen AH, Porteous ME, Pujana MA, Radice P, Ramser J, Rantala J, Rashid MU, Rhiem K, Rizzolo P, Robson ME, Rookus MA, Rossing CM, Ruddy KJ, Santos C, Saule C, Scarpitta R, Schmutzler RK, Schuster H, Senter L, Seynaeve CM, Shah PD, Sharma P, Shin VY, Silvestri V, Simard J, Singer CF, Skytte AB, Snape K, Solano AR, Soucy P, Southey MC, Spurdle AB, Steele L, Steinemann D, Stoppa-Lyonnet D, Stradella A, Sunde L, Sutter C, Tan YY, Teixeira MR, Teo SH, Thomassen M, Tibiletti MG, Tischkowitz M, Tognazzo S, Toland AE, Tommasi S, Torres D, Toss A, Trainer AH, Tung N, van Asperen CJ, van der Baan FH, van der Kolk LE, van der Luijt RB, van Hest LP, Varesco L, Varon-Mateeva R, Viel A, Vierstraete J, Villa R, von Wachenfeldt A, Wagner P, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Wieme G, Yadav S, Yannoukakos D, Yoon SY, Zanzottera C, Zorn KK, DAmico AV, Freedman ML, Pomerantz MM, Chenevix-Trench G, Antoniou AC, Neuhausen SL, Ottini L, Nielsen HR, Rebbeck TR (2019). Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res, 80(3), 624-638.
Zhu J, Huang J, Zhang P, Li Q, Kohli M, Huang CC, Wang L (2019). Advantages of Single-Stranded DNA Over Double-Stranded DNA Library Preparation for Capturing Cell-Free Tumor DNA in Plasma. Mol Diagn Ther, 24(1), 95-101.
Parisi G, Saco J, Salazar F, Tsoi J, Krystofinski P, Puig Saus C, Zhang R, Zhou J, Cheung-Lau G, Garcia AJ, Grasso CS, Tavar R, Hu-Lieskovan S, Mackay S, Zalevsky J, Bernatchez C, Diab A, Wu A, Comin-Anduix B, Charych DH, Ribas A (Jan 2020). Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat Commun, 11(1), 660.
Pauley K, Koptiuch C, Greenberg S, Gammon A, Nevala-Plagemann C, Vagher J, Espinel W, Gilcrease GW, Kohlmann W, Garrido-Laguna I (2020). Case series examining somatic test results for patients with hereditary cancer syndromes associated with gastrointestinal cancer risk [Abstract]. 38(2020), (suppl 4; abstr 680).
Baron K, Nevala-Plagemann CD, Moser J, Haaland B, Wang X, Garrido-Laguna I (2020). Survival outcomes based on sequence of therapy using FOLFIRINOX and nab-paclitaxel + gemcitabine in metastatic pancreatic ductal adenocarcinoma [Abstract]. 38(2020), (suppl 4; abstr 657).
Parsons M, Tao R, Lloyd S, Johnson SB, Scaife CL, Garrido-Laguna I, Varghese T (2020). Refusal of surgery results in inferior survival in esophageal cancer [Abstract]. 38(2020), (suppl 4; abstr 364).
Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, Agarwal N, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Velho PI, Hahn N, Liu S, Buznego LA, Duran I, Moses M, Jain J, Murgic J, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Lyman GH, Grivas P (2020). Histologic Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. J Urol, 101097JU0000000000000761.
Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA, GENEPSO, Nogus C, Gauthier-Villars M, Caron O, Gesta P, Pujol P, Lortholary A, EMBRACE, Barrowdale D, Frost D, Evans DG, Izatt L, Adlard J, Eeles R, Brewer C, Tischkowitz M, Henderson A, Cook J, Eccles D, HEBON, van Engelen K, Mourits MJE, Ausems MGEM, Koppert LB, Hopper JL, John EM, Chung WK, Andrulis IL, Daly MB, Buys SS, kConFab Investigators, Benitez J, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Van Leeuwen FE, Arver B, Olsson H, Schmutzler RK, Engel C, Kast K, Phillips KA, Terry MB, Milne RL, Goldgar DE, Rookus MA, Andrieu N, Easton DF, IBCCS, kConFab, BCFR (2020). Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res, 22(1), 8.
Hahn AW, Sirohi D, Agarwal N (2019). The Role of PD-L1 Testing in Advanced Genitourinary Malignancies. Eur Urol Focus, 6(1), 11-13.
Agarwal N, Nussenzveig RH, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks JL, Santos VS, Nachaegari G, Wang X, Boucher KM, Haaland B, Maughan BL (2020). Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. (Epub ahead of print) Clin Cancer Res.
Moser JC, Wei G, Colonna SV, Grossmann KF, Patel S, Hyngstrom JR (2020). Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol, 1-4.
Kerrigan K, Patel SB, Haaland B, Ose D, Chalmers AW, Haydell T, Meropol NJ, Akerley WL (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncology Practice, 16(4), 313-323.
Kerrigan K, Patel SB, Haaland B, Ose D, Weinberg Chalmers A, Haydell T, Meropol NJ, Akerley W (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncol Pract, JOP1900329.
Vaklavas C, Blume SW, Grizzle WE (2020). Hallmarks and Determinants of Oncogenic Translation Revealed by Ribosome Profiling in Models of Breast Cancer. . Translational Oncology, 13(2), 452-470.
Johnson ED, Kerrigan K, Butler K, Patel SB (2019). Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy. J Oncol Pharm Pract, 26(1), 224-227.
Johnson E, Nussenzveig R, Agarwal N, Swami U (2019). Germline variants and response to systemic therapy in advanced prostate cancer. Pharmacogenomics, 21(1), 75-81.
Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN, Vlachostergios PJ, Tagawa ST, Bryce AH, McNatty AL, Reichert ZR, Dreicer R, Sartor O, Lotan TL, Hussain M (2020). CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precis Oncol, 4, 370-381.
Hahn AW, Agarwal N (2020). The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas. Cancer Treat Res Commun, 24, 100190.
Pal SK, Swami U, Agarwal N (2019). Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How. Eur Urol, 77(1), 22-23.
McComas KN, Torgeson AM, Ager BJ, Hellekson C, Burt LM, Maurer KA, Werner TL, Gaffney DK (2019). The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system. Gynecol Oncol, 156(1), 85-92.
Johnson E, Nussenzveig R, Agarwal N, Swami U (2019). Germline variants and response to systemic therapy in advanced prostate cancer. Pharmacogenomics, 21(1), 75-81.
Kehm RD, Genkinger JM, MacInnis RJ, John EM, Phillips KA, Dite GS, Milne RL, Zeinomar N, Liao Y, Knight JA, Southey MC, Chung WK, Giles GG, McLachlan SA, Whitaker KD, Friedlander M, Weideman PC, Glendon G, Nesci S, Investigators K, Andrulis IL, Buys SS, Daly MB, Hopper JL, Terry MB (2019). Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. Cancer Res, 80(1), 116-125.
Moses M, Niu A, Lilly MB, Hahn AW, Nussenzveig R, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J, Agarwal N, Sartor O, Barata PC (2020). Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun, 24, 100193.
Esther J, Dorff TB, Maughan BL (2020). Recent developments in the treatment of non-metastatic castration resistant prostate cancer. Cancer Treat Res Commun, 24, 100181.
Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA (2020). NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Compr Canc Netw, 18(1), 12-22.
Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, Soucy P, Lemaon A, Lush M, Tyrer JP, Ghoussaini M, Moradi Marjaneh M, Jiang X, Agata S, Aittomki K, Alonso MR, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Aronson KJ, Arun BK, Auber B, Auer PL, Azzollini J, Balmaa J, Barkardottir RB, Barrowdale D, Beeghly-Fadiel A, Benitez J, Bermisheva M, Biakowska K, Blanco AM, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borg A, Bosse K, Brauch H, Brenner H, Briceno I, Brock IW, Brooks-Wilson A, Brning T, Burwinkel B, Buys SS, Cai Q, Calds T, Caligo MA, Camp NJ, Campbell I, Canzian F, Carroll JS, Carter BD, Castelao JE, Chiquette J, Christiansen H, Chung WK, Claes KBM, Clarke CL, GEMO Study Collaborators, EMBRACE Collaborators, Colle JM, Cornelissen S, Couch FJ, Cox A, Cross SS, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Domchek SM, Drk T, Dos-Santos-Silva I, Droit A, Dubois S, Dumont M, Duran M, Durcan L, Dwek M, Eccles DM, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Floris G, Flyger H, Foretova L, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gago-Dominguez M, Gambino G, Ganz PA, Gapstur SM, Garber J, Garca-Senz JA, Gaudet MM, Georgoulias V, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, Gonzlez-Neira A, Tibiletti MG, Greene MH, Grip M, Gronwald J, Grundy A, Gunel P, Hahnen E, Haiman CA, Hkansson N, Hall P, Hamann U, Harrington PA, Hartikainen JM, Hartman M, He W, Healey CS, Heemskerk-Gerritsen BAM, Heyworth J, Hillemanns P, Hogervorst FBL, Hollestelle A, Hooning MJ, Hopper JL, Howell A, Huang G, Hulick PJ, Imyanitov EN, KConFab Investigators, HEBON Investigators, ABCTB Investigators, Isaacs C, Iwasaki M, Jager A, Jakimovska M, Jakubowska A, James PA, Janavicius R, Jankowitz RC, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kang D, Kapoor PM, Karlan BY, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Kirk J, Kitahara CM, Ko YD, Konstantopoulou I, Kosma VM, Koutros S, Kubelka-Sabit K, Kwong A, Kyriacou K, Laitman Y, Lambrechts D, Lee E, Leslie G, Lester J, Lesueur F, Lindblom A, Lo WY, Long J, Lophatananon A, Loud JT, Lubiski J, MacInnis RJ, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Matsuo K, Maurer T, Mavroudis D, Mayes R, McGuffog L, McLean C, Mebirouk N, Meindl A, Miller A, Miller N, Montagna M, Moreno F, Muir K, Mulligan AM, Muoz-Garzon VM, Muranen TA, Narod SA, Nassir R, Nathanson KL, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nikitina-Zake L, Norman A, Offit K, Olah E, Olopade OI, Olsson H, Orr N, Osorio A, Pankratz VS, Papp J, Park SK, Park-Simon TW, Parsons MT, Paul J, Pedersen IS, Peissel B, Peshkin B, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Presneau N, Prokofyeva D, Pujana MA, Pylks K, Radice P, Ramus SJ, Rantala J, Rau-Murthy R, Rennert G, Risch HA, Robson M, Romero A, Rossing M, Saloustros E, Snchez-Herrero E, Sandler DP, Santamaria M, Saunders C, Sawyer EJ, Scheuner MT, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schttker B, Schrmann P, Scott C, Scott RJ, Senter L, Seynaeve CM, Shah M, Sharma P, Shen CY, Shu XO, Singer CF, Slavin TP, Smichkoska S, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Stoppa-Lyonnet D, Sutter C, Swerdlow AJ, Tamimi RM, Tan YY, Tapper WJ, Taylor JA, Teixeira MR, Tengstrm M, Teo SH, Terry MB, Teul A, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Torres D, Torres-Meja G, Troester MA, Truong T, Tung N, Tzardi M, Ulmer HU, Vachon CM, van Asperen CJ, van der Kolk LE, van Rensburg EJ, Vega A, Viel A, Vijai J, Vogel MJ, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wildiers H, Winqvist R, Wolk A, Wu AH, Yannoukakos D, Zhang Y, Zheng W, Hunter D, Pharoah PDP, Chang-Claude J, Garca-Closas M, Schmidt MK, Milne RL, Kristensen VN, Fre (2020). Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet, 52(1), 56-73.
Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH (2020). Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. JCO Precis Oncol, 4, 442-465.
Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN, Vlachostergios PJ, Tagawa ST, Bryce AH, McNatty AL, Reichert ZR, Dreicer R, Sartor O, Lotan TL, Hussain M (2020). CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precis Oncol, 4, 370-381.
Tripathi A, Balakrishna P, Agarwal N (2020). PARP inhibitors in castration-resistant prostate cancer. Cancer Treat Res Commun, 24, 100199.
You B, Mercier F, Assenat E, Langlois-Jacques C, Glehen O, Soul J, Payen L, Kepenekian V, Dupuy M, Belouin F, Morency E, Saywell V, Flacelire M, Elies P, Liaud P, Mazard T, Maucort-Boulch D, Tan W, Vire B, Villeneuve L, Ychou M, Kohli M, Joubert D, Prieur A (2019). The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine, 51, 102574.
Nevala-Plagemann C, Powers P, Mir-Kasimov M, Rose R (2019). A Fatal Case of Septic Shock Secondary to Acinetobacter Bacteremia Acquired from a Platelet Transfusion. Case Report Med, 2019, 3136493.
Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR (2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.doi:10.1002/cam4.2625 [Abstract].
Swami U, Yap JT, Agarwal N (2019). Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer. (Epub ahead of print) JAMA Oncol.
Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, van der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran H (2019). Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol, JCO1902768.
Swami U, Yap JT, Agarwal N (2019). Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer. (Epub ahead of print) JAMA Oncol.
Abril-Rodriguez G, Torrejon T, Zaretsky J, Nowicki T, Tsoi J, Baselga Carretero I, Medina E, Quist M, Senapedis W, Baloglu E, Cheung-Lau G, Puig-Saus C, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Grasso C, Ribas A (Jan 2020). PAK4 inhibition reverses T cell exclusion in cancer and improves PD-1 blockade immunotherapy. Nature Cancer, 1, 46-58.
Greco A, Safi D, Swami U, Ginader T, Milhem M, Zakharia Y (2019). Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. Cancers (Basel), 11(12).
Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR (2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer Med, 8(18), 7637-7643.
Zeinomar N, Knight JA, Genkinger JM, Phillips KA, Daly MB, Milne RL, Dite GS, Kehm RD, Liao Y, Southey MC, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, kConFab Investigators, Andrulis IL, Buys SS, John EM, MacInnis RJ, Hopper JL, Terry MB (2019). Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). Breast Cancer Res, 21(1), 128.
Griswold CR, Kerrigan K, Patel SB (2019). Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report. Case Rep Oncol, 12(3), 866-871.
Rieth JM, Swami U, Greenlee J, Zanaty M, Bossler A, Jennings B, Henry M, Vanneste M, Mott S, Milhem MM (2019). Impact of surgery on outcomes in melanoma patients with brain metastases in the era of immunotherapy. The 16TH International Congress of the Society for Melanoma Research (SMR) [Abstract].
Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, ONeil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger C (2019). Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. J Clin Oncol, 37(33), 3090-3098.
Horwich A, Babjuk M, Bellmunt J, Bruins HM, Reijke TM, Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Comprat E, Crabb S, Culine S, Bari B, Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espins E, Lgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Mller AC, Mller CR, NDow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprt M, Rouvire O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskime E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA (2019). EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. (Epub ahead of print) Ann Oncol.
Kaur A, Swami U, Fatima M, Ginn M, Stein J, Gao Y, Zakharia Y, Singh Y (2019). Safety of Immune Checkpoint Inhibitors in Patients Treated for Cancer with Pre-existing Autoimmune Diseases, 2019 ACR/ARP Annual Meeting [Abstract].
Ledet EM, Lilly MB, Sonpavde G, Lin E, Nussenzveig RH, Barata PC, Yandell M, Nagy RJ, Kiedrowski L, Agarwal N, Sartor O (2019). Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. (Epub ahead of print) Oncologist.
Khan A, Cohen S A, Weir C, Greenberg S (2019). Analysis of Key Factors in the Implementation of new Service Delivery Models in Genetic Counseling Practice [Abstract].
Harris KL, Maurer KA, Jarboe E, Werner TL, Gaffney D (2019). LVSI positive and NX in early endometrial cancer: Surgical restaging (and no further treatment if N0), or adjuvant ERT? (Epub ahead of print) Gynecol Oncol.
Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR (Nov 2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer Med.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, zgrolu M, Jurez Soto, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN, TITAN investigators (2019). Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol, 20(11), 1518-1530.
Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs CM, ABCTB Investigators, Adank MA, Adlard J, Agata S, Cadoo K, Agnarsson BA, Ahearn T, Aittomki K, Ambrosone CB, Andrews L, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Arun BK, Asseryanis E, Auber B, Auvinen P, Azzollini J, Balmaa J, Barkardottir RB, Barrowdale D, Barwell J, Beane Freeman LE, Beauparlant CJ, Beckmann MW, Behrens S, Benitez J, Berger R, Bermisheva M, Blanco AM, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Borg A, Brady AF, Brauch H, Brenner H, Brning T, Burwinkel B, Buys SS, Calds T, Caliebe A, Caligo MA, Campa D, Campbell IG, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Claes KBM, Clarke CL, Collavoli A, Conner TA, Cox DG, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Ditsch N, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Durda K, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, Foulkes WD, Friebel TM, Friedman E, Gabrielson M, Gaddam P, Gago-Dominguez M, Gao C, Gapstur SM, Garber J, Garca-Closas M, Garca-Senz JA, Gaudet MM, Gayther SA, GEMO Study Collaborators, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, Gunel P, Gutierrez-Barrera AM, Haeberle L, Haiman CA, Hkansson N, Hall P, Hamann U, Harrington PA, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hopper JL, Hosgood HD 3rd, Howell A, Hu C, Hulick PJ, Hunter DJ, Imyanitov EN, KConFab, Isaacs C, Jakimovska M, Jakubowska A, James P, Janavicius R, Janni W, John EM, Jones ME, Jung A, Kaaks R, Karlan BY, Khusnutdinova E, Kitahara CM, Konstantopoulou I, Koutros S, Kraft P, Lambrechts D, Lazaro C, Le Marchand L, Lester J, Lesueur F, Lilyquist J, Loud JT, Lu KH, Luben RN, Lubinski J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martens JWM, Maurer T, Mavroudis D, Mebirouk N, Meindl A, Menon U, Miller A, Montagna M, Nathanson KL, Neuhausen SL, Newman WG, Nguyen-Dumont T, Nielsen FC, Nielsen S, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Olshan AF, Olson JE, Olsson H, Osorio A, Ottini L, Peissel B, Peixoto A, Peto J, Plaseska-Karanfilska D, Pocza T, Presneau N, Pujana MA, Punie K, Rack B, Rantala J, Rashid MU, Rau-Murthy R, Rennert G, Lejbkowicz F, Rhenius V, Romero A, Rookus MA, Ross EA, Rossing M, Rudaitis V, Ruebner M, Saloustros E, Sanden K, Santamaria M, Scheuner MT, Schmutzler RK, Schneider M, Scott C, Senter L, Shah M, Sharma P, Shu XO, Simard J, Singer CF, Sohn C, Soucy P, Southey MC, Spinelli JJ, Steele L, Stoppa-Lyonnet D, Tapper WJ, Teixeira MR, Terry MB, Thomassen M, Thompson J, Thull DL, Tischkowitz M, Tollenaar RAEM, Torres D, Troester MA, Truong T, Tung N, Untch M, Vachon CM, van Rensburg EJ, van Veen EM, Vega A, Viel A, Wappenschmidt B, Weitzel JN, Wendt C, Wieme G, Wolk A, Yang XR, Zheng W, Ziogas A, Zorn KK, Dunning AM, Lush M, Wang Q, McGuffog L, Parsons MT, Pharoah PDP, Fostira F, Toland AE, Andrulis IL, Ramus SJ, Swerdlow AJ, Greene MH, Chung WK, Milne RL, Chenevix-Trench G, Drk T, Schmidt MK, Easton DF, Radice P, Hahnen E, Antoniou AC, Couch FJ, Nevanlinna H, Surralls J, Peterlongo P (2019). The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. NPJ Breast Cancer, 5, 38.
Greenberg S, Buys SS, Edwards SL, Espinel W, Fraser A, Gammon A, Hafen B, Herget KA, Kohlmann W, Roundy C, Sweeney C (2019). Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing. Cancer Med, 8(15), 6789-6798.
Boothe D, Orton A, Kim J, Poppe MM, Werner TL, Gaffney DK (2019). Does Early Chemotherapy Improve Survival in Advanced Endometrial Cancer? Am J Clin Oncol, 42(11), 813-817.
Pal S, Hu-Lieskovan S, Agarwal N (2019). Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours? Lancet Oncol, 20(11), 1473-1474.
Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, CGC, Hammond LJ, Zuccarino-Catania G (2019). NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Netw, 17(11), 1278-1285.
Wei M, Maurer KA, Henry NL (2019). Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy. Breast J, 25(6), 1254-1256.
Hahn AW, Klaassen Z, Agarwal N, Haaland B, Esther J, Ye XY, Wang X, Pal SK, Wallis CJD (2019). First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Oncol, 2(6), 708-715.
Kerrigan, K, Haaland B, Adamson B, Patel S, Akerley W (2019). MA14.09 Real-World Survival of Relapsed Compared to De-Novo Stage IV Diagnosis of Advanced Non-Small Cell Lung Cancer [Abstract]. 14(10), S307-S308.
Kerrigan K, Haaland B, Adamson B, Patel S, Akerley W (2019). P1.01-35 Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers [Abstract]. 14(10), S369-S370.
Lim F, Ponce S, Patel S, Van Herpen C, Kurkjian C, Lou Y, Liu Y, Ramsingh G, Pal S, Neal J (2019). P1.01-113 Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) [Abstract]. 14(10), S405-S406.
Hahn AW, Pal SK, Agarwal N (2019). Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. (Epub ahead of print) Oncologist.
Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L (Oct 2019). Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell Stem Cell, 25(4), 542-557.e9.
Sacristan Santos V, Esther J, Maughan B, Wesolowski S, Lin E, Hahn A, Sirohi D, Rathi N, Swami U, Nussenzveig R, Agarwal N (2019). Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS [Abstract]. 30(5).
Moser J, Wei G, Colonna S, Grossmann KF, Patel S, Hyngstrom J (2019). Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma [Abstract]. 30.
Pederzoli F, Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Thodore C, Rosenberg JE, Harshman LC, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Necchi A, RISC Investigators (2019). Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. Eur Urol, 76(4), 425-429.
Nandagopal L, Sonpavde GP, Agarwal N (2019). Investigational MET inhibitors to treat Renal cell carcinoma. Expert Opin Investig Drugs, 28(10), 851-860.
Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS (2019). First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer, 145(7), 1798-1808.
Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, Sondak VK, Messina JL, Schell MJ, DeCaprio JA, Tsai KY, Brohl AS (2019). The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res, 25(19), 5961-5971.
Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U, Ladoire S, Theodore C, Agarwal N, Yu EY, Niegisch G, Sternberg CN, Srinivas S, Vaishampayan U, Necchi A, Liontos M, Rosenberg JE, Powles T, Bellmunt J, Galsky MD (2019). The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. Oncologist, 24(10), 1348-1355.
Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Ben-Baruch N, Werner TL, Oaknin A, Nam JH, Leath CA, Nicum S, Cella D, Sullivan DM, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA (2019). VELIA/GOG-3005: Integration of veliparib with front-line chemotherapy+maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin [Abstract]. 30, 895-896.
Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA (2019). Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. (Epub ahead of print) N Engl J Med.
Pal S, Hu-Lieskovan S, Agarwal N (Sep 2019). Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours? 20(11), 1473-1474.
Canady TD, Li N, Smith LD, Lu Y, Kohli M, Smith AM, Cunningham BT (2019). Digital-resolution detection of microRNA with single-base selectivity by photonic resonator absorption microscopy. Proc Natl Acad Sci U S A, 116(39), 19362-19367.
Yadav S, Hart SN, Hu C, Hillman D, Lee KY, Gnanaolivu R, Na J, Polley EC, Couch FJ, Kohli M (2019). Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome. JCO Precis Oncol, 3.
Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N (2019). A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. (Epub ahead of print) Oncologist.
Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N (2019). A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. (Epub ahead of print) Oncologist.
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen Y, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA (2019). Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 17(9), 1109-1133.
Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR (2019). A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist, 24(9), 1151-e817.
Tripathi A, Lin E, Agarwal N (2019). Biomarkers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors. Ann Transl Med, 7(Suppl 6), S203.
Goel S, Swami U, Kumar K, Dittrich C, Reyderman L, Jain M, Aisner J, Song J, Petrylak DP (2019). A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer. Cancer Chemother Pharmacol, 84(3), 567-578.
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA (2019). Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 17(9), 1109-1133.
Boru G, Grosel TW, Pilarski R, Stautberg M, Massengill JB, Jeter J, Singh A, Marino MJ, McElroy JP, Davidorf FH, Cebulla CM, Abdel-Rahman MH (2019). Germline large deletion of BAP1 and decreased expression in non-tumor choroid in uveal melanoma patients with high risk for inherited cancer. Genes Chromosomes Cancer, 58(9), 650-656.
Mirza MR, vall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, r Knudsen A, Staff S, Krog Vistisen A, Bjrge L, Menp JU, AVANOVA investigators (2019). Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. (Epub ahead of print) Lancet Oncol.
Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP (2019). Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol, 10(4), 647-687.
Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N (2019). Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. [Letter to the editor]. J Geriatr Oncol.
Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N (2019). Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. [Letter to the editor]. J Geriatr Oncol.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, OMalley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM (2019). NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw, 17(8), 896-909.
Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Target Oncol, 14(4), 417-421.
Kohli M, Oberg AL, Mahoney DW, Riska SM, Sherwood R, Zhang Y, Zenka RM, Sahasrabudhe D, Qin R, Zhang S (2019). Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer. Clin Genitourin Cancer, 17(4), 248-253.e7.
Riaz IB, Faridi W, Husnain M, Malik SU, Sipra QUAR, Gondal FR, Xie H, Yadav S, Kohli M (2019). Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis. Mayo Clin Proc, 94(8), 1524-1534.
Siena S, Demetri G, Doebele R, Chae Y, Conkling P, Garrido-Laguna I, Garrido P, Rolfo C, Sigal D, Eng S, Simmons B, Ye C, Ciardiello F (July 2019). Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001) [Abstract]. 2019(Abstract #0-024).
Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (Jul 2019). Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab [Abstract]. J Clin Oncol, 4(4), e000539.
Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (July 2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 4(4), e000539.
Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 4(4), e000539.
Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 4(4), e000539.
Al-Toubah T, Schell M, Cives M, Zhou JM, Soares H, Strosberg JR (2019). A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Neuroendocrinology, doi: 10.1159/000502383.
Swami U, Monga V, Bossler AD, Zakharia Y, Milhem M (2019). Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. J Oncol, 2019, 1856594.
Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. (Epub ahead of print) Target Oncol.
Snyders T, Chakos D, Swami U, Latour E, Chen Y, Fleseriu M, Milhem M, Zakharia Y, Zahr R (2019). Ipilimumab-induced hypophysitis, a single academic center experience. (Epub ahead of print) Pituitary.
Moschini M, Xylinas E, Zamboni S, Mattei A, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A, RISC Investigators (2019). Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. (Epub ahead of print) Eur Urol Oncol.
Blackburn BE, Soisson S, Rowe K, Snyder J, Fraser A, Deshmukh V, Newman M, Smith K, Herget K, Kirchhoff AC, Kepka D, Werner TL, Gaffney D, Mooney K, Hashibe M (2019). Prognostic factors for rural endometrial cancer patients in a population-based cohort. BMC Public Health, 19(1), 921.
Pal SK, Swami U, Agarwal N (2019). Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How. Eur Urol.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Jurez Soto, Merseburger AS, zgrolu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S, TITAN Investigators (2019). Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med, 381(1), 13-24.
Hu-Lieskovan S, Ott P, Naing A, Gates S, Kohler V, Curran R, Besada R, Bushway M, Scherer J, Balogh K, Scuito T, Ting Y, Rooney M, Harjanto D, Huang Z, Huang Y, Ware Y, Lamb A, Cleary L, Moles M, Gaynor R, Goldstein M, Brail L, Greshock J, Srinivasan L (July 2019). The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: correlations with clinical outcome [Abstract]. 79(13 Supplement), Abstract 942.
Hu-Lieskovan S, Braiteh F, Grilley-Olson J, Potluri S, Wang X, Forgie A, Bonato V, Chou J, Johnson M (July 2019). Predictive biomarkers and pharmacodynamic (PD) changes in tumor RNA expression in a phase I study of anti PD-1 monoclonal antibody (mAb) PF-06801591 [Abstract]. 79(13 Supplement), Abstract CT046.
Swords DS, Francis SR, Lloyd S, Garrido-Laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife CL (2018). Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. J Gastrointest Surg, 23(7), 1401-1413.
Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomki K, Andrulis IL, Arnold N, Arun BK, Ausems MGEM, Azzollini J, Barrowdale D, Barwell J, Benitez J, Biakowska K, Bonadona V, Borde J, Borg A, Bradbury AR, Brunet J, Buys SS, Calds T, Caligo MA, Campbell I, Carter J, Chiquette J, Chung WK, Claes KBM, Colle JM, Collonge-Rame MA, Couch FJ, Daly MB, Delnatte C, Diez O, Domchek SM, Dorfling CM, Eason J, Easton DF, Eeles R, Engel C, Evans DG, Faivre L, Feliubadal L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Gehrig A, Glendon G, Godwin AK, Gmez Garcia EB, Hamann U, Hauke J, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, Janavicius R, John EM, Karlan BY, Kets CM, Laitman Y, Lzaro C, Leroux D, Lester J, Lesueur F, Loud JT, Lubiski J, ukomska A, McGuffog L, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Mouret-Fourme E, Nathanson KL, Nehoray B, Neuhausen SL, Nevanlinna H, Nielsen FC, Offit K, Olah E, Ong KR, Oosterwijk JC, Ottini L, Parsons MT, Peterlongo P, Pfeiler G, Pradhan N, Radice P, Ramus SJ, Rantala J, Rennert G, Robson M, Rodriguez GC, Salani R, Scheuner MT, Schmutzler RK, Shah PD, Side LE, Simard J, Singer CF, Steinemann D, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Terry MB, Thomassen M, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Venat-Bouvet L, Vierstraete J, Wagner G, Walker L, Weitzel JN, Yannoukakos D, KConFab Investigators, HEBON Investigators, GEMO Study Collaborators, EMBRACE Collaborators, Antoniou AC, Goldgar DE, Olopade OI, Chenevix-Trench G, Rebbeck TR, Huo D, CIMBA (2019). Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer, 121(2), 180-192.
Garcia A, Frahm C, Jeter JM, Abraham I, Chambers SK, Cragun JM, McBride A (2019). Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations. J Adv Pract Oncol, 10(5), 428-439.
Chalmers A, Cannon L, Akerley W (2018). Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. Oncologist, 24(7), 963-972.
Cannon-Albright LA, Carr SR, Akerley W (2019). Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer. J Thorac Oncol, 14(7), 1184-1191.
Swami U, Pal SK, Agarwal N (2019). Ideal Glucocorticoid Regimen With Abiraterone Acetate: Options and Challenges. (Epub ahead of print) JAMA Oncol.
Swami U, Pal SK, Agarwal N (2019). Ideal Glucocorticoid Regimen With Abiraterone Acetate: Options and Challenges. (Epub ahead of print) JAMA Oncol.
Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Lew DL, Lowy AM, Hochster HS (2019 Annual ASCO Meeting). Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513 [Abstract]. 37(2019), (suppl; abstr 4014).
Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R (2018). Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs, 37(3), 473-481.
Torrejon D, Abril-Rodriguez G, Tsoi J, Champhekar A, Kalbasi A, Campbell K, Parisi G, Puig-Saus C, Cheung-Lau G, Wohlwender T, Berent-Maoz B, Grasso C, Comin-Anduix B, Hu-Lieskovan S, Ribas A (2019). Overcoming genetically based resistance mechanisms to PD-1 blockade [Abstract]. 37(15 Supplement), Abstract 2584.
Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, Jeter J, Martin JR, Babiker HM, McBride A, Abraham I (2019). The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate, 79(8), 880-895.
Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma S (2018). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. Invest New Drugs, 37(3), 482-489.
Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma S (2018). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. Invest New Drugs, 37(3), 482-489.
Buttigliero C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, Hirsh V, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti GV (2018). Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Oncologist, 24(6), e251-e259.
Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N (2019). Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urol Oncol, 37(6), 352.e19-352.e24.
Johnson ML, Braiteh F, Grilley-Olson JE, Chou J, Davda J, Forgie A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan S (May 2019). Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. JAMA Oncol.
Yap T, Papadopoulos K, LoRusso P, Wong D, Hu-Lieskovan S, Holz J-B (May 2019). A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy [Abstract]. 37(15 Supplement), TPS2652.
Hu-Lieskovan S, Lisberg A, Zaretsky J, Wells D, Han M, Shintaku I, Wolf B, Abarca P, Slamon D, Goldman JW, Dubinett S, Ribas A, Garon EB (May 2019). Tumor characteristics associated with benefit from pembrolizumab in advanced non-small cell lung cancer. Clin Cancer Res.
Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S (Jan 2019). Mechanisms of Resistance to Immune Checkpoint Blockade: Why Doesn't Checkpoint Inhibitor Immunotherapy Work for All Patients? In ASCO Educational Book 39 (2019) (pp. 147-164).
Chi KN, Agarwal N, Bjartell A, Chung BH, Gomes AJPS, Given RW, Soto AJ, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy SA, Chowdhury S (2019). First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT) (suppl; abstr 5006) [Abstract]. 37.
Rathkopf DE, Saleh MN, Tsai FYC, Bilen MA, Rosen LS, Gottardis M, Infante JR, Adams BJ, Liu L, Theuer CP, Freddo JL, Agarwal N (2019). An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (suppl; abstr e16542) [Abstract]. 37.
Appleman LJ, Puligandla M, Pal SK, Harris W, Agarwal N, Costello BA, Ryan CW, Pins M, Kolesar J, Vaena DA, Parikh RA, Hashmi M, Dutcher JP, DiPaola RS, Haas NB, Carducci MA (2019). Randomized, double-blind phase III study of pazopanib versus placebo in patients with mtastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810) (suppl; abstr 4502). [Abstract]. 37.
Hahn AW, Lin E, Esther J, Anderson N, Rathi N, Yandell M, Maughan BL, Agarwal N (2019). Genomic landscape of metastatic hormone senstitive prostate cancer (mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by circulating tumor DNA (ctDNA) (suppl; abstr 5043) [Abstract]. 37.
Grivas P, Puligandla M, Cole S, Courtney KD, Dreicer R, Gartrell BA, Cetnar JP, Dallera M, Galsky MD, Jain RK, Maughan BL, Agarwal N, Koshkin VS, Hahn NM, Carducci MA (2019). PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC) (suppl; abstr TPS4594). [Abstract]. 37.
Lin E, Nussenzveig R, Hahn AW, Yandell M, Harshman LC, Agarwal N, Tripathi A (2019). Immune correlates of CD73 expression in patients with urothelial carcinoma (UC) (suppl; abstr 4548) [Abstract]. 37.
Tripathi A, Lin E, Nussenzveig R, Yandell M, Pal SK, Agarwal N (2019). An analysis from The Cancer Genome Atlas database (suppl; abstr e16591) [Abstract]. 37.
Agarwal N, Shore ND, Dunshee C, Karsh LI, Sullivan B, Santo ND, Elmeliegy M, Lin X, Quek RGW, Czibere AG, Fizazi K (2019). TALAPRO-2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) (suppl; abstr TPS5092) [Abstract]. 37.
Lin E, Hahn AW, Sonpavde G, Lilly MB, Nussenzveig R, Ledet E, Pal SK, Grivas P, Rich TA, Raymond VM, Sartor O, Yandell M, Agarwal N (2019). Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients (suppl; abstr 5032) [Abstract]. 37.
Bandini M, Pederzoli Filippo, Madison R, Briganti A, Plimack ER, Ross JS, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Rosenberg JE, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Ali SM, Chung J, Necchi A (2019). Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets (suppl; abstr 4535) [Abstract]. 37.
Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, Giorgi UD, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Sternberg CN, Bellmunt J, Baniel J, Niegisch G (2019). Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival (suppl; abstr e16017) [Abstract]. 37.
Agarwal N, Shore ND, Dunshee C, Karsh LI, Sullivan B, Santo ND, Elmeliegy M, Lin X, Czibere AG, Fizazi K (2019). Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) (suppl; abstr 5076) [Abstract]. 37.
Tagawa ST, Petrylak DP, Grivas P, Agarwal N, Sternberg CN, Hernandez C, Siemon-Hryczyk P, Goswami T, Loriot Y (2019). TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy (suppl; abstr TPS3153) [Abstract]. 37.
Necchi A, Pal SK, Ross JS, Madison R, Agarwal N, Sonpavde G, Joshi M, Yin M, Miller VA, Grivas P, Chung J, Ali SM (2019). Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development (suppl; abstr 4581) [Abstract]. 37.
Tannir NM, Agarwal N, Pal SK, Formiga MN, Guo J, Tagliaferri MA, Hannah AL, Zhang JY, OKeeffe BA, Cho DC (2019). A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator’s choice) in patients with previously untreated advanced renal cell carcinoma(suppl; abstr TPS4595) [Abstract]. 37.
Allen CT, Lee S, Norberg SM, Kovalovsky D, Ye H, Clavijo PE, Hu-Lieskovan S, Schlegel R, Schlom J, Strauss J, Gulley JL, Trepel J, Hinrichs CS (May 2019). Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. Journal for Immunotherapy of Cancer, 7(1), 119.
Swami U, Grivas P, Agarwal N (2019). The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma. Oncologist, 24(5), 580-583.
Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I (2018). Response to Katona et al. [Letter to the editor]. J Natl Cancer Inst, 111(5), 524-525.
Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol, 37(13), 1051-1061.
Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Thodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A (2018). Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. Eur Urol Oncol, 2(3), 248-256.
Esther J, Hale P, Hahn AW, Agarwal N, Maughan BL (2019). Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. 36(5), 395-401.
Corn PG, Agarwal N, Araujo JC, Sonpavde G (2017). Taxane-based Combination Therapies for Metastatic Prostate Cancer. Eur Urol Focus, 5(3), 369-380.
Esther J, Hale P, Hahn AW, Agarwal N, Maughan BL (2019). Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. 36(5), 395-401.
Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M (2019). Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med (25(5), p. 861). United States.
Swami U, Grivas P, Agarwal N (2019). The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma. Oncologist, 24(5), 580-583.
Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB (2019). Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer, 125(9), 1459-1469.
Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK (2019). Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol, 37(12), 1015-1027.
Ager BJ, Francis SR, Do OA, Huang YJ, Soisson AP, Dodson MK, Werner TL, Sause WT, Grant JD, Gaffney DK (2019). Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer?LID - S1538-4721(18)30764-5 [pii]LID - 10.1016/j.brachy.2019.03.001 [doi]. (Epub ahead of print) Brachytherapy.
Davda J, Declerck P, Hu-Lieskovan S, Hickling T, Jacobs I, Chou J, Salek-Ardakani S, Kraynov E (April 2019). Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. [Review]. J Immunother Cancer, 7, Article: 105.
Nowicki T, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran A, Grasso C, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A (Apr 2019). A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination With or Without Ipilimumab. Clin Cancer Res, 25(7), 2096-2108.
Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE (2019). Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol, 37(10), 834-849.
Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M (2019). Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med, 25(4), 620-627.
Lloyd S, Baraghoshi D, Tao R, Garrido-Laguna I, Gilcrease GW 3rd, Whisenant J, Weis JR, Scaife C, Pickron TB, Huang LC, Monroe MM, Abdelaziz S, Fraser AM, Smith KR, Deshmukh V, Newman M, Rowe KG, Snyder J, Samadder NJ, Hashibe M (2019). Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. Am J Clin Oncol, 42(4), 355-362.
Colonna S, Sweetenham J, Burgon TB, Buys SS, Lynch R, Au T, Johnson E, Kubal T, Paculdo D, Acelajado MC, Peabody JW (2018). A Better Pathway? Building Consensus and Engaging Providers with Feedback to Improve and Standardize Cancer Care. Clin Breast Cancer, 19(2), e376-e384.
Martnez Chanz N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC (2019). Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol, 20(4), 581-590.
Lloyd S, Baraghoshi D, Tao R, Garrido-Laguna I, Gilcrease GW 3rd, Whisenant J, Weis JR, Scaife C, Pickron TB, Huang LC, Monroe MM, Abdelaziz S, Fraser AM, Smith KR, Deshmukh V, Newman M, Rowe KG, Snyder J, Samadder NJ, Hashibe M (2019). Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. Am J Clin Oncol, 42(4), 355-362.
Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF (2019). Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. J Immunother Cancer, 7(1), 84.
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V (2019). TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol, 37(9), 714-722.
Johnson ED, Kerrigan K, Butler K, Patel SB (2019). Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy. J Oncol Pharm Pract, 1078155219835912.
Johnson ED, Kerrigan K, Bulter K, Patel SB (2019). Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy [Abstract]. Journal of Oncology Pharmacy Practice.
Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde GP (2019). Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. (Epub ahead of print) Eur Urol Oncol.
Swami U, Swick B, Zakharia Y, Milhem M (2019). Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma. Case Reports in Oncological Medicine, 2019, 4683531.
Hahn AW, Gill DM, Poole A, Nussenzveig RH, Wilson S, Farnham JM, Stephenson RA, Cannon-Albright LA, Maughan BL, Agarwal N (2018). Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). Mol Cancer Ther, 18(3), 726-729.
Swami U, Nussenzveig RH, Haaland B, Agarwal N (2019). Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. Ann Transl Med, 7(Suppl 1), S18.
Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K, Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of InvasiveAdvanced Cancer of the Urothelium group (2019). Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. Eur Urol Focus, 5(2), 242-249.
Swami U, Monga V, Freesmeier M, Zhang W, Bossler AD, Zakharia Y, Milhem M (2019). Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma. (Epub ahead of print) Melanoma Res.
Hahn AW, Gill DM, Poole A, Nussenzveig RH, Wilson S, Farnham JM, Stephenson RA, Cannon-Albright LA, Maughan BL, Agarwal N (2019). Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). Mol Cancer Ther, 18(3), 726-729.
Jimenez RE, Atwell TD, Sicotte H, Eckloff B, Wang L, Barman P, Sinnwell JP, Eiken PW, McMenomy BP, Tan W, Wang L, Carlson RE, Kohli M (2019). A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens. Mayo Clin Proc Innov Qual Outcomes, 3(1), 14-22.
Tannir NM, Agarwal N, Dawson NA, Motzer RJ, Jacobs CM, Choueiri TK, Hrom JS, Geynisman DM, Davis NB, Figlin RA, OKeeffe MK, Parikh JR, Vaena DA, Liu PY, OKeeffe B, Tran X, Escudier B (2019). CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma (suppl 7S; abstr TPS682) [Abstract]. Journal of Clinical Oncology, 37.
Hahn AW, Drake CG, Denmeade SR, Zakharia Y, Maughan BL, Kennedy EP, Link CJ, Vahanian NN, Hammers HJ, Agarwal N (2019). Efficacy of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients (pts) with refractory metastatic renal cell carcinoma (mRCC) (suppl 7S; abstr 590) [Abstract]. Journal of Clinical Oncology, 37.
Agarwal N, Pal SK, Lauer RC, Chatta GS, Goel S, Singh P, Sundararajan S, Heaton C, Peterson C, Benaim E, Tagawa ST (2019). Results of a phase II study to evaluate the safety and efficacy of RX-0201 in combination with everolimus in subjects with metastatic renal cell carcinoma (mRCC) (suppl 7S; abstr 646) [Abstract]. Journal of Clinical Oncology, 37.
Pal SK, Vaishampayan UN, Castellano DE, Necchi A, Van Herpen CML, Ramsingh G, Loriot Y, Agarwal N (2019). Phase 1b (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC) (suppl 7S; abstr TPS683) [Abstract]. Journal of Clinical Oncology, 37.
Hahn AW, Haaland B, Rathi N, Dizman N, Maughan BL, Pal SK, Agarwal N (2019). Receipt of systemic therapy in older versus younger patients (pts) with metastatic renal cell carcinoma (mRCC) (suppl 7S; abstr 580) [Abstract]. Journal of Clinical Oncology, 37.
Agarwal N (2019). Why I Attend. 2019 Genitourinary Oncology Symposium (GU ASCO) https://dailynews.ascopubs.org/do/10.5555/ADN.19.190070/full/ [Web]. San Francisco, CA.
Tagawa ST, Petrylak DP, Grivas P, Agarwal N, Sternberg CN, Siemon-Hryczyk P, Goswam T, Loriot Y (2019). TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy (suppl 7S; abstr TPS495) [Abstract]. Journal of Clinical Oncology, 37.
Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, ODonnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE (2018). Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer, 125(4), 533-540.
Ko L, Lilly MB, Hahn AW, Nussenzveig R, Moses MM, Ledet E, Manogue C, Cotogno P, Lewis BE, Layton JL, Agarwal N, Sartor AO, Barata PC (2019). Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate (suppl 7S; abstr 320) [Abstract]. Journal of Clinical Oncology, 37.
Griswold CR, Bailey EB, Mauser JC, Boucher KM, Agarwal N, Gupta S, Maughan BL (2019). Risk factors for venous thromboembolism (VTE) during chemotherapy in patients with germ cell tumors (GCT) (suppl 7S; abstr 520) [Abstract]. Journal of Clinical Oncology, 37.
Tward JD, ONeil B, Stephenson RA, Agarwal N, Farr T, Petragallo R, Lowrance WT (2019). Survival outcomes for adjuvant or salvage radiation in men with pN+M0 prostate cancer (suppl 7S; abstr 276) [Abstract]. Journal of Clinical Oncology, 37.
Teerlink C, Hahn AW, Esther J, Rathi N, Farnham JM, Agarwal N, Cannon-Albright L (2019). Genome-wide association study of metastatic prostate cancer (suppl 7S; abstr 160) [Abstract]. Journal of Clinical Oncology, 37.
Lin E, Hahn AW, Sonpavde G, Lilly MB, Nussenzveig R, Ledet E, Pal SK, Grivas P, Rich TA, Raymond VM, Sartor AO, Yandell M, Agarwal N (2019). Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) (suppl 7S; abstr 226) [Abstract]. Journal of Clinical Oncology, 37.
Pal SK, Szeto C, Reddy SK, Nussenzveig R, Lam RY, Scholz MC, Agarwal N (2019). Concomitant characterization of androgen receptor (AC) and immune checkpoints (ICs) in cell-free (cf) DNA and RNA from patients with metastatic castration resistant prosate cancer (mCRPC) (suppl 7S; abstr 286) [Abstract]. Journal of Clinical Oncology, 37.
Agarwal N, Shore ND, Dunshee C, Karsh LI, Sullivan B, Santo ND, Elmeliegy M, Casey M, Quek RGW, Czibere A, Fizazi K (2019). TALAPRO-2: A two-part, placebo-controlled phase III study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) (suppl 7S; abstr TPS337) [Abstract]. Journal of Clinical Oncology, 37.
Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P (2019). Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). J Immunother Cancer (7(1), p. 46). England.
Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P (2019). Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). J Immunother Cancer.
Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW (2019). Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Curr Treat Options Oncol, 20(2), 14.
Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW (2019). Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Curr Treat Options Oncol, 20(2), 14.
Liang WS, Vergilio J, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F (2019 Feb). Comprehensive genomic profiling of Hodgkin lymphoma reveals recurrently mutated genes and increased mutation burden. Oncologist, 24(2), 219-228.
Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Sthler V, Wells JC, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Chin Heng DY (2019). Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. Clin Genitourin Cancer, 17(1), 65-71.
Nhola LF, Abdelmoneim SS, Villarraga HR, Kohli M, Grothey A, Bordun KA, Cheung M, Best R, Cheung D, Huang R, Barros-Gomes S, Pitz M, Singal PK, Jassal DS, Mulvagh SL (2018). Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. J Am Soc Echocardiogr, 32(2), 267-276.
Hahn AW, Pal SK, Agarwal N (2019). Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome. Oncologist, 24(2), 143-145.
Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, ORegan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R (2019). NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw, 17(2), 118-126.
Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC, RISC Investigators (2019). Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. (Epub ahead of print) Eur Urol Oncol.
Kerrigan K (2019). Incorporation PROs Can Improve Patient Care and Outcomes [Web]. OncLive Oncology Fellows Magazine.
Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houldsworth J, Pal SK, Agarwal N (2019). Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS ONE, 14(1), e0210415.
Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houldsworth J, Pal SK, Agarwal N (2019). Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS ONE, 14(1), e0210415.
Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS (2019). First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer.
Vaishnavi A, Scherzer M, Kinsey C, Garrido-Laguna I, McMahon M (2019). MEK1/2 Inhibition Forestalls the Onset of Acquired Resistance to Entrectinib in a New Preclinical Model of TPR-NTRK1 Driven Pancreatic Cancer [Abstract].
Gruhl J, Francis SR, Tao R, Solomon BL, Nevala-Plagemann CD, Garrido-Laguna I, Lloyd S (01/18/2019). The impact of histology (adenocarcinoma vs. SCC) on outcomes in nonmetastatic pancreatic cancer.Presented ASCO 2019 Gastrointestinal Cancers Symposium [Abstract]. J Clin Oncol, 37(2019), suppl 4 abstr 419.
Pelzer U, Bendell JC, Womack MS, Bahary N, Macarulla T, Borazanci EH, Levy DE, Mo G, Ramage SC, Garrido-Laguna I (01/18/2019). A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.Presented AASCO 2019 Gastrointestinal Cancers Symposium [Abstract]. J Clin Oncol, 37(2019), suppl 4; abstr 330.
Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H (2018). Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression. Mol Cell, 73(1), 22-35.e6.
Thomas EA, Mijangos JL, Hansen PA, White S, Walker D, Reimers C, Beck AC, Garland EL (2019). Mindfulness-Oriented Recovery Enhancement Restructures Reward Processing and Promotes Interoceptive Awareness in Overweight Cancer Survivors: Mechanistic Results From a Stage 1 Randomized Controlled Trial. Integrative Cancer Therapies, 18, 1534735419855138.
Hahn AW, Stenehjem D, Nussenzveig R, Carroll E, Bailey E, Batten J, Maughan BL, Agarwal N (2019). Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. Cancer Treat Res Commun, 19, 100120.
Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N (2019). Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precis Oncol, 3.
Hahn AW, Stenehjem D, Nussenzveig R, Carroll E, Bailey E, Batten J, Maughan BL, Agarwal N (2019). Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. Cancer Treat Res Commun, 19, 100120.
Colonna S, Curtin K, Johnson E, Kohlmann W, Wright J, Kirchhoff A, Tavtigian S, Schiffman J (2019). Family History of Breast Cancer Associated with Breast Cancer in Survivors of Hodgkin Lymphoma. Int J Cancer Clin Res, 6(1).
Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL Jr, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB (2018). Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer, 125(1), 18-44.
Twardowski P, Wong JYC, Pal SK, Maughan BL, Frankel PH, Franklin K, Junqueira M, Prajapati MR, Nachaegari G, Harwood D, Agarwal N (2019). Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. Cancer Treat Res Commun, 19, 100116.
Hale P, Hahn AW, Rathi N, Pal SK, Haaland B, Agarwal N (2019). Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. J Geriatr Oncol, 10(1), 149-154.
Twardowski P, Wong JYC, Pal SK, Maughan BL, Frankel PH, Franklin K, Junqueira M, Prajapati MR, Nachaegari G, Harwood D, Agarwal N (2018). Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. Cancer Treat Res Commun, 19, 100116.
Wang HL, McMillan SC, Vijayakumar N, McDonald S, Huang LT, Gwede C, Padhya T, Russell J, Vondruska K, Buck HG, Huang Y, Visovsky C (2018). A Behavioral Physical Activity Intervention to Manage Moderate and Severe Fatigue Among Head and Neck Cancer Patients-Pre-efficacy Study in the National Institutes of Health ORBIT Model. Cancer Nurs, 42(1), E1-E14.
Luther C, Swami U, Zhang J, Milhem M, Zakharia Y (2018). Advanced stage melanoma therapies: Detailing the present and exploring the future. Crit Rev Oncol Hematol, 133, 99-111.
P Twardowski, J YCWong, SKPal, B LMaughan, P H Frankel, K Franklin, M Junqueira, M RPrajapati, G Nachaegari, D Harwood, N Agarwal (12/28/2018). Randomized phase II trial of Sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer [Abstract]. Cancer Treatment and Research Communications (doi: 10.1016/j.ctarc.2018.100116), 20 December 2018, 100116.
Maughan BL, Pal SK, Gill D, Boucher K, Martin C, Salgia M, Nussenzveig R, Liu T, Hawks JL, Batten J, Nachaegari G, Stephenson R, Lowrance W, Jones J, Dechet C, Agarwal N (2018). Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. Oncologist, 23(12), 1413-e151.
Grogan N, Swami U, Bossler AD, Zakharia Y, Milhem M (2018). Toxicities with targeted therapies after immunotherapy in metastatic melanoma. Melanoma Res, 28(6), 600-604.
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Retrospective International Study of InvasiveAdvanced Cancer of the Urothelium RISC (2018). Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. Eur Urol Focus, 4(6), 937-945.
Maughan BL, Pal SK, Gill D, Boucher K, Martin C, Salgia M, Nussenzveig R, Liu T, Hawks JL, Batten J, Nachaegari G, Stephenson R, Lowrance W, Jones J, Dechet C, Agarwal N (2018). Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. Oncologist, 23(12), 1413-e151.
Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S (2018). Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. [Review]. J Gastrointest Oncol, 9(6), 1014-1026.
Agarwal N, Nussenzveig R, Pal SK (2018). Biomarkers in renal-cell carcinoma: building on clinical paradigms. Lancet Oncol, 19(12), 1560-1561.
Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S (2018). Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. J Gastrointest Oncol, 9(6), 1014-1026.
Soisson S, Ganz PA, Gaffney D, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Hanson HA, Wu YP, Stanford J, Al-Sarray A, Werner TL, Setiawan VW, Hashibe M (2018). Long-term Cardiovascular Outcomes Among Endometrial Cancer Survivors in a Large, Population-Based Cohort Study. J Natl Cancer Inst, 110(12), 1342-1351.
Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd S (2018). Large database utilization in health outcomes research in pancreatic cancer: an update. J Gastrointest Oncol, 9(6), 996-1004.
Sirohi D, Smith SC, Agarwal N, Maughan BL (2018). Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. Res Rep Urol, 10, 205-217.
Sirohi D, Smith SC, Agarwal N, Maughan BL (November 2018). Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities [Abstract]. Dove Medical Press, 2018(10), 205-217.
Hu-Lieskovan S, Govindan R, Naing A, Friedlander T, Margolin K, Lin J, Bhardwaj N, Hellmann M, Srinivasan L, Greshcok J, Moles M, Gaynor R, Goldstein M, Ott P (November 2018). The personal vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo tumor-related immunity in patients with advanced cancer [Abstract]. Abstract O7.
Hu-Lieskovan S, Govindan R, Naing A, Griedlander T, Marolin K, Lin J, Bhardwaj N, Hellmann M, Srinivasan L, Greshcok J, Moles M, Gaynor R, Goldstein M, Ott P (November 2018). PAK4 inhibition reverses immune cell exclusion and overcomes resistance to checkpoint blockade therapy [Abstract]. Abstract O39.
Evans E, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Howell A, Balch L, Leonard J, Fisher T, Allen C, Clavijo P, Lesinki G, Wu C, Hu-Lieskovan S, Ribas A, Greengard E, Smith E, Zauderer M (November 2018). Reprogramming suppressive myeloid cells in tumor microenvironment with pepinemab, first-in-class Semaphorin 4D Mab, enhances combination immunotherapy [Abstract]. O20.
Castro, D, Abril-Rodriguez G, Tsoi J, Champhekar A, Parisi G, Cheung-Lau G, Onyshchenko M, Berent-Maoz B, Grasso C, Comin-Anduix B, Hu-Lieskovan S, Ribas A (November 2018). Overcoming genetically-based PD-1 blockade resistance [Abstract]. Abstract P557.
Sharma S, Moore KN, Mettu NB, Garrido-Laguna I, Ulahannan SV, Khemka V, Kapoun A, Faoro L, Bendell J (Nov 2018). Initial results from a phase 1a/b study of etigilimab (OMP-313M32), an anti-T cell immunoreceptor with lg and ITIM domains (TIGIT) antibody, in advanced solid tumors [Abstract]. SITC 2018, Washington, D.C.
Coman G, Moser J, Hyngstrom J, Grossmann K, Patel SB, Colonna S, Andtbacka R (2018). Overall Survival of Patients Treated with Single Agent Ipilimumab or Combination Nivolumab and Ipilimumab in Second Line Setting After Progression on Frontline Anti-PD-1 Therapy [Abstract].
Solomon BL, Garrido-Laguna I (1/11/2018). Novel Therapies in Pancreatic Cancer: Opportunities and Challenges for Precision Medicine. 2018 Gastrointestinal Cancers Symposium Daily News (January 11, 2018). San Francisco.
Riaz IB, Wang L, Kohli M (2018). Liquid biopsy approach in the management of prostate cancer. Transl Res, 201, 60-70.
Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I (2017). BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. J Natl Cancer Inst, 110(11), 1178-1189.
Solomon BL, Garrido-Laguna I (2018). TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunol Immunother, 67(11), 1659-1667.
Chalmers A, Haaland B, Patel SB, Moynahan K, Cannon L, Akerley W (2018). P3.01-13 Prognosis of Non-Driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC) [Abstract]. Journal of Thoracic Oncology, 13(10), S872.
Smith L, Kohli M, Smith AM (2018). Expanding the Dynamic Range of Fluorescence Assays through Single-Molecule Counting and Intensity Calibration. J Am Chem Soc, 140(42), 13904-13912.
Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Puig-Saus C, Cebon J, Ribas A, Yang L, Witte ON, Baltimore D (Oct 2018). Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. Proc Natl Acad Sci U S A.
Ott P, Govindan R, Niang A, Friedlander T, Margolin K, Lin J, Bhardwaj N, Hellmann M, Srinivasan L, Greshock J, Moles M, Gaynor R, Goldstein M, Hu-Lieskovan S (October 2018). A Personal Neoantigen Vaccine, NEO-PV-01, with anti-PD1 Induces Broad De Novo Anti-Tumor Immunity in Patients with Metastatic Melanoma, NSCLC, and Bladder Cancer [Abstract]. 29(Supplement 8), viii400-viii441.
Hamid O, Hu-Lieskovan S, Ros W, Diab A, El-Khoueiry A, Thompson J, Eskens F, X Doi T, Wasser J, Spano J, Angevin E, Rizvi N, Wasser J, Ott P, Chiappori A, Joh T, Krupka H, Potluri S, Wang X, Ganguly B, Chou J, Doi T (October 2018). Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs) [Abstract]. 29(Supplement 8), viii400-viii441.
Gaffney DK, Hasibe M, Kepka D, Maurer KA, Werner TL (2018). Too many women are dying from cervix cancer: Problems and solutions. Gynecol Oncol.
A NecchiD Pouessel, R Leibowitz-Amit, A Flechon, S Gupta, P Barthelemy, M Maio, X Zhu, E Asatiani, G Serbest, H Zhen, Y Loriot (10/01/2018). Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). [Abstract]. ESMO Annual Meeting 2018.
Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Santana-Davila R, Williams CC, Hoffmann KG, Hughes M (2018). NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. J Natl Compr Canc Netw, 16(10), 1171-1182.
Swami U, Zakharia Y, Zhang J (2018). Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. J Immunother, 41(8), 359-360.
Agarwal N, Lanman RB, Pal SK (2018). Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. [Letter to the editor]. JAMA Oncol, 4(10), 1429-1430.
Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Venkat PS, Ahmed KA, Demetriou S, Frakes JM, Kim Y, Kish JA, Russell JS, Otto KJ, Chung CH, Harrison LB, Trotti A, Caudell JJ (2018). Patient choice for high-volume center radiation impacts head and neck cancer outcome. Cancer Med, 7(10), 4964-4979.
Hahn AW, Froerer C, VanAlstine S, Rathi N, Bailey EB, Stenehjem DD, Agarwal N (2018). Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. Clin Genitourin Cancer, 16(5), 365-368.
Patel SB, Akerley WL, Ose D, Haydell T, Martineau J, Dunson WA, Chalmers AW, Cannon L, Meropol NJ, Haaland B (2018). Prognostic value of patient-reported outcomes (PROs) in advanced cancer [Abstract]. Journal of Clinical Oncology, 36.
McPherson JP, Patel SB, Igumnova E, Pettit J, Ose D, Haydell T, Martineau J, Meropol NJ, Beck AC (2018). Real-time assessment of resource utilization and subsequent cost analysis in cancer patients (pts) near the end of life (EOL) [Abstract]. Journal of Clinical Oncology, 36.
Hamieh L, Choueiri TK, Ogrek B, Khabibullin D, Rosebrock D, Livitz D, Fay A, Pignon JC, McDermott DF, Agarwal N, Gao W, Signoretti S, Kwiatkowski DJ (2018). Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet, 14(9), e1007679.
Blee AM, He Y, Yang Y, Ye Z, Yan Y, Pan Y, Ma T, Dugdale J, Kuehn E, Kohli M, Jimenez R, Chen Y, Xu W, Wang L, Huang H (2018). TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer. Clin Cancer Res, 24(18), 4551-4565.
Necchi A, Pond GR, Moschini M, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Vaishampayan U, Theodore C, Sridhar SS, Rosenberg JE, Bellmunt J, Gallina A, Colombo R, Montorsi F, Briganti A, Galsky MD (2018). Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. PMID: 30292628 [Abstract]. Clinical Genitourinary Cancer.
Tripathi A, Agarwal N (2018). Editorial Comment. PMID: 30189185 [Abstract]. The Journal of Urology.
Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, Costello BA, Quevedo F, Pagliaro L, Kohli M (2018). Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis, 21(3), 431-437.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA (2018). NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw, 16(9), 1041-1053.
DAngelo SP, Russell J, Lebb C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL (2018). Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol, 4(9), e180077.
Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L (2018). Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis, 21(3), 411-418.
Swami U, Smith M, Zhang J (2018). Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response. [Letter to the editor]. J Thorac Oncol, 13(9), e183-e184.
Stenehjem DD, Cavalieri CC, Swanson E, Solomon B, Whisenant J, Tran D, Weis J, Gilcrease GW, Sharma S, Garrido-Laguna I (201u). Pembrolizumab in advanced gastrointestinal malignancies with defective dna mismatch repair: A case series. J Immunother Precis Oncol, 1(1), 1-6.
Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, OReilly EM, Philip PA, Ramanathan RK, Ruggiero JT, Shah MA, Urba S, Uronis HE, Lau MW, Laheru D (2018). Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol, 36(24), 2545-2556.
Zhen JT, Syed J, Nguyen KA, Leapman MS, Agarwal N, Brierley K, Llor X, Hofstatter E, Shuch B (2018). Genetic testing for hereditary prostate cancer: Current status and limitations. Cancer, 124(15), 3105-3117.
Hahn AW, Gill DM, Nussenzveig RH, Poole A, Farnham J, Cannon-Albright L, Agarwal N (2018). Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer, 16(4), 288-292.
Rathi N, Anderson N, Greenberg S, Vagher J, Agarwal N, Hahn AW (2018). DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC). 9(4), 119-122.
Cuellar LE, Anampa-Guzmn A, Holgun AM, Velarde J, Portillo-Alvarez D, Zuiga-Ninaquispe MA, Luna-Reyes ER, Vsquez J, Jeter JM, Winkfield KM (2018). Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience. Infect. Agents Cancer, 13, 27.
Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 3(5), e000386.
Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 3(5), e000386.
Kingsford R, Pitt D, Low S, Weaver L, Moehle J, Cohen Al, Werner TL (2018). How to Be a Principal Investigator: Developing and Implementing of a Practical Training Program [Abstract]. 10th Annual AACI CRI Meeting Abstract Template.
Schrijver LH, Olsson H, Phillips KA, Terry MB, Goldgar DE, Kast K, Engel C, Mooij TM, Adlard J, Barrowdale D, Davidson R, Eeles R, Ellis S, Evans DG, Frost D, Izatt L, Porteous ME, Side LE, Walker L, Berthet P, Bonadona V, Leroux D, Mouret-Fourme E, Venat-Bouvet L, Buys SS, Southey MC, John EM, Chung WK, Daly MB, Bane A, van Asperen CJ, Gomez Garcia EB, Mourits MJE, Roos-Blom MJ, Friedlander ML, McLachlan SA, Singer CF, Foretova L, Gerdes AM, Caldes T, Olah E, Jakubowska A, Nogues C, Andrieu N, Easton DF, van Leeuwen FE, Hopper JL, Milne RL, Antoniou AC, Rookus MA, on behalf of EMBRACE, GENEPSO, BCFR, HEBON, kConFab, and IBCCS (2018). Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. doi: 10.1093/jncics/pky023. JNCI Cancer Spectrum, 2(3).
Diab A, Hamid O, Thompson J, Schellens J, Eskens F, Doi T, Hu-Lieskovan S, Long H Joh T, Potluri S, Wang X, Fleener C, Taylor C, Ganguly B, Chou J, El-Khoueiry A (July 2018). Pharmacodynamic changes in tumor RNA expression and the peripheral blood T cell receptor (TCR) repertoire in a Phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600 [Abstract]. 78(13 Supplement), Abstract CT010.
Nowicki T, Berent-Maoz B, Huang R, Wang X, Cheung-Lau G, Kaplan-Lefko P, Cabrera P, Tran J, Carretero I, Grasso C, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A (July 2018). A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab in patients with sarcoma and melanoma [Abstract]. 78(13 Supplement), CT008.
Abril-Rodriguez G, Grasso C, Zaretsky J, Berent-Maoz B, Hu-Lieskovan S, Ribas A (July 2018). Role of PAK4 in cancer immune cell exclusion [Abstract]. 78(13 Supplement), Abstract 4755.
Parisi G, Saco J, Bergara F, Krstofinski P, Zhang R, Saus C, Hu-LIeskovan S, Comin-Anduix B, Wu A, Charych D, Ribas A (July 2018). Enhanced expansion and tumor targeting of adoptively transferred T cells with NKTR-214 [Abstract]. 78(13 Supplement), Abstract 3566.
Ott P, Ramaswamy G, Naing A, Friedlander T, Margolin K, Lin J, Bhardwaj N, Hellmann M, Srinivasan L, Greshock J, Moles M, Gaynor R, Goldstein M, Hu-Lieskovan S (July 2018). A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer [Abstract]. 89(13 Supplement), Abstract CT125.
Evans E, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Howell A, Balch L, Leonard J, Fisher T, Allen C, Clavijo P, Lesinski G, Wu C, Hu-Lieskovan S, Ribas A, Greengard E, Smith E, Zauderer M (July 2018). Shifting the tumor microenvironment with first-in-class Semaphorin 4D mab for combination immunotherapy [Abstract]. 78(13 Supplement), Abstract 1762.
Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grnwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF (2018). Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Cancer Discov, 8(7), 812-821.
Swami U, Ma D, Zhang J (2018). Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion. [Letter to the editor]. J Thorac Oncol, 13(7), e129-e130.
Qin S, Liu D, Kohli M, Wang L, Vedell PT, Hillman DW, Niu N, Yu J, Weinshilboum RM, Wang L (2017). TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. Clin Pharmacol Ther, 104(1), 201-210.
Carr SR, Akerley W, Cannon-Albright LA (2018). Genetic Contribution to Nonsquamous, Non-Small Cell Lung Cancer in Nonsmokers. J Thorac Oncol, 13(7), 938-945.
Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, DAmico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2018). NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw, 16(7), 807-821.
Schrijver LH, Olsson H, Phillips KA, Terry MB, Goldgar DE, Kast K, Engel C, Mooij TM, Adlard J, Barrowdale D, Davidson R, Eeles R, Ellis S, Evans DG, Frost D, Izatt L, Porteous ME, Side LE, Walker L, Berthet P, Bonadona V, Leroux D, Mouret-Fourme E, Venat-Bouvet L, Buys SS, Southey MC, John EM, Chung WK, Daly MB, Bane A, van Asperen CJ, Gmez Garcia EB, Mourits MJE, van Os TAM, Roos-Blom MJ, Friedlander ML, McLachlan SA, Singer CF, Tan YY, Foretova L, Navratilova M, Gerdes AM, Caldes T, Simard J, Olah E, Jakubowska A, Arver B, Osorio A, Nogus C, Andrieu N, Easton DF, van Leeuwen FE, Hopper JL, Milne RL, Antoniou AC, Rookus MA, EMBRACE GENEPSO BCFR HEBON kConFab and IBCCS (2018). Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectr, 2(2), pky023.
Young EL, Thompson BA, Neklason DW, Firpo MA, Werner T, Bell R, Berger J, Fraser A, Gammon A, Koptiuch C, Kohlmann WK, Neumayer L, Goldgar DE, Mulvihill SJ, Cannon-Albright LA, Tavtigian SV (2018). Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer, 18(1), 697.
Nemunaitis JM, Brown-Glabeman U, Soares H, Belmonte J, Liem B, Nir I, Phuoc V, Gullapalli RR (2018). Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. BMC Cancer, 18(1), 665.
Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT (Jun 2018). Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. . Clin Cancer Res.
Yousef Zakharia, Olivier Rixe, John Harris Ward, Joseph J Drabick, Montaser F Shaheen, Mohammed M Milhem, David Munn, Eugene Paul Kennedy, Nicholas N Vahanian, Charles J Link, Robert R McWilliams, University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA, GRU Cancer Center, Augusta, GA, Huntsman Cancer Inst Univ of Utah, Salt Lake City, UT, Penn State Hershey Medical Center, Hershey, PA, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, Georgia Cancer Center, Augusta University, Augusta, GA, NewLink Genetics Corporation, Ames, IA, Mayo Clinic, Rochester, MN (06/04/2018). Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.Presented at 2018 ASCO Annual meeting June 4, 2018. [Abstract]. J Clin Oncology, 36(suppl. abstr 9512).
Petros Grivas, Gregory Russell Pond, Rebecca J Nagy, Pedro C Barata, Prateek Mendiratta, Dharmesh Gopalakrishnan, Alexandra Drakaki, Sumati Gupta, Neeraj Agarwal, Jue Wang, Bishoy Faltas, Ulka N Vaishampayan, Gurudatta Naik, Bradley Alexander McGregor, Sumanta K Pal, Lesli Ann Kiedrowski, Richard B Lanman, Guru Sonpavde (06/01/2018). Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC). ASCO Annual Meeting 2018 [Abstract].
Pant S, Spira AI, Cho SBC, Goel S, Hoimes CJ, Alva AS, Balaraman R, Bauer TM, Lowry PA, Ramaekers RC, Siegel RD, Werner TL, Tannir NM, Faltaos D, Potvin D, Neuteboom ST, Christensen J, Chao RC, Kyriakopoulos C (2018). Evalution of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT) [Abstract]. J Clin Oncol, 36.
Vaklavas C, Zinn KR, Samuel SL, Meng Z, Grizzle WE, Choi H, Blume SW (2018). Translational control of the undifferentiated phenotype in ER‑positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibition. Oncol Rep, 39(6), 2482-2498.
Hu-Lieskovan S, Torrejon D, Zaretsky J, Tsoi J, Cheung-Lau G, Vega-Crespo A, Meeth K, Prins R, Graeber T, Besenberg M, Grasso C, Comin-Anduix B, Rbias A (June 2018). Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716) [Abstract]. 36(15 Supplement), TPS9603.
Vandersalde A, Latkovic-Taber M, Hu-Lieskovan S, Grossmann K, Sosman J, Campos D, Wu M, Ribas A36 (June 2018). Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616) [Abstract]. 36(15 Supplement), TPS9597.
Kendra K, Moon J, Hu-Lieskovan S, Carson III W, Campos D, Cochran A, Wu M, Ribas A (June 2018). SWOG S1512: A phase II and pilot trial of Pembrolizumab in patients with resectable or unresectable desmoplastic melanoma (DM) [Abstract]. 36(15 Supplement), TPS9608.
Hu-Lieskovan S, Torrejon D, Zaretsky J, Tsoi J, Cheung-Lau G, Vega-Crespo A, Meeth K, Prins R, Graeber T, Besenberg M, Grasso C, Comin-Anduix B, Rbias A (June 2018). CD4 cells are essential in the complete anti-tumor response to PD1 blockade in a syngeneic murine melanoma model with activated WNT signaling [Abstract]. 36(15 Supplement), 12013.
Lu H, Cummings A, Goldman J, Lisberg A, Hu-Lieskovan S, Grogan T, Gukasyan J, Madrigal J, Carroll J, Bornazyan K, Jones B, Noor Z, Zaretsky J, Elashoff D, Slamon D, Dubinett S, Garon E (June 2018). Human leukocyte antigen (HLA) B44 supertype and immunotherapy outcomes in non-small cell lung cancer (NSCLC) [Abstract]. 36(15 Supplement), Abstract 3025.
Swami U, Lenert P, Furqan M, Abu Hejleh T, Clamon G, Zhang J (2018). Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities? [Letter to the editor]. J Thorac Oncol, 13(6), e102-e103.
Scagliotti GV, Shuster D, Orlov S, von Pawel J, Shepherd FA, Ross JS, Wang Q, Schwartz B, Akerley W (2017). Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study. J Thorac Oncol, 13(6), 849-854.
Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR (2018). Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study. Cancer Med, 7(6), 2360-2369.
Maughan BL, Guedes LB, Boucher K, Rajoria G, Liu Z, Klimek S, Zoino R, Antonarakis ES, Lotan TL (2018). p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis, 21(2), 260-268.
Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C (2018). Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol, 73(6), 847-855.
Bahary N, Wang-Gillam A, Haraldsdottir S, Somer BG, Lee JS, ORourke MA, Nayak-Kapoor A, Beatty GL, Liu M, Delman D, Rossi GR, Kennedy EP, Vahanian NN, Link CJ, Garrido-Laguna I (2018 ASCO Annual Meeting). Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer. [Abstract]. J Clin Oncol 36, 2018 (suppl; abstr 4015).
Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N (2018). Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. J Manag Care Spec Pharm, 24(6), 525-533.
Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N (2018). Metastatic Castration-Sensitive Prosate Cancer: Optimizing Patient Selection and Treatment. PMID: 30231388 [Abstract]. American Society of Clinical Oncology (ASCO) Educational Book.
Zhang P, Xia JH, Zhu J, Gao P, Tian YJ, Du M, Guo YC, Suleman S, Zhang Q, Kohli M, Tillmans LS, Thibodeau SN, French AJ, Cerhan JR, Wang LD, Wei GH, Wang L (2018). High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing. Nat Commun, 9(1), 2022.
Patel SB, Haaland B, Ose D, Haydell T, Martineau J, Dunson WA, Chalmers AW, Cannon L, Kissell B, Meropol NJ, Akerley WL (2018). Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer (abstr 10101) [Abstract]. Journal of Clinical Oncology, 36(15).
Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P (2018). Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer, 124(10), 2115-2124.
Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P (2018). Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. 124(10), 2115-2124.
Boothe D, Clyde JW, Christensen M, Patel SB, Lloyd S (2018). A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy. J Radiat Oncol, 7(3), 223-232.
Boothe D, Clyde JW, Christensen M, Patel SB, Lloyd S (2018). A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy [Abstract]. (7), 223–232.
Martin C, Leiser CL, ONeil B, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson HA (2017). Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 110(5), 527-533.
Dorff TB, Agarwal N (2018). Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. Asian J Androl, 20(3), 215-220.
Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod HL, Cavallari LH (2018). Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp Clin Trials, 68, 7-13.
Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal Sumanta K, Stenehjem DD, Agarwal N (2018). Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. J Oncol Pharm Pract, 3, 190-197.
Park J, Blackburn BE, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Burt L, Werner TL, Gaffney DK, Lopez A, Mooney A (2018). Rural-metropolitan disparities in ovarian cancer survival: A statewide population-based study. Ann Epidemiol.
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ (2018). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol, 36(11), 1080-1087.
Hahn AW, Pal SK, Agarwal N (2018). HSD3B1-A Predictive Biomarker in Advanced Prostate Cancer. JAMA Oncol, 4(4), 562-563.
Maia MC, Grivas P, Agarwal N, Pal SK (2018). Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions. Eur Urol, 73(4), 541-542.
Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal SK, Stenehjem DD, Agarwal N (2018). Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. J Oncol Pharm Pract, 24(3), 190-197.
Gupta S, Albertson D, Gaston D, Heilbrun ME, Agarwal N, Boucher K, Parnell TJ, Liu T, Morgans A, Madison R, Gowen K, Miller VA, Ross JS, Ali SM, Millis SZ (2017). Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. Clin Genitourin Cancer, 16(2), e373-e382.
Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA (2018). NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw, 16(4), 359-369.
Gupta S, Albertson D, Gaston D, Heilbrun ME, Agarwal N, Boucher K, Parnell TJ, Liu T, Morgans A, Madison R, Gowen K, Miller VA, Ross JS, Ali SM, Millis SZ (2018). Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. Clin Genitourin Cancer, 16(2), e373-e382.
Solomon BL, Garrido-Laguna I (2018). Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncol, 14(10), 947-962.
Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD, Retrospective International Study of InvasiveAdvanced Cancer of the Urothelium Group (2018). Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clin Genitourin Cancer, 16(2), e483-e490.
Stukalin I, Wells CJ, Fraccon A, Pasini F, Porta C, Lalani AA, Srinivas S, Bowman AI, Brugarolas J, Lee JL, Donskov F, Beuselinck B, Bamias A, Rini BI, Sim HW, Agarwal N, Rha SY, Kanesvaran R, Choueiri TK, Heng DYC (2018). Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Kidney Cancer, 2(1), 31-36.
Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI (2018). Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.LID - S1470-2045(18)30107-4 [pii]LID - 10.1016/S1470-2045(18)30107-4 [doi]. (Epub ahead of print) Lancet Oncol.
Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels MS, Grady WM, Hsu L, Hu-Lieskovan S, Huyghe JR, Kim YJ, Krystofinski PE, Leiserson MD, Montoya DJ, Nadel BB, Pellegrini M, Pritchard CC, Puig-Saus C, Quist EH, Raphael BJ, Salipante SJ, Shin DS, Shinbrot E, Shirts B, Shukla S, Stanford JL, Sun W, Tsoi J, Upfill-Brown A, Wheeler DA, Wu CJ, Yu M, Zaidi SH, Zaretsky JM, Gabriel SB, Lander ES, Garraway LA, Hudson TJ, Fuchs CS, Ribas A, Ogino S, Peters U (Mar 2018). Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov.
Cannon JGD, Russell JS, Kim J, Chang ALS (2018). A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery. JAAD Case Rep, 4(3), 248-250.
Soisson S, Ganz PA, Gaffney D, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Hanson HA, Wu YP, Stanford J, Werner TL, Setiawan VW, Hashibe M (2018). Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study. Gynecol Oncol, 148(3), 499-506.
Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C (2018). Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol, 29(3), 646-653.
Chalmers AW, Patel SB, Akerley W (2018). Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care? J Thorac Dis, 10(3), 1198-1200.
Cives M, Anaya DA, Soares H, Coppola D, Strosberg J (2017). Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors. J Natl Cancer Inst, 110(3), 282-289.
Catino AB, Hubbard RA, Chirinos JA, Townsend R, Keefe S, Haas NB, Puzanov I, Fang JC, Agarwal N, Hyman D, Smith AM, Gordon M, Plappert T, Englefield V, Narayan V, Ewer S, ElAmm C, Lenihan D, Ky B (2018). Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Circ Heart Fail, 11(3), e004408.
He Y, Lu J, Ye Z, Hao S, Wang L, Kohli M, Tindall DJ, Li B, Zhu R, Wang L, Huang H (2017). Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. Nucleic Acids Res, 46(4), 1895-1911.
Monga V, Swami U, Tanas M, Bossler A, Mott SL, Smith BJ, Milhem M (2018). A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.LID - E53 [pii]LID - 10.3390/cancers10020053 [doi]. Cancers (Basel), 10(2).
Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, Kohli M, Westendorf JJ, Li B, Zhu R, Huang H, Xu W (2017). PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. Clin Cancer Res, 24(4), 834-846.
Gill DM, Agarwal N (2018). Updates in the rapidly changing treatment landscape of metastatic renal cell carcinoma. ASCO daily news “expert commentary” [Web]. Available: https://goo.gl/T9n1Gi.
Sanhueza C, Kohli M (2018). Clinical and Novel Biomarkers in the Management of Prostate Cancer. Curr Treat Options Oncol, 19(2), 8.
Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH (2018). Publisher Correction: Combating subclonal evolution of resistant cancer phenotypes. 9(1), 572.
Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD (2018). Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Ann Oncol, 29(2), 361-369.
Francis S, Orton A, Stoddard G, Tao R, Hitchcock YJ, Akerley W, Kokeny KE (2017). Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer. J Clin Oncol, 36(4), 333-341.
Cheng HH, Plets M, Li H, Higano CS, Tangen CM, Agarwal N, Vogelzang NJ, Hussain M, Thompson IM Jr, Tewari M, Yu EY (2018). Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate, 78(2), 121-127.
Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M (2017). A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol, 29(2), 352-360.
Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH (2018). Publisher Correction: Combating subclonal evolution of resistant cancer phenotypes. Nat Commun, 8(1), 1231.
Sumati Gupta, Andrew Butterfield, Timothy Parnell, Alexis Weston, Mohan Kaadige, Sunil Sharma (2018). Reversible LSD1 (KDM1A) inhibition with HCI2509 is growth inhibitory in bladder cancer cell lines and causes gene expression changes that reveal rational therapeutic partners [Abstract]. Presented at Targeting DNA Methylation and Chromatin for Cancer Therapy in Atlanta March 2018.
Jacob Adashek, Sumanta K Pal, Vincent M Chung, Scott T Tagawa, Joel Picus, Hani M Babiker, Sumati Gupta, Raymond Couric Wadlow, Julie Poore, Christine Peterson, Ely Benaim (2018). Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC). ASCO Annual Meeting 2018 [Abstract].
Ou JY, Fowler B, Ding Q, Kirchhoff AC, Pappas L, Boucher K, Akerley W, Wu Y, Kaphingst K, Harding G, Kepka D (2018). A statewide investigation of geographic lung cancer incidence patterns and radon exposure in a low-smoking population. BMC Cancer, 18(1), 115.
Torgeson A, Garrido-Laguna I, Tao R, Cannon GM, Scaife CL, Lloyd S (2018). Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. 3(1), e000282.
Gill DM, Hahn AW, Hale P, Maughan BL (2018). Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Curr Treat Options Oncol, 19(1), 6.
Swords DS, Garrido-Laguna I, Mulvihill SJ, Stoddard GJ, Firpo MA, Scaife CL (January 2018). Association of adjuvant chemotherapy with overall survival in resected pancreatic adenocarcinoma previously treated with neoadjuvant therapy. [Abstract]. J Clin Oncol 36, 2018 (suppl 4S; abstr 404).
Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, DAngelo SP, Shih KC, Lebb C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P (2018). Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer, 6(1), 7.
Pishvaian MJ, Rolfo CD, Liu SV, Multani PS, Maneval EC, Garrido-Laguna I (January 2018). Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions. [Abstract]. J Clin Oncol 36, 2018 (suppl 4S., abstr 521).
Bendell JC, Pelzer U, Womack MS, Borazanci EH, Bahary N, Garrido-Laguna I, Maur M, Prater T, Levy DE, Cronier D, Ramage S, Macarulla T, Cannon S (January 2018). A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer. [Abstract]. J Clin Oncol 36, 2018 (suppl 4S; abstr TPS524).
Eroglu Z Zaretsky J Hu-Lieskovan S Kim DW, Algazi A, Johnson D, Liniker E, Kong B, Munhoz R, Rapisuwon S, Chmielowski B, Homet Moreno B, Cherry G, Berent-Maoz B, Comin-Anduix B, Wang X, Tumeh PC, Shintaku IP, Hugo W, Lo RS, Sosman JA, Joseph R, Postow M, Hwu W-J, Messina J, Long G, Ribas A Equal contribution as first authors, Corresponding authors (Jan 2018). High response to PD-1 blockadein desmoplastic melanoma. Nature, 553(7688), 347-350.
Nevala-Plagemann CD, Francis S, Cavalieri CC, LLoyd S, Garrido-Laguna I (January 2018). The effect of adjuvant chemotherapy in patients without local nodal metastases following neoadjuvant chemoradiotherapy and esophagectomy for locally advanced esophageal cancer. [Abstract]. J Clin Oncol 36, 2018 (suppl 4S; abstr 111).
Francis S, Nevala-Plagemann CD, Cavalieri CC, Lloyd S, Garrido-Laguna I (January 2018). Postoperative chemotherapy in patients who are pN+ following neoadjuvant chemoradiation for locally advanced esophageal cancer. [Abstract]. J Clin Oncol 36, 2018 (suppl 4S, abstr 97).
Gupta S, Doyle K, Mosbruger TL, Butterfield A, Weston A, Ast A, Kaadige M, Verma A, Sharma S (2018). Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells. Oncotarget, 9(11), 9907-9924.
Maughan BL, Guedes LB, Boucher K, Rajoria G, Liu Z, Klimek S, Zoino R, Antonarakis ES, Lotan TL (2018). p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis, 10.1038(s41391-017).
Nowicki T, Hu-Lieskovan S, Ribas A (Jan/Feb 2018). Mechanisms of Resistance to PD-1 and PD-L1 blockade. [Review]. Cancer J, 24(1), 47-53.
Kawakita D, Lee YA, Gren LH, Buys SS, La Vecchia C, Hashibe M (2018). The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort. Br J Cancer, 118(2), 299-306.
Gubens MA, Chuang JC, Akerley W, Langer CJ, Clment-Duchne C, San Pedro-Salcedo M, Colevas AD, Dragnev K, Socinski MA, Wakelee HA (2018). A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. J Thorac Dis, 10(1), 219-227.
Taurin S, Yang CH, Reyes M, Cho S, Coombs DM, Jarboe EA, Werner TL, Peterson CM, Janat-Amsbury MM (2018). Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model. Int J Gynecol Cancer, 28(1), 152-160.
Swami U, Monga V, Knutson T, Bossler A, Zakharia Y, Milhem M (2018). Prognostic markers for progression free survival (PFS) to anti PD-1 therapies in metastatic melanoma [Abstract]. J Clin Oncol, 36(suppl; abstr e21527).
Herde RF, Kokeny KE, Reddy CB, Akerley WL, Hu N, Boltax JP, Hitchcock YJ (2015). Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience. Am J Clin Oncol, 41(1), 24-29.
Gustafson A, Goldfrank D, Dunson WA, Mulkerin D, Caires R, Eaton K (2018). Pregnancy Screening in patients with cancer. J Natl Compr Canc Netw, 16, 99-103.
Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH (2018). Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. Eur Urol, 73(1), 71-78.
Dang C, Ewer MS, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, de la Cruz Merino L, Lucas J, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Eng-Wong J, Swain SM (2017). Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study. 2017 San Antonio Breast Cancer Symposium.
Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, Lewis M, Kim R, Scaife C, Tao R (2017). Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis. Ann Surg Oncol, 24(13), 4001-4008.
Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L (2017). Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(12), 1520-1541.
Gill DM, Agarwal N (2017). Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers. [Review]. Urol Oncol, 35(12), 676-677.
Steffen LE, Du R, Gammon A, Mandelblatt JS, Kohlmann WK, Lee JH, Buys SS, Stroup AM, Campo RA, Flores KG, Vicua B, Schwartz MD, Kinney AY (2017). Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode. Cancer Epidemiol Biomarkers Prev, 26(12), 1772-1780.
Hahn AW, Gill DM, Agarwal N, Maughan BL (2017). PD-1 checkpoint inhibition: toxicities and management. Urol Oncol, 10.1016(35(12)), 701-701.
Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN Jr, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM Jr, Twardowski PW, Van Veldhuizen PJ Jr, Agarwal N, Carducci MA, Monk JP, Quinn DI (2017). Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer, 15(6), 635-641.
Butterfield A, Gupta S (2017). Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor. 6(6), 1198-1202.
Hahn AW, Gill DM, Agarwal N, Maughan BL (2017). PD-1 checkpoint inhibition: Toxicities and management. [Review]. Urol Oncol, 35(12), 701-707.
Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindstrm S, Hui S, Lemaon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, Wang Q, Aalfs CM, ABCTB Investigators, Adams M, Adlard J, Agata S, Ahmed S, Ahsan H, Aittomki K, Al-Ejeh F, Allen J, Ambrosone CB, Amos CI, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Auber B, Auer PL, Ausems MGEM, Azzollini J, Bacot F, Balmaa J, Barile M, Barjhoux L, Barkardottir RB, Barrdahl M, Barnes D, Barrowdale D, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Bernstein L, Bignon YJ, Blazer KR, Blok MJ, Blomqvist C, Blot W, Bobolis K, Boeckx B, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Brresen-Dale AL, Bozsik A, Bradbury AR, Brand JS, Brauch H, Brenner H, Bressac-de Paillerets B, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Brunet J, Brning T, Burwinkel B, Buys SS, Byun J, Cai Q, Calds T, Caligo MA, Campbell I, Canzian F, Caron O, Carracedo A, Carter BD, Castelao JE, Castera L, Caux-Moncoutier V, Chan SB, Chang-Claude J, Chanock SJ, Chen X, Cheng TD, Chiquette J, Christiansen H, Claes KBM, Clarke CL, Conner T, Conroy DM, Cook J, Cordina-Duverger E, Cornelissen S, Coupier I, Cox A, Cox DG, Cross SS, Cuk K, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, Davidson R, De Leeneer K, Devilee P, Dicks E, Diez O, Ding YC, Ditsch N, Doheny KF, Domchek SM, Dorfling CM, Drk T, Dos-Santos-Silva I, Dubois S, Dugu PA, Dumont M, Dunning AM, Durcan L, Dwek M, Dworniczak B, Eccles D, Eeles R, Ehrencrona H, Eilber U, Ejlertsen B, Ekici AB, Eliassen AH, EMBRACE, Engel C, Eriksson M, Fachal L, Faivre L, Fasching PA, Faust U, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gaddam P, Gammon MD, Ganz PA, Gapstur SM, Garber J, Garcia-Barberan V, Garca-Senz JA, Gaudet MM, Gauthier-Villars M, Gehrig A, GEMO Study Collaborators, Georgoulias V, Gerdes AM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, Gonzlez-Neira A, Goodfellow P, Greene MH, Alns GIG, Grip M, Gronwald J, Grundy A, Gschwantler-Kaulich D, Gunel P, Guo Q, Haeberle L, Hahnen E, Haiman CA, Hkansson N, Hallberg E, Hamann U, Hamel N, Hankinson S, Hansen TVO, Harrington P, Hart SN, Hartikainen JM, Healey CS, HEBON, Hein A, Helbig S, Henderson A, Heyworth J, Hicks B, Hillemanns P, Hodgson S, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover B, Hopper JL, Hu C, Huang G, Hulick PJ, Humphreys K, Hunter DJ, Imyanitov EN, Isaacs C, Iwasaki M, Izatt L, Jakubowska A, James P, Janavicius R, Janni W, Jensen UB, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kast K, kConFabAOCS Investigators, Keeman R, Kerin MJ, Kets CM, Keupers M, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Konstantopoulou I, Kosma VM, Kristensen VN, Kruse TA, Kwong A, Lnkholm AV, Laitman Y, Lalloo F, Lambrechts D, Landsman K, Lasset C, Lazaro C, Le Marchand L, Lecarpentier J, Lee A, Lee E, Lee JW, Lee MH, Lejbkowicz F, Lesueur F, Li J, Lilyquist J, Lincoln A, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Loud JT, Lubinski J, Luccarini C, Lush M, MacInnis RJ, Maishman T, Makalic E, Kostovska IM, Malone KE, Manoukian S, Manson JE, Margolin S, Martens JWM, Martinez ME, Matsuo K, Mavroudis D, Mazoyer S, McLean C, Meijers-Heijboer H, Menndez P, Meyer J, Miao H, Miller A, Miller N, Mitchell G, Montagna M, Muir K, Mulligan AM, Mulot C, Nadesan S, Nathanson KL, NBSC Collaborators, Neuhausen SL, Nevanlinna H, Nevelsteen I, Niederacher D, Nielsen SF, Nordestgaard BG, Norman A, Nussbaum RL, Olah E, Olopade OI, Olson JE, Olswold C, Ong KR, Oosterwijk JC, Orr N, Osorio A, Pankratz VS, Papi L, Park-Simon TW, Paulsson-Karlsson Y, Lloyd R, Pedersen IS, Peissel B, Peixoto A, Perez JIA, Peterlongo P, Peto J, Pfeiler G, Phelan CM, Pinchev M, Plaseska-Karanfilska D, Poppe B, Porteous ME, Prentice R, Presneau N, Prokofieva D, Pugh E, Pujana MA, Pylks K, Rack B, R (2017). Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet, 49(12), 1767-1778.
Wainberg ZA, Alsina M, Soares HP, Braa I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J (2017). A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol, 12(6), 775-785.
Pal SK, Maia MC, Dizman N, Agarwal N (2017). Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma? Eur Urol, 72(6), 972-973.
Chalmers A, Jensen L, Akerley W (2017). Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report. Lung Cancer, 114, 68-69.
Flaig TW, Plets M, Hussain MHA, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM Jr (2017). Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol, 3(11), e170231.
Evans E, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Foster C, Howell A, Balch L, Leonard J, Fisher T, Jenkins D, Allen C, Clavijo P, Hu-Lieskovan S, Ribas A, Smith E, Zauderer M (November 2017). Targeting the tumor microenvironment with first-in-class Semaphorin4D MAb for combination immunotherapy. [Abstract]. 5(87), Abstract P268.
Giridhar KV, Sosa CP, Hillman DW, Sanhueza C, Dalpiaz CL, Costello BA, Quevedo FJ, Pitot HC, Dronca RS, Ertz D, Cheville JC, Donkena KV, Kohli M (2017). Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma. Int J Mol Sci, 18(11).
Werner TL, Ray A, Lamb JG, VanBrocklin M, Hueftle K, Cohen AL, Beck AC, Buys SS, Dyess DL, Butler TW, Dumlao TL, Neumayer L, Khong HT (2017). A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. PMID: 28579139. Clin Breast Cancer, 17(7), 503-9.
Werner TL, Ray A, Lamb JG, VanBrocklin M, Hueftle K, Cohen AL, Beck AC, Buys SS, Dyess DL, Butler TW, Dumlao TL, Neumayer L, Khong HT (2017). A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. Clin Breast Cancer, 17(7), 503-509.
Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH (2017). Combating subclonal evolution of resistant cancer phenotypes. Nat Commun, 8(1), 1231.
Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH (2017). Combating subclonal evolution of resistant cancer phenotypes. Nat Commun, 8(1), 1231.
Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N (2017). Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. Adv Ther, 34(11), 2452-2465.
Bergerot P, Agarwal N, Pal SK, Jones J (2017). Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far from the Tree. Clin Cancer Res, 23(21), 6381-6383.
Hahn AW, Hale P, Rathi N, Agarwal N (2017). Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. Curr Opin Urol, 27(6), 559-565.
Zakharia Y, Monga V, Swami U, Bossler AD, Freesmeier M, Frees M, Khan M, Frydenlund N, Srikantha R, Vanneste M, Henry M, Milhem M (2017). Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study. Oncotarget, 8(51), 89182-89193.
Gupta S, Greenberg S, Grimmett J, Gaston D, Agarwal N, Lowrance W, Schiffman J, Kohlmann W (2017). Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers. Fam Cancer, 16(4), 545-550.
Motzer RJ, Figlin RA, Martini JF, Hariharan S, Agarwal N, Li CX, Williams JA, Hutson TE (2017). Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. Clin Genitourin Cancer, 15(5), 526-533.
Ross JS, Gay LM, Wang K, Vergilio JA, Suh J, Ramkissoon S, Somerset H, Johnson JM, Russell J, Ali S, Schrock AB, Fabrizio D, Frampton G, Miller V, Stephens PJ, Elvin JA, Bowles DW (2017). Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann Oncol, 28(10), 2539-2546.
Giridhar KV, Kohli M (2017). Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. Mayo Clin Proc, 92(10), 1564-1582.
Hahn AW, Nussenzveig RH, Pal SK, Agarwal N (2017). Blood- and tissue-based tumor genomics: a battle royale or match made in heaven? Ann Oncol, 28(10), 2333-2335.
Gupta S, Greenberg S, Grimmett J, Gaston D, Agarwal N, Lowrance W, Schiffman J, Kohlmann W (2017). Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers. Fam Cancer, 16(4), 545-550.
Mackay DR, Howa AC, Werner TL, Ullman KS (2017). Nup153 and Nup50 promote recruitment of 53BP1 to DNA repair foci by antagonizing BRCA1-dependent events. J Cell Sci, 130(19), 3347-3359.
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA (2017). Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(10), 1240-1267.
Torgeson A, Lloyd S, Boothe D, Tao R, Whisenant J, Garrido-Laguna I, Cannon GM (2017). Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer, 123(19), 3816-3824.
Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman RB, Banks KC, Choueiri TK (2017). Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur Urol, 72(4), 557-564.
Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ (2017). A Phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer, Sep 12; 17(1), 646.
Hamid O, Ros W, Thomson J, Hu-Lieskovan S, Eskens F, Diab A, Doi T, Wasser J, Spano J, Rizvi N, Angevin E, Chiappori A, Ott P, Ganguly B, Fleener C, Dell V, Liao K, Tenshang J, Chou J, El-Khoueiry A (September 2017). Safety, Pharmacokinetics and Pharmacodynamics Data from a Phase I Dose-Escalation Study of OX40 Agonistic Monoclonal Antibody (mAb) PF-04518600 in Combination with Utomilumab, A 4-1BB Agonistic mAb [Abstract]. 28(5 Supplement), v403-v427.
Hu-Lieskovan S, Braiteh F, Grilley-Olson J, Chou J, Davda J, Jin B, Forgie A, Rassam D, Youssef S, Johnson M (September 2017). Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF‑06801591, an anti-PD1 antibody administered intravenously (IV) or subcutaneously (SC) [Abstract]. 28(5 Supplement), v403-v427.
Ott P, Naing A, Ramaswamy G, Margolin K, Moles M, Gaynor R, Goldstein M, Hu-Lieskovan S (September 2017). An open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder. [Abstract]. 28(5 Supplement), v403-v427.
Shuch B, Hahn AW, Agarwal N (2017). Current Treatment Landscape of Advanced Papillary Renal Cancer. J Clin Oncol, 35(26), 2981-2983.
Ahmad Halwani, Zachary Burningham, Kelli M Rasmussen, Vikas Patil, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C Sauer (2017). Practice Patterns in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Evidence From the Veterans Health Administration [Abstract]. ESMO Annual Meeting 2017.
Sumanta Pal, Vincent Chun, Scott Tagawa, Joel Picus, Sumati Gupta, Julie Poore, Christine Peterson and Ely Benaim (2017). RX-3117, an Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Metastatic Bladder Cancer [Abstract]. ESMO Annual Meeting 2017.
Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N (2017). Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clin Genitourin Cancer, S1558-7673(10.1016/j.).
Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N (2017). Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. (Epub ahead of print) Clin Genitourin Cancer.
Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ Jr, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X (2017). Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol, 35(25), 2885-2892.
Pulluri B, Kumar A, Shaheen M, Jeter J, Sundararajan S (2017). Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. Pharmacol Res, 123, 95-102.
Smith-Cohn MA, Gill D, Voorhies BN, Agarwal N, Garrido-Laguna I (2017). Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. Immunotherapy, 9(10), 797-804.
Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, De Giorgi U, Hussain S, Alva AS, Baniel J, Agarwal N, Rosenberg JE, Vaishampayan UN, Galsky MD, Yu EY, RISC Investigators (2017). Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. (Epub ahead of print) Clin Genitourin Cancer.
Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM (2017). Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clin Cancer Res, 23(16), 4704-4715.
Maia MC, Yang ES, Agarwal N, Pal SK (2017). A step towards predicting checkpoint inhibitor response in kidney cancer. Lancet Oncol, 18(8), 982-983.
Shenoy N, Dronca R, Quevedo F, Boorjian SA, Cheville J, Costello B, Kohli M, Witzig T, Pagliaro L (2017). Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity? Chin J Canc Res, 29(4), 374-378.
Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ (2017). Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis. Clin Genitourin Cancer, 15(4), e573-e582.
Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal N (2017). Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clin Genitourin Cancer, 15(4), e599-e602.
Scannell Bryan M, Argos M, Andrulis IL, Hopper JL, Chang-Claude J, Malone K, John EM, Gammon MD, Daly M, Terry MB, Buys SS, Huo D, Olopade O, Genkinger JM, Jasmine F, Kibriya MG, Chen L, Ahsan H (2017). Limited influence of germline genetic variation on all-cause mortality in women with early onset breast cancer: evidence from gene-based tests, single-marker regression, and whole-genome prediction. Breast Cancer Res Treat, 164(3), 707-717.
Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal N (2017). Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clin Genitourin Cancer, 15(4), e599-e602.
Vaklavas C, Blume SW, Grizzle WE (2017). Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development. Front Oncol, 7, 158.
Du M, Giridhar KV, Tian Y, Tschannen MR, Zhu J, Huang CC, Kilari D, Kohli M, Wang L (2017). Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. Oncotarget, 8(38), 63703-63714.
Nelson KL, Stenehjem D, Driscoll M, Gilcrease GW (2017). Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib. Front Oncol, 7, 150.
Narayan V, Keefe S, Haas N, Wang L, Puzanov I, Putt M, Catino A, Fang J, Agarwal N, Hyman D, Smith AM, Finkelman BS, Narayan HK, Ewer S, ElAmm C, Lenihan D, Ky B (2017). Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res, 23(14), 3601-3609.
Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, Rodriguez G, Schorge JO, Sherman M, Daly MB, Rutherford T, Brewster WR, OMalley DM, Partridge E, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek S, Davidson SA, Edwards R, Elg SA, Wakeley K, Phillips KA, Armstrong D, Horowitz I, Fabian CJ, Walker J, Sluss PM, Welch W, Minasian L, Horick NK, Kasten CH, Nayfield S, Alberts D, Finkelstein DM, Lu KH (2017). Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res, 23(14), 3628-3637.
Chalmers A, Akerley W (2017). Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naïve, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice. [Letter to the editor]. J Clin Oncol, 35(20), 2340.
Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin Al Olama A, Tyrer JP, Southey M, John EM, Conner TA, Goldgar DE, Buys SS, Janavicius R, Steele L, Ding YC, Neuhausen SL, Hansen TVO, Osorio A, Weitzel JN, Toss A, Medici V, Cortesi L, Zanna I, Palli D, Radice P, Manoukian S, Peissel B, Azzollini J, Viel A, Cini G, Damante G, Tommasi S, Peterlongo P, Fostira F, Hamann U, Evans DG, Henderson A, Brewer C, Eccles D, Cook J, Ong KR, Walker L, Side LE, Porteous ME, Davidson R, Hodgson S, Frost D, Adlard J, Izatt L, Eeles R, Ellis S, Tischkowitz M, EMBRACE, Godwin AK, Meindl A, Gehrig A, Dworniczak B, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Hauke J, Rhiem K, Kast K, Arnold N, Ditsch N, Wang-Gohrke S, Wappenschmidt B, Wand D, Lasset C, Stoppa-Lyonnet D, Belotti M, Damiola F, Barjhoux L, Mazoyer S, GEMO Study Collaborators, Van Heetvelde M, Poppe B, De Leeneer K, Claes KBM, de la Hoya M, Garcia-Barberan V, Caldes T, Perez Segura P, Kiiski JI, Aittomki K, Khan S, Nevanlinna H, van Asperen CJ, HEBON, Vaszko T, Kasler M, Olah E, Balmaa J, Gutirrez-Enrquez S, Diez O, Teul A, Izquierdo A, Darder E, Brunet J, Del Valle J, Feliubadalo L, Pujana MA, Lazaro C, Arason A, Agnarsson BA, Johannsson OT, Barkardottir RB, Alducci E, Tognazzo S, Montagna M, Teixeira MR, Pinto P, Spurdle AB, Holland H, KConFab Investigators, Lee JW, Lee MH, Lee J, Kim SW, Kang E, Kim Z, Sharma P, Rebbeck TR, Vijai J, Robson M, Lincoln A, Musinsky J, Gaddam P, Tan YY, Berger A, Singer CF, Loud JT, Greene MH, Mulligan AM, Glendon G, Andrulis IL, Toland AE, Senter L, Bojesen A, Nielsen HR, Skytte AB, Sunde L, Jensen UB, Pedersen IS, Krogh L, Kruse TA, Caligo MA, Yoon SY, Teo SH, von Wachenfeldt A, Huo D, Nielsen SM, Olopade OI, Nathanson KL, Domchek SM, Lorenchick C, Jankowitz RC, Campbell I, James P, Mitchell G, Orr N, Park SK, Thomassen M, Offit K, Couch FJ, Simard J, Easton DF, Chenevix-Trench G, Schmutzler RK, Antoniou AC, Ottini L (2017). Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol, 35(20), 2240-2250.
Parisi G, Saco J, Hu-Lieskovan S, Zhang R, Krystofinski P, Puig Saus C, Charych D, Ribas A (July 2017). Antitumor activity of NKTR-214 in combination with pmel-1 ACT in an aggressive murine melanoma model [Abstract]. 77(13 Supplement), Abstract 2671.
Zaretsky J, Garcia-Diaz A, Shin D, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Eroglu Z, Torrejon D, Tumeh P, Lo R, Ribas A (July 2017). Mechanisms of resistance to anti-PD-1 immunotherapy through interferon pathway mutations [Abstract]. 77(13 Supplement), Abstract NG04.
Torrejon D, Zaretsky J, Shin D, Onyshchenko M, Abril-Rodriguez G, Vega-Crespo A, Puig-Saus C, Cheung-Lau G, Long C, Comin-Anduix B, Hu-Lieskovan S, Ribas A (July 2017). Interrogating resistance mechanisms to PD-1 blockade therapy with CRISPR [Abstract]. 35(15 Supplement), Abstract 3077.
Naing A, HuLieskovan S, Govindan R, Margolin K, Moles M, Gaynor R, Goldstein M, Ott P (July 2017). An open‐label, Phase IB study of NEO‐PV‐01 + Adjuvant with Nivolumab in Patients with Melanoma, Non‐Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder [Abstract]. 35(15 Supplement), Abstract TPS3116.
Hu-Lieskovan S, Eroglu Z, Zaretsky J, Kim D, Algazi A, Johnson D, Liniker E, Kong B, Munhoz R, Rapisuwon S, Chmielowski B, Sosman J, Scolyer R, Joseph R, Postow M, Carlina M, Hwu W-J, Long G, Ribas A (July 2017). Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors [Abstract]. 35(15 Supplement), Abstract 9558.
Evans E, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Foster C, Howell A, Comeau S, Balch L, Knapp A, Leonard J, Fisher T, Hu-Lieskovan S, Ribas A, Smith E, Zauderer M (July 2017). Breaking down the barrier restricting infiltration and differentiation of APC in the tumor microenvironment with a first-in-class antibody targeting Semaphorin4D, and rational combination therapies [Abstract]. 77(13 Supplement), Abstract 3661.
Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, Domchek SM, Robson M, Spurdle AB, Ramus SJ, Mavaddat N, Terry MB, Neuhausen SL, Schmutzler RK, Simard J, Pharoah PDP, Offit K, Couch FJ, Chenevix-Trench G, Easton DF, Antoniou AC (2017). Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.LID - 10.1093/jnci/djw302 [doi]. PMID: 28376175. J Natl Cancer Inst, 109(7).
Tolcher A, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, Thall AD, Pathan N, Schmidt EV, Chow LQ (Jun 2017). Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab in patients with advanced solid tumors. Clin Cancer Res.
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017). Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA, 317(23), 2402-2416.
Terry MB, Keegan THM, Houghton LC, Goldberg M, Andrulis IL, Daly MB, Buys SS, Wei Y, Whittemore AS, Protacio A, Bradbury AR, Chung WK, Knight JA, John EM (2017). Pubertal development in girls by breast cancer family history: the LEGACY girls cohort. Breast Cancer Res, 19(1), 69.
Garrido-Laguna I, Krop IE, Burris H, Hamilton EP, Braiteh FS, Weise A, Abu-Khalaf MM, Zopf C, Lakshminarayanan M, Holland JS, Baffa R, Hong DS (2017). A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer. Presented at the 2017 ASCO Annual Meeting on June 5, 2017. [Abstract]. J Clin Oncol, 35(suppl; abstr 2511).
El-Khoueiry A, Hamid O, Thompson JA, Ros W, Eskens FA, Doi T, Hu-Lieskovan S, Chou J, Liao K, Ganguly BJ, Fleener CA, Joh T, Diab A (2017). The Relationship of Pharmacodynamics (PD) and Pharmacokinetics (PK) to Clinical Outcomes in a Phase I Study of OX40 Agonistic Monoclonal Antibody (mAb) PF-04518600 (PF-8600) [Abstract]. 35(15 Supplement), Abstract 3027.
Terada N, Maughan BL, Akamatsu S, Kobayashi T, Yamasaki T, Inoue T, Kamba T, Ogawa O, Antonarakis ES (2017). Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. Int J Urol, 24(6), 441-448.
De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK (2017). Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer, 15(3), 403-410.e2.
Zhang FF, Haslam DE, Terry MB, Knight JA, Andrulis IL, Daly MB, Buys SS, John EM (2017). Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry. Cancer, 123(11), 2070-2079.
Agarwal N, Hahn AW, Gill DM, Farnham JM, Poole AI, Cannon-Albright L (2017). Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer. JAMA Oncol, 3(6), 856-857.
Boothe D, Williams N, Odei B, Poppe MM, Werner TL, Suneja G, Gaffney DK (2017). The Addition of Adjuvant Chemotherapy to Radiation in Early-Stage High-Risk Endometrial Cancer: Survival Outcomes and Patterns of Care. Int J Gynecol Cancer, 27(5), 912-922.
Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R (2017). Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(6), 804-834.
Knepper TC, Freeman ML, Gibney GT, McLeod HL, Russell JS (2017). Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma. JAMA Dermatol, 153(6), 607-609.
Akerley WL, Arnaud AM, Reddy B, Page RD (2017). Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer. Curr Med Res Opin, 33(6), 1091-1097.
Trang H Au, Kai Wang, David Stenehjem, Ignacio Garrido-Laguna (2017). Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol, 8(3), 387-404.
Hahn AW, Gill DM, Pal SK, Agarwal N (2017). The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy, 9(8), 681-692.
Hansberry DR, Donovan AL, Prabhu AV, Agarwal N, Cox M, Flanders AE (2017). Enhancing the Radiologist-Patient Relationship through Improved Communication: A Quantitative Readability Analysis in Spine Radiology. AJNR Am J Neuroradiol, 38(6), 1252-1256.
Gill DM, Agarwal N, Vaishampayan U (2017). Evolving Treatment Paradigm in Metestatic Renal Cell Carcinoma. PMID: 28561652. Am Soc Clin Oncol Educ Book.
Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DYC (2017). Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol, 71(6), 970-978.
Pandha HS, Ralph C, Harrington K, Curti BD, Sanborn RE, Akerley WL, Gupta S, Rudin CM, Rosenberg JE, Kaufman DR, Schmidt EV, Grose M, Shafren D (2017). Keynote-200 phase 1b: A novel combination study of intravenously delivered coxsackievirus A21 and pembrolizumab in advanced cancer patients [Abstract]. ASCO Annual Meeting 2017.
Grivas P, Nagy RJ, Pond GR, Gupta S, Wang J, Vaishampayan UN, Pal SK, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata P, Lanman RB, Talasaz AA, Sonpavde G (2017). Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape [Abstract]. ASCO Annual Meeting 2017.
Choueiri TK, Larkin JMG, Oya M, Thistlethwaite FC, Martignoni M, Nathan PD, Powles T, McDermott DF, Robbins PB, Chism DD, Cho DC, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, di Pietro A, Rini BI (2017). First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. [Abstract]. ASCO Annual Meeting 2017.
Gong J, Chung VM, Picus J, Tagawa ST, Gupta S, Poore J, Peterson C, Benaim E, Pal SK (2017). Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ia/IIb study. [Abstract]. ASCO Annual Meeting 2017.
Swami U, Monga V, Tanas M, Bossler A, Mott S, Smith B, Milhem M (2017). A pilot study targeting angiogenesis using bevacizumab combined with gemcitabine/docetaxel and valproic acid (VPA), a histone deacetylase inhibitor (HDACi) in advanced soft tissue sarcomas (STS) [poster presentation also given at the American Association for Cancer Research Special Conference on Advances in Sarcomas: From Basic Science to Clinical Translation, Philadelphia, PA, May, 18, 2017 [Abstract]. Clinical Cancer Research, 24(2 suppl), B23.
Michaelson MD, Gupta S, Agarwal N, Szmulewitz RZ, Powles T, Pili R, Bruce JY, Vaishampayan UN, Larkin JMG, Rosbrook B, Lechuga M, Valota O, Tarazi JC, Shepard DR (2017). Axitinib plus crizotinib in patients with advanced solid tumors and metastatic renal cell carcinoma (mRCC): Preliminary phase 1b results [Abstract]. Journal of Clinical Oncology.
De Bono JS, Hussain M, Thiery-Vuillemin A, Mateo J, Sartor AO, Chi KN, Fizazi K, Twardowski P, Agarwal N, Sandhu SK, Olmos D, Shore ND, Saad F, Liu S, Goessl CD, Burgents J (2017). PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration [Abstract]. Journal of Clinical Oncology.
Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal N (2017). Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget, 8(20), 33614-33620.
Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal N (2017). Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget, 8(20), 33614-33620.
Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, Sharma L, Saam J, Lancaster J, Daly MB (2017). A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. PMID: 28085182. Cancer, 123(10), 1721-30.
Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A (2017). Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep, 19(6), 1189-1201.
Garland EL, Thielking P, Thomas EA, Coombs M, White S, Lombardi J, Beck A (2016). Linking dispositional mindfulness and positive psychological processes in cancer survivorship: a multivariate path analytic test of the mindfulness-to-meaning theory. Psychooncology, 26(5), 686-692.
Gill DM, Sonpavde G, Pal SK, Agarwal N (2017). Which checkpoint inhibitor? An embarrassment of riches for bladder cancer. Immunotherapy, 9(6), 463-466.
Akerley W (2017). Biomarker-Based Treatment Selection in Non-Small Cell Lung Cancer. J Natl Compr Canc Netw, 15(5S), 689-691.
Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC Jr, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N, AOCS study group, Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaa J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KBM, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, DAloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Drk T, Dossus L, Duran M, Drst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlertsen B, Ekici AB, Ellis S, Elvira M, EMBRACE Study, Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, Garca MJ, Garcia-Barberan V, Gehrig A, GEMO Study Collaborators, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Hkansson N, Hamann U, Hansen TVO, Harrington PA, Harris HR, Hauke J, HEBON Study, Hein A, Henderson A, Hildebrandt MAT, Hillemanns P, Hodgson S, Hgdall CK, Hgdall E, Hogervorst FBL, Holland H, Hooning MJ, Hosking K, Huang RY, Hulick PJ, Hung J, Hunter DJ, Huntsman DG, Huzarski T, Imyanitov EN, Isaacs C, Iversen ES, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jernetz M, Jensen A, Jensen UB, John EM, Johnatty S, Jones ME, Kannisto P, Karlan BY, Karnezis A, Kast K, KConFab Investigators, Kennedy CJ, Khusnutdinova E, Kiemeney LA, Kiiski JI, Kim SW, Kjaer SK, Kbel M, Kopperud RK, Kruse TA, Kupryjanczyk J, Kwong A, Laitman Y, Lambrechts D, Larraaga N, Larson MC, Lazaro C, Le ND, Le Marchand L, Lee JW, Lele SB, Leminen A, Leroux D, Lester J, Lesueur F, Levine DA, Liang D, Liebrich C, Lilyquist J, Lipworth L, Lissowska J, Lu KH, Lubinski J, Luccarini C, Lundvall L, Mai PL, Mendoza-Fandio G, Manoukian S, Massuger LFAG, May T, Mazoyer S, McAlpine JN, McGuire V, McLaughlin JR, McNeish I, Meijers-Heijboer H, Meindl A, Menon U, Mensenkamp AR, Merritt MA, Milne RL, Mitchell G, Modugno F, Moes-Sosnowska J, Moffitt M, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Nathanson KL, Nedergaard L, Ness RB, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Odunsi K, Olah E, Olopade OI, Olsson H, Olswold C, OMalley DM, Ong KR, Onland-Moret NC, OPAL study group, Orr N, Orsulic S, Osorio A, Palli D, Papi L, Park-Simon TW, Paul J, Pearce CL, Pedersen IS, Peeters PHM, Peissel B, Peixoto A, Pejovic T, Pelttari LM, Permuth JB, Peterlongo P, Pezzani L, Pfeiler G, Phillips KA, Piedmonte M, Pike MC, Piskorz AM, Poblete SR, Pocza T, Poole EM, Poppe B, Porteous ME, Prieur F, Prokofyeva D, Pugh E, Pujana MA, Pujol P, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rhiem K, Rice P, Richardson A, Robson M, Rodriguez GC, Rodrguez-Antona C, Romm J, Rookus MA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Salvesen HB, Sandler DP, Schoemaker MJ, Senter L, Setiawan VW, Severi G, Sharma P, Shelford T, Siddiqui N, Side LE, Sieh W, Singer CF, Sobol H, Song H, Southey MC, Spurdle AB, Stadler Z, Steinemann D, Stoppa-Lyonnet D, Sucheston-Campbell LE, Sukiennicki G, Sutphen R, Sutter C, Swerdlow AJ, Szabo CI, Szafron L, T (2017). Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet, 49(5), 680-691.
Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC (2017). Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Med, 6(5), 902-909.
Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, Nakabayashi M, McKay R, Pomerantz M, Mucci LA, Taplin ME, Sweeney CJ, Lee GM, Kantoff PW (2017). The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate, 77(13)(10.1002/pr), 1303-1311.
Swami U, Shah U, Goel S (2017). Eribulin in non-small cell lung cancer: challenges and potential strategies. [Review]. Expert Opin Investig Drugs, 26(4), 495-508.
Carmichael H, Matsen C, Freer P, Kohlmann W, Stein M, Buys SS, Colonna S (2017). Breast cancer screening of pregnant and breastfeeding women with BRCA mutations. Breast Cancer Res Treat, 162(2), 225-230.
Cohen AL, Neumayer L, Boucher K, Factor R, Shtrestha G, Wade M, Lamb G, Arbogast Ky, Piccolo S, Riegert J, Schabel M, Bild A, Werner TL (4/2017). A Window of Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker [Abstract]. JCO Precision Oncology, 1(April 2017), 1-11.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, DAmico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2017). Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(4), 504-535.
Carmichael H, Matsen C, Freer P, Kohlmann W, Stein M, Buys SS, Colonna S (2017). Breast cancer screening of pregnant and breastfeeding women with BRCA mutations. PMID: 28138892. [Review]. Breast Cancer Res Treat, 162(2), 225-30.
Tao R, Lloyd S, Burt L, Whisenant J, Garrido-Laguna I, Das P (2017). Pelvic Reirradiation for the Treatment of Locally Recurrent Rectal Cancer. Current Colorectal Cancer Reports, 13(2), 175-82.
Hawkins ML, Buys SS, Gren LH, Simonsen SE, Kirchhoff AC, Hashibe M (2017). Do cancer survivors develop healthier lifestyle behaviors than the cancer-free population in the PLCO study? J Cancer Surviv, 11(2), 233-245.
Bowen ME, Mone MC, Buys SS, Sheng X, Nelson EW (2017). Surgical Outcomes for Mastectomy Patients Receiving Neoadjuvant Chemotherapy: A Propensity-Matched Analysis. Ann Surg, 265(3), 448-456.
Nikita Pandya, Robert Hanlon, Andrew Butterfield, Sumati Gupta (2017). Epigenetics in Cancer: A Review. Can Stu The J 2017.
Rengifo-Cam W, Jasperson K, Garrido-Laguna I, Colman H, Scaife C, Samowitz W, Samadder NJ (2017). A 30-Year-Old Man with Three Primary Malignancies: A Case of Constitutional Mismatch Repair Deficiency. ACG Case Reports Journal, 4, e34.
Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK (2017). Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag, 4(1), 13-37.
Mooney KH, Beck SL, Wong B, Dunson W, Wujcik D, Whisenant M, Donaldson G (2017). Automated home monitoring and management of patient-reported symptoms during chemotherapy: results of the symptom care at home RCT. Cancer Med, 6(3), 537-546.
Zhang BY, Riska SM, Mahoney DW, Costello BA, Kohli R, Quevedo JF, Cerhan JR, Kohli M (2016). Germline genetic variation in JAK2 as a prognostic marker in castration-resistant prostate cancer. BJU Int, 119(3), 489-495.
Ahmad Halwani, Kelli M Rasmussen, Vikas Patil, Zachary Burningham, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie N Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C, Saier (2017). Racial Disparities in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Evidence from the Veteran’s Health Administration (VHA) AACR [Abstract]. Prostate Cancer: Advances in Basic, Translational, and Clinical Research meeting 2017.
Kelli M Rasmussen, Vikas Patil, Zachary Burningham, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C Sauer, Ahmad Halwani (2017). The role of academic affiliation in the treatment of metastatic castrate-resistant prostate cancer in the Veterans Health Administration Abstract- AVAHO 2017 [Abstract]. AVAHO 2017.
Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ (2016). Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget, 8(9), 16052-16074.
Gill DM, Stenehjem DD, Cheng HH, Kessler ER, Hahn AW, Gupta S, Alex A, Patel S, Chittoria N, Twardowski P, Vaishampayan UN, Agarwal N (2017). Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC) [Abstract]. Journal of Clinical Oncology, 35(6S suppl), abstract 265.
Poole A, Gill DM, Hahn AW, Johnson E, Carroll E, Batten JA, Gupta S, Boucher KM, Maughan BL, Agarwal N (2017). Incidence and characterization of antiandrogen withdrawal syndrome (AAWS) after enzalutamide (ENZA) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). [Abstract]. GU ASCO 2017.
Hahn AW, Gill DM, Streeter J, Bailey EB, Carroll E, Aryal L, Batten JA, Gupta S, Agarwal N, Maughan BL (2017). Intra-individual genomic diversity between circulating tumor cell-free DNA (cfDNA) and tumor tissue testing in metastatic renal cell carcinoma (mRCC) [Abstract]. GU ASCO 2017.
Gupta S, Albertson DJ, Parnell T, Dalley B, O Shea J, Weston A, Butterfield A, Pappas LM, Schiffman JD, Sharma S, Agarwal N (2017). Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC) [Abstract]. GU ASCO 2017.
Gupta S, Albertson DJ, Gaston D, Heilbrun ME, Agarwal N, Liu T, Miller VA, Ross JS, Milis SZ, Ali SM (2017). Comprehensive genomic sequencing of urothelial tumors to identify rare driver genomic alterations in SMARCB1 in a subset of patients [Abstract]. GU ASCO 2017.
Carroll E, Gill DM, Poole A, Hahn AW, Bailey EB, Streeter J, Batten JA, Gupta S, Agarwal N, Maughan BL (2017). Genomic diversity between primary tumor tissue and tumor circulating cell-free DNA (cfDNA) in patients (pts) with metastatic prostate cancer [Abstract]. GU ASCO 2017.
Grivas P, Nagy RJ, Pond GR, Gupta S, Wang J, Vaishampayan UN, Pal SK, Bilen MA, Naik G, Ghatalia P, Gopalakrishnan D, Barata P, Lanman RB, Talasaz AA, Sonpavde G (2017). Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy. [Abstract]. GU ASCO 2017.
Gill DM, Stenehjem DD, Cheng HH, Kessler ER, Hahn, AW, Gupta S, Alex A, Patel SB, Chittoria N, Twardowski P, Vaishampayan UN, Agarwal N (2017). Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC) [Abstract]. GU ASCO 2017.
Sharma P, Hu-Lieskovan S, Wargo J, Ribas A (February 2017). Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. [Review]. Cell, 168(4), 707-723.
Patel S, Mason CC, Glenn MJ, Paxton CN, South ST, Cessna MH, Asch J, Cobain EF, Bixby DL, Smith LB, Reshmi S, Gastier-Foster JM, Schiffman JD, Miles RR (2017). Genomic analysis of adult B-ALL identifies potential markers of shorter survival. Leuk Res, 56, 44-51.
Parker SJ, Pond GR, Agarwal N, Alex A, Heilbrun ME, Sonpavde G (2017). Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer, 15(1), 53-59.
Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, Bjarnason GA, Yamamoto H, Beuselinck B, Rini BI, Knox JJ, Agarwal N, Ernst DS, Pal SK, Wood LA, Bamias A, Alva AS, Kanesvaran R, Choueiri TK, Heng DY (2017). Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol, 71(2), 204-209.
Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S (2016). Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clin Genitourin Cancer, 15(1), 31-41.e4.
Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S (2017). Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clin Genitourin Cancer, 15(1), 31-41.e4.
Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L, RISC Investigators (2017). Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol, 71(2), 281-289.
Pendurti G, Shah U, Swami U, Hou Y, Ghalib MH, Chaudhary I, Polineni R, Klobocista M, Mukherjee P, Chuy JW, Kaubisch A, Rajdev L, Aparo S, Goel S (2017). Developing a novel prognostic model to predict overall survival (OS) and 90 day mortality rate (90DM) for metastatic colorectal cancer (mCRC) patients in phase I trials [Abstract].
Goel S, Moran T, Coronado C, Ramirez SV, Chaudhary I, Ghalib MH, Swami U, Hou Y, Carcereny E, Alcantara J, Dios JLI, Miguel BD, Buges C, Rosell R (2017). Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors [Abstract].
Carmicheal H, Matsen C, Freer P, Kohlmann W, Stein M, Buys SS, Colonna S, MD (2017). Breast cancer screening of pregnant and breastfeeding women with BRCA mutations. doi: 10.1007/s10549-017-4122-y. Review. PubMed PMID: 28138892. Breast Cancer Res Treat, 162(2), 225-230.
Shah U, Pendurti G, Swami U, Hou Y, Ghalib MH, Chaudhary I, Mani S, Goel S, Aparo S (2017). Clinical outcome for patients with metastatic colorectal cancer (mCRC) enrolled in phase I clinical trials: Single institution experience [Abstract].
Gupta S, Gill D, Poole A, Agarwal N (2017). Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions. Cancers (Basel), 9(2).
Cavalieri CC, Swanson E, Whisenant JR, Weis JR, Gilcrease GW, Stenehjem DD, Sharma S, Garrido-Laguna I (Jan 2017). Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience. Presented at the 2017 Gastrointestinal Cancers Symposium, Poster Session C: Cancers of the Colon, Rectum, and Anus. [Abstract]. J Clin Oncology, 35(suppl 4S; abstract 792).
Theresa Louise Werner, Esther Kannapel, Melissa Chen, Judy Chen, Adam Louis Cohen (2017). Safety and PK results from a phase Ib study of AL3818 (anlotinib) hydrochloride in subjects with ovarian, cervical, and endometrial cancer [Abstract]. 35(15).
Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N (2017). Neutrophil-lymphocyte ratio as a predictive biomarker for response to high does interleukin-2 in patients with renal cell carcinoma. BMC Urology.
Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N (2017). Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urology, 17(1), 1.
Hu-Lieskovan S, Ribas R (Jan/Feb 2017). New combination strategies using PD-1/ L1 checkpoint inhibitors as a backbone. [Review]. Cancer J, 23(1), 10-22.
Maughan BL, Bailey E, Gill DM, Agarwal N (2017). Incidence of Immune-Related Adverse Events with Program Death Receptor-1-and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers. Front Oncol, 7, 56.
Hu-Lieskovan S, Chmielowski B, Ribas A (2017). Cancer Immunotherapy. In Chmielowski B, Territo MC (Eds.), Manual of Clinical Oncology (Eighth Edition). Lippincott Williams & Wilkins.
Odei B, Boothe D, Suneja G, Werner TL, Gaffney DK (2017). Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival [Epub ahead of Print]. Am J Clin Oncol.
Thibault J, Patel SB (2017). A Case of Mytomycin-C Induced Pulmonary Veno-Occlusive Disease [Abstract]. AVAHO Updates.
Swami U, Monga V, Milhem M (2017). Gastrointestinal stromal tumors-are we stuck and the way forward. Transl Gastroenterol Hepatol, 2, 93.
Hamdi Y, Soucy P, Kuchenbaeker KB, Pastinen T, Droit A, Lemaon A, Adlard J, Aittomki K, Andrulis IL, Arason A, Arnold N, Arun BK, Azzollini J, Bane A, Barjhoux L, Barrowdale D, Benitez J, Berthet P, Blok MJ, Bobolis K, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caligo MA, Chiquette J, Chung WK, Claes KB, Daly MB, Damiola F, Davidson R, De la Hoya M, De Leeneer K, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Eccles D, Eeles R, Einbeigi Z, Ejlertsen B, EMBRACE, Engel C, Gareth Evans D, Feliubadalo L, Foretova L, Fostira F, Foulkes WD, Fountzilas G, Friedman E, Frost D, Ganschow P, Ganz PA, Garber J, Gayther SA, GEMO Study Collaborators, Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gronwald J, Hahnen E, Hamann U, Hansen TV, Hart S, Hays JL, HEBON, Hogervorst FB, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Joseph V, Just W, Kaczmarek K, Karlan BY, KConFab Investigators, Kets CM, Kirk J, Kriege M, Laitman Y, Laurent M, Lazaro C, Leslie G, Lester J, Lesueur F, Liljegren A, Loman N, Loud JT, Manoukian S, Mariani M, Mazoyer S, McGuffog L, Meijers-Heijboer HE, Meindl A, Miller A, Montagna M, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Nussbaum RL, Olah E, Olopade OI, Ong KR, Oosterwijk JC, Osorio A, Papi L, Park SK, Pedersen IS, Peissel B, Segura PP, Peterlongo P, Phelan CM, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Richardson A, Robson M, Rodriguez GC, Rookus MA, Schmutzler RK, Sevenet N, Shah PD, Singer CF, Slavin TP, Snape K, Sokolowska J, Snderstrup IM, Southey M, Spurdle AB, Stadler Z, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Tan Y, Tea MK, Teixeira MR, Teul A, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van den Ouweland AM, van der Luijt RB, van Engelen K, van Rensburg EJ, Varon-Mateeva R, Wappenschmidt B, Wijnen JT, Rebbeck T, Chenevix-Trench G, Offit K, Couch FJ, Nord S, Easton DF, Antoniou AC, Simard J (2017). Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat, 161(1), 117-134.
Li H, Feng B, Miron A, Chen X, Beesley J, Bimeh E, Barrowdale D, John EM, Daly MB, Andrulis IL, Buys SS, Kraft P, kConFab investigators, Thorne H, Chenevix-Trench G, Southey MC, Antoniou AC, James PA, Terry MB, Phillips KA, Hopper JL, Mitchell G, Goldgar DE (2017). Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. Genet Med, 19(1), 30-35.
Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY (2017). Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Med, 6(1), 186-194.
Maughan BL, Luber B, Nadal R, Antonarakis ES (2017). Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. Prostate, 77(1), 33-40.
Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S (2017). NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. J Natl Compr Canc Netw, 15(1), 9-20.
Strom T, Naghavi AO, Messina JL, Kim S, Torres-Roca JF, Russell J, Sondak VK, Padhya TA, Trotti AM, Caudell JJ, Harrison LB (2016). Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck. Head Neck, 39(1), 48-55.
Kam AE, Chaudhary I, Ghalib MH, Shah UH, Swami U, Kuo DYS, Hwang C, Elrafei TN, Cohen B, Gartrell BA, Kaledzi E, Chuy JW, Cheng H, Rajdev L, Haigentz M Jr, Mani S, Goel S (2017). Risks and benefits of phase I trials: Eighteen-year experience from a single institution [Abstract]. J Clin Oncol, 35(suppl; abstr e18146).
Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung, Higano CS (2017). Reply to M.A.N. Sendur et al and J. Michels. J Clin Oncol, 35(1), 123.
Albright FS, Stephenson RA, Agarwal N, Cannon-Albright LA (2017). Relative Risks for Lethal Prostate Cancer Based on Complete Family History of Prostate Cancer Death. Prostate, 77(1), 41-48.
Strom TJ, Naghavi AO, Trotti AM, Russell J, Kish JA, McCaffrey J, Otto KJ, Harrison LB, Caudell JJ (2016). Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years. J Geriatr Oncol, 8(1), 50-55.
Swami U, Monga V, Zakhraia Y, Milhem M (2017). Immunomodulation of pembrolizumab (pembro) treated metastatic melanoma patients (pts) after progression with sequential temozolomide (TMZ): A case series [Abstract]. J Clin Oncol, 35(suppl 7S; abstract 123).
Wang K, Russell JS, McDermott JD, Elvin JA, Khaira D, Johnson A, Jennings TA, Ali SM, Murray M, Marshall C, Oldham DS, Washburn D, Wong SJ, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Serracino HS, Ross JS, Bowles DW (2016). Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. Clin Cancer Res, 22(24), 6061-6068.
Johnson ED, Gulbahce E, McNally J, Buys SS (2016). Malignant Phyllodes Tumor Presenting in Bone, Brain, Lungs, and Lymph Nodes. Case Rep Oncol, 9(3), 861-868.
Gill D, Hahn AW, Sonpavde G, Agarwal N (2016). Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Hum Vaccin Immunother, 12(12), 2997-3004.
Powers JL, Buys SS, Fletcher D, Melis R, Johnson-Davis KL, Lyon E, Malmberg EM, McMillin GA (2016). Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. J Clin Pharmacol, 56(12), 1570-1581.
Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP (2016). Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother, 65(12), 1533-1544.
Maughan BL, Suzman DL, Luber B, Wang H, Glavaris S, Hughes R, Sullivan R, Harb R, Boudadi K, Paller C, Eisenberger M, Demarzo A, Ross A, Antonarakis ES (2016). Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol, 78(6), 1297-1304.
Colonna SV, Gammon A (2016). Management of the Patient with a Genetic Predisposition for Breast Cancer. In Dr. Ismail Jatoi and Dr. Achim Rody (Eds.), Management of Breast Diseases (Second Edition).
Ribas A, Hu-Lieskovan S (November 2016). What does PD-L1 positive or negative tumors mean? Perspective for Clinical Correlates of Immunotherapy. [Review]. J Exp Med, 213(13), 2835-2840.
Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Abril Rodriguez G, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A (Nov 2016). Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov.
Agarwal N (2016). Vaccine Therapy in Metastatic Renal Cell Carcinoma: Past, Present, and Future. ASCO Post. [Web]. Available: http://goo.gl/CqKjqd.
Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, Apostolou P, Arnold N, Arun BK, Barrowdale D, Benitez J, Berger R, Berthet P, Borg A, Buys SS, Caldes T, Carter J, Chiquette J, Claes KB, Couch FJ, Cybulski C, Daly MB, de la Hoya M, Diez O, Domchek SM, Nathanson KL, Durda K, Ellis S, Evans DG, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Glendon G, Godwin AK, Greene MH, Gronwald J, Hahnen E, Hallberg E, Hamann U, Hansen TV, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska-Bieniek K, John EM, Karlan BY, Kaufman B, Investigators K, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Loman N, Lubinski J, Manoukian S, Mitchell G, Montagna M, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Offit K, Olah E, Olopade OI, Park SK, Piedmonte M, Radice P, Rappaport-Fuerhauser C, Rookus MA, Seynaeve C, Simard J, Singer CF, Soucy P, Southey M, Stoppa-Lyonnet D, Sukiennicki G, Szabo CI, Tancredi M, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Toland AE, Toloczko-Grabarek A, Tung N, van Rensburg EJ, Villano D, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Zidan J, Zorn KK, McGuffog L, Easton D, Chenevix-Trench G, Antoniou AC, Ramus SJ (2016). Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. PMID: 27836010. Breast Cancer Res, 18(1), 112.
Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L (2016). miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer, 15(1), 70.
Pal SK, Karam JA, Bergerot P, Agarwal N (2016). Developing a Clear Path Forward for Non-Clear-Cell Renal Carcinoma. J Clin Oncol, 34(32), 3825-3826.
Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal N (2016). A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer Chemother Pharmacol, 78(5), 1059-1071.
Maughan BL, Eisenberger MA (2016). A Potential Predictive Role for Prostate-specific Antigen Changes at 4 Weeks? Eur Urol, 70(5), 732-733.
Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, Gohagan J, Berg CD, Prorok PC (2016). Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol Oncol, 143(2), 270-275.
Pal SK, Agarwal N, Dizman N, Sonpavde G (2016). Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar. Lancet Oncol, 17(11), 1477-1478.
Kerrigan K, Shoben A, Otterson G (2016). Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer, 17(6), 523-527.
Willmore-Payne C, Damjanovich-Colmenares K, Pasi AV, Werner TL, Gulbahce HE, Downs-Kelly E, Geiersbach KB (2016). Inconsistent Results With Different Secondary Reflex Assays for Resolving HER2 Status. Am J Clin Pathol, 146(5), 618-626.
Lowry PA, Freeman ML, Russell JS (2016). Nursing Management of Advanced Merkel Cell Carcinoma. Oncol Nurs Forum, 43(6), 680-683.
Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D (2016). Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol, 34(31), 3740-3748.
Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal N (2016). A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer Chemother Pharmacol, 78(5), 1059-1071.
Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal N (2016). A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer Chemother Pharmacol, 78(5), 1059-1071.
Agarwal N (2016). Newly Diagnosed Metastatic Prostate Cancer Patient. [Web]. Available: http://goo.gl/x4aGWO.
Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DYC, Choueiri TK (2016). Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol, 34(30), 3655-3663.
Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F (2016). Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 7(41), 67521-67531.
Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S Ribas A Corresponding Authors (Oct 2016). Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells. Cancer Immunol Res, 4(10), 845-857.
Agarwal N, Shuch B, Pal SK (2016). Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in Treatment-Naive Patients With Metastatic Renal Cell Carcinoma. JAMA Oncol, 2(10), 1273-1274.
Strom T, Carr M, Zager JS, Naghavi A, Smith FO, Cruse CW, Messina JL, Russell J, Rao NG, Fulp W, Kim S, Torres-Roca JF, Padhya TA, Sondak VK, Trotti AM, Harrison LB, Caudell JJ (2016). Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. Ann Surg Oncol, 23(11), 3572-3578.
Vaklavas C, Grizzle WE, Choi H, Meng Z, Zinn KR, Shrestha K, Blume SW (2016). IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells. Tumour Biol, 37(10), 13247-13264.
Dahal A, Bellows BK, Sonpavde G, Tantravahi SK, Choueiri TK, Galsky MD, Agarwal N (2016). Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis. Am J Clin Oncol, 39(5), 497-506.
Wynn D, Merriman J, Patel AB, Hitchcock YJ, Garrido-Laguna I, Renner D, Clardy SL (2016). Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue. Clin Neurol Neurosurg, 149, 11-4.
Shenoy N, Kohli M (2016). Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer. Indian J Urol, 32(4), 257-261.
Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, DAngelo SP, Shih KC, Lebb C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P (2016). Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol, 17(10), 1374-1385.
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C (2016). NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw, 14(10), 1213-1224.
Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, Carlson R, Rangel L, Reagan K, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, Sharifi N (2016). HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol, 17(10), 1435-1444.
D Stenehjem, S Gupta, M Wade, G Gilcrease, I Garrido-Laguna, JR Weis, J Whisenant, S Sharma (1 Oct 2016). A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies [Abstract]. Ann Oncol, 27(suppl_6), 1071.
Agarwal N, Alex AB, Farnham JM, Patel S, Gill D, Buckley TH, Stephenson RA, Cannon-Albright L (2016). Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer. J Urol, 196(4), 1112-6.
Stenehjem D, Gupta S, Wade M, Gilcrease G, Garrido-Laguna I, Weis JR, Whisenant J, Sharma S (2016). A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies [Abstract]. Center for Investigational Therapeutics, Huntsman Cancer Institute, Salt Lake City, UT, USA, 2016.
Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N (2016). Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience, 10, 676.
Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N (2016). Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience, 10, 676.
Swami U, Ghalib MH, Chaudhary I, Hou JY, Aparo S, Einstein MH, Goldberg GL, Elrafei TN, Gajavelli S, Cohen B, Rajdev L, Kaubisch A, Haigentz M, Mani S, Goel S (2016). Risks and Benefits of phase I trials: Twelve years experience from a single institution [Abstract].
Swami U, Petrylak DP, Raftopoulos H, Shuster DE, Wang G, Kumar V, Martinez G, Goel S, Aisner J (2016). Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors [Abstract].
Chaudhary I, Rajdev L, Swami U, Wilhelm F, Cohen B, Haigentz M, Kaubisch A, Goel S, Mani S, Ghalib MH (2016). Phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors [Abstract].
Ohnuma T, Holland JF, Goel S, Wilck E, Lehrer D, Ghalib MH, Chaudhary I, Wilhelm F, Swami U, Mani S (2016). Final results of a Phase I dose-escalation study of ON01910.Na in combination with oxaliplatin in patients with advanced solid tumors [Abstract].
Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clark PE, Plimack ER (2016). National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol, 34(27), 3346-8.
Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomki K, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Bandera EV, Barile M, Barkardottir RB, Barrowdale D, Beckmann MW, Benitez J, Berchuck A, Bisogna M, Bjorge L, Blomqvist C, Blot W, Bogdanova N, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brresen-Dale AL, Brauch H, Brennan P, Brenner H, Bruinsma F, Brunet J, Buhari SA, Burwinkel B, Butzow R, Buys SS, Cai Q, Caldes T, Campbell I, Canniotto R, Chang-Claude J, Chiquette J, Choi JY, Claes KB, GEMO Study Collaborators, Cook LS, Cox A, Cramer DW, Cross SS, Cybulski C, Czene K, Daly MB, Damiola F, Dansonka-Mieszkowska A, Darabi H, Dennis J, Devilee P, Diez O, Doherty JA, Domchek SM, Dorfling CM, Drk T, Dumont M, Ehrencrona H, Ejlertsen B, Ellis S, EMBRACE, Engel C, Lee E, Evans DG, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foretova L, Fostira F, Foulkes WD, Fridley BL, Friedman E, Frost D, Gambino G, Ganz PA, Garber J, Garca-Closas M, Gentry-Maharaj A, Ghoussaini M, Giles GG, Glasspool R, Godwin AK, Goldberg MS, Goldgar DE, Gonzlez-Neira A, Goode EL, Goodman MT, Greene MH, Gronwald J, Gunel P, Haiman CA, Hall P, Hallberg E, Hamann U, Hansen TV, Harrington PA, Hartman M, Hassan N, Healey S, Hereditary Breast and Ovarian Cancer Research Group Netherlands HEBON, Heitz F, Herzog J, Hgdall E, Hgdall CK, Hogervorst FB, Hollestelle A, Hopper JL, Hulick PJ, Huzarski T, Imyanitov EN, KConFab Investigators, Australian Ovarian Cancer Study Group, Isaacs C, Ito H, Jakubowska A, Janavicius R, Jensen A, John EM, Johnson N, Kabisch M, Kang D, Kapuscinski M, Karlan BY, Khan S, Kiemeney LA, Kjaer SK, Knight JA, Konstantopoulou I, Kosma VM, Kristensen V, Kupryjanczyk J, Kwong A, de la Hoya M, Laitman Y, Lambrechts D, Le N, De Leeneer K, Lester J, Levine DA, Li J, Lindblom A, Long J, Lophatananon A, Loud JT, Lu K, Lubinski J, Mannermaa A, Manoukian S, Le Marchand L, Margolin S, Marme F, Massuger LF, Matsuo K, Mazoyer S, McGuffog L, McLean C, McNeish I, Meindl A, Menon U, Mensenkamp AR, Milne RL, Montagna M, Moysich KB, Muir K, Mulligan AM, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Nord S, Nussbaum RL, Odunsi K, Offit K, Olah E, Olopade OI, Olson JE, Olswold C, OMalley D, Orlow I, Orr N, Osorio A, Park SK, Pearce CL, Pejovic T, Peterlongo P, Pfeiler G, Phelan CM, Poole EM, Pylks K, Radice P, Rantala J, Rashid MU, Rennert G, Rhenius V, Rhiem K, Risch HA, Rodriguez G, Rossing MA, Rudolph A, Salvesen HB, Sangrajrang S, Sawyer EJ, Schildkraut JM, Schmidt MK, Schmutzler RK, Sellers TA, Seynaeve C, Shah M, Shen CY, Shu XO, Sieh W, Singer CF, Sinilnikova OM, Slager S, Song H, Soucy P, Southey MC, Stenmark-Askmalm M, Stoppa-Lyonnet D, Sutter C, Swerdlow A, Tchatchou S, Teixeira MR, Teo SH, Terry KL, Terry MB, Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, Toland AE, Tomlinson I, Torres D, Truong T, Tseng CC, Tung N, Tworoger SS, Vachon C, van den Ouweland AM, van Doorn HC, van Rensburg EJ, Vant Veer LJ, Vanderstichele A, Vergote I, Vijai J, Wang Q, Wang-Gohrke S, Weitzel JN, Wentzensen N, Whittemore AS, Wildiers H, Winqvist R, Wu AH, Yannoukakos D, Yoon SY, Yu JC, Zheng W, Zheng Y, Khanna KK, Simard J, Monteiro AN, French JD, Couch FJ, Freedman ML, Easton DF, Dunning AM, Pharoah PD, Edwards SL, Chenevix-Trench G, Antoniou AC, Gayther SA (2016). Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun, 7, 12675.
Zaretsky JM, Garcia Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Rodriguez GA, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez P, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher T, Lo RS, Ribas A (Sep 2016). Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med, 375(9), 819-29.
Valderrabano P, Montilla-Soler J, Mifsud M, Leon M, Centeno B, Khazai L, Padhya T, McCaffrey T, Russell J, McIver B, Otto K (2016). Hypermetabolism on (18)F-Fluorodeoxyglucose Positron Emission Tomography Scan Does Not Influence the Interpretation of Thyroid Cytopathology, and Nodules with a SUVmax <2.5 Are Not at Increased Risk for Malignancy. Thyroid, 26(9), 1300-7.
Patnaik A, Tolcher A, Papadopoulos KP, Beeram M, Rasco D, Werner TL, Bauman JW, Scheuber A, Cox DS, Patel BR, Zhou Y, Hamid M, Schramek D, Sharma S (2016). Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours. Cancer Chemother Pharmacol, 78(3), 491-500.
Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, OMalley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M (2016). Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 14(9), 1134-63.
Kinney AY, Steffen LE, Brumbach BH, Kohlmann W, Du R, Lee JH, Gammon A, Butler K, Buys SS, Stroup AM, Campo RA, Flores KG, Mandelblatt JS, Schwartz MD (2016). Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up. J Clin Oncol, 34(24), 2914-24.
Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bogemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartsmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M (2016). Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol, 34(22), 2636-43.
Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Pal S, Eigl BJ (2016). Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. Clin Genitourin Cancer, 14(4), 331-40.
Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, Redman B, Agarwal N, Alva A (2016). Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunol Immunother, 65(8), 941-9.
Pal SK, Agarwal N (2016). Kidney cancer: Finding a niche for girentuximab in metastatic renal cell carcinoma. Nat Rev Urol, 13(8), 442-3.
Binder M, Zhang BY, Hillman DW, Kohli R, Kohli T, Lee A, Kohli M (2016). Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. Int J Mol Sci, 17(7).
Park JW, et al, I-SPY2 Investigators (2016). Adaptive Randomization of Neratinib in Early Breast Cancer. New England Journal of Medicine, 375(1), 11-22.
Rugo HS, et al, I-SPY2 Investigators (2016). Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. New England Journal of Medicine, 375(1), 23-34.
Agarwal N, Sonpavde G, Choueiri TK, Pal SK (2016). Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. Eur Urol, 70(1), 42-44.
Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ (2016). Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol, 17(7), 917-927.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M (2016). NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw, 14(7), 825-36.
Alex AB, Pal SK, Agarwal N (2016). CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. [Review]. Ther Adv Med Oncol, 8(4), 267-75.
Terry MB, Goldberg M, Schechter S, Houghton LC, White ML, OToole K, Chung WK, Daly MB, Keegan TH, Andrulis IL, Bradbury AR, Schwartz L, Knight JA, John EM, Buys SS (2016). Comparison of Clinical, Maternal, and Self Pubertal Assessments: Implications for Health Studies. Pediatrics, 138(1).
Cives M, Soares HP, Strosberg J (2016). Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol, 28(4), 359-66.
Zeng C, Guo X, Long J, Kuchenbaecker KB, Droit A, Michailidou K, Ghoussaini M, Kar S, Freeman A, Hopper JL, Milne RL, Bolla MK, Wang Q, Dennis J, Agata S, Ahmed S, Aittomki K, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Arun BK, Arver B, Bacot F, Barrowdale D, Baynes C, Beeghly-Fadiel A, Benitez J, Bermisheva M, Blomqvist C, Blot WJ, Bogdanova NV, Bojesen SE, Bonanni B, Borresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Broeks A, Brning T, Burwinkel B, Buys SS, Cai Q, Caldes T, Campbell I, Carpenter J, Chang-Claude J, Choi JY, Claes KB, Clarke C, Cox A, Cross SS, Czene K, Daly MB, de la Hoya M, De Leeneer K, Devilee P, Diez O, Domchek SM, Doody M, Dorfling CM, Drk T, Dos-Santos-Silva I, Dumont M, Dwek M, Dworniczak B, Egan K, Eilber U, Einbeigi Z, Ejlertsen B, Ellis S, Frost D, Lalloo F, EMBRACE, Fasching PA, Figueroa J, Flyger H, Friedlander M, Friedman E, Gambino G, Gao YT, Garber J, Garca-Closas M, Gehrig A, Damiola F, Lesueur F, Mazoyer S, Stoppa-Lyonnet D, behalf of GEMO Study Collaborators, Giles GG, Godwin AK, Goldgar DE, Gonzlez-Neira A, Greene MH, Gunel P, Haeberle L, Haiman CA, Hallberg E, Hamann U, Hansen TV, Hart S, Hartikainen JM, Hartman M, Hassan N, Healey S, Hogervorst FB, Verhoef S, HEBON, Hendricks CB, Hillemanns P, Hollestelle A, Hulick PJ, Hunter DJ, Imyanitov EN, Isaacs C, Ito H, Jakubowska A, Janavicius R, Jaworska-Bieniek K, Jensen UB, John EM, Joly Beauparlant C, Jones M, Kabisch M, Kang D, Karlan BY, Kauppila S, Kerin MJ, Khan S, Khusnutdinova E, Knight JA, Konstantopoulou I, Kraft P, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Le Marchand L, Lee CN, Lee MH, Lester J, Li J, Liljegren A, Lindblom A, Lophatananon A, Lubinski J, Mai PL, Mannermaa A, Manoukian S, Margolin S, Marme F, Matsuo K, McGuffog L, Meindl A, Menegaux F, Montagna M, Muir K, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Newcomb PA, Nord S, Nussbaum RL, Offit K, Olah E, Olopade OI, Olswold C, Osorio A, Papi L, Park-Simon TW, Paulsson-Karlsson Y, Peeters S, Peissel B, Peterlongo P, Peto J, Pfeiler G, Phelan CM, Presneau N, Radice P, Rahman N, Ramus SJ, Rashid MU, Rennert G, Rhiem K, Rudolph A, Salani R, Sangrajrang S, Sawyer EJ, Schmidt MK, Schmutzler RK, Schoemaker MJ, Schrmann P, Seynaeve C, Shen CY, Shrubsole MJ, Shu XO, Sigurdson A, Singer CF, Slager S, Soucy P, Southey M, Steinemann D, Swerdlow A, Szabo CI, Tchatchou S, Teixeira MR, Teo SH, Terry MB, Tessier DC, Teul A, Thomassen M, Tihomirova L, Tischkowitz M, Toland AE, Tung N, Turnbull C, van den Ouweland AM, van Rensburg EJ, Ven den Berg D, Vijai J, Wang-Gohrke S, Weitzel JN, Whittemore AS, Winqvist R, Wong TY, Wu AH, Yannoukakos D, Yu JC, Pharoah PD, Hall P, Chenevix-Trench G, KConFab, AOCS Investigators, Dunning AM, Simard J, Couch FJ, Antoniou AC, Easton DF, Zheng W (2016). Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res, 18(1), 64.
Zhao J, Zhao Y, Wang L, Zhang J, Karnes RJ, Kohli M, Wang G, Huang H (2015). Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. Oncotarget, 7(25), 38551-38565.
Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS (2016). Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J Clin Oncol, 34(18), 2098-106.
Xia Y, Huang CC, Dittmar R, Du M, Wang Y, Liu H, Shenoy N, Wang L, Kohli M (2015). Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget, 7(24), 35818-35831.
Tolcher A, Sznol M, Hu-Lieskovan S, Papadopoulos K, Patnaik A, Rasco D, DiGravio D, Huang8 B, Gambhire D, Chen Y, Pathan N, Wang K, Schmidt E, Chow L (June 2016). Phase 1b Study of Pf 05082566 in Combination With Pembrolizumab in Patients with Advanced Solid Tumors [Abstract]. 34(15 Supplement), Abstract 3002.
Bergerot PG, Sonpavde G, Nelson RA, Agarwal N, Costa CN, Hsu J, Choueiri TK, Pal SK (2016). Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): An updated report using the National Cancer Database (NCDB). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 4540).
Alex A, Stenehjem DD, Twardowski P, Cheng HH, Gill DM, Buckley H, Patel SB, Kessler ER, Chittoria N, Poudel A, Vaishampayan UN, Agarwal N (2016). Impact of prior definitive therapy on survival outcomes in men with new hormone-sensitive metastatic prostate cancer (mHSPC) [Abstract]. Journal of Clinical Oncology, 34(suppl), abstr 5083.
Kuzman JA, Stenehjem DD, Patel SB, Merriman J, Gill DM, Hahn A, Agarwal AM, Gupta S, Albertson D, Alex A, Agarwal N (2016). Neutrophil-lymphocyte ratio (NLR) as a predictive biomarker for response to high dose interleukin 2 (HDIL-2) in patients with metastatic renal cell carcinoma (mRCC) [Abstract]. Journal of Clinical Oncology, 34(suppl), abstr e 16087.
Sonpavde G, Nagy RJ, Agarwal N, Gourdin TS, Naik G, Eshaghian S, Wang J, Armstrong AJ, Vaishampayan UN, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB (2016). Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 5035).
Alex A, Stenehjem DD, Twardowski P, Cheng HH, Gill DM, Buckley H, Patel SB, Kessler ER, Chittoria N, Poudel A, Vaishampayan UN, Agarwal N (2016). Impact of prior definitive therapy on survival outcomes in men with new hormone-sensitive metastatic prostate cancer (mHSPC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 5083).
Agarwal N, Tagawa ST, Chatta GS, Pal SK, Goel S, Mazhari R, Heaton C, Benaim E (2016). Results from a phase 1b/2 study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma. Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 2559).
Agarwal N, Heemers H, Farnham JM, Patel SB, Gill DM, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright LA (2016). Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC) [Abstract]. Journal of Clinical Oncology, 34(suppl), abstr 5066.
Agarwal N, Heemers H, Farnham JM, Patel SB, Gill DM, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright LA (2016). Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 5066).
Pond GR, Sonpavde G, Plets M, Tangen CM, Hussain M, Lara P, Goldkorn A, Garzotto M, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk P, Quinn DI (2016). Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421. Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 5079).
Sonpavde G, Nelson RA, Trinh Q, Agarwal N, Nix J, Kardos S, Bellmunt J, Choueiri TK, Pal SK (2016). Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 4524).
Goldkorn A, Plets M, Agarwal N, Hussain M, Lara P, Vaena DA, MacVicar GR, Crispino T, Harzstark AL, Twardowski P, Tangen CM, Hugen CM, Xu T, Xu Y, Pinski JK, Ingles SA, Higano CS, Vogelzang NJ, Thompson IM, Quinn DI (2016). Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 11516).
Nagy RJ, Agarwal N, Gupta S, Pal SK, Grivas P, Vaishampayan UN, Wang J, Naik G, Lanman RB, Talasaz A, Sonpavde G (2016). Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma of the bladder. Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 4528).
Wells JC, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Knox JJ, Beuselinck B, Rha SY, Agarwal N, Brugarolas J, Lee JL, Pal SK, Srinivas S, Ernst DS, Vaishampayan UN, Wood L, Simpson R, Velasco G, Choueiri TK, Heng DYC (2016). Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 4554).
Bauer T, Adkins D, Schwartz GK, Werner TL, Alva AS, Hong DS, Carvaja RD, Saleh MN, Bazhenova L, Goel S, Eaton KD, Siegel RD, Wang D, Lauer RC, Neuteboom STC, Faltaos D, Chen I, Christensen J, Chao RC, Heist RS (2016). A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors. [Abstract]. J Clin Oncol, 2016 ASCO Annual Meeting, 34(2016), suppl;abstr 2575.
Cohen A, Neumayer L, Factor R, Boucher K, Wade ML, Lamb JG, Arbogast K, Piccolo S, Shrestha G, Riegert J, Schabel M, Bild A, Werner TL (2016). A phase 1 window of opportunity study of valproic acid (VPA) in breast cancer testing a gene expression biomarker. [Abstract]. J Clin Oncol, 2016 ASCO Annual Meeting, 34(2016), suppl;abst 1084.
Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, Sharma S (2016). Reversible Lysine-Specific Demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-myc in castration-resistant and docetaxel-resistant prostate cancer cells. Prostate Cancer Prostatic Dis.
Werner T, Sachdev J, Swisher E, Gutierrez M, Kittaneh M, Stein M, Xiong H, Dunbar M, Sullivan D, Ansell P, Hetman R, Komarnitsky P, McKee M, Tan A (2016). Veliparib (ABT-888) extended-release formulations: a phase 1 study on safety, pharmacokinetics (PK), and bioavailability in patients with advanced solid tumors. [Abstract]. J Clin Oncol, 2016 ASCO Annual Meeting, 34(2016), suppl;abstr 2579.
Boothe D, Orton A, Odei B, Stoddard G, Suneja G, Poppe MM, Werner TL, Gaffney DK (2016). Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival. Gynecol Oncol, 141(3), 421-427.
Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T, Claes K, Brunet J, Izquierdo A, Teul A, Lee JW, Kim SW, Arun B, Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA, Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E (2016). An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat, 157(2), 319-327.
Boothe D, Williams, N, Odel B, Poppe M, Werner TL, Suneja G, Gaffney D (2016). The addition of adjuvant chemotherapy to radiation in high risk endometrial cancer: Survival outcomes and patterns of care. [Abstract]. J Clin Oncol, 2016 ASCO Annual Meeting, 34(2016), suppl;abstr 5587.
Colonna SV, Higgins AK, Alvarez J, Saville BR, Lawrence J, Abramson VG (2015). Analysis of Risk of Recurrence by Subtype in ≤ 1-cm Breast Tumors. Clin Breast Cancer, 16(3), 223-31.
Nagy RJ, Agarwal N, Gupta S, Pal SK, Grivas P, Vaishampayan UN, Wang J, Naik G, Lanman RB, Talasaz AA, Sonpavde G (2016). Circulating cell-free DNA profiling of patients with advanced urotheial carcinoma of the bladderÏ [Abstract]. ASCO Annual Meeting 2016.
Agarwal N, Heemers H, Farnham JM, Patel SB, Gill D, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright LA (2016). Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC) [Abstract]. 2016 ASCO.
Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen E, Krajewski KM, Porta C, Pal S, Bellmunt J, McDermott DF, Heng DYC, Gray KP, Signoretti S (2016). Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res, 22(10), 2445-2452.
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS (2016). Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet, 387(10032), 2008-16.
Agarwal N (2016). Prognostication Based on Site of Metastatic Disease in Castration Refractory Prostate Cancer: Implications for Patient Care and Clinical Trial Design, Journal of Clinical Oncology [Podcast]. Available: https://goo.gl/YE04QE.
Agarwal N, Alex AB, Farnham JM, Patel SB, Gill D, Buckley TH, Stephenson RA, Cannon-Albright L (2016). Inherited variants in SULT1E1 and response to abiraterone acetate in men with metastatic castration refractory prostate cancer (mCRPC). J Urol.
Ovarian Cancer Association Consortium Breast Cancer Association Consortium and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A, Australian Ovarian Cancer Study Group, Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brand JS, Brauch H, Breast Cancer Family Register, Brenner H, Brinton L, Brooks-Wilson A, Bruinsma F, Brunet J, Brning T, Budzilowska A, Bunker CH, Burwinkel B, Butzow R, Buys SS, Caligo MA, Campbell I, Carter J, Chang-Claude J, Chanock SJ, Claes KBM, Colle JM, Cook LS, Couch FJ, Cox A, Cramer D, Cross SS, Cunningham JM, Cybulski C, Czene K, Damiola F, Dansonka-Mieszkowska A, Darabi H, de la Hoya M, deFazio A, Dennis J, Devilee P, Dicks EM, Diez O, Doherty JA, Domchek SM, Dorfling CM, Drk T, Silva IDS, du Bois A, Dumont M, Dunning AM, Duran M, Easton DF, Eccles D, Edwards RP, Ehrencrona H, Ejlertsen B, Ekici AB, Ellis SD, EMBRACE, Engel C, Eriksson M, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Fontaine A, Fortuzzi S, Fostira F, Fridley BL, Friebel T, Friedman E, Friel G, Frost D, Garber J, Garca-Closas M, Gayther SA, GEMO Study Collaborators, GENICA Network, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goodman MT, Gore M, Greene MH, Grip M, Gronwald J, Gschwantler Kaulich D, Gunel P, Guzman SR, Haeberle L, Haiman CA, Hall P, Halverson SL, Hamann U, Hansen TVO, Harter P, Hartikainen JM, Healey S, HEBON, Hein A, Heitz F, Henderson BE, Herzog J, T Hildebrandt MA, Hgdall CK, Hgdall E, Hogervorst FBL, Hopper JL, Humphreys K, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska K, Jensen A, Jensen UB, Johnson N, Jukkola-Vuorinen A, Kabisch M, Karlan BY, Kataja V, Kauff N, KConFab Investigators, Kelemen LE, Kerin MJ, Kiemeney LA, Kjaer SK, Knight JA, Knol-Bout JP, Konstantopoulou I, Kosma VM, Krakstad C, Kristensen V, Kuchenbaecker KB, Kupryjanczyk J, Laitman Y, Lambrechts D, Lambrechts S, Larson MC, Lasa A, Laurent-Puig P, Lazaro C, Le ND, Le Marchand L, Leminen A, Lester J, Levine DA, Li J, Liang D, Lindblom A, Lindor N, Lissowska J, Long J, Lu KH, Lubinski J, Lundvall L, Lurie G, Mai PL, Mannermaa A, Margolin S, Mariette F, Marme F, Martens JWM, Massuger LFAG, Maugard C, Mazoyer S, McGuffog L, McGuire V, McLean C, McNeish I, Meindl A, Menegaux F, Menndez P, Menkiszak J, Menon U, Mensenkamp AR, Miller N, Milne RL, Modugno F, Montagna M, Moysich KB, Mller H, Mulligan AM, Muranen TA, Narod SA, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nielsen SF, Nordestgaard BG, Nussbaum RL, Odunsi K, Offit K, Olah E, Olopade OI, Olson JE, Olson SH, Oosterwijk JC, Orlow I, Orr N, Orsulic S, Osorio A, Ottini L, Paul J, Pearce CL, Pedersen IS, Peissel B, Pejovic T, Pelttari LM, Perkins J, Permuth-Wey J, Peterlongo P, Peto J, Phelan CM, Phillips KA, Piedmonte M, Pike MC, Platte R, Plisiecka-Halasa J, Poole EM, Poppe B, Pylks K, Radice P, Ramus SJ, Rebbeck TR, Reed MWR, Rennert G, Risch HA, Robson M, Rodriguez GC, Romero A, Rossing MA, Rothstein JH, Rudolph A, Runnebaum I, Salani R, Salvesen HB, Sawyer EJ, Schildkraut JM, Schmidt MK, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schrauder MG, Schumacher F, Schwaab I, Scuvera G, Sellers TA, Severi G, Seynaeve CM, Shah M, Shrubsole M, Siddiqui N, Sieh W, Simard J, Singer CF, Sinilnikova OM, Smeets D, Sohn C, Soller M, Song H, Soucy P, Southey MC, Stegmaier C, Stoppa-Lyonnet D, Sucheston L, SWE-BRCA, Swerdlow A, Tangen IL, Tea MK, Teixeira MR, Terry KL, Terry MB, Thomassen M, Thompson PJ, Tihomirova L, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Torres D, Truong T, Ts (2016). No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol, 141(2), 386-401.
Watt MH, Kimani SM, Skinner D, Meade CS (2015). "Nothing Is Free": A Qualitative Study of Sex Trading Among Methamphetamine Users in Cape Town, South Africa. Arch Sex Behav, 45(4), 923-33.
Valderrabano P, Leon ME, Centeno BA, Otto KJ, Khazai L, McCaffrey JC, Russell JS, McIver B (2016). Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests. Eur J Endocrinol, 174(5), 621-9.
Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN (2016). Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol, 34(13), 1500-9.
Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE (2016). Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunol Res, 4(5), 390-9.
Geiersbach K, Willmore-Payne C, Pasi Av, Paxton C, Werner TL, Xu X, Wittwer CT, Gulbahce HE, Downs-Kelly E (2016). Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers. Am J Clin Pathol, Oct;146(4), 439-47.
Agarwal N, Machiels JP, Suarez C, Lewis N, Higgins M, Wisinski K, Awada A, Maur M, Stein M, Hwang A, Mosher R, Wasserman E, Wu G, Zhang H, Zieba R, Elmeliegy M (2016). Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. Oncologist, 21(5), 535-6.
John EM, Terry MB, Keegan TH, Bradbury AR, Knight JA, Chung WK, Frost CJ, Lilge L, Patrick-Miller L, Schwartz LA, Whittemore AS, Buys SS, Daly MB, Andrulis IL (2016). The LEGACY Girls Study: Growth and Development in the Context of Breast Cancer Family History. Epidemiology, 27(3), 438-48.
Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, Aittomki K, Ambrosone C, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Barile M, Barkardottir RB, Barrowdale D, Beckmann L, Beckmann MW, Benitez J, Blank SV, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldes T, Caligo MA, Canzian F, Carpenter J, Chang-Claude J, Chanock SJ, Chung WK, Claes KB, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, de la Hoya M, Devilee P, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Dumont M, Dunning AM, Eccles DM, Ehrencrona H, Ekici AB, Eliassen H, Ellis S, Fasching PA, Figueroa J, Flesch-Janys D, Frsti A, Fostira F, Foulkes WD, Friebel T, Friedman E, Frost D, Gabrielson M, Gammon MD, Ganz PA, Gapstur SM, Garber J, Gaudet MM, Gayther SA, Gerdes AM, Ghoussaini M, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, Gonzlez-Neira A, Greene MH, Gronwald J, Gunel P, Gunter M, Haeberle L, Haiman CA, Hamann U, Hansen TV, Hart S, Healey S, Heikkinen T, Henderson BE, Herzog J, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Humphreys K, Hunter DJ, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Jones M, Kabisch M, Kar S, Karlan BY, Khan S, Khaw KT, Kibriya MG, Knight JA, Ko YD, Konstantopoulou I, Kosma VM, Kristensen V, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Lee E, Le Marchand L, Lester J, Lindblom A, Lindor N, Lindstrom S, Liu J, Long J, Lubinski J, Mai PL, Makalic E, Malone KE, Mannermaa A, Manoukian S, Margolin S, Marme F, Martens JW, McGuffog L, Meindl A, Miller A, Milne RL, Miron P, Montagna M, Mazoyer S, Mulligan AM, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson JE, Osorio A, Park SK, Peeters PH, Peissel B, Peterlongo P, Peto J, Phelan CM, Pilarski R, Poppe B, Pylks K, Radice P, Rahman N, Rantala J, Rappaport C, Rennert G, Richardson A, Robson M, Romieu I, Rudolph A, Rutgers EJ, Sanchez MJ, Santella RM, Sawyer EJ, Schmidt DF, Schmidt MK, Schmutzler RK, Schumacher F, Scott R, Senter L, Sharma P, Simard J, Singer CF, Sinilnikova OM, Soucy P, Southey M, Steinemann D, Stenmark-Askmalm M, Stoppa-Lyonnet D, Swerdlow A, Szabo CI, Tamimi R, Tapper W, Teixeira MR, Teo SH, Terry MB, Thomassen M, Thompson D, Tihomirova L, Toland AE, Tollenaar RA, Tomlinson I, Truong T, Tsimiklis H, Teul A, Tumino R, Tung N, Turnbull C, Ursin G, van Deurzen CH, van Rensburg EJ, Varon-Mateeva R, Wang Z, Wang-Gohrke S, Weiderpass E, Weitzel JN, Whittemore A, Wildiers H, Winqvist R, Yang XR, Yannoukakos D, Yao S, Zamora MP, Zheng W, Hall P, Kraft P, Vachon C, Slager S, Chenevix-Trench G, Pharoah PD, Monteiro AA, Garca-Closas M, Easton DF, Antoniou AC (2016). Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun, 7, 11375.
Zhao Y, Wang L, Ren S, Wang L, Blackburn PR, McNulty MS, Gao X, Qiao M, Vessella RL, Kohli M, Zhang J, Karnes RJ, Tindall DJ, Kim Y, MacLeod R, Ekker SC, Kang T, Sun Y, Huang H (2016). Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. Cell Rep, 15(3), 599-610.
Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R (2016). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res, 22(8), 1932-9.
Hart SN, Ellingson MS, Schahl K, Vedell PT, Carlson RE, Sinnwell JP, Barman P, Sicotte H, Eckel-Passow JE, Wang L, Kalari KR, Qin R, Kruisselbrink TM, Jimenez RE, Bryce AH, Tan W, Weinshilboum R, Wang L, Kohli M (2016). Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open, 6(4), e010332.
Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R (2016). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res, 22(8), 1932-9.
Gupta S, Agarwal N (2016). Cancer Immunotherapy with Interleukin-2-Current Status and Future Developments. In Katrina Mountfort (Ed.), Oncology & Hematology Review (12, pp. 82-8).
Camp NJ, Lin W, Bigelow A, Burghel GJ, Mosbruger T, Parry M, Waller R, Rigas SH, Rajamanickam V, Cosby R, Brock IW, Jones B, Connley D, Sargent R, Wang G, Cannon-Albright LA, Werner TL, Factor RE, Bernard P, Knight S, Abo R, Reed MWR, Gertz J, Cox A (2016). Discordant Haplotype Sequencing Identifies Candidate Functional Variants from Disease-Association studies: Breast Cancer Risk at 2q33. doi: 10.1158/0008-5472.CAN-15-1629. PMID: 26795348. Cancer Research, 76(7), 1916-25.
Himes DO, Clayton MF, Donaldson GW, Ellington L, Buys SS, Kinney AY (2016). Breast Cancer Risk Perceptions among Relatives of Women with Uninformative Negative BRCA1/2 Test Results: The Moderating Effect of the Amount of Shared Information. PMID: 26245632. J Genet Couns, 25(2), 258-69.
Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal N (2016). Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clin Genitourin Cancer, 14(2), 153-9.
Himes DO, Clayton MF, Donaldson GW, Ellington L, Buys SS, Kinney AY (2015). Breast Cancer Risk Perceptions among Relatives of Women with Uninformative Negative BRCA1/2 Test Results: The Moderating Effect of the Amount of Shared Information. J Genet Couns, 25(2), 258-69.
Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal N (2016). Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clin Genitourin Cancer, 14(2), 153-9.
Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R (2016). Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Mol Cancer Ther, 15(4), 533-47.
Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J, Wang Q, Hopper JL, Southey MC, Broeks A, Schmidt MK, Lophatananon A, Muir K, Beckmann MW, Fasching PA, Dos-Santos-Silva I, Peto J, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Gunel P, Truong T, Bojesen SE, Flyger H, Gonzlez-Neira A, Perez JI, Anton-Culver H, Eunjung L, Arndt V, Brenner H, Meindl A, Schmutzler RK, Brauch H, Hamann U, Aittomki K, Blomqvist C, Ito H, Matsuo K, Bogdanova N, Drk T, Lindblom A, Margolin S, Kosma VM, Mannermaa A, Tseng CC, Wu AH, Lambrechts D, Wildiers H, Chang-Claude J, Rudolph A, Peterlongo P, Radice P, Olson JE, Giles GG, Milne RL, Haiman CA, Henderson BE, Goldberg MS, Teo SH, Yip CH, Nord S, Borresen-Dale AL, Kristensen V, Long J, Zheng W, Pylks K, Winqvist R, Andrulis IL, Knight JA, Devilee P, Seynaeve C, Figueroa J, Sherman ME, Czene K, Darabi H, Hollestelle A, van den Ouweland AM, Humphreys K, Gao YT, Shu XO, Cox A, Cross SS, Blot W, Cai Q, Ghoussaini M, Perkins BJ, Shah M, Choi JY, Kang D, Lee SC, Hartman M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Brennan P, Sangrajrang S, Ambrosone CB, Toland AE, Shen CY, Wu PE, Orr N, Swerdlow A, McGuffog L, Healey S, Lee A, Kapuscinski M, John EM, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ejlertsen B, Hansen TV, Osorio A, Benitez J, Rando R, Weitzel JN, Bonanni B, Peissel B, Manoukian S, Papi L, Ottini L, Konstantopoulou I, Apostolou P, Garber J, Rashid MU, Frost D, EMBRACE, Izatt L, Ellis S, Godwin AK, Arnold N, Niederacher D, Rhiem K, Bogdanova-Markov N, Sagne C, Stoppa-Lyonnet D, Damiola F, GEMO Study Collaborators, Sinilnikova OM, Mazoyer S, Isaacs C, Claes KB, De Leeneer K, de la Hoya M, Caldes T, Nevanlinna H, Khan S, Mensenkamp AR, HEBON, Hooning MJ, Rookus MA, Kwong A, Olah E, Diez O, Brunet J, Pujana MA, Gronwald J, Huzarski T, Barkardottir RB, Laframboise R, Soucy P, Montagna M, Agata S, Teixeira MR, kConFab Investigators, Park SK, Lindor N, Couch FJ, Tischkowitz M, Foretova L, Vijai J, Offit K, Singer CF, Rappaport C, Phelan CM, Greene MH, Mai PL, Rennert G, Imyanitov EN, Hulick PJ, Phillips KA, Piedmonte M, Mulligan AM, Glendon G, Bojesen A, Thomassen M, Caligo MA, Yoon SY, Friedman E, Laitman Y, Borg A, von Wachenfeldt A, Ehrencrona H, Rantala J, Olopade OI, Ganz PA, Nussbaum RL, Gayther SA, Nathanson KL, Domchek SM, Arun BK, Mitchell G, Karlan BY, Lester J, Maskarinec G, Woolcott C, Scott C, Stone J, Apicella C, Tamimi R, Luben R, Khaw KT, Helland, Haakensen V, Dowsett M, Pharoah PD, Simard J, Hall P, Garca-Closas M, Vachon C, Chenevix-Trench G, Antoniou AC, Easton DF, Edwards SL (2016). Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet, 48(4), 374-86.
Gupta S, Agarwal N (2016). Cancer Immunotherapy with Interleukin-2-Current Status and Future Developments [Web]. Immunotherapy. Available: https://goo.gl/pNFqvI.
Gupta S, Gouw L, Wright J, Chawla S, Pitt D, Wade M, Boucher K, Sharma S (2016). Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Invest New Drugs, 34(2), 243-52.
Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS (Mar 2016). Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 165(1), 35-44.
Piccolo SR, Hoffman LM, Conner T, Shrestha G, Cohen AL, Marks JR, Neumayer LA, Agarwal CA, Beckerle MC, Andrulis IL, Spira AE, Moos PJ, Buys SS, Johnson WE, Bild AH (2016). Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Mol Syst Biol, 12(3), 860.
Pal SK, Agarwal N, Grivas P, Choueiri T (2016). Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence. J Clin Oncol, 34(8), 777-9.
Swami U, Abbi KKS, Dozeman L, Tricot A, Tricot GJ (2016). Cytomegalovirus and Human Herpes Virus-6 Reactivation Following Tandem Transplantation Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma (MM) [Abstract].
Samadder NJ, Smith KR, Hanson H, Pimentel R, Wong J, Boucher K, Akerley W, Gilcrease G, Ulrich CM, Burt RW, Curtin K (2016). Familial Risk in Patients With Carcinoma of Unknown Primary. JAMA Oncol, 2(3), 340-6.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2016). NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw, 14(3), 255-64.
Lara PN Jr, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL 3rd, Hirsch FR, Mack PC, Gandara DR (2016). SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol, 11(3), 420-5.
Samadder NJ, Smith KR, Hanson H, Pimentel R, Wong J, Boucher K, Akerley W, Gilcrease G, Ulrich CM, Burt RW, Curtin K (2016 Mar). Familial Risk in Patients With Carcinoma of Unknown Primary. JAMA Oncol, 2(3), 340-346.
Frakes JM, Naghavi AO, Demetriou SK, Strom TJ, Russell JS, Kish JA, McCaffrey JC, Otto KJ, Padhya TA, Harrison LB, Trotti AM, Caudell JJ (2015). Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. Cancer, 122(4), 634-41.
Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW, kConFab Investigators, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmaa J, Diez O, Ivady G, Papp J, Olah E, Kwong A, Hereditary Breast and Ovarian Cancer Research Group Netherlands HEBON, Nevanlinna H, Aittomki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S, EMBRACE, Hamann U, Garber J, Fostira F, Fountzilas G, Pasini B, Giannini G, Rizzolo P, Russo A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes AM, Ejlertsen B, Hansen TV, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly MB, Bane A, Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L (2016). Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res, 18(1), 15.
Robert L, Ribas A, Hu-Lieskovan S (February 2016). Combining targeted therapy with immunotherapy. Can 1 + 1 equal more than 2? [Review]. Semin Immunol, 28(1), 73-80.
Wang L, Nie J, Sicotte H, Li Y, Eckel-Passow JE, Dasari S, Vedell PT, Barman P, Wang L, Weinshiboum R, Jen J, Huang H, Kohli M, Kocher JP (2016). Measure transcript integrity using RNA-seq data. BMC Bioinformatics, 17, 58.
Jeter JM, Curiel-Lewandrowski C, Stratton SP, Myrdal PB, Warneke JA, Einspahr JG, Bartels HG, Yozwiak M, Bermudez Y, Hu C, Bartels P, Alberts DS (2015). Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm. Cancer Prev Res (Phila), 9(2), 128-34.
Merriman J, Tward J, Albertson D, Dechet C, Agarwal N (2016). Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma. J Immunother, 39(2), 101-3.
Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, McGuffog L, Ellis S, Feng B, Buys SS, Hopper JL, Southey MC, Tesoriero A, James PA, Bruinsma F, Campbell IG, Broeks A, Schmidt MK, Hogervorst FB, Beckman MW, Fasching PA, Fletcher O, Johnson N, Sawyer EJ, Riboli E, Banerjee S, Menon U, Tomlinson I, Burwinkel B, Hamann U, Marme F, Rudolph A, Janavicius R, Tihomirova L, Tung N, Garber J, Cramer D, Terry KL, Poole EM, Tworoger SS, Dorfling CM, van Rensburg EJ, Godwin AK, Guenel P, Truong T, Stoppa-Lyonnet D, Damiola F, Mazoyer S, Sinilnikova OM, Isaacs C, Maugard C, Bojesen SE, Flyger H, Gerdes AM, Hansen TV, Jensen A, Kjaer SK, Hogdall C, Hogdall E, Pedersen IS, Thomassen M, Benitez J, Gonzalez-Neira A, Osorio A, Hoya Mde L, Segura PP, Diez O, Lazaro C, Brunet J, Anton-Culver H, Eunjung L, John EM, Neuhausen SL, Ding YC, Castillo D, Weitzel JN, Ganz PA, Nussbaum RL, Chan SB, Karlan BY, Lester J, Wu A, Gayther S, Ramus SJ, Sieh W, Whittermore AS, Monteiro AN, Phelan CM, Terry MB, Piedmonte M, Offit K, Robson M, Levine D, Moysich KB, Cannioto R, Olson SH, Daly MB, Nathanson KL, Domchek SM, Lu KH, Liang D, Hildebrant MA, Ness R, Modugno F, Pearce L, Goodman MT, Thompson PJ, Brenner H, Butterbach K, Meindl A, Hahnen E, Wappenschmidt B, Brauch H, Bruning T, Blomqvist C, Khan S, Nevanlinna H, Pelttari LM, Aittomaki K, Butzow R, Bogdanova NV, Dork T, Lindblom A, Margolin S, Rantala J, Kosma VM, Mannermaa A, Lambrechts D, Neven P, Claes KB, Maerken TV, Chang-Claude J, Flesch-Janys D, Heitz F, Varon-Mateeva R, Peterlongo P, Radice P, Viel A, Barile M, Peissel B, Manoukian S, Montagna M, Oliani C, Peixoto A, Teixeira MR, Collavoli A, Hallberg E, Olson JE, Goode EL, Hart SN, Shimelis H, Cunningham JM, Giles GG, Milne RL, Healey S, Tucker K, Haiman CA, Henderson BE, Goldberg MS, Tischkowitz M, Simard J, Soucy P, Eccles DM, Le N, Borresen-Dale AL, Kristensen V, Salvesen HB, Bjorge L, Bandera EV, Risch H, Zheng W, Beeghly-Fadiel A, Cai H, Pylkas K, Tollenaar RA, Ouweland AM, Andrulis IL, Knight JA, Narod S, Devilee P, Winqvist R, Figueroa J, Greene MH, Mai PL, Loud JT, Garcia-Closas M, Schoemaker MJ, Czene K, Darabi H, McNeish I, Siddiquil N, Glasspool R, Kwong A, Park SK, Teo SH, Yoon SY, Matsuo K, Hosono S, Woo YL, Gao YT, Foretova L, Singer CF, Rappaport-Feurhauser C, Friedman E, Laitman Y, Rennert G, Imyanitov EN, Hulick PJ, Olopade OI, Senter L, Olah E, Doherty JA, Schildkraut J, Koppert LB, Kiemeney LA, Massuger LF, Cook LS, Pejovic T, Li J, Borg A, Ofverholm A, Rossing MA, Wentzensen N, Henriksson K, Cox A, Cross SS, Pasini BJ, Shah M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Gronwald J, Agnarsson BA, Kupryjanczyk J, Moes-Sosnowska J, Fostira F, Konstantopoulou I, Slager S, Jones M, Antoniou AC, Berchuck A, Swerdlow A, Chenevix-Trench G, Dunning AM, Pharoah PD, Hall P, Easton DF, Couch FJ, Spurdle AB, Goldgar DE (2016). BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.LID - 10.1093/jnci/djv315 [doi]LID - djv315 [pii]. PMID: 26586665. J Natl Cancer Inst, 108(2).
Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother Pharmacol, 77(2), 299-308.
Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother Pharmacol, 77(2), 299-308.
Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother Pharmacol, 77(2), 299-308.
Karsy M, Hoang N, Barth T, Burt L, Dunson W, Gillespie DL, Jensen RL (2016). Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies. World Neurosurg, 86, 210-9.
Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow S (2016). Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw, 14(2), 153-62.
Ramadhani HO, Bartlett JA, Thielman NM, Pence BW, Kimani SM, Maro VP, Mwako MS, Masaki LJ, Mmbando CE, Minja MG, Lirhunde ES, Miller WC (2016). The Effect of Switching to Second-Line Antiretroviral Therapy on the Risk of Opportunistic Infections Among Patients Infected With Human Immunodeficiency Virus in Northern Tanzania. Open Forum Infect Dis, 3(1), ofw018.
Yuan T, Huang X, Woodcock M, Du M, Dittmar R, Wang Y, Tsai S, Kohli M, Boardman L, Patel T, Wang L (2016). Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep, 6, 19413.
Fabian CJ, Meyskens FL Jr, Bajorin DF, George TJ Jr, Jeter JM, Khan S, Tyne CA, William WN Jr (2015). Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group. J Clin Oncol, 34(2), 186-93.
Ramos, J, Wong YN, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, Hussain SA, Baniel J, Golshayan AR, Powles T, Rosenberg JE, Giorgi UD, Vaishampayan UN, Agarwal N, Pal SK, Harshman LC, Necchi A, Recine F, Galsky MD, Yu EY, RISC Investigators (2016). Venous thromboembolism (VTE) risk in patients with localized urinary tract tumors (UTT). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 422).
Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD (2016). Effect of concomitant proton pump inhibitor (PPI) on effectiveness of tyrosine kinase inhibitor (TKI) in patients with metastatic renal cell carcinoma (mRCC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 608.
Li H, Kroeger N, deVelasco G, Donskov F, Sim HW, Wells C, Stukalin I, Agarwal N, Parekh HD, Rini BI, Knox JJ, Pantuck AJ, Choueiri TK, Heng DYC (2016). The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy. Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 552).
Alex A, Stenehjem DD, Twardowski P, Cheng HH, Buckley TH, Gill DM, Patel SB, Vaishampayan U, Agarwal N (2016). Impact of prior definitive therapy on survival outcomes in men with new hormone sensitive metastatic prostate cancer (mHSPC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 269.
Parker SJ, Pond GR, Sonpavde G, Alex A, Heilbrun ME, Agarwal N (2016). Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 191).
Escudier BJ, Motzer RJ, Powles T, Tannir NM, Davis ID, Donskov F, Grunwald V, Heng DYC, Hutson T, Melichar B, Nosov D, Rini BI, Salman P, Sternberg CN, Szczylik C, Wolter P, Arroyo AM, Mangeshkar M, Agarwal N, Choueiri TK (2016). Subgroup analysis of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 499).
Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD (2016). Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 610.
Buckley TH, Alex A, Franham JM, Gill DM, Patel SB, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA, Agarwal N (2016). Association of single nucleotide polymorphisms (SNPs) in SULT1E1 with response to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 222.
Sonpavde G, Nagy RJ, Apolo AB, Agarwal N, Pal SK, Grivas P, Vaishampayan UN, Lanman RB, Talasaz A (2016). Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma. Oral Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 358).
Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD (2016). Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 610).
Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood L, Kollmannsberger CK, Rha SY, North SA, Kanesvaran R, Rini BI, Broom RJ, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK (2016). DiscontinuingVEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC). Oral Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 503).
Davis ID, Xie W, Pezaro CJ, Donskov F, Wells C, Agarwal N, Srinivas Sandhya, Yuasa T, Beuselinck B, Wood L, Ernst DS, Kanesvaran R, Knox JJ, Pantuck AJ, Saleem S, Alva AS, Rini BI, Lee JL, Choueiri TK, Heng DYC (2016). Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy. Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 534).
Alex A, Stenehjem DD, Twardowski P, Cheng HH, Buckley TH, Gill D, Patel SB, Vaishampayan UN, Agarwal N (2016). Impact of prior definitive therapy on survival outcomes in men with new hormone sensitive metastatic prostate cancer (mHSPC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 269).
Gill D, Alex A, Farnham JM, Buckley TH, Patel SB, Agarwal AM, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA, Agarwal N (2016). Association of single nucleotide polymorphism in four genes and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive prostate cancer (aHSPC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 224).
Gill DM, Alex A, Farnham JM, Buckley TH, Patel SB, Agarwal AM, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA, Agarwal N (2016). Association of single nucleotide polymorphism in four genes and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive prostate cancer (aHSPC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 224.
Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD (2016). Effect of concomitant proton pump inhibitor (PPI) on effectiveness of tyrosine kinase inhibitor (TKI) in patients with metastatic renal cell carcinoma (mRCC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 608).
Buckley TH, Alex A, Farnham JM, Gill D, Patel SB, Teerlink C, Albright FS, Stephenson, RA, Cannon-Albright LA, Agarwal N (2016). Assiciation of single nucleotide polymorphisms (SNPs) in SULT1E1 with response to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 222).
Bergerot PG, Nelson RA, Ye DW, Grivas P, Singh P, Agarwal N, Choueiri TK, Pal SK (2016). Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic magnancies. Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 363).
Nathan Bahary, Ignacio Garrido-Laguna, Andrea Wang-Gillam, Asha Nyak-Kapoor, Eugene Kennedy, Nicholas N Vahanian, Charles J Link (2016). Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer. [Abstract]. J Clin Oncol 34, 2016 (suppl 4S; abstr 452).
Swami U, Abbi KKS, Dozeman L, Tricot A, Tricot GJ (2016). Cytomegalovirus and Human Herpes Virus-6 Reactivation Following Tandem Transplantation Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma (MM) [Abstract]. Biology of Blood and Marrow Transplantation, 22(3), S177-8.
Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Kohli M, Agur Z (2015). Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data. Prostate, 76(1), 48-57.
Gupta S (2016). A Phase 2 Study of the Histone Deacetylase (HDAC) Inhibitor Mocetinostat in Patients with Urothelial Carcinoma (UC) and Inactivating Alterations of Acetyltransferase Genes [Abstract]. ASCO 2015 Annual Meeting.
Kharkar VJ, Ast A, Gupta S, Sharma S (2016). LSD2/KDM1B/AOF1 and Human Cancer Pathways: A Literature Review. Can Stu The J (1(1), pp. 1-5).
Patel SB, Gill D, Garrido-Laguna I (2016). Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. [Review]. Onco Targets Ther, 9, 75-86.
Chang Y, Near AM, Butler KM, Hoeffken A, Edwards SL, Stroup AM, Kohlmann W, Gammon A, Buys SS, Schwartz MD, Peshkin BN, Kinney AY, Mandelblatt JS, Chang Y, Near AM, Butler KM, Hoeffken A, Edwards SL, Stroup AM, Kohlmann W, Gammon A, Buys SS, Schwartz MD, Peshkin BN, Kinney AY, Mandelblatt JS (2016). Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas. J Oncol Pract, 12(1), 59, e1-13.
Singh P, Albertson D, Pal SK, Agarwal N (2016). Mucinous, Signet Ring, Ductal, and Sarcomatoid Variants of Prostate Cancer. In Lance Pagliaro (Ed.), Rare Genitourinary Tumors (First Edition). New York: Springer.
Agarwal N, Buckley TH, Farnham JM, Patel SB, Agarwal A, Tantravahi SK, Teerlink C, Albright FS, Stephenson RA, Alex A, Cannon-Albright LA (2016). Association of single nucleotide polymorphisms (SNPs) in STS and SULT2B1 and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive prostate cancer (aHSPC) [Abstract]. Clinical Cancer Research, 22(1 suppl), 39.
Patel SB, Gill D, Garrido-Laguna I (2016). Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. Onco Targets Ther, 9, 75-86.
Evans E, Hu-Lieskovan S, Bussler H, Torno S, Mallow C, Reilly C, Scrivens M, Klimatcheva K, Winter LA, Kirk R, Howell A, Balch L, Veerarghavan J, Jonason Jr A, Leonard J, Paris M, Fisher T, Ribas T, Smith E, Zauderer M (December 2015). Antibody blockade of Semaphorin 4D Breaks Down Barriers To Enhance Tumoricidal Immune Infiltration And Supports Rational Immunotherapy Combinations [Abstract]. (4), Poster 1494.
Kohli M, Wang L, Xie F, Sicotte H, Yin P, Dehm SM, Hart SN, Vedell PT, Barman P, Qin R, Mahoney DW, Carlson RE, Eckel-Passow JE, Atwell TD, Eiken PW, McMenomy BP, Wieben ED, Jha G, Jimenez RE, Weinshilboum R, Wang L (2015). Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. PLoS ONE, 10(12), e0145176.
Swami U, Dozeman L, Tricot A, Abbi KKS, Tricot GJ (2015). Collection of Peripheral Blood Stem Cells in Patients with Multiple Myeloma after Stem Cell Transplant: A Single Institution Experience [Abstract].
Patel SB, Mason CC, Glenn MJ, Paxton CN, South ST, Cessna MH, Asch J, Cobain EF, Bixby DL, Smith LB, Reshmi SR, Gastier-Foster JM, Schiffman JD, Miles RR (2015). Genomic analysis of adult B-ALL identifies changes in copy number profile at relapse and IKZF1/CDKN2A co-deletion at diagnosis as a marker of shorter survival [Abstract]. Blood, 126(23), 1427.
Swami U, Dozeman L, Tricot A, Abbi KKS, Tricot GJ (2015). Collection of Peripheral Blood Stem Cells in Patients with Multiple Myeloma after Stem Cell Transplant: A Single Institution Experience [Abstract]. Blood, 126(23), 5435.
Werner TL, Wade ML, Agarwal N, Boucher K, Patel J, Luebke A, Sharma S (2015). A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-beta, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Invest New Drugs, 33(6), 1217-24.
Werner TL, Wade ML, Agarwal N, Boucher K, Patel J, Luebke A, Sharma S (2015). A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-beta, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Invest New Drugs, 33(6), 1217-24.
Maughan BL, Antonarakis ES (2015). Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. Curr Treat Options Oncol, 16(12), 57.
Werner TL (December 2015). Chapter 4 - Breast Cancer Bone Metastases. In R. Lor Randall (Ed.), Metastatic Bone Disease: Essentials for the Orthopedic Surgeon (pp. 45-54). Springer International.
Pal SK, Vuong W, Zhang W, Deng J, Liu X, Carmichael C, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin RA, Agarwal N, Jones JO (2015). Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer. Mol Cancer Ther, 14(12), 2896-900.
Piccolo SR, Andrulis IL, Cohen AL, Conner T, Moos PJ, Spira AE, Buys SS, Johnson WE, Bild AH (2015). Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility. BMC Med Genomics, 8, 72.
Hu-Lieskovan S, Patnaik A, Eisenberg P, Sachdev J, Weise A, PLX and Merck, Ribas T (November 2015). Phase 1/2a Study of Double Immune Suppression Blockade by Combining a CSF1R Inhibitor (Pexidartinib/PLX3397) with an anti PD-1 Antibody (Pembrolizumab) to Treat Advanced Melanoma and Other Solid Tumors [Abstract]. 26(Supplement 8), vii5.
Carr SR, Akerley W, Hashibe M, Cannon-Albright LA (2015). Evidence for a genetical contribution to non-smoking-related lung cancer. Thorax, 70(11), 1033-9.
Bradbury AR, Patrick-Miller L, Schwartz L, Egleston B, Sands CB, Chung WK, Glendon G, McDonald JA, Moore C, Rauch P, Tuchman L, Andrulis IL, Buys SS, Frost CJ, Keegan TH, Knight JA, Terry MB, John EM, Daly MB (2015). Psychosocial Adjustment in School-age Girls With a Family History of Breast Cancer. Pediatrics, 136(5), 927-37.
Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES (2015). Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Prostate, 75(15), 1814-20.
Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM (2015). NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. J Natl Compr Canc Netw, 13(11), 1337-46.
Pal SK, Agarwal N, Jones JO (2015). Circulating tumor cells in prostate cancer: Does (nuclear) size matter? Cancer, 121(18), 3190-2.
Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM (2015). FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging, 15, 15.
Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R (2015). A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol, 138(3), 513-8.
Hashibe M, Galeone C, Buys SS, Gren L, Boffetta P, Zhang ZF, La Vecchia C (2015). Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort. Br J Cancer, 113(5), 809-16.
Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B (2015). Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 33(24), 2667-74.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS (2015). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med, 373(8), 737-46.
Homet Moreno B, Mok S, Robert L, Comin-Anduix B, Hu-Lieskovan S, Ribas A (Aug 2015). Combined Treatment with Dabrafenib and Trametinib with Immune-stimulating Antibodies for BRAF Mutant Melanoma. Oncoimmunology, 5(7), e1052212.
Bordun KA, Premecz S, daSilva M, Mandal S, Goyal V, Glavinovic T, Cheung M, Cheung D, White CW, Chaudhary R, Freed DH, Villarraga HR, Herrmann J, Kohli M, Ravandi A, Thliveris J, Pitz M, Singal PK, Mulvagh S, Jassal DS (2015). The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. Am J Physiol Heart Circ Physiol, 309(4), H692-701.
Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S (2015). Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors. J Med Chem, 58(15), 5854-62.
Swami U, Shah U, Goel S (2015). Eribulin in Cancer Treatment. [Review]. Mar Drugs, 13(8), 5016-58.
Patel SB, Buckley TH, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N (2015). Correlation of baseline serum testosterone (T) and serum prostate-specific antigen (PSA) at 7 months (7 mo PSA) in patients with new hormone sensitive metastatic prostate cancer (mHSPC) treated with continuous androgen deprivation therapy (cADT) [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 231.
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE (2015). Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer, 121(15), 2586-93.
Patel SB, Mason CC, Glenn MJ, Paxton CN, South ST, Cessna MH, Asch J, Cobain EF, Bixby DL, Smith LB, Schiffman JD, Miles RR (2015). IKZF1/CDKN2A Co-Deletion Predicts Shorter Survival in Adult B-ALL [Abstract]. Cancer Research, 75(15 suppl), 1723.
Morris GJ, Dawood S, Cortes J, Ward JH, Vaklavas C, Forero A, Ward S, Toppmeyer D (2015). Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat? Semin Oncol, 42(4), e67-79.
Kohli M, Young CY, Tindall DJ, Nandy D, McKenzie KM, Bevan GH, Donkena KV (2015). Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer. Onco Targets Ther, 8, 1915-22.
Turner NC, et al, PALOMA3 Study Group (2015). Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. New England Journal of Medicine, 373(3), 209-19.
Rajkumar SV, Kohli M (2015). Introduction to the Symposium on Neoplastic Hematology and Medical Oncology. Mayo Clin Proc, 90(7), 848-9.
Meade CS, Towe SL, Watt MH, Lion RR, Myers B, Skinner D, Kimani S, Pieterse D (2015). Addiction and treatment experiences among active methamphetamine users recruited from a township community in Cape Town, South Africa: A mixed-methods study. Drug Alcohol Depend, 152, 79-86.
Metterle L, Russell JS, Patel NS (2015). An overview of the medical management of nonmelanoma skin cancer. Curr Probl Cancer, 39(4), 226-36.
Wainberg ZA, Soares HP, Patel R, DiCarlo B, Park DJ, Liem A, Wang HJ, Yonemoto L, Martinez D, Laux I, Brennan M, Hecht JR (2015). Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers. Cancer Chemother Pharmacol, 76(1), 61-7.
Strom TJ, Trotti AM, Kish J, Russell JS, Rao NG, McCaffrey J, Padhya TA, Otto KJ, Caudell JJ (2015). Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. Oral Oncol, 51(7), 704-8.
Munster P, VanDer Noll R, Voest E, Specht J, Werner TL, Dees EC, Tan AR, Daud A, Schellens J, Lolkema MP, Griffin M, Agarwal N, Falchook GS, Kleha JF, Durante M, Smith DA, Adams L, Greshock J, Morris SR, Kurzrock R (2015). PI3K kinase inhibitor GSK2126458 (GSK458): Clinical activity in select patient (pt) populations defined by predictive markers (Study P3K112826). Oral Presentation European Society of Medical Oncology, September 2012, Vienna, Austria. [Abstract]. European Society of Medical Oncology. [Abstract]. Clinical Cancer Research.
Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, Huang CC, Wang L (2015). Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget, 6(18), 16411-21.
Paoletti C, Li Y, Muiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ Jr, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF, Translational Breast Cancer Research Consortium TBCRC (2015). Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clin Cancer Res, 21(12), 2771-9.
Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC, Translational Breast Cancer Research Consortium TBCRC (2015). TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res, 21(12), 2722-9.
Hu-Lieskovan S, Homet Moreno B, Ribas A (June 2018). Excluding T cells: Is β-catenin the full story? 27(6), 749-750.
Garrido-Laguna I, Hidalgo M (2015). Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol, 12(6), 319-34.
Colonna SV, Curtin K, Kohlmann W, Wright J, Tavtigian S, Schiffman J (2015). Family history of breast cancer in Hodgkin disease and future risk of breast cancer. [Abstract]. J Clin Oncol, 33(suppl), abstr 1522.
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R (2015). Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw, 13(6), 772-99.
Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY (2015). Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis, 18(2), 122-7.
Harshman LC, Werner L, Wong Y, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Recine F, Bellmunt J, Galsky MD, RISC Investigators (2015). Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 4524).
Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Straubhar AM, Agarwal AM, Van Atta J, Grossmann KF, Samlowski WE, Redman BG, Agarwal N, Alva AS (2015). Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2). Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015(suppl; abstr 4565).
Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (2015). Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs, 33(3), 691-9.
Lum MM, Belnap TW, Frandsen J, Brown AP, Sause WT, Soisson AP, Dodson MK, Werner T, Gaffney DK (2015). Survival Analysis of Cancer Patients With FIGO Stage IIIA Endometrial Cancer. Am J Clin Oncol, 38(3), 283-8.
Li H, Choueiri TK, Welss C, Agarwal N, Donskov F, Lee J, Broom RJ, Yuasa T, Rini BI, Pal SK, Wood L, Ernst DS, Kollmannsberger CK, Vaishampayan UN, Rha SY, Bjarnason GA, Knox JJ, Saleem S, Beuselinck B, Heng DYC (2015). Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC). Poster Presentation. ASCO Annual Meeting May 29-June1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 4558).
Palmbos PL, Feng FY, Tomlins SA, Kelly WK, Morgans AK, Taplin M, Agarwal N, Antonarakis ES, Twardowski P, Jacobson J, Davenport MS, Daignault S, Knudsen KE, Hussain M (2015). A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer. Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr TPS5074).
Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (2015). Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs, 33(3), 691-9.
Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD, Agarwal N (2015). Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clin Genitourin Cancer, 13(3), e131-7.
Menes TS, Terry MB, Goldgar D, Andrulis IL, Knight JA, John EM, Liao Y, Southey M, Miron A, Chung W, Buys SS (2015). Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry. PMID: 25975955. Breast Cancer Res Treat, 151(3), 653-60.
Agarwal N, Alex A, Farnham JM, Patel SB, Tantravahi SK, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA (2015). Association of single nucleotide polymorphisms (SNPs) in ESR1 and PRMT8 and reponse to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 5048).
Twardowski P, Plets M, Plimack ER, Agarwal N, Tangen CM, Vogelzang NJ, Thompson IM, Lara P (2015). SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC). Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 4523).
Fay AP, Kwiatkowski DJ, Gray KP, Thorner A, Rini BI, Agarwal N, Ho TH, Song J, Barrios PM, Albiges L, Mendel Van Allen E, Krajewski KM, Porta C, Pal SK, Bellmunt J, McDermott DF, Heng DYC, Signoretti S, Choueiri TK (2015). Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort. Poster Presentation. ASCO Annual Meeting May 29-June1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 4519).
Nevala-Plagemann C, Lee C, Tolar J (2015). Placenta-based therapies for the treatment of epidermolysis bullosa. Cytotherapy, 17(6), 786-795.
Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD, Agarwal N (2015). Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clin Genitourin Cancer, 13(3), e131-7.
Kohlmann W, Champine M, Colonna SV (May 31, 2015). Communicating Genetic Test Results to Patients and Their Families. ASCO Daily News.
Patel SB, Buckley TH, Gill D, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N (2015). Correlation of baseline serum testosterone and serum prostate-specific antigen at 7 months in patients with new hormone sensitive metastatic prostate cancer treated with continuous androgen deprivation therapy [Abstract]. Journal of Clinical Oncology, 33(15 suppl), e16019.
Patel SB, Stenehjem DD, Hsu J, Tantravahi SK, Gill D, Agarwal A, Batten JA, Agarwal N, Pal SK (2015). Comparative effectiveness of first line vascular endothelial growth factor inhibitor followed by second line therapy with either a VEGF-TKI or an mTOR inhibitor in patients with metastatic renal cell carcinoma [Abstract]. Journal of Clinical Oncology, 33(15 suppl), e15589.
Bailey E, Tantravahi SK, Poole A, Wells C, Batten J, Merriman J, Stenehjem D, Agarwal N (May 2015). Association of hand-foot syndrome (HFS), treatment dose reductions (TDRs), and outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL [Abstract]. J Clin Oncol.
H Park, I Garrido-Laguna, A Naing, S Fu, GS Falchook, SA Piha-Paul, JJ Wheler, DS Hong, V Subbiah, AM Tsimberidou, AO Kaseb, Y Oki, R Zinner, S Patel, V Velez Bravo, MA Fanale, F Meric Bernstam, R Kurzrock, F Janku (2015). Phase 1 study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies. ASCO Annual Meeting May 29-June 2,2015 [Abstract]. J Clin Oncol, 33, 2015(suppl; abstr 2584)).
K Wang, A Johnson, I Garrido-Laguna, J Chmielecki, R Yelensky, D Lipson, JA Elvin, JA Vergilio, SA Ali, V Miller, PJ Stephens, JS Ross (2015). Amplification of CRKL in human cancer: a rare event associated with potential sensitivity to targeted therapy. ASCO Annual Meeting May 29-June 2,2015. Abstract Number: 1526 [Abstract]. J Clin Oncol, 33, 2015(suppl; abstr 1526).
DS Hong, I Garrido-Laguna, IE Krop, V Subbiah, TL Werner, CM Cotter, EP Hamilton, K Velastegui, D Xuan, R Bugarini, A Gollerkeri, HA Burris (2015). First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors. ASCO Annual Meeting May 29-June 2,2015 (Abst. # to be released on May 13th) [Abstract].
Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr (2015). SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol, 33(14), 1601-8.
Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, Graeber TG, Ribas A (May 2015). Inhibition of CSF-1R Improves Antitumor Efficacy of BRAF Inhibition. BMC Cancer, 15(1), 356.
Thanarajasingam G, Milone M, Kohli M (2015). Paraneoplastic encephalopathy: an unusual presenting feature of bladder cancer metastasis. BMJ Case Rep, 2015.
Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, Lu KH (2015). Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prev Res (Phila), 8(5), 342-8.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, National comprehensive cancer network (2015). Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw, 13(5), 515-24.
Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS, Breast Cancer Family Registry, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Gerdes AM, Ejlertsen B, Nielsen FC, Hansen TV, Osorio A, Benitez J, Conejero RA, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, EMBRACE, Douglas F, Cook J, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Tischkowitz M, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Cole T, Godwin AK, Isaacs C, Claes K, De Leeneer K, Meindl A, Gehrig A, Wappenschmidt B, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Schmutzler RK, Preisler-Adams S, Markov NB, Wang-Gohrke S, de Pauw A, Lefol C, Lasset C, Leroux D, Rouleau E, Damiola F, GEMO Study Collaborators, Dreyfus H, Barjhoux L, Golmard L, Uhrhammer N, Bonadona V, Sornin V, Bignon YJ, Carter J, Van Le L, Piedmonte M, DiSilvestro PA, de la Hoya M, Caldes T, Nevanlinna H, Aittomki K, Jager A, van den Ouweland AM, Kets CM, Aalfs CM, van Leeuwen FE, Hogervorst FB, Meijers-Heijboer HE, HEBON, Oosterwijk JC, van Roozendaal KE, Rookus MA, Devilee P, van der Luijt RB, Olah E, Diez O, Teul A, Lazaro C, Blanco I, Del Valle J, Jakubowska A, Sukiennicki G, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Agnarsson BA, Maugard C, Amadori A, Montagna M, Teixeira MR, Spurdle AB, Foulkes W, Olswold C, Lindor NM, Pankratz VS, Szabo CI, Lincoln A, Jacobs L, Corines M, Robson M, Vijai J, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Greene MH, Mai PL, Rennert G, Imyanitov EN, Mulligan AM, Glendon G, Andrulis IL, Tchatchou S, Toland AE, Pedersen IS, Thomassen M, Kruse TA, Jensen UB, Caligo MA, Friedman E, Zidan J, Laitman Y, Lindblom A, Melin B, Arver B, Loman N, Rosenquist R, Olopade OI, Nussbaum RL, Ramus SJ, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Mitchell G, Karlan BY, Lester J, Orsulic S, Stoppa-Lyonnet D, Thomas G, Simard J, Couch FJ, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC, Mazoyer S, Phelan CM, Sinilnikova OM, Cox DG (2015). An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res, 17, 61.
WS Liang, B Salhia, A Helland, S Sekar, I Garrido-Laguna, M Fanale, Y Oki, JR Westin, RE Davis, F Meric-Bernstam, F Janku (2015). Identification of mutations in histrone modification genes in Hodgkin lymphoma. AACR 106th Annual Meeting, April 18-22 (LB-176) [Abstract].
Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI (2015). Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer, 136(8), 1856-62.
Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, CIMBA Consortium, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlertsen B, Gerdes AM, Hansen Tv, Ramn y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Izatt L, Adlard J, Donaldson A, Ellis S, Sharma P, Schmutzler RK, Wappenschmidt B, Becker A, Rhiem K, Hahnen E, Engel C, Meindl A, Engert S, Ditsch N, Arnold N, Plendl HJ, Mundhenke C, Niederacher D, Fleisch M, Sutter C, Bartram CR, Dikow N, Wang-Gohrke S, Gadzicki D, Steinemann D, Kast K, Beer M, Varon-Mateeva R, Gehrig A, Weber BH, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Houdayer C, Belotti M, Gauthier-Villars M, Damiola F, Boutry-Kryza N, Lasset C, Sobol H, Peyrat JP, Muller D, Fricker JP, Collonge-Rame MA, Mortemousque I, Nogues C, Rouleau E, Isaacs C, De Paepe A, Poppe B, Claes K, De Leeneer K, Piedmonte M, Rodriguez G, Wakely K, Boggess J, Blank SV, Basil J, Azodi M, Phillips KA, Caldes T, de la Hoya M, Romero A, Nevanlinna H, Aittomki K, van der Hout AH, Hogervorst FB, Verhoef S, Colle JM, Seynaeve C, Oosterwijk JC, Gille JJ, Wijnen JT, Gmez Garcia EB, Kets CM, Ausems MG, Aalfs CM, Devilee P, Mensenkamp AR, Kwong A, Olah E, Papp J, Diez O, Lazaro C, Darder E, Blanco I, Salinas M, Jakubowska A, Lubinski J, Gronwald J, Jaworska-Bieniek K, Durda K, Sukiennicki G, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Zowocka-Perowska E, Menkiszak J, Arason A, Barkardottir RB, Simard J, Laframboise R, Montagna M, Agata S, Alducci E, Peixoto A, Teixeira MR, Spurdle AB, Lee MH, Park SK, Kim SW, Friebel TM, Couch FJ, Lindor NM, Pankratz VS, Guidugli L, Wang X, Tischkowitz M, Foretova L, Vijai J, Offit K, Robson M, Rau-Murthy R, Kauff N, Fink-Retter A, Singer CF, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Berger A, Greene MH, Mai PL, Imyanitov EN, Toland AE, Senter L, Bojesen A, Pedersen IS, Skytte AB, Sunde L, Thomassen M, Moeller ST, Kruse TA, Jensen UB, Caligo MA, Aretini P, Teo SH, Selkirk CG, Hulick PJ, Andrulis I (2015). Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA, 313(13), 1347-61.
Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G (2015). Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. Clin Genitourin Cancer, 13(2), 178-84.
Gupta S, Gill D, Pal SK, Agarwal N (2015). Activin receptor inhibitors--dalantercept. [Review]. Curr Oncol Rep, 17(4), 14.
Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J, Rozengurt E (2015). Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Mol Cancer Ther, 14(4), 1014-23.
Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, Torres A, Hernandez S, Lau C, Agarwal N, Kawachi M, Yen Y, Jones JO (2015). Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. Clin Genitourin Cancer, 13(2), 130-6.
Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI (2015). Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer, 13(2), e79-85.
Oliver TG, Patel J, Akerley W (2015). Squamous non-small cell lung cancer as a distinct clinical entity. Am J Clin Oncol, 38(2), 220-6.
Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R (2015). A Phase II Trial of Trebananib (AMG 386; IND#111071), a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients with Persistent/Recurrent Carcinoma of the Endometrium: A Gynecologic Oncology Group Study [Abstract]. SGO March 2015, 137(supp 1), 24.
Colonna S, Halwani A, Ying J, Buys S, Sweeney C (2015). Women with breast cancer in the Veterans Health Administration: demographics, breast cancer characteristics, and trends. PMID: 25767969. Med Care, 53(4 Suppl 1), S149-55.
Williams NL, Werner TL, Jarboe EA, Gaffney DK (2015). Adenocarcinoma of the cervix: should we treat it differently? [Review]. Curr Oncol Rep, 2015 Apr, 17(4):17.
Gupta S, Weston A, Bearrs J, Soldi R, Sharma S (2015). Effect of LSD-1 inhibition on docetaxel resistance in prostate cancer cells [Abstract]. AACR Annual Meeting, April 2015.
Colonna S, Halwani A, Ying J, Buys S, Sweeney C (2015). Women with breast cancer in the Veterans Health Administration: demographics, breast cancer characteristics, and trends. Med Care, 53(4 Suppl 1), S149-55.
Fay AP, Xie WL, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishamayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, Choueiri TK, Heng DY (2015). Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. Clin Genitourin Cancer, 13(2), 150-5.
Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, Wang K, Ross JS, Sharma S (2015). N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience, 2(3), 285-93.
Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Koya KC, Graeber T, Comin-Anduix B, Ribas A (Mar 2015). Improved Antitumor Activity of Immunotherapy with BRAF and MEK inhibitors in BRAFV600E mutant melanoma. Sci Transl Med, 7(279), 279.
Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R (2015). Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol, 33(7), 723-31.
Albright F, Stephenson RA, Agarwal N, Teerlink CC, Lowrance WT, Farnham JM, Albright LA (2015). Prostate cancer risk prediction based on complete prostate cancer family history. Prostate, 75(4), 390-8.
Campo RA, Light KC, OConnor K, Nakamura Y, Lipschitz D, LaStayo PC, Pappas LM, Boucher KM, Irwin MR, Hill HR, Martins TB, Agarwal N, Kinney AY (2015). Blood pressure, salivary cortisol, and inflammatory cytokine outcomes in senior female cancer survivors enrolled in a tai chi chih randomized controlled trial. J Cancer Surviv, 9(1), 115-25.
Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY (2015). The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol, 16(3), 293-300.
Flaig TW, Tangen CM, Hussain M, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM (February 2015). Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Eigl BJ (February 2015). Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
Ramos J, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Sternberg CN, Alva AS, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY (February 2015). Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT). Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
Buckley TH, Patel SB, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N (2015). Correlation of baseline serum testosterone and serum prostate-specific antigen at 7 months in patients with new hormone sensitive metastatic prostate cancer treated with continuous androgen deprivation therapy [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 231.
Shiven B Patel, Danielle Tometich, Zachary L Reese, Sunil Sharma, Ignacio Garrido-Laguna (2015). Exceptional responses in patients with metastatic colorectal cancer enrolled in first-in-man studies from 2002 through 2012. Presented at the 2015 Gastrointestinal Cancers Symposium [Abstract]. J Clin Oncol, 33(suppl 3 abstr 687).
Zachary L Reese, Danielle Tometich, Shiven B Patel, Sunil Sharma, Ignacio Garrido-Laguna (2015). Exceptional responses in patients with upper gastrointestinal malignancies enrolled in first-in-man studies: 2002-2012. Presented at the 2015 Gastrointestinal Cancers Symposium., Abstract 311 [Abstract]. J Clin Oncol, 33(suppl 3), abstr 311.
Agarwal N, Buckley TH, Farnham JM, Patel SB, Alex A, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA (February 2015). Germ line predictors of response to androgen deprivation therapy in men with advanced prostate cancer. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
Albright FS, Agarwal N, Lowrance WT, Stephenson RA, Alex A, Cannon-Albright LA (February 2015). Risk for death from prostate cancer predicted from complete family history of lethal prostate cancer (LPC). Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
Patel SB, Agarwal N, Hsu J, Tantravahi SK, Gill D, Vuong W, Batten JA, Stenehjem DD, Pal SK (February 2015). Everolimus (EVE) versus temsirolimus (TEM) after first-line treatment with VEGF TKI in patients with metastatic renal cell carcinoma. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
Tanravahi SK, Patel SB, Ravulapati S, Batten JA, Merriman J, Stenehjem D, Agarwal N (February 2015). Long-term response in metastatic renal cell carcinoma patients receiving first-line therapy with VEGF TKIs. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
Buckley TH, Patel SB, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N (February 2015). Correlation of baseline serum testosterone (T) and prostate-specific antigen (PSA) at 7 months (7 mo PSA) in patients (pts) with new hormone sensitive metastatic prostate cancer (mHSPC) treated with continous androgen deprivation therapy (cADT). Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
Patel SB, Tantravahi SK, Gill D, Poole A, Merriman J, Batten JA, Stenehjem DD, Agarwal N (February 2015). Comparative effectiveness of first-line VEGF TKI followed by second-line therapy with either a VEGF TKI or an mTOR in patients with metastatic renal cell carcinoma. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
Cannon-Albright LA, Teerlink C, Alex A, Albright FS, Stephenson RA, Agarwal N (February 2015). A genome-wide linkage study of lethal prostate cancer predisposition gene in a set of high-risk pedigrees. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V (2015). Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med, 19(103), 109-16.
Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V (2015). Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discov Med, 19(103), 101-8.
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R, National comprehensive cancer network (2015). Kidney cancer, version 3.2015. J Natl Compr Canc Netw, 13(2), 151-9.
Cheng TH, Gorman M, Martin L, Barclay E, Casey G, Saunders B, Thomas H, Clark S, Tomlinson I (2015). Common colorectal cancer risk alleles contribute to the multiple colorectal adenoma phenotype, but do not influence colonic polyposis in FAP. PMID: 24801760. Eur J Hum Genet, 23(2), 260-3.
Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jnson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S, EMBRACE, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM, GEMO Study Collaborators, Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M, OMalley DM, de la Hoya M, Caldes T, Aittomki K, Nevanlinna H, Colle JM, Rookus MA, Oosterwijk JC, Breast Cancer Family Registry, Tihomirova L, Tung N, Hamann U, Isaccs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB, HEBON, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR, KConFab Investigators, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmalm M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J, Australian Cancer Study Ovarian Cancer Investigators, Australian Ovarian Cancer Study Group, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-Claude J, Wang-Gohrke S, Eilber U, Moysich KB, Odunsi K, Sucheston L, Lele S, Wilkens LR, Goodman MT, Thompson PJ, Shvetsov YB, Runnebaum IB, Drst M, Hillemanns P, Drk T, Antonenkova N, Bogdanova N, Leminen A, Pelttari LM, Butzow R, Modugno F, Kelley JL, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kjaer SK, Hogdall E, Hasmad HN, Azmi MA, Teo SH, Woo YL, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MA, Wu X, Levine DA, Bisogna M, Berchuck A, Iversen ES, Schildkraut JM, Concannon P, Weber RP, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Krakstad C, Salvesen HB, Tangen IL, Bjorge L, van Altena AM, Aben KK, Kiemeney LA, Massuger LF, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Cybulski C, Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall L, Nedergaard L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Ji BT, Zheng W, Shu XO, Gao YT, Rosen B, Risch HA, McLaughlin JR, Narod SA, Monteiro AN, Chen A, Lin HY, Permuth-Wey J, Sellers TA, Tsai YY, Chen Z, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Harrington P, Lee AW, Wu AH, Pearce CL, Coetzee G, Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J, Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP, Antoniou AC, Chenevix-Trench G, Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (2015). Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet, 47(2), 164-71.
Singh P, Agarwal N, Pal SK (2015). Sequencing systemic therapies for metastatic kidney cancer. [Review]. Curr Treat Options Oncol, 16(1), 316.
Meade CS, Towe SL, Watt MH, Hobkirk AL, Skinner D, Myers B, Kimani SM, Pieterse D (2014). HIV testing behaviors and attitudes among community recruited methamphetamine users in a South African township. AIDS Behav, 19(1), 186-91.
Sharma S, Hu-Lieskovan S, Dubinett SM, Moon Lee J (2015). Addressing inflammation with immunotherapy. In Dubinett S (Ed.), Inflammation and Lung Cancer (Second Edition). New York: Springer.
Agarwal N, Buckley TH, Farnham JM, Patel SB, Alex A, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA (2015). Germline predictors of response to androgen deprivation therapy in men with advanced prostate cancer [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 162.
Patel SB, Tometich D, Reese ZL, Sharma S, Garrido-Laguna I (2015). Exceptional responses in patients with metastatic colorectal cancer enrolled in first-in-man studies from 2002-2012 [Abstract]. Journal of Clinical Oncology, 33(3 suppl), 687-687.
Reese ZL, Tometich D, Patel SB, Sharma S, Garrido-Laguna I (2015). Exceptional responses in patients with upper gastrointestinal malignancies enrolled in first-in-man studies: 2002-2012 [Abstract]. Journal of Clinical Oncology, 33(3 suppl), abstr 311.
Maughan BL, Antonarakis ES (2015). Androgen pathway resistance in prostate cancer and therapeutic implications. [Review]. Expert Opin Pharmacother, 16(10), 1521-37.
Nguyen-Dumont T, Hammet F, Mahmoodi M, Tsimiklis H, Teo ZL, Li R, Pope BJ, Terry MB, Buys SS, Daly M, Hopper JL, Winship I, Goldgar DE, Park DJ, Southey MC (2015). Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry. PMID: 25575445. Breast Cancer Res Treat, 149(2), 547-54.
Pendurti G, Shah U, Swami U, Hou Y, Ghalib MH, Chaudhary I, Polineni R, Klobocista M, Mukherjee P, Chuy JW, Kaubisch A, Rajdev L, Aparo S, Goel S (2015). Developing a novel prognostic model to predict overall survival (OS) and 90 day mortality rate (90DM) for metastatic colorectal cancer (mCRC) patients in phase I trials [Abstract]. J Clin Oncol, 33(suppl; abstr e14618).
Tantravahi SK, Patel SB, Ravulapati S, Batten J, Merriman J, Stenehjem DD, Agarwal N (2015). Long term response in metastatic renal cell carcinoma patients receiving first line therapy with vascular endothelial growth factor inhibitors with VEGF TKIs [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 436.
Colonna SV, Werner T (2015). Breast cancer bone metastases. In Lor Randall (Ed.), Metastatic Bone Disease: Essentials for the Orthopedic Surgeon. Springer International.
Reese Z, Straubhar A, Pal SK, Agarwal N (2015). Ipilimumab in the treatment of prostate cancer. Future Oncol, 11(1), 27-37.
Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L (2014). Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol, 67(1), 33-41.
Swami U, Shah U, Goel S (2015). Marine sponge derived Eribulin in preclinical and clinical studies for cancer. In Handbook of Anticancer Drugs from Marine Origin (pp. 59-100). Cham, Switzerland: Springer International Publishing.
Gilcrease GW, Kinsey C, Stenehjem D (2015). Environmental and genetic risk factors in hepatocellular carcinoma. In Torre A, Uscanga L (Eds.), Medicina Individualizada De La Evidencia A La Práctica Clínica (pp. 155-62). Permanyer México.
Patel SB, Agarwal N, Hsu J, Tantravahi SK, Gill D, Vuong W, Batten JA, Stenehjem DD, Pal SK (2015). Everolimus (EVE) versus temsirolimus (TEM) after first-line treatment with VEGF TKI in patients with metastatic renal cell carcinoma [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 460.
Grenache DG, Heichman KA, Werner TL, Vucetic Z (2015). Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass. Clin Chim Acta, 438, 358-63.
Singh P, Pal SK, Alex A, Agarwal N (2015). Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol, 11(15), 2137-48.
Maughan BL, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES (2015). Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) [Abstract]. J Clin Oncol, 33(Suppl 7), abstr 252.
Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, Stenehjem DD, Agarwal N (2015). Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. J Oncol, 2015, 181926.
Marcus PM, Broski KG, Buys SS, Childs J, Church TR, Gohagan JK, Gren LH, Higgins D, Jaggi R, Jenkins V, Johnson CC, Lappe K, OBrien B, Ogden SL, Prorok PC, Reding D, Shambaugh V, Yokochi LA, Yurgalevitch S (2015). Building Successful Relationships in the PLCO Cancer Screening Trial. PMID: 26238208. Rev Recent Clin Trials, 10(3), 181-6.
Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gmez Garcia EB, Olopade OI, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Karlan BY, Orsulic S, Lester J, Chung WK, Miron A, Southey MC, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Ding YC, Neuhausen SL, Hansen TV, Gerdes AM, Ejlertsen B, Jnson L, Osorio A, Martnez-Bouzas C, Benitez J, Conway EE, Blazer KR, Weitzel JN, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Barile M, Ficarazzi F, Mariette F, Fortuzzi S, Viel A, Giannini G, Papi L, Martayan A, Tibiletti MG, Radice P, Vratimos A, Fostira F, Garber JE, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Davidson R, Hodgson SV, Ellis S, Cole T, EMBRACE, Godwin AK, Claes K, Van Maerken T, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Wappenschmidt B, Wang-Gohrke S, Bressac-de Paillerets B, Buecher B, Delnatte C, Houdayer C, Stoppa-Lyonnet D, Damiola F, Coupier I, Barjhoux L, Venat-Bouvet L, Golmard L, Boutry-Kryza N, Sinilnikova OM, Caron O, Pujol P, Mazoyer S, Belotti M, GEMO Study Collaborators, Piedmonte M, Friedlander ML, Rodriguez GC, Copeland LJ, de la Hoya M, Segura PP, Nevanlinna H, Aittomki K, van Os TA, Meijers-Heijboer HE, van der Hout AH, Vreeswijk MP, Hoogerbrugge N, Ausems MG, van Doorn HC, Colle JM, HEBON, Olah E, Diez O, Blanco I, Lazaro C, Brunet J, Feliubadalo L, Cybulski C, Gronwald J, Durda K, Jaworska-Bieniek K, Sukiennicki G, Arason A, Chiquette J, Teixeira MR, Olswold C, Couch FJ, Lindor NM, Wang X, Szabo CI, Offit K, Corines M, Jacobs L, Robson ME, Zhang L, Joseph V, Berger A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Glendon G, Tchatchou S, Andrulis IL, Toland AE, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Laitman Y, Rantala J, von Wachenfeldt A, Ehrencrona H, Askmalm MS, Borg, Kuchenbaecker KB, McGuffog L, Barrowdale D, Healey S, Lee A, Pharoah PD, Chenevix-Trench G, KConFab Investigators, Antoniou AC, Friedman E (2015). Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev, 24(1), 308-16.
Vaklavas C, Meng Z, Choi H, Grizzle WE, Zinn KR, Blume SW (2015). Small molecule inhibitors of IRES-mediated translation. Cancer Biol Ther, 16(10), 1471-85.
Patel SB, Tantravahi SK, Gill D, Poole A, Merriman J, Batten JA, Stenehjem DD, Agarwal N (2015). Comparative effectiveness of first line vascular endothelial growth factor inhibitor followed by second line therapy with either a VEGF-TKI or an mTOR inhibitor in patients with metastatic renal cell carcinoma [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 495.
Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, Stenehjem DD, Agarwal N (2015). Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. J Oncol, 2015, 181926.
Gupta S (2015). Epigenetics in Bladder Cancer. Focus on Phase I Newsletter.
Agarwal N, Alex A, Farnham JM, Patel SB, Tantravahi SK, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA (2015). Association of single nucleotide polymorphisms in ESR1 and PRMT8 and response to treatment with abiraterone acetate in men with metastatic castration refractory prostate cancer [Abstract]. Journal of Clinical Oncology, 33(suppl), abstr 5048.
Ming M, Sinnett-Smith J, Wang J, Soares HP, Young SH, Eibl G, Rozengurt E (2014). Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PLoS ONE, 9(12), e114573.
Samadder NJ, Curtin K, Wong J, Tuohy TM, Mineau GP, Smith KR, Pimentel R, Pappas L, Boucher K, Garrido-Laguna I, Provenzale D, Burt RW (2014). Epidemiology and familial risk of synchronous and metachronous colorectal cancer: a population-based study in Utah. Clin Gastroenterol Hepatol, 12(12), 2078-84.e1-2.
Reese Z, Patel S, Stenehjem DD, Garrido-Laguna I (2014). Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX. J Gastrointest Cancer, 45 Suppl 1, 278-81.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2014). Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw, 12(12), 1738-61.
Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V (2014). Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med, 18(101), 331-9.
Goyal A, Soul D, Annunziata G, Swami U, Choudhury M (Winter 2014). A self destructing reaction to a self destructive habit: Levamisole tainted cocaine causing autoimmune vasculitis. New York Medical Journal, 8(1).
Reese Z, Patel S, Stenehjem DD, Garrido-Laguna I (2014). Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX. J Gastrointest Cancer, 45 Suppl 1, 278-81.
Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V (2014). Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discov Med, 18(101), 323-30.
Agarwal N (2014). Perspective opinion on “Gleason score associated with time to development of neuroendocrine prostate cancer [Web]. Available: https://goo.gl/eKj1Q1.
Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, Naeim A, Church TR, Silvestri GA, Gorelick J, Gatsonis C (2014). Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med, 371(19), 1793-802.
Kinney AY, Butler KM, Schwartz MD, Mandelblatt JS, Boucher KM, Pappas LM, Gammon A, Kohlmann W, Edwards SL, Stroup AM, Buys SS, Flores KG, Campo RA (2014). Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial. J Natl Cancer Inst, 106(12).
Loprinzi PD, Kohli M (2013). Health characteristics and sedentary behavior impact on prostate-specific antigen levels in a national U.S. sample. J Phys Act Health, 11(8), 1587-92.
Rozengurt E, Soares HP, Sinnet-Smith J (2014). Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther, 13(11), 2477-88.
Maughan BL, Antonarakis ES (2014). Enzalutamide in chemo-naive castration-resistant prostate cancer: effective for most but not for all. Asian J Androl, 16(6), 807-8.
Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN (2014). Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer, 24(9), 1583-9.
Patel SB, Rodgers GM (2014). Continuous infusion of human plasma-derived von Willebrand factor concentrate as an effective therapy in a patient with acquired von Willebrand disease. [Letter to the editor]. Haemophilia, 20(6), e411-4.
Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R (2014). A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience, 1(10), 614-623.
Falk RT, Maas P, Schairer C, Chatterjee N, Mabie JE, Cunningham C, Buys SS, Isaacs C, Ziegler RG (2014). Alcohol and risk of breast cancer in postmenopausal women: an analysis of etiological heterogeneity by multiple tumor characteristics. PMID: 25150269. Am J Epidemiol, 180(7), 705-17.
Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK (2014). Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol, 66(4), 704-10.
Kimani SM, Watt MH, Merli MG, Skinner D, Myers B, Pieterse D, MacFarlane JC, Meade CS (2014). Respondent driven sampling is an effective method for engaging methamphetamine users in HIV prevention research in South Africa. Drug Alcohol Depend, 143, 134-40.
Bodelon C, Pfeiffer RM, Buys SS, Black A, Sherman ME (2014). Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis. J Natl Cancer Inst, 106(10).
Ramadhani HO, Bartlett JA, Thielman NM, Pence BW, Kimani SM, Maro VP, Mwako MS, Masaki LJ, Mmbando CE, Minja MG, Lirhunde ES, Miller WC (2014). Association of first-line and second-line antiretroviral therapy adherence. Open Forum Infect Dis, 1(2), ofu079.
Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC (2014). A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer, 120(17), 2684-93.
Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J (2014). New agents for prostate cancer. [Review]. Ann Oncol, 25(9), 1700-9.
Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T (2014). Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother, 37(7), 360-5.
Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M (2014). Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc, 89(9), 1287-306.
Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD (2014). Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol, 9(3), 195-204.
Agarwal N, Dorff T, Goldkorn A (2014). New prostate cancer drugs: extending and improving life. Lancet Oncol, 15(10), 1052-4.
Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Maehle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramon y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, Moss S, Eeles RA (2014). Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. PMID: 24484606. Eur Urol, 66(3), 489-99.
Harris D, Patrick-Miller L, Schwartz L, Lantos J, Daugherty C, Daly M, Andrulis IL, Buys SS, Chung WK, Frost CJ, John EM, Keegan TH, Knight JA, Terry MB, Bradbury AR (2014). Human subjects protection: an event monitoring committee for research studies of girls from breast cancer families. J Adolesc Health, 55(3), 352-7.
Agarwal N, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD (2014). Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma. Oncologist, 19(9), 915-6.
Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R (2014). Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. PMID: 25190698. J Natl Compr Canc Netw, 12(9), 1326-38.
Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, Daniel Barrowdale, Katri Pylks, Jonathan Roberts, Andrew Lee, Deepak Subramanian, Kim De Leeneer, Florentia Fostira, Eva Tomiak, Susan L Neuhausen, Zhi L Teo, Sofia Khan, Kristiina Aittomki, Jukka S Moilanen, Clare Turnbull, Sheila Seal, Arto Mannermaa, Anne Kallioniemi, Geoffrey J Lindeman, Buys SA, Irene L Andrulis, Paolo Radice, Carlo Tondini, Siranoush Manoukian, Amanda E Toland, Penelope Miron, Jeffrey N Weitzel, Susan M Domchek, Bruce Poppe, Katheen BM Claes, Drakoulis Yannoukakos, Patrick Concannon, Jonine L Bernstein, Paul A James, Douglas F Easton, David E Goldgar, John L Hopper, Nazneen Rahman, Paolo Peterlongo, Heli Nevanlinna, Mary-Claire King, Fergus J Couch, Melissa C Southey, Robert Winqvist, William D Foulkes, Marc Tischkowitz (2014). Inherited Loss-of-Function Mutations in PALB2 and Breast Cancer Risk. N Engl J Med, 371, 497-506.
Welch BT, Callstrom MR, Morris JM, Kurup AN, Schmit GD, Weisbrod AJ, Lohse CM, Kohli M, Costello BA, Olivier KR, Thompson RH, Boorjian SA, Atwell TD (2014). Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. J Urol, 192(2), 357-63.
Dizon DS, Mackay HJ, Thomas GM, Werner TL, Kohn EC, Hess D, Rose PG, Covens AL (2014). State of the science in cervical cancer: where we are today and where we need to go. Cancer, 120(15), 2282-8.
Russell JS, Brown JM (2014). Circulating mouse Flk1+/c-Kit+/CD45- cells function as endothelial progenitors cells (EPCs) and stimulate the growth of human tumor xenografts. Mol Cancer, 13, 177.
Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A (July 2014). Combining targeted therapy with immunotherapy in BRAF mutant melanoma: promise and challenges. [Review]. J Clin Oncol, 32(21), 2248-2254.
Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R (2014). Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer, 120(14), 2164-73.
Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA, National Comprehensive Cancer Network (2014). Occult primary, version 3.2014. J Natl Compr Canc Netw, 12(7), 969-74.
Swami U, Annunziata G, Fulger I (2014). Experience with vena cava filters at a large community hospital and level-I trauma center: indications, complications, and compliance barriers. Clin Appl Thromb Hemost, 20(5), 546-52.
Park DJ, Tao K, Le Calvez-Kelm F, Nguyen-Dumont T, Robinot N, Hammet F, Odefrey F, Tsimiklis H, Teo ZL, Thingholm LB, Young EL, Voegele C, Lonie A, Pope BJ, Roane TC, Bell R, Hu H, Shankaracharya, Huff CD, Ellis J, Li J, Makunin IV, John EM, Andrulis IL, Terry MB, Daly M, Buys SS, Snyder C, Lynch HT, Devilee P, Giles GG, Hopper JL, Feng BJ, Lesueur F, Tavtigian SV, Southey MC, Goldgar DE (2014). Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers. Cancer Discov, 4(7), 804-15.
Stenehjem D, Parikh K, Batten J, Van Atta J, Crispin H, Sageser D, Grossmann K, Wang J, Tantravahi SK, Samlowski W, Agarwal N (2014). Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). [Abstract]. Journal Of Clinical Oncology.
Vaa B, Kohli M, Price KA, Swetz KM (2014). Solitary cystic cerebellar metastasis in a patient with invasive transitional cell carcinoma of the bladder. BMJ Case Rep, 2014.
Agarwal N, Tangen C, Hussain M, Lara Jr P, Higano C, Vaena D, MacVicar G, Li H, Crispino T, Quinn D, Vogelzang N, Thompson Jr I (May 2014). SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) + TAK-700 with ADT + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer (HSPC) (NCT01809691). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted. [Abstract].
Shepard D, Bruce J, Garrido-Laguna I, et al (2014). Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid tumors [Abstract]. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4596).
Hu-Lieskovan S, Mok S, Robert L, Goedert L, Comin-Anduix B, Koya RC, Ribas A (June 2014). Combinatorial effect of dabrafenib, trametinib, and adoptive cell transfer (ACT) in an immune-competent murine model of BRAFV600E mutant melanoma [Abstract]. 32(5 Supplement), Abstract 2512.
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR (2014). Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol, 15(7), 700-12.
Cannon-Albright LA, Farnham JM, Bailey M, Albright FS, Teerlink CC, Agarwal N, Stephenson RA, Thomas A (2014). Identification of specific Y chromosomes associated with increased prostate cancer risk. Prostate, 74(9), 991-8.
Yadav BS, George P, Sharma SC, Gorsi U, McClennan E, Martino MA, Chapman J, Chen LM, Prakash G, Malhotra P, Tantravahi SK, Glenn MJ, Werner TL, Baksh K, Sokol L, Morris GJ (2014). Primary non-Hodgkin lymphoma of the ovary. Semin Oncol, 41(3), e19-30.
Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY (2014). Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol, 65(6), 1086-92.
Vaklavas C, Forero A (2014). Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE). BioDrugs, 28(3), 253-63.
Cheng H, Li H, Higano C, Tangen C, Agarwal N, Yan J, Vogelzang N, Hussain M, Thompson Jr I, Tewari M, Yu E (May 2014). Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer. Poster discussion session. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted. [Abstract].
Galsky M, Harshman L, Crabb S, Wong YN, Yu E, Chowdhury S, Powles T, Pal SK, Moshier E, Ladoire S, Hussain S, Agarwal N, Vaishampayan U, Recine F, Berthold D, Necchi A, Theodore C, Milowsky M, Bellmunt J, Rosenberg J (May 2014). Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). Poster discussion session. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL Accepted. [Abstract].
Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal A, Sendilnathan A, Van Atta J, Batten J, Grossmann K, Samlowski W, Stenehjem D, Agarwal N (May 2014). Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). Poster Presentation. 2014 ASCO Annual Meeting May 30–June 3, 2014, Chicago, IL [Abstract]. J Clin Oncol.
Diamond JR, Agarwal N, Bowles D, Lam ET, Werner T, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (May 2014). Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors. Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL Accepted. [Abstract].
Albiges L, Xie W, Lee JL, Rini B, Srinivas S, Bjarnason G, Ernst S, Wood L, Vaishamayan U, Rha SH, Agarwal N, Yuasa T, Pal SK, Koutsoukos K, Fay AP, Preston M, Cho E, Chin Heng DY, Choueiri T (May 2014). The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell cancer database consortium. Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL Accepted. [Abstract].
Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, De Wit R, De Bono JS, Cruz F, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak P, Lee C, Tejura B, Borgstein NG, Dreicer R (May 2014). Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel. Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL Accepted. [Abstract].
Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal A, Sendilnathan A, Van Atta J, Batten J, Grossmann K, Samlowski W, Stenehjem D, Agarwal N (May 2014). Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted. [Abstract].
Reynolds K, Juric D, Baselga J, Garrido-Laguna I, Bang, Y et al (2014). A Phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer or HER2-overexpressing metastatic breast or gastric cancer [Abstract]. J Clin Oncol 32:5s, 2014 (suppl; abstr 2517), 2014 ASCO Annual Meeting.
Yu E, Tangen C, Higano C, Agarwal N, Pal SK, Alva AS, Heath E, Tat Lam E, Gupta S, Lilly M, Inoue Y, Chi K, Vogelzang N, Quinn D, Li H, Cheng H, Plymate S, Hussain M, Thompson Jr I (May 2014). SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. Oral Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted. [Abstract].
Agarwal N, Parikh K, Tantravahi SK, Van Atta J, Batten J, Sageser D, Samlowski W, Grossmann K, Wang J, Stenehjem D (May 2014). Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted. [Abstract]. Journal of Clinical Oncology.
Kinsey C, Balakrishnan V, ODell MR, Huang JL, Newman L, Whitney-Miller CL, Hezel AF, Land H (2014). Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression. Cell Rep, 7(4), 1143-55.
Garrido-Laguna I, Tometich D, Hu Nan, Boucher K, Sharma S (2014). N of 1 Case Reports of Exceptional Responders Among Pancreatic Cancer Patients Enrolled in First-in-man studies from 2002 through 2012. Pancreatic Cancer: Innovation in Research and Treatment 2014 New Orleans, abst # B93 [Abstract].
Wu Q, Kohli M, Bergen HR 3rd, Cheville JC, Karnes RJ, Cao H, Young CY, Tindall DJ, McNiven MA, Donkena KV (2014). Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther, 13(5), 1067-77.
Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, ODonnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G (2014). A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int, 113(5b), E137-43.
Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY (2014). First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer, 110(8), 1917-22.
Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ (2014). Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol, 32(11), 1136-42.
Osorio A, Milne RL, Kuchenbaecker K, Vaclov T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Dez O, Ramn Y Cajal T, Konstantopoulou I, Martnez-Bouzas C, Andrs Conejero R, Soucy P, McGuffog L, Barrowdale D, Lee A, SWE-BRCA, Arver B, Rantala J, Loman N, Ehrencrona H, Olopade OI, Beattie MS, Domchek SM, Nathanson K, Rebbeck TR, Arun BK, Karlan BY, Walsh C, Lester J, John EM, Whittemore AS, Daly MB, Southey M, Hopper J, Terry MB, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Hansen TV, Jnson L, Ejlertsen B, Gerdes AM, Infante M, Herrez B, Moreno LT, Weitzel JN, Herzog J, Weeman K, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Bonanni B, Mariette F, Volorio S, Viel A, Varesco L, Papi L, Ottini L, Tibiletti MG, Radice P, Yannoukakos D, Garber J, Ellis S, Frost D, Platte R, Fineberg E, Evans G, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Eccles D, Cook J, Hodgson S, Brewer C, Tischkowitz M, Douglas F, Porteous M, Side L, Walker L, Morrison P, Donaldson A, Kennedy J, Foo C, Godwin AK, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Damiola F, Poppe B, Claes K, Piedmonte M, Tucker K, Backes F, Rodrguez G, Brewster W, Wakeley K, Rutherford T, Calds T, Nevanlinna H, Aittomki K, Rookus MA, van Os TA, van der Kolk L, de Lange JL, Meijers-Heijboer HE, van der Hout AH, van Asperen CJ, Gmez Garcia EB, Hoogerbrugge N, Colle JM, van Deurzen CH, van der Luijt RB, Devilee P, HEBON, Olah E, Lzaro C, Teul A, Menndez M, Jakubowska A, Cybulski C, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Johannsson OT, Maugard C, Montagna M, Tognazzo S, Teixeira MR, Healey S, KConFab Investigators, Olswold C, Guidugli L, Lindor N, Slager S, Szabo CI, Vijai J, Robson M, Kauff N, Zhang L, Rau-Murthy R, Fink-Retter A, Singer CF, Rappaport C, Geschwantler Kaulich D, Pfeiler G, Tea MK, Berger A, Phelan CM, Greene MH, Mai PL, Lejbkowicz F, Andrulis I, Mulligan AM, Glendon G, Toland AE, Bojesen A, Pedersen IS, Sunde L, Thomassen M, Kruse TA, Jensen UB, Friedman E, Laitman Y, Shimon SP, Simard J, Easton DF, Offit K, Couch FJ, Chenevix-Trench G, Antoniou AC, Benitez J (2014). DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet, 10(4), e1004256.
Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri TK (2014). The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol, 65(4), 723-30.
Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G (2014). Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 12(2), 130-7.
Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G (2014). Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 12(2), 130-7.
Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM (2014). A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol, 73(4), 839-45.
Yuan T, Huang X, Dittmar RL, Du M, Kohli M, Boardman L, Thibodeau SN, Wang L (2014). eRNA: a graphic user interface-based tool optimized for large data analysis from high-throughput RNA sequencing. BMC Genomics, 15, 176.
Alwan LM, Grossmann K, Sageser D, Van Atta J, Agarwal N, Gilreath JA (2014). Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target Oncol, 9(1), 63-71.
Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M (2013). Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer, 120(5), 692-701.
Campo RA, Agarwal N, LaStayo PC, OConnor K, Pappas L, Boucher KM, Gardner J, Smith S, Light KC, Kinney AY (2014). Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong. J Cancer Surviv, 8(1), 60-9.
Watt MH, Meade CS, Kimani S, MacFarlane JC, Choi KW, Skinner D, Pieterse D, Kalichman SC, Sikkema KJ (2013). The impact of methamphetamine ("tik") on a peri-urban community in Cape Town, South Africa. Int J Drug Policy, 25(2), 219-25.
Ferris JS, Daly MB, Buys SS, Genkinger JM, Liao Y, Terry MB (2014). Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry. Br J Cancer, 110(4), 1074-80.
Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ (2014). Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget, 5(3), 824-40.
Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD (2014). Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev, 40(1), 190-6.
Kohli M, Loprinzi PD (2013). Serum prostate-specific antigen association with neutrophil counts: results from the National Health and Nutrition Examination Survey 2001-2010. [Letter to the editor]. Int J Urol, 21(2), 224-5.
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R, Natiomal compresensive cancer networks (2014). Kidney cancer, version 2.2014. J Natl Compr Canc Netw, 12(2), 175-82.
Tantravahi SK, Stenehjem DD, Agarwal A, Kollepara SL, Batten JA, Ward M, Albertson D, Wang JF, Liu T, Agarwal N (January 2014). Clinical outcomes and survival of patients (pts) with sarcomatoid metastatic renal cell carcinoma (smRCC). Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 535.
Ko JJ, Xie W, Heng DY, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Harshman LC, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Bamias A, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK (January 2014). The international metastatic renal cell carcinoma database consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT). Oral Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 398.
Heng DY, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Kanesvaran R, Choueiri TK (January 2014). Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Oral Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Jorunal of Clinical Oncology, 32(suppl 4), abstr 396.
Batten JA, Samlowski W, Parikh K, Sendilnathan A, Van Atta J, Batten JA, Sagesser D, Grossmann K, Tantravahi SK, Stenehjem DD, Agarwal N (January 2014). The association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2) Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstra 487.
Cheng HH, Nadal R, Gulati R, Azad A, Twardowski P, Vaishampayan U, Agarwal N, Heath E, Pal SK, Rehman H, Leiter A, Batten J, Montgomery RB, Galsky MD, Chi KN, Antonarakis ES, Yu EY (January 2015). The Effect of Prior Abiraterone (Abi) Use on the Efficacy of Enzalutamide (Enza) in Men with mCRPC. Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 18.
Parikh K, Stenehjem DD, Sendilnathan A, Crispin H, VanAtta J, Batten JA, Sagesser D, Grossmann K, Samlowski W, Tantravahi SK, Agarwal N (January 2014). Conditional survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD-IL2). Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 460.
Tsao CK, Agarwal N, Apolo AB, Lee KM, Godbold JH, Oh WK, Galsky MD (January 2014). Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma. Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 18.
Diamond JR, Agarwal N, Bowles DW, Lan ET, Werner TL, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (2014). Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib and paclitaxel (PTX) in patients (pts) with advanced solid tumors [Abstract]. ASCO Annual Meeting, 2014, Chicago, Illinois.
Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S (2014). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res, 20(2), 480-9.
Khan A, Laronde DM (2014). Waterpipe smoking - a "healthy" alternative to cigarettes or a health hazard in disguise. [Review]. Canadian Journal of Dental Hygiene, 48(1), 27-33.
Poole A, Alva A, Batten JA, Agarwal N (2014). Metastatic Castrate Resistant Prostate cancer: Role of Androgen Signaling Inhibitors. In Dicker AP, Trabulsi EJ, Kelly W (Eds.), Multidisciplinary Approach to Prostate Cancer. New York: Demos Medical Publishing.
Halwani A, Colonna SV, Ying J, Buys S, Sweeney C (2014). Geographic distribution of rural-urban status of women with breast cancer in the Veterans Health Administration using two schemes: Rural Urban Continuum and Rural Urban Commuting Areas [Abstract]. Association of VA Hematology/Oncology.
Colonna SV, Halwani A, Ying J, Sweeney C, Buys S (2014). Breast cancer treatment among rural and urban veterans at the Veterans Health Administration: also presented as a poster. [Abstract]. Association of VA Hematology/Oncology.
Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood LA (2014). Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol, 25(1), 149-54.
Agarwal N, Fishman M (2014). Immunologic Therapy of Renal Cell Carcinoma. In Oncology & Hematology Review (10, pp. 54-60).
Janku F, Garrido-Laguna I, Velez-Bravo V et al (2013). Significant activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients [Abstract]. Blood (ASH Annual Meeting Abstracts), 122(21), 3048.
Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G (2013). Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer, 11(4), 495-500.
Nelson RE, Stenehjem D, Akerley W (2013). A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung Cancer, 82(3), 461-8.
Light KC, Agarwal N, Iacob E, White AT, Kinney AY, VanHaitsma TA, Aizad H, Hughen RW, Bateman L, Light AR (2013). Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome. Psychoneuroendocrinology, 38(12), 2983-95.
Swierczek S, Agarwal AM, Naidoo K, Lorenzo FR, Whisenant J, Nussenzveig RH, Agarwal N, Coetzer TL, Prchal JT (2013). Novel exon 2 alpha spectrin mutation and intragenic crossover: three morphological phenotypes associated with four distinct alpha spectrin defects. Haematologica, 98(12), 1972-9.
Agarwal N, Hussain M (2013). Management of hormone-sensitive metastatic prostate cancer. [Review]. Hematol Oncol Clin North Am, 27(6), 1221-41, viii.
Ma L, Kohli M, Smith A (2013). Nanoparticles for combination drug therapy. ACS Nano, 7(11), 9518-25.
Udomaksorn S, Stenehjem D, Welch BM, Cheng Y, Anderson L, Colonna S, Neumayer L, Brixner D (2013). Evaluation of variable relevance and accessibility to support personalized medicine in breast cancer [Abstract]. ISPOR 16th Annual European Congress, Dublin, Ireland.
Campo RA, OConnor K, Light KC, Nakamura Y, Lipschitz DL, LaStayo PC, Pappas L, Boucher K, Irwin MR, Agarwal N, Kinney AY (2013). Feasibility and acceptability of a Tai Chi Chih randomized controlled trial in senior female cancer survivors. Integrative Cancer Therapies, 12(6), 464-74.
Qin R, Kohli M (2018). Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology. Per Med, 10(8), 859-869.
Kohli M (2013). Does our "flight and fight" response have a link with cancer? Mayo Clin Proc, 88(11), 1185-7.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, OMalley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M (2013). Ovarian cancer, version 2.2013. J Natl Compr Canc Netw, 11(10), 1199-209.
Hou JY, Aparo S, Ghalib M, Chaudhary I, Shah U, Swami U, Einstein M, Goldberg GL, Mani S, Goel S (2013). Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: a single institution experience from 1999 to 2010. Gynecol Oncol, 131(1), 163-8.
Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, Sharma S (2013). A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs, 31(5), 1257-64.
Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R (2014). Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology, 60(127), 1611-23.
Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, Sharma S (2013). A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs, 31(5), 1257-64.
Sangle NA, Mao R, Shetty S, Schiffman JD, Dechet C, Layfield L, Agarwal N, Liu T (2013). Novel molecular aberrations and pathologic findings in a tubulocystic variant of renal cell carcinoma. Indian J Pathol Microbiol, 56(4), 428-33.
Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G (2013). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 11(3), 316-20.
Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, MacKenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY (2013). The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol, 8(3), 203-209.
Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G (2013). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 11(3), 316-20.
Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY (2013). Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer, 119(16), 2999-3006.
Acharya UH, Jeter JM (2013). Use of ipilimumab in the treatment of melanoma. Clin Pharmacol, 5(Suppl 1), 21-7.
Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr (2013). Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol, 14(9), 893-900.
Birmingham WC, Agarwal N, Kohlmann W, Aspinwall LG, Wang M, Bishoff J, Dechet C, Kinney AY (2013). Patient and provider attitudes toward genomic testing for prostate cancer susceptibility: a mixed method study. BMC Health Serv Res, 13, 279.
Russell JS, Brown JM (2013). The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Front Physiol, 4, 157.
Zhang B, Malouf J, Young P, Kohli M, Dronca R (2013). Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease. Rare Tumors, 5(3), e29.
Hu-Lieskovan S, Ribas A (2013). ASCO 2013 Highlights: Melanoma (review) [Web]. Available: Oncofacts.com.
Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National comprehensive cancer network (2013). Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw, 11(6), 645-53; quiz 653.
Swami U, Goel S, Mani S (2013). Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. [Review]. Curr Drug Targets, 14(7), 777-97.
Kunkalla K, Liu Y, Qu C, Leventaki V, Agarwal NK, Singh RR, Vega F (2013). Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype. Ann Hematol, 92(6), 777-87.
Vaklavas C, Meredith RF, Shen S, Knox SJ, Micallef IN, Shah JJ, LoBuglio AF, Forero-Torres A (2013). Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. Cancer Biother Radiopharm, 28(5), 370-9.
Colonna SV, Higgins AK, Alvarez J, Saville B, Lawrence JA, Abramson VA (2013). Analysis of recurrence risk by subtype in <1cm breast tumors [Abstract]. Journal of Clinical Oncology.
Zhang TY, Agarwal N, Sonpavde G, DiLorenzo G, Bellmunt J, Vogelzang NJ (2013). Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. [Review]. Curr Urol Rep, 14(3), 174-83.
Sonpavde G, Pond GR, Agarwal N, Choueiri TK, Qu AQ, Fougeray R, Salhi Y, Vaughn DJ, James ND, Niegisch G, Albers P, Galsky MD, Wong YN, Stadler WM, ODonnell PH, Vogelzang NH, Sridhar SS, Ko YJ, Sternberg CN, Bellmunt J (2013). Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC). Poster Discussion. American Society of Clinical Oncology (ASCO) Annual Meeting Chicago IL. May 31-Jun 4, 2013. [Abstract].
Chittoria N, Zhu H, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox J, Bjarnason BA, MacKenzie MK, Wood L, Vaishamayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, North SA, Rini BI, Yick D, Heng C (2013). Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium. Poster Presentation. May 31-Jun 4, 2013.ASCO annual meeting Washington D.C. [Abstract].
Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, Liang M, Dittmar RL, Liu Y, Liang M, Kohli M, Thibodeau SN, Boardman L, Wang L (2013). Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics, 14, 319.
Cohen AL, Factor R, Schabel M, Bild A, Werner TL (2013). Effect of short course, high-dose valproic acid on proliferation in breast adenocarcinomas. [Abstract]. Journal of Clinical Oncology, 2013 ASCO Annual Meeting Abstracts 31:15s, 2013(May 20 Supplement), e13522.
Akerley WL, Nelson RE, Cowie RH, Spinella DG, Hornberger J (2013). The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer. Curr Med Res Opin, 29(5), 517-25.
Horvath LE, Werner T, Boucher K, Jones K (2013). The relationship between tumor size and stage in early versus advanced ovarian cancer. Med Hypotheses, 80(5), 684-7.
Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network (2013). Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 11(5), 594-615.
Pinsky PF, Zhu C, Skates SJ, Black A, Partridge E, Buys SS, Berg CD (2013). Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. PMID: 23065684. Int J Cancer, 132(9), 2127-33.
Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National Comprehensive Cancer Network (2013). Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 11(5), 562-76.
Agarwal N, Wade M, Batten J, Davidson C, Sun SL, Sharma S (2013). Phase I Study of Histone Deacetylase Inhibitor Belinostat in Combination with Warfarin in Patients with Solid Tumors or Hematological Malignancies. Accepted for Poster Presentation (Abstract: 1187): April, 8, 2013 AACR annual meeting. Washington, DC [Abstract].
Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network NCCN (2013). Bladder cancer. J Natl Compr Canc Netw, 11(4), 446-75.
Yadav BS, Bansal A, Sharma SC, Javid SH, Anderson BO, Vaklavas C, Forero A, Ravi V, Patel S, Boudadi K, Chugh R, Morris GJ (2013). A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer. Semin Oncol, 40(2), 135-44.
Dunson, W, Mooney K, Beck S, Wong B, Wujcik D (2013). NCCN Symptom Guidelines Coupled with Nurse Practitioner Follow-up Reduce Moderate to Severe Symptom Days by Half or Greater in Cancer Patients Receiving Outpatient Chemotherapy [Abstract]. Journal of the National Comprehensice Cancer Network, 11/Number 3(March 2013), 244.
Nelson-Moseke AC, Jeter JM, Cui H, Roe DJ, Chambers SK, Laukaitis CM (2012). An unusual BRCA mutation distribution in a high risk cancer genetics clinic. Fam Cancer, 12(1), 83-7.
Tilburt JC, Kim S, Kohli M, Nahbhan M (2013). In reply. [Letter to the editor]. Mayo Clin Proc, 88(3), 308.
Akerley W, Boucher K, Rich N, Egbert L, Harker G, Bylund J, Van Duren T, Reddy C (2013). A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer, 79(3), 307-11.
Kollepara SS, Tantravahi SK, Batten J, Agarwal N (2013). Integrating Emerging Science into Clinical Practice:Targeting Androgen Signaling in Castration Resistant Metastatic Prostate Cancer”. In Lopaczynski W, Srivastava R, and Maksymowicz W. (Eds.), Lost in Translation: Barriers in Incentives for Translational Research. Singapore: World Scientific Publishing Co Pte. Ltd.
Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK (2013). External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol, 14(2), 141-8.
Forero A, Vaklavas C, LoBuglio AF (2013). Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies. In Antibody- Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications; Cancer Drug Discovery and Development series (pp. 161-75). Springer.
Vaklavas C, LoBuglio AF, Saleh M, Yelin M, Forero A (2013). CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE). In Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications; Cancer Drug Discovery and Development series (pp. 211-20). Springer.
Nelson Q, Agarwal N, Stephenson R, Cannon-Albright LA (2013). A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer. Front Genet, 4, 152.
Shah U, Pendurti G, Swami U, Hou Y, Ghalib MH, Chaudhary I, Mani S, Goel S, Aparo S (2013). Clinical outcome for patients with metastatic colorectal cancer (mCRC) enrolled in phase I clinical trials: Single institution experience [Abstract]. J Clin Oncol, 31(suppl; abstr e13550).
Patel JC, Maughan BL, Agarwal AM, Batten JA, Zhang TY, Agarwal N (2013). Emerging molecularly targeted therapies in castration refractory prostate cancer. [Review]. Prostate Cancer, 2013, 981684.
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW Jr, Merritt RE, Moran CA, Niell HB, OMalley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, Gregory K, Hughes M, National Comprehensive Cancer Network (2013). Small cell lung cancer. J Natl Compr Canc Netw, 11(1), 78-98.
Patel JC, Maughan BL, Agarwal AM, Batten JA, Zhang TY, Agarwal N (2013). Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer, 2013, 981684.
Colonna SV, Goff L, Berlin J (2013). Biliary Tree Cancer. In Decision Support in Medicine: Oncology.
Loprinzi PD, Kohli M (2012). Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003-2006. Mayo Clin Proc, 88(1), 11-21.
Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E (2013). Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS ONE, 8(2), e57289.
Samadder NJ, Curtin K, Wong J, Pappas L, Tuohy T, Mineau G, Smith K, Pimentel R, Boucher K, Garrido-Laguna I, Provenzale D, Burt, R (2013). Epidemiology and Familial Risk of Synchronous and Metachronous Colorectal Cancer: A Population-based Study in Utah. Abs P599, ACG Annual Meeting, San Diego 2013 [Abstract].
Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, Michailidou K, Stram DO, Beckmann L, Rhie SK, Ambrosone CB, Aittomaki K, Amiano P, Apicella C, Baglietto L, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Brauch H, Brinton L, Bui QM, Buring JE, Buys SS, Campa D, Carpenter JE, Chasman DI, Chang-Claude J, Chen C, Clavel-Chapelon F, Cox A, Cross SS, Czene K, Deming SL, Diasio RB, Diver WR, Dunning AM, Durcan L, Ekici AB, Fasching PA, Feigelson HS, Fejerman L, Figueroa JD, Fletcher O, Flesch-Janys D, Gaudet MM, Gerty SM, Rodriguez-Gil JL, Giles GG, van Gils CH, Godwin AK, Graham N, Greco D, Hall P, Hankinson SE, Hartmann A, Hein R, Heinz J, Hoover RN, Hopper JL, Hu JJ, Huntsman S, Ingles SA, Irwanto A, Isaacs C, Jacobs KB, John EM, Justenhoven C, Kaaks R, Kolonel LN, Coetzee GA, Lathrop M, Le Marchand L, Lee AM, Lee IM, Lesnick T, Lichtner P, Liu J, Lund E, Makalic E, Martin NG, McLean CA, Meijers-Heijboer H, Meindl A, Miron P, Monroe KR, Montgomery GW, Muller-Myhsok B, Nickels S, Nyante SJ, Olswold C, Overvad K, Palli D, Park DJ, Palmer JR, Pathak H, Peto J, Pharoah P, Rahman N, Rivadeneira F, Schmidt DF, Schmutzler RK, Slager S, Southey MC, Stevens KN, Sinn HP, Press MF, Ross E, Riboli E, Ridker PM, Schumacher FR, Severi G, Dos Santos Silva I, Stone J, Sund M, Tapper WJ, Thun MJ, Travis RC, Turnbull C, Uitterlinden AG, Waisfisz Q, Wang X, Wang Z, Weaver J, Schulz-Wendtland R, Wilkens LR, Van Den Berg D, Zheng W, Ziegler RG, Ziv E, Nevanlinna H, Easton DF, Hunter DJ, Henderson BE, Chanock SJ, Garcia-Closas M, Kraft P, Haiman CA, Vachon CM (2012). A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. PMID: 22976474. Hum Mol Genet, 21(24), 5373-84.
Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R (2012). Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer, 11(4), 297-303.
Jeter JM, Alberts DS (2012). Difluoromethylornithine: the proof is in the polyamines. Cancer Prev Res (Phila), 5(12), 1341-4.
Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R (2012). PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget, 3(12), 1566-75.
Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olson JJ, Evans BA, Jensen RL (2012). Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. J Neurooncol, 110(2), 257-64.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, OMalley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA (2012). Ovarian cancer, version 3.2012. J Natl Compr Canc Netw, 10(11), 1339-49.
Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG (2012). A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw, 10(11), 1391-8.
Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, Raftery J, Johansen M, Di Tanna GL, Miladinovic B, Soares HP, Vist GE, Chalmers I (2012). New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev, 10, MR000024.
Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW Jr, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM, NCCN National Comprehensive Cancer Network (2012). Non-small cell lung cancer. J Natl Compr Canc Netw, 10(10), 1236-71.
Sandler A, Hirsh V, Reck M, von Pawel J, Akerley W, Johnson DH (2012). An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. [Review]. Lung Cancer, 78(1), 1-7.
Munster P, van der Noll R, Voest E, Specht J, Werner TL, Dees EC, Tan AR, Daud A, Schellens J, Lolkema MP, Griffin M, Agarwal N, Falchook GS, Kleha JF, Durante M, Smith DA, Adams L, Greshock J, Morris SR, Kurzrock R (9/2012). PI3K kinase inhibitor GSK2126458 (GSK458): Clinical activity in select patient (pt) populations defined by predictive markers (Study P3K112826). Oral Presentation European Society of Medical Oncology, September 2012, Vienna, Austria. [Abstract]. European Society of Medical Oncology.
Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK (2012). Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol, 13(9), 927-35.
Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA, Feskanich D (2012). Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study. Cancer Causes Control, 23(9), 1451-61.
Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M (2014). An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. J Mens Health, 9(3), 182-189.
Kinney A, Birmingham W, Kohlmann W, Agarwal N (August 2012). Patients and providers cognitions regarding genomic risk assessments for prostate cancer susceptibility and cancer prevention. Oral Presentation Aug 2012 Prague, Czech Republic [Abstract]. European Health Psychology Society.
Agarwal N, Vogelzang NJ (2012). Beyond the abstract- Development of novel immune interventions for prostate cancer. [Review]. UroToday, UroToday.
Agarwal N, Vogelzang NJ (2012). Beyond the abstract- Development of novel immune interventions for prostate cancer. In UroToday. UroToday.com.
Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, Kaufman B, SWE-BRCA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Gronwald J, Huzarski T, Cybulski C, Bryski T, Osorio A, Cajal TR, Stavropoulou AV, Benitez J, Hamann U, HEBON, Rookus M, Aalfs CM, de Lange JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Gomez Garcia EB, Hoogerbrugge N, Jager A, van der Luijt RB, EMBRACE, Easton DF, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Godwin AK, Pathak H, GEMO Study Collaborators, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Barjhoux L, Leone M, Gauthier-Villars M, Caux-Moncoutier V, de Pauw A, Hardouin A, Berthet P, Dreyfus H, Ferrer SF, Collonge-Rame MA, Sokolowska J, Buys SS, Daly M, Miron A, Terry MB, Chung W, John EM, Southey M, Goldgar D, Singer CF, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Hansen TV, Ejlertsen B, Johannsson OT, Offit K, Sarrel K, Gaudet MM, Vijai J, Robson M, Piedmonte MR, Andrews L, Cohn D, DeMars LR, DiSilvestro P, Rodriguez G, Toland AE, Montagna M, Agata S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Ramus SJ, Sucheston L, Karlan BY, Gross J, Ganz PA, Beattie MS, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Nevanlinna H, Aittomaki K, Simard J, KConFab Investigators, Spurdle AB, Beesley J, Chen X, Tomlinson GE, Weitzel J, Garber JE, Olopade OI, Rubinstein WS, Tung N, Blum JL, Narod SA, Brummel S, Gillen DL, Lindor N, Fredericksen Z, Pankratz VS, Couch FJ, Radice P, Peterlongo P, Greene MH, Loud JT, Mai PL, Andrulis IL, Glendon G, Ozcelik H, OCGN, Gerdes AM, Thomassen M, Jensen UB, Skytte AB, Caligo MA, Lee A, Chenevix-Trench G, Antoniou AC, Neuhausen SL, Consortium of Investigators of Modifiers of BRCA12 CIMBA (2012). A non-synonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.Epub 2012 June 22. Erratum In: Cancer Epidemiol Biomarkers Prev. 2012 Dec; 21(12):2278. PMID: 22729394. Cancer Epidemiol Biomarkers Prev, Aug;21(8), 1362-70.
Vaklavas C, Forero-Torres A (2013). Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol, 3(4), 209-25.
Mukherjee B, Delancey JO, Raskin L, Everett J, Jeter J, Begg CB, Orlow I, Berwick M, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Culver HA, Rosso S, Zanetti R, Kanetsky PA, From L, Gruber SB, GEM Study Investigators (2012). Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. J Natl Cancer Inst, 104(12), 953-6.
Garrido-Laguna I, McGregor K, Wade M, et al (6/9/2012). Testing targeted demethylation to overcome resistance to epidermal growth factor receptor (EGFR) blocking agents in wild-type (wt) KRAS metastatic colorectal cancer patients (mCRC). 2012 ASCO Annual Meeting, Chicago, IL. (Abstract number 3057) [Abstract].
Agarwal N, Padmanabh S, Vogelzang NJ (2012). Development of novel immune interventions for prostate cancer. [Review]. Clin Genitourin Cancer, 10(2), 84-92.
Heng DYC, Xie WL, Choueiri TK, Lee J, Harshman LC, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Vaishampayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, and Choueiri TK (2012). An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials. Oral Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol 30, 2012 (suppl 5; abstr 353).
Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A (2012). Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol, 65(6), 602-9.
Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC (2011). The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc, 87(6), 540-7.
Agarwal N, Sonpavde G, Sternberg CN (2012). Novel molecular targets for the therapy of castration-resistant prostate cancer. [Review]. Eur Urol, 61(5), 950-60.
Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA (2012). Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol, 30(12), 1371-7.
Albright F, Teerlink C, Werner TL, Cannon-Albright LA (2012). Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site. BMC Cancer, 12, 138.
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB, National Comprehensive Cancer Network (2012). Testicular cancer. J Natl Compr Canc Netw, 10(4), 502-35.
Tantravahi SK, Werner TL (2012). Locally recurrent endometrial cancer: a case report. J Natl Compr Canc Netw, 10(4), 442-5.
Swierczek SI, Piterkova L, Jelinek J, Agarwal N, Hammoud S, Wilson A, Hickman K, Parker CJ, Cairns BR, Prchal JT (2012). Methylation of AR locus does not always reflect X chromosome inactivation state. Blood, 119(13), e100-9.
Garrido-Laguna I, Janku F (2012). Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity? J Clin Oncol, 30(8), 892-3.
Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R (2012). PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol, 30(8), 777-82.
Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R (2012). Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer, 118(5), 1422-8.
Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR (2011). Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc, 87(3), 240-6.
Jones JM, Kohli M, Loprinzi CL (2012). Androgen deprivation therapy-associated vasomotor symptoms. Asian J Androl, 14(2), 193-7.
Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R (2011). Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer, 118(5), 1422-8.
Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, Buys SS, Isaacs C, Keefer LK, Veenstra TD, Berg CD, Hoover RN, Ziegler RG (2012). Estrogen metabolism and risk of breast cancer in postmenopausal women. PMID: 22232133. J Natl Cancer Inst, 104(4), 326-39.
Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak VK (2012). Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res, 18(4), 1129-37.
Agarwal N, Boucher KM, Maughan B, Hussain SA, Kaufman DS, LorussoV, Moore MJ, Galsky MD, Sonpavde G (2012). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. (Abstract #308). Poster Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol, 30(Suppl 5), abstr 308.
Heng DYC, ChoueiriTK, Lee JL, Harshman LC, Bjarnason G, Knox JJ, MacKenzie MJ, Vaishampayan UL, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North, S, A, Rini BI, Wood L (2012). A multicentered population based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials. (Abstract 353). Oral Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol 30, 2012.
Choueiri TK, Xie WL, Harshman LC, Bjarnason G, Knox JJ, MacKenzie MJ, Wood L, Vaishampayan UL, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, Heng DYC (2012). Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) targeted therapy (TT): Results from the international mRCC database consortium. Poster Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol, 30(suppl 5), abstr 358.
Heng DYC, Lee JL, Harshman LC, Bjarnason G, Razak AR, MacKenzie MJ, Wood L, Vaishampayan UI, Tan MH, Ran SY, Donskov F, Agarwal N, Kollmannsberger CK, North S, Rini BI, Choueiri TK, International mRCC Database Consortium (2012). A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). Poster Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA. [Abstract]. J Clin Oncol 30, 2012 (suppl 5; abstr 387).
Swami U, Chaudhary I, Ghalib MH, Goel S (2012). Eribulin -- a review of preclinical and clinical studies. [Review]. Crit Rev Oncol Hematol, 81(2), 163-84.
Gaffney DK, Werner TL (2012). Curative Treatment for Recurrent and Metastatic Cervical Cancer [Abstract]. Expert Rev Obstet Gynecol, 7(6), 521-523.
Kohli M, Qin R, Jimenez R, Dehm SM (2012). Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol, 2012, 781459.
Kanth P, Stayner J, Grossman K, Agarwal N, Peterson K, Boynton K, Fang J, Valentine J, Bronner M, Burt R, Jewel Samadder N (2012). Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody (Ipilimumab) Associated Enterocolitis. Poster Presentation (P861)ACG), 77th Annual Meeting, October 19 - 24, 2012, Las Vegas, Nevada [Abstract]. American College of Gasteroenterology.
Colonna SV, Douglas Case L, Lawrence JA (2011). A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor. Breast Cancer Res Treat, 131(1), 325-31.
Smit WS, Sufliarsky J, Werner TL, Dizon D, Wagnerova M, Hirte HW, Spirtos N, Oza A, Dirix L, El-Hashimy M, Acharyya S, Tan EY, Weber D, Schellens JH (2012). A phase II study of Patupilone (EPO906) in patients with platinum- resistant or -refractory ovarian cancer. January 2012. [Abstract]. Clin Ovarian Cancer Other Gynecol Malig.
Goel S, Moran T, Coronado C, Ramirez SV, Chaudhary I, Ghalib MH, Swami U, Hou Y, Carcereny E, Alcantara J, Dios JLI, Miguel BD, Buges C, Rosell R (2012). Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors [Abstract]. J Clin Oncol, 30(suppl; abstr 3093).
Fishman M, Hutson T, Agarwal N, Jonasch E (2012). Paradigm towards Tailored Therapies and Complete Responses in the Treatment of Metastatic Renal Cell Carcinoma. In Oncology & Hematology Review (8, pp. 30-8).
Kimura BJ, Gilcrease GW 3rd, Showalter BK, Phan JN, Wolfson T (2012). Diagnostic performance of a pocket-sized ultrasound device for quick-look cardiac imaging. Am J Emerg Med, 30(1), 32-6.
Poruk KE, Firpo MA, Boucher KM, Akerley WL, Neumayer LA, Sklow B, Scaife CL, Mulvihill SL (01/01/2012). Assessment of Serum Platelet Factor 4 as a Predictive Marker for VTE and as a Prognostic Biomarker in Pancreatic, Colorectal, Breast, and Lung Cancer. J Surg Res, 172(2), 242-243.
Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network (2012). Malignant pleural mesothelioma. J Natl Compr Canc Netw, 10(1), 26-41.
Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV (2012). Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. Evid Based Complement Alternat Med, 2012, 303019.
Vaklavas C, Ross JR, Nabell LM, Forero A, Heslin MJ, Wood TE (2012). By the pricking of my thumbs, something wicked this way comes: sporadic cancers versus eponymous hereditary cancer predisposition syndromes. J Natl Compr Canc Netw, 10(1), 7-13.
Fishman M, Hutson T, Agarwal N, Jonasch E (2012). Paradigm towards Tailored Therapies and Complete Responses in the Treatment of Metastatic Renal Cell Carcinoma. [Review]. Oncol Hematol Rev, 8(1): 30-8.
Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R (2012). KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS ONE, 7(5), e38033.
Russell JS, Colevas AD (2012). The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. Chemother Res Pract, 2012, 761518.
Jeter JM, Cranmer LD, Hersh EM (2012). Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clin Med Insights Oncol, 6, 275-86.
Vaklavas C, Steciuk MR, Ren Y, Baird MF, Mikhail FM, Foran JM (2011). A case of acute promyelocytic leukemia without RARα rearrangement and apparently normal cytogenetics. Clin Lymphoma Myeloma Leuk, 11(6), 521-4.
Vaklavas C, Forero-Torres A (2011). How do I treat "triple-negative" disease. Curr Treat Options Oncol, 12(4), 369-88.
Montejo ME, Shrieve DC, Bentz BG, Hunt JP, Buchman LO, Agarwal N, Hitchcock YJ (2011). IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys, 81(5), e845-52.
Hess D, Hagner N, Clive S, Gelderblom H, Rossmann E, Agarwal N, Grazia Porro M, Hengelage T, St-Pierre A, Gazi L, Li J, Woo MM, Sharma S (Nov 2011). Effects of Hepatic Funtion on the Pharmacokinetics and Safety of Panobinostate in Patients with Advanced Cancer: A Phase I Study. (ASH Annual Meeting Abstracts). [Abstract]. Blood, 118, 5007.
Sharma S, Voest E, Hagner N, Witteveen PO, Lolkema M, Agarwal N, Valera S, Li J, Mires D, Porro MG, Woo MM, and Hess D (Nov 2011). Effects of Renal Function on the Pharmacokinetics of Panobinostate in Patients with Advanced Cancer: A Phase I Study. [Abstract]. Blood, 118, 5001.
Cannon Albright LA, Teerlink C, Agarwal N, Stephenson R (2011). Evidence for a strong genetic contribution to lethal prostate cancer (Abstract-1205W). Poster Presentation International Congress of Human Genetics/ American Society of Human Genetics. October 11-15, 2011, Montreal, Quebec, Canada [Abstract].
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, OMalley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, National Comprehensive Cancer Network (2011). Small cell lung cancer. J Natl Compr Canc Netw, 9(10), 1086-113.
Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD (2011). Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther, 12(7), 598-609.
Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M (2011). Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res, 17(17), 5793-800.
Agarwal N (2011). Editorial comment. J Urol, 186(3), 887; author reply 888.
Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R (2011). Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol, 6(9), 1601-12.
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB, National Comprehensive Cancer Network (2011). Kidney cancer. J Natl Compr Canc Netw, 9(9), 960-77.
Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV (2011). Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J, 13(3), 365-77.
Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH (2011). Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol, 29(24), 3307-15.
Garrido-Laguna I, Hidalgo M, Kurzrock R (2011). The inverted pyramid of biomarker-driven trials. Nat Rev Clin Oncol, 8(9), 562-6.
Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, Grimminger PP, Hlscher AH, Semrau R, Arnold D, Dellas K, Debucquoy A, Haustermans K, Machiels JP, Sempoux C, Rdel C, Bracko M, Velenik V, Lenz HJ (Aug 2011). EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. . Clin Cancer Res, 17(15), 5161-9.
Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW (2011). Recent advances in immunotherapy for the treatment of prostate cancer. [Review]. Expert Opin Biol Ther, 11(8), 997-1009.
Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D (2011). A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther, 10(8), 1311-6.
Wong J, Werner TL (July 2011). Kikuchi-Fujimoto Lymphadenitis: A Case of Misdiagnosed Breast Cancer. Am J Case Rep, 12, 80-82.
Patel SB, Gojo I, Tidwell ML, Sausville EA, Baer MR (2011). Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma, 52(7), 1211-4.
Agarwal N, Vogelzang NJ (2011). Secondary hormonal manipulations in the treatment of castration refractory prostate cancer. BJU Int, 108(2), 227-8.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, ODay SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group, Akerley WL (2011 June 30). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011 Jun(364(26):), 2507-16.
Patel SB, Gojo I, Tidwell M, Sausville EA, Baer MR (2011). Subdural hematomas in patients with Philadelphia chromosome positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy [Abstract]. Journal of Clinical Oncology, 29(15 suppl), abstr 6579.
Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason GA, Wood L, Vaishampayan UL, MacKenzie MJ, Knox JJ, Agarwal N, Kollmannsberger CK, Tan MH, Rha SY, Donskov F, North S, Choueiri TK, Heng DYC (2011). The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (pts). Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011 [Abstract]. J Clin Oncol 29:2011 (suppl; abstr 5563.
Agarwal N, Sahu M, Abhyankar DJ, Werner TL, Benjamin B, Srinivas R, Sharma S (2011). A drug-drug interaction study of everolimus (a mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF and EphB4 receptors, in patients with advanced urologic tumors. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011. [suppl; abstr e15077] [Abstract]. J Clin Oncol, 29(suppl), e15077.
Lam ET, Wong MKK, Agarwal N, Redman BG, Logan T, Flaig TW, Monk III JP, Jarkowski A, Sendilnathan A, Bolden M, Kuzel T, Olencki T (2011). Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma. [Abstract]. J Clin Oncol, 29(suppl), e15079.
Cohen, AL, Schabel M, Bild AH, Werner TL (2011). VAST (Valproic Acid Signature Trial): A proof-of-principle study correlating pharmacology, pathology, and advanced imaging with genomic prediction of drug sensitivity in breast cancer. Poster Presentation Oncology Annual Meeting, Chicago, Illinois, June 2011. (suppl; abstr TPS148) [Abstract]. J Clin Oncol, 29(15s).
Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ (2010). Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol, 64(6), 583-93.
Akerley W, Edwards S, Wilson R, Van Duren T, Akerley D, Tranter S, Sharry S (2011 June). Awareness of Radon - Associated Health Risks in Utah. Utah's Health: An Annual Review, 16(2011), 58-60.
Agarwal, N, Sahu M, Abhyankar J, Werner TL, Benjamin B, Srinivas NR, Sharma S (June 2011). A drug-drug interaction study of Everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF2, PDGF, and EphB4 receptors, in patients with advanced urologic tumors. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2011. Published in J Clin Oncol 29:15s, 2011 (suppl; abstr e15077). [Abstract]. Journal of Clinical Oncology, 29(15s).
Grossmann KF, Blankenship MB, Akerley W, Terrazas MC, Kosak KM, Boucher KM, Buys SS, Jones K, Werner TL, Agarwal N, Weis J, Sharma S, Ward JH, Shami PJ (2011). A phase I clinical study investigating disulfiram and copper gluconate in patients with advanced treatment-refractory solid tumors involving the liver [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; Abstract 1308 AACR. 2011 Apr 2-6; Orlando, Florida (FL): 2011. [Abstract].
Fury MG, Sherman EJ, Lisa DM, Agarwal N, Algazy KM, Brockstein B, Langer CJ, Lim D, Mehra R, Rajan SK, Jafri N, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng KK, Xiao H, Haque S, Pfister DG (05/23/2011). A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June, 2011 [Abstract]. J Clin Oncol, 29(Suppl), abstr 5563.
Janku F, Garrido-Laguna I, Wheler JJ, Hong DS, Naing A, Falchook GS, Fu S, Moulder SL, Luthra R, Lee JJ, Tsimberidou AM, Kurzrock R (2011). Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. [Abstract]. J Clin Oncol, 29(15_suppl), 10507.
Garrido-Laguna I, Kurzrock R, Wheler JJ, Falchook GS, Piha-Paul SA, Fu S, Naing A, Hinojosa C, Mistry R, Scamardo A, Culotta KS, Ekmekcioglu S, Wen S, Camacho LH, Ivy SP, Hong DS (2011). Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors. [Abstract]. J Clin Oncol, 29(15_suppl), 3065.
Vaklavas C, Chatzizisis YS, Tsimberidou AM (2011). Common cardiovascular medications in cancer therapeutics. Pharmacol Ther, 130(2), 177-90.
Garrido-Laguna I, Janku F, Falchook GS, et al (2011). KRAS mutations in colorectal cancer may predict a pattern of organ-specific metastasis. AACR 102nd Annual Meeting, April 2-6, 2011; Orlando, FL. (Abstract # 2264) [Abstract].
Janku F, Garrido-Laguna I, Hong DS et al (2011). Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors. AACR 102nd Annual Meeting 2011; April 2-6, 2011; Orlando, FL (Abstract #1279) [Abstract].
Block MS, Kohli M (2011). Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. Clin Adv Hematol Oncol, 9(4), 335-8.
Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R (2011). PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther, 10(3), 558-65.
Kimura BJ, Dalugdugan R, Gilcrease GW 3rd, Phan JN, Showalter BK, Wolfson T (2011). The effect of breathing manner on inferior vena caval diameter. Eur J Echocardiogr, 12(2), 120-3.
Garrido-Laguna I, Janku F, Falchook GS, Naing A, Fu S, Wheler J, Tsimberidou AM, Hong DS, Kurzrock R (Feb 2011). Retrospective study to elucidate a K-ras phenotype in patients with colorectal cancer.PMID: 27985389 [Abstract]. J Clin Oncol, 29(4_suppl), 462.
Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ (Jan 2011). A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol, 22(1), 104-9.
Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R (2011). PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE, 6(7), e22769.
Janku F, Garrido-Laguna I, Kurzrock R (2011). Early-Phase Cancer Clinical Trials: Are the Goals Scientific of Therapeutic? In Am Soc Clin Oncol Educ Book.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, OMalley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL (2011). Epithelial ovarian cancer. J Natl Compr Canc Netw, 9(1), 82-113.
Swami U, Ghalib MH, Chaudhary I, Hou JY, Aparo S, Einstein MH, Goldberg GL, Elrafei TN, Gajavelli S, Cohen B, Rajdev L, Kaubisch A, Haigentz M, Mani S, Goel S (2011). Risks and Benefits of phase I trials: Twelve years experience from a single institution [Abstract]. J Clin Oncol, 29(suppl; abstr 6098).
Patel SB, Gojo I, Tidwell M, Ning Y, Zhao XF, Sausville EA, Baer MR (2011). Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with multi-agent chemotherapy [Abstract]. Journal of Clinical Onocology, 29(suppl), abstr 6579.
Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M (2011). Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther, 10(1), 3-8.
Agarwal N, Sonpavde G, Sartor O (2011). Cabazitaxel for the treatment of castration-resistant prostate cancer. Future Oncol, 7(1), 15-24.
Garrido-Laguna I, Kurzrock R, Falchook GS, et al (2011). Dual inhibition of VEGF pathway: Phase 1 trial of bevacizumab and cediranib in advanced solid tumors. 2011 ASCO Annual Meeting, Chicago, IL. (Abstract No: 3057) [Abstract].
Kohli M, Williams K, Yao JL, Dennis RA, Huang J, Reeder J, Ricke WA (2010). Thrombin expression in prostate: a novel finding. Cancer Invest, 29(1), 62-7.
Vaklavas C, Chatzizisis YS (2010). The changing perspective of cardiology in cancer care. Expert Rev Cardiovasc Ther, 9(1), 1-3.
Ohnuma T, Holland JF, Goel S, Wilck E, Lehrer D, Ghalib MH, Chaudhary I, Wilhelm F, Swami U, Mani S (2011). Final results of a Phase I dose-escalation study of ON01910.Na in combination with oxaliplatin in patients with advanced solid tumors [Abstract]. J Clin Oncol, 29(suppl; abstr e13584).
Jeter JM, Bonner JD, Johnson TM, Gruber SB (2011). Nonsteroidal anti-inflammatory drugs and risk of melanoma. J Skin Cancer, 2011, 598571.
Janku F, Garrido-Laguna I, Tsimberidou A, et al (2011). Screening for PIK3CA Mutations, PTEN Loss and RAS/RAF mutations in Early-Phase Protocols with PI3K/mTOR Pathway Inhibitors. 2011 ASCO Annual Meeting, Chicago, IL. (Abstract No: 10507) [Abstract].
Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R (2011). Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist, 16(3), 327-35.
Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R (2010). Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer, 117(1), 77-85.
Agarwal N, Vogelzang NJ (2011). Development of novel immune interventions for genitor-urinary cancers. In Adrian Bot, Mihail Obrocea & Francesco Marincola (Eds.), Cancer Vaccines (1st Edition). London, UK: Informa Healthcare.
Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R (2010). Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare Tumors, 2(4), e65.
Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R (2010). Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther, 9(12), 3410-9.
Russell JS, Sawhney R, Monto A, Nanavati S, Davoren JB, Aslam R, Corvera CU (2010). Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center. Am J Surg, 200(5), 659-64.
Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network (2010). Thymic malignancies. J Natl Compr Canc Netw, 8(11), 1302-15.
Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R (2010). Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol, 28(31), e633-6.
Vaklavas C, Sotelo-Rafiq EP, Lovy J, Escobar MA, Tsimberidou AM (2010). Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. Virol J, 7, 256.
Brown AP, Neeley ES, Werner T, Soisson AP, Burt RW, Gaffney DK (2010). A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations. Int J Radiat Oncol Biol Phys, 78(1), 127-35.
Mani S, Swami U (2010). Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer. Drugs Today (Barc), 46(9), 641-53.
Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M (2010). Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer, 103(5), 649-55.
Hodi FS, ODay SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363(8), 711-23.
Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R (2010). Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res, 16(15), 4031-7.
Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC, NCCN Non-Small Cell Lung Cancer Panel Members (2010). Non-small cell lung cancer. J Natl Compr Canc Netw, 8(7), 740-801.
Winder T, Zhang W, Yang D, Ning Y, Bohanes PO, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EKLenz H (June 2010). Use of germ-line polymorphisms in genes involved in the IGF pathway to predict efficacy of cetuximab independent of K-ras in mCRC patients (IMCL-0144) [Abstract]. 28(15 Supplement), Abstract 3562.
Hu-LIeskovan S, Yang D, Grimminger PP, Arnold D, Dellas K, Machiels JH, Roedel C, Velenik V, Lenz H, Vallbohmer D (June 2010). Use of EGFa+61G and TS-5’UTR 2R/3R polymorphisms to predict complete pathologic response in locally advanced rectal cancer patients undergoing preoperative cetuximab-based chemoradiation followed by surgery [Abstract]. 28(15 Supplement), Abrtact 3641.
Narayanan S, Callis-Duffin K, Batten J, Agarwal N (2010). Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci, 339(6), 580-1.
Gilcrease GW, Stein JB (2010). A delayed case of fatal atrioesophageal fistula following radiofrequency ablation for atrial fibrillation. J Cardiovasc Electrophysiol, 21(6), 708-11.
Alva AS, Agarwal N, Siefker-Radtke AO, Roth BJ, Smith DC, Daignault S, Srinivas S, Bradley DA, Hussain M (2010). Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab. Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 4-8, 2010. [J Clin Oncol 28:7s, 2010 (suppl; abstr TPS239)] [Abstract]. J Clin Oncol 28:7s, 2010 (suppl; abstr TPS239).
Soares HP, Lutzky J (2010). Velimogene aliplasmid. Expert Opin Biol Ther, 10(5), 841-51.
Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G (2010). Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. [Review]. Future Oncol, 6(5), 665-79.
Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, STOPIT-2 Study Group, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schnemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T (2010). Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA, 303(12), 1180-7.
Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD (2010). Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf, 33(3), 171-87.
Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson LJ, Arceci R, Kornblau SM, Wieder E, Cayre YE, Corey SJ (2010). Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res, 16(4), 1149-58.
Agarwal N (2010). Hormonal therapy for prostate cancer in men with heart disease. [Letter to the editor]. JAMA, 303(1), 32-3; author reply 33.
Janku F, Tsimberidou A, Garrido-Laguna I et al (2010). Screening for PIK3CA, Ras and Raf mutations in trials with PI3K/Akt/mTOR signaling pathway inhibitors. 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics”, Berlin [Abstract].
Garrido-Laguna I, Janku F, Falchook GS, et al (2010). Clinical outcomes of patients with advanced head and neck tumors enrolled in phase I trials is not inferior to outcomes with last treatment line based on an FDA-approved drug. AACR 101st Annual Meeting, April 17-21, 2010, Washington, DC. (Abst #2773) [Abstract].
Swami U, Petrylak DP, Raftopoulos H, Shuster DE, Wang G, Kumar V, Martinez G, Goel S, Aisner J (2010). Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors [Abstract]. J Clin Oncol, 28:15s(suppl; abstr 2589).
Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM (2010). Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist, 15(2), 130-41.
Chaudhary I, Rajdev L, Swami U, Wilhelm F, Cohen B, Haigentz M, Kaubisch A, Goel S, Mani S, Ghalib MH (2010). Phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors [Abstract]. J Clin Oncol, 28(suppl; abstr e13133).
Cranmer LD, Jeter JM, Morgan SS, Hersh EM, Stea B (2010). Whole-brain radiation therapy in melanoma: an open question. [Letter to the editor]. Lancet Oncol, 11(1), 13; author reply 13-4.
Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A, Sahsrabudhe D (2010). Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark, 7(2), 101-8.
Kohli M, Tindall DJ (2010). New developments in the medical management of prostate cancer. Mayo Clin Proc, 85(1), 77-86.
Colonna SV, Douglas Case L, Lawrence JA (2009). Correlation of the Metabolic Syndrome with Estrogen Receptor Negative Breast Cancer in a Retrospective Review [Abstract].
Kurzrock R, Wheler J, Hong DS, Guo Z, Mulcahy MF, Benson III AB, Goel S, Swami U, Mani S, Buchbinder A (2009). Phase I, first in human dose escalation study of EZN-2208, a novel anticancer agent, in patients with advanced malignancies [Abstract].
Bild AH, Sun Y, Soldi R, Conner T, Walker D, Werner T, Spira A, Andrulis I, Buys SS, Johnson E (2009). A Genomic Biomarker for Breast Cancer Development in High-Risk Women. Poster Presentation. CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2009. Published in Cancer Res 2009; 69(Suppl.): (24). Dec 15, 2009. [Abstract]. Cancer Res, 69(24).
Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W (2009). Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol, 27(31), 5255-61.
Aguilera DG, Vaklavas C, Tsimberidou AM, Wen S, Medeiros LJ, Corey SJ (2009). Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience. J Pediatr Hematol Oncol, 31(11), 803-11.
Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R (2009). Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab, 94(11), 4423-32.
Agarwal N, Nussenzveig RH, Swierczek SI, Parker CJ, Prchal JT (2009). Does HUMARA assay for assessment of clonal hematopoiesis have shortcomings? [Letter to the editor]. Blood, 114(11), 2357-8; author reply 2358-9.
Rubenstein JH, Waljee AK, Jeter JM, Velayos FS, Ladabaum U, Higgins PD (2009). Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol, 104(9), 2222-32.
Stinchcombe TE, Hodgson L, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Niell HB, Atkins JN, Akerley W, Green MR, Vokes EE, Cancer and Leukemia Group B (2009). Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol, 4(9), 1117-25.
Montejo M, Werner TL, Gaffney D (2009). Current challenges in clinical management of endometrial cancer. Adv Drug Deliv Rev, 61(10), 883-9.
Agarwal N, Batten J (2009). Optimal treatment in the postorchiectomy management of clinical stage I seminoma. Oncology (Williston Park), 23(9), 764, 767.
Agarwal N, Gordeuk VR, Prchal JT (2009). Genetic Mechanisms Underlying Regulation of Hemoglobin Mass. In Roach RC, Wagner PD, and Hackett PH (Eds.), Hypoxia and Circulation (2007, pp. 195-210). New York: Springer.
Agarwal N, Rodgers GM (2009). Miscellaneous Causes of Thrombocytopenia. In Greer JP, Foerster J, Rodgers GM et al. (Eds.), Wintrobe's Clinical Hematology (Edition 12, 2, pp. 1326-1334). Lippincott Williams & Wilkins.
Briel M, Lane M, Montori VM, Bassler D, Glasziou P, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Culebro CR, da Silva SA, Flynn DN, Elamin MB, Strahm B, Murad MH, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Abu Elnour NO, You JJ, Karanicolas PJ, Bucher HC, Lampropulos JF, Nordmann AJ, Burns KE, Mulla SM, Raatz H, Sood A, Kaur J, Bankhead CR, Mullan RJ, Nerenberg KA, Vandvik PO, Coto-Yglesias F, Schnemann H, Tuche F, Chrispim PP, Cook DJ, Lutz K, Ribic CM, Vale N, Erwin PJ, Perera R, Zhou Q, Heels-Ansdell D, Ramsay T, Walter SD, Guyatt GH (2009). Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). Trials, 10, 49.
Agarwal N, Hussain M (2009). Management of bladder cancer: current and emerging strategies. [Review]. Drugs, 69(9), 1173-87.
Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J (2009). NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw, 7(6), 672-93.
Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J (2009). NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw, 7(6), 618-30.
Tan A, Jimeno A, Garrido-Laguna I, Uson M, De Oliveira E, Wilson A, Rubio-Viqueira B, Rajeshkumar NV, Hidalgo M (May 2009). Use of amolecular mimicry approach to identify effective agents in pancreatic cancer.PMID: 27964150 [Abstract]. J Clin Oncol, 27(15_suppl), 4603.
Garrido-Laguna I, Rudek M, Tan A, Uson M, Iacobuzio-Donahue C, Angenendt M, Jimeno A, Laheru D, Barret M, Hidalgo M (May 2009). Preclinical identification of biomarkers of response to mTOR inhibitors and subsequent application in a phase II trial of sirolimus in pancreatic cancer patients refractory to gemcitabine.PMID: 27964189 [Abstract]. J Clin Oncol, 27(15_suppl), 4612.
Hidalgo M, Garrido-Laguna I, Uson M, De Oliveira E, Schulick R, Hruban RH, Maitra A, Jimeno A, Rubio-Viqueira B, Rajeshkumar NV (May 2009). Activity of gemcitabine in direct patient-derived xenografts and clinical outcome: Validation of an in vivo model for drug development.PMID: 27962716 [Abstract]. J Clin Oncol, 27(15_suppl), 4528.
Lim HY, Werner TL, Agarwal N, Rodgers GM (2008). Management of Thrombotic Microangiopathy with Underlying Malignancy. Review Series - Oncology, 12(2), 18-21.
Chen A, Agarwal N (2009). Reversible posterior leucoencephalopathy syndrome associated with sunitinib. [Letter to the editor]. Internal Medicine Journal Online, 39(5), 341-2.
Yao JL, Ryan CK, Francis CW, Kohli M, Taubman MB, Khorana AA (2009). Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest, 27(4), 430-4.
Lim HY, Agarwal AM, Agarwal N, Ward JH (2009). Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J, 50(5), e178-80.
Smit WM, Sufliarksy J, Werner TL, Dizon D, Wagnerova M, Hirte HW, Delaney R, Li J, Weber D, Schellens JH (2009). A phase II study evaluating the safety and efficacy of Patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer. Poster Presentation. American Society of Clinical Oncology Annual Meeting, Orlando, Florida, May 2009. Published in J Clin Oncol 27:15s, 2009 (suppl; abstr 5563). [Abstract]. Journal of Clinical Oncology, 27(15s), 5563.
Garrido-Laguna I, Amador ML, Ruiz J, Corts-Funes H (2009). Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer. Clin Transl Oncol, 11(3), 183-5.
Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T (2009). A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol, 4(2), 214-9.
Janku F, Garrido-Laguna I, Hong D, Tsimberidou A, et al (2009). PIK3CA mutations in patients with advanced cancers treated in phase I clinical trials. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. B134). Boston [Abstract].
Villaroel MC, Tan AC, Garrido-Laguna I, Rubio-Viqueira B, De Oliveira E, Rajeshkumar NV, Jimeno A, Hidalgo M (2009). Orthotopic cancer models are better predictors of clinical response than s.c. models. AACR 100th Annual Meeting in Denver (Permanent abst number 2320). [Abstract].
Rajeshkumar NV, De Oliveira E, Ottenhof N, Garrido-LagunaI I, et al (2009). MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions in pancreatic tumor xenografts. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. A251). Boston [Abstract].
Maitra A, Rajeskhumar NV, Rudek M, Garrido-Laguna I, Laheru D, Iglesias J, Desai N, Von Hoff D, Hidalgo M (2009). Nab-paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic models. C246. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. C246). Boston [Abstract].
Garrido-Laguna I (2009). Targeted Therapies. In Ettinger DS, Donehower RC, Olsen M, Schwartz RN (Eds.), Current Cancer Therapeutics, Springer Editorial (5th).
Mishra A, Feldmann G, Garrido-Laguna I, Dadon T, Strock C, Bannerji R, Hidalgo M, Maitra A, Nelkin B (2009). SCH727965, a novel potent cyclin dependent kinase inhibitor, inhibits pancreatic tumor growth and Ras-mediated tumorigenic signaling. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. A243). Boston [Abstract].
Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD (2008). Molecular basis of statin-associated myopathy. Atherosclerosis, 202(1), 18-28.
Garrido-Laguna I, Tan AC, Villarroel MC, Angenendt M, Pastori W, Rajeshkumar NV, Ciomei M, Jimeno A, Rubio-Viqueira B, Hidalgo M (2009). Activity of PHA-848125 in pancreatic cancer xenografts is related to downregulation of S6 via p53 pathway. AACR 100th Annual Meeting in Denver (Permanent abst number 1798). [Abstract].
Agarwal N, Prchal JT (2009). Dyshemoglobinemia. In Steinberg MH, Forget BG, Higgs DR, Nagel RL (Eds.), Disorders of Hemoglobin, Genetics, Pathophysiology, and Clinical Management (2nd ed, pp. 607-622). New York: Cambridge University Press.
Agarwal N, Prchal JT (2009). Anemia of chronic disease (anemia of inflammation). Acta Haematol, 122(2-3), 103-8.
Kurzrock R, Wheler J, Hong DS, Guo Z, Mulcahy MF, Benson III AB, Goel S, Swami U, Mani S, Buchbinder A (2009). Phase I, first in human dose escalation study of EZN- 2208, a novel anticancer agent, in patients with advanced malignancies [Abstract]. Mol Cancer Ther, 8(12 suppl), C216.
Hidalgo M, Strawn S, Wick M, Rajeshkumar NV, Garrido-Laguna I, Sidranski D, Bruckheimer E (2009). From mice to men: Guiding cancer treatment through Personalized Tumorgraft models results in prolongued clinical responses in patients with refractory advanced cancers and discovery of novel predictive biomarkers. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. A19). Boston [Abstract].
Agarwal N, Prchal JT (2009). Methemoglobinemia and Other Dyshemoglobinemias. In Kaushansky K, Lichtman M, Beutler E, et al. (Eds.), Williams Hematology (8th edition). New York: McGraw-Hill.
Trufelli DC, Bensi CG, Garcia JB, Narahara JL, Abro MN, Diniz RW, Miranda Vda C, Soares HP, Del Giglio A (2008). Burnout in cancer professionals: a systematic review and meta-analysis. Eur J Cancer Care (Engl), 17(6), 524-31.
Camp NJ, Werner TL, Cannon-Albright LA (2008). Familial myeloma. [Letter to the editor]. N Engl J Med, 359(16), 1734-5; author reply 1735.
Swierczek SI, Agarwal N, Nussenzveig RH, Rothstein G, Wilson A, Artz A, Prchal JT (2008). Hematopoiesis is not clonal in healthy elderly women. Blood, 112(8), 3186-93.
Martin-Santamaria S, Rodriguez JJ, de Pascual-Teresa S, Gordon S, Bengtsson M, Garrido-Laguna I, Rubio-Viqueira B, Lopez-Casas PP, Hidalgo M, de Pascual-Teresa B, Ramos A (2008). New scaffolds for the design of selective estrogen receptor modulators. Org Biomol Chem, 6(19), 3486-96.
Agarwal N, Prchal JT (2008). Erythropoietic agents and the elderly. [Review]. Semin Hematol, 45(4), 267-75.
McMurray HR, Sampson ER, Compitello G, Kinsey C, Newman L, Smith B, Chen SR, Klebanov L, Salzman P, Yakovlev A, Land H (2008). Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature, 453(7198), 1112-6.
Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS (2008). Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med, 121(6), 475-483.e3.
Zwerner P, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ, May WA (May 2008). The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene, 27(23), 3282-91.
Zwerner J, Warner K, Christensen L, Hu-Lieskovan S, Triche T, May W (May 2008). The EWS/FLI1 oncogenic transcription factor deregulates GLI1 [Abstract]. 68(9), 865.
Wada DA, Agarwal N, Florell SR, Lim MS (2008). Recurrent squamous cell carcinoma and follicular lymphoma arising in the scalp after treatment for lymphoma. [Letter to the editor]. Pathology, 40(3), 316-20.
Chatzizisis YS, Vaklavas C, Giannoglou GD (2007). Coenzyme Q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy? [Letter to the editor]. Am J Cardiol, 101(7), 1071.
Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL (2008). Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med, 168(6), 632-42.
Yoon D, Agarwal N, Prchal JT (2008). Does erythropoietin promote tumor growth? [Letter to the editor]. Clin Cancer Res, 14(6), 1920; author reply 1920-1.
Ettinger DS, Akerley W, Bepler G, Chang A, cheney Rt, Chirieac LR, DAmico TA, Demmy TL et al (2008). Non-small cell lung cancer. J Natl Compr Canc Netw, 6(3), 228-269.
Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, fossella F, Grecula JC et al (2008). Small cell lung cancer. J Natl Compr Canc Netw, 6(3), 294-314.
Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Feigenberg SJ, Figlin RA, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Patel JD, Robert F, Sugarbaker DJ, Wood DE (2008). Non-small cell lung cancer. J Natl Compr Canc Netw, 6(3), 228-69.
Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC Jr (2008). Small cell lung cancer. J Natl Compr Canc Netw, 6(3), 294-314.
Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF (2008). Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med, 49(3), 480-508.
Anderson M, Hartz A, Nordin T, Rosenbaum M, Noyes R, James P, Ely J, Agarwal N, Anderson S (2008). Community physicians' strategies for patients with medically unexplained symptoms. Fam Med, 40(2), 111-8.
Lim HY, Werner T, Agarwal N, Rodgers GM (2008). Management of thrombotic microangiopathy with underlying malignancy. Helix Review Series: Oncology. 2008; 13(2):18-21. [Review]. Helix Review Series, 13(2), 18-21.
Agarwal N, Swierczek S, Nussenzveig RH, Samuelson S, Parker CJ, Prchal JT (2008). Validation of a novel clonality assay in patients with clonal hematologic disorders. [Abstract]. Blood 2008; 112: Abstract 3718.
Kaushal V, Mukunyadzi P, Siegel ER, Dennis RA, Johnson DE, Kohli M (2007). Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol, 16(1), 1-6.
Lim HY, Werner TL, Agarwal N, Rodgers GM (2008). Management of Thrombotic Microangiopathy with Underlying Malignancy. In Review Series Oncology (12, pp. 18-21).
Agarwal N, Swierczek S, Naidoo K, Prchal JT, Coetzer TL (2007). A novel Mutation of the aSpectrin Gene in a Family of Northern European Descent is Associated with Three Different Phenotypes. [Abstract]. Blood. 2007; 110 (11): abstract 1717.
Agarwal N, Kutlar F, Mojica-Henshaw MP, Ou CN, Gaikwad A, Reading NS, Bailey L, Kutlar A, Prchal JT (2007). Missense mutation of the last nucleotide of exon 1 (G->C) of beta globin gene not only leads to undetectable mutant peptide and transcript but also interferes with the expression of wild allele. Haematologica, 92(12), 1715-6.
Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler G (2007). A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol, 2(12), 1091-7.
Agarwal, N, Swierczek S, Rothstein G, Nussenzveig R, Prchal J (2007). Is Hematopoiesis Clonal in Healthy Elderly Females? [Abstract]. Blood, 2007; 110 (11): abstract 2243, 110(11), abstract 2243.
Spahr JE, Agarwal N, Rodgers GM (2007). Treatment of Immune-Mediated Thrombocytopenia Purpura with Concurrent IVIg and Platelet Transfusion: A Retrospective Review of 40 Patients. [Abstract]. Blood "Supplement", 108(11), A1598.
Agarwal N, Mojica-Henshaw MP, Simmons ED, Hussey D, Ou CN, Prchal JT (2007). Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia. Int J Med Sci, 4(4), 232-6.
Agarwal AM, Agarwal N, Tryka AF, Ward JH, Lim MS (2007). Blastic Transformation of Follicular lymphoma. [Abstract]. Archives of Pathology and Laboratory Medicine (supplement), September 2007.
Garrido-Laguna I, Fernandez Hidalgo O, Garcia Foncillas J (2007). MRI evaluation of breast cancer. N Engl J Med, 357(2), 191; author reply 193.
Agarwal N, Fletcher D, Ward J (2007). Obesity and treatment of prostate cancer: what is the right dose of Lupron Depot? [Letter to the editor]. Clin Cancer Res, 13(13), 4027.
Rocha-Lima CM, Soares HP, Raez LE, Singal R (2007). EGFR targeting of solid tumors. Cancer Control, 14(3), 295-304.
Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, Gandara DR, SWOG (2007). Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol, 2(6), 526-30.
Horvath LE, Werner T, Jones K (2007). The Relationship between Tumor Size and Stage in Early versus Advanced Ovarian Cancer: A Retrospective Chart Review. Poster Presentation. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2007. Published in J Clin Oncol, 25:18s, 2007 (suppl; abstr 5580). [Abstract]. Journal Of Clinical Oncology, 25(18s), 5580.
Agarwal AM, Agarwal N, Glenn MJ, Lim MS (2007). Blastic transformation of low-grade follicular lymphoma. J Clin Oncol, 25(16), 2326-8.
Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A (2006). 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res, 31(5), 691-4.
Agarwal N, Gordeuk VR, Prchal JT (2007). Are erythropoietin receptors expressed in tumors? Facts and fiction--more careful studies are needed. [Letter to the editor]. J Clin Oncol, 25(13), 1813-4; author reply 1815.
Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR (2007). Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol, 25(13), 1698-704.
Werner TL, Agarwal N, Carney HM, Rodgers GM (2007). Management of cancer-associated thrombotic microangiopathy: what is the right approach? [Review]. Am J Hematol, 82(4), 295-8.
Werner TL, Agarwal N, Carney HM, Rodgers GM (2007). Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol, 82(4), 295-8.
Kumar A, Soares HP, Balducci L, Djulbegovic B, National Cancer Institute (2007). Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol, 25(10), 1272-6.
Behera M, Kumar A, Soares HP, Sokol L, Djulbegovic B (2007). Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control, 14(2), 160-6.
Garrido-Laguna I, Ponz M, Espinos J (2007). Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma? J Clin Oncol, 25(9), 1149; author reply 1149-51.
Agarwal N, Spahr JE, Rodgers GM (2007). Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa. [Review]. Blood Coagul Fibrinolysis, 18(2), 205-7.
Soares HP, Kumar A, Djulbegovic B (2006). Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 33(1), 87-9.
Agarwal N, Gordeuk RV, Prchal JT (2007). Genetic mechanisms underlying regulation of hemoglobin mass. [Review]. Adv Exp Med Biol, 618, 195-210.
Agarwal N, Gordeuk VR, Prchal JT (2007). Genetic Mechanisms Underlying Regulation of Hemoglobin Mass. In Roach RC, Wagner PD, and Hackett PH (Eds.), Hypoxia and Circulation. New York: Springer.
Kinsey CG, Bussolati G, Bosco M, Kimura T, Pizzorno MC, Chernin MI, Cassoni P, Novak JF (2007). Constitutive and ligand-induced nuclear localization of oxytocin receptor. J Cell Mol Med, 11(1), 96-110.
Soares HP, Kumar A, Djulbegovic B (2006). Evidence profiles for lung cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 32(8), 652-5.
Agarwal N, Mojica-Henshaw MP, Kutlar F, Gaikwad A, Ou CN, Kutlar A, Prchal JT (2006). Novel Mechanism of β0 Thalassemia: Missense Mutation of the Last Nucleotide of β Globin Exon 1 (G->C) Leads to Undetectable Transcript and Mutant Peptide. [Abstract]. Blood (supplement), 2006; 108: A1598.
Kumar A, Soares HP, Djulbegovic B (2006). Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 32(7), 577-80.
Djulbegovic B, Soares HP, Kumar A (2006). What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. Cancer Treat Rev, 32(7), 572-6.
Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH (2006). Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol, 24(31), 5025-33.
Agarwal N, Tepe EM, Mishra A, Ward JH (2006). Relapse of acute promyelocytic leukemia presenting as granulocytic sarcoma in the hip. [Letter to the editor]. Ann Hematol, 85(10), 741-2.
Kumar A, Soares HP (2006). Salvage radiotherapy increases survival in people with residual disease after chemotherapy for advance diffuse large cell lymphoma. Cancer Treat Rev, 32(6), 487-90.
Akerley W, Safran H, Zaner K, Ready N, Mega T, Kennedy T (2006). Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. Cancer, 107(5), 1050-4.
Wada D, Agarwal N, Florell SR, Lim M (2006). Recurrent Squamous cell carcinoma and fallicular lymphoma arising in the scalp two years after treatment for lymphoma. [Abstract]. Arch Pathol Lab Med, 130, 1362-1403 (P14).
Blumenthal DT, Salzman KL, Digre KB, Jensen RL, Dunson WA, Dalmau J (2006). Early pathologic findings and long-term improvement in anti-Ma2-associated encephalitis. Neurology, 67(1), 146-9.
Kohli M, Schaefer R (2005). Management of solitary palatal metastasis from renal cell carcinoma. Nature Clinical Practice Urology, 3(7), 392-6; quiz following 396.
Nordin TA, Hartz AJ, Noyes R Jr, Anderson MC, Rosenbaum ME, James PA, Ely JW, Agarwal N, Levy BT (2006). Empirically identified goals for the management of unexplained symptoms. Fam Med, 38(7), 476-82.
Alikhan MA, Williams R, Udaya K, Shaefer RF, Viswamitra SC, Kohli M (2006). Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma. Int J Urol, 13(6), 798-800.
Kohli S, Kohli M (2006). Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer: are there implications for blood pressure management in patients receiving chemotherapy? [Letter to the editor]. J Clin Oncol, 24(15), 2399; author reply 2399-400.
Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2006). Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst, 98(8), 516-21.
Jeter JM, Kohlmann W, Gruber SB (2006). Genetics of colorectal cancer. Oncology (Williston Park), 20(3), 269-76; discussion 285-6, 288-9.
Kaushal V, Kohli M, Dennis RA, Siegel ER, Chiles WW, Mukunyadzi P (2005). Thrombin receptor expression is upregulated in prostate cancer. Prostate, 66(3), 273-82.
Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN, National Comprehensive Cancer Network (2006). Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw, United States, 4(2), 156-76.
Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM (2006). Acquired amegakaryocytic thrombocytopenic purpura. Am J Hematol, 81(2), 132-5.
Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM (2006). Acquired amegakaryocytic thrombocytopenic purpura. Am J Hematol, 81(2), 132-5.
Garrido-Laguna I (2006). Emergencies in Oncology. In Manual de Diagnostico y Terapeutica Medica Hospital Universitario 12 de Octubre, (Manual of Emergency University Hospital 12 de Octubre) (6th). MSD Editorial.
Kohli M, Siegel E, Bhattacharya S, Khan MA, Shah R, Suva LJ (2007). Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark, 2(6), 249-58.
Kohli M (2005). Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. [Letter to the editor]. Cancer, 106(1), 234-5; author reply 235.
Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I, Djulbegovic B, Childrens Oncology Group (2005). Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ, 331(7528), 1295.
Kim DW, Shyr Y, Chen H, Akerley W, Johnson DH, Choy H (2005). Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 63(4), 1029-36.
Wada D, Agarwal N, Lim M (2005). Case of the Quarter: Society of Hematopathology [Web]. Society for Hematopathology. Available: http://www.sh-eahp.org/.
Kim DW, Shyr Y, Shaktour B, Akerley W, Johnson DH, Choy H (2005). Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer, 50(2), 235-45.
Julian D, April KL, Patel S, Stein JR, Wohlgemuth SE (2005). Mitochondrial depolarization following hydrogen sulfide exposure in erythrocytes from a sulfide-tolerant marine invertebrate. J Exp Biol, 208(Pt 21), 4109-22.
Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (Oct 2005). Sequence-specific knockdown of EWS-FLI1 by targeted, non-viral delivery of siRNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res, 65(19), 8984-8992.
Challagundla S, Gokden M, Viswamitra S, Kohli M (2005). Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage. Clinical Prostate Cancer, 4(2), 134-7.
Alikhan M, Spencer HJ, Kohli M (2005). High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon. [Letter to the editor]. J Clin Oncol, 23(25), 6267-8; author reply 6268-9.
Popielarski SR, Hu-Lieskovan S, French SW, Triche TJ, Davis ME (Aug 2005). A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjug Chem, 16(5), 1071-80.
Harris RE, Jeter J, Chan P, Higgins P, Kong FM, Fazel R, Bramson C, Gillespie B (2005). Using acupressure to modify alertness in the classroom: a single-blinded, randomized, cross-over trial. J Altern Complement Med, 11(4), 673-9.
Akerley W, Herndon JE Jr, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green MR (2005). Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clin Lung Cancer, 7(1), 47-53.
Schluep T, Jensen GS, Chen J, Heidel JD, Bartlett DW, Hu S, Triche TJ, Davis ME (June 2005). Camptothecin-polymer conjugate shows improved biodistribution and preclinical efficacy in vivo [Abstract]. 46(9 Supplement), 328.
Hu-Lieskovan S, Zhang J, Schofield DE, Shimada H, Wu L, Triche TJ (Jun 2005). EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing’s family of tumors. Cancer Res, 65(11), 4633-44.
Hu S, Zhang J, Liu X-F, Schofield D, Triche T (June 2005). EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed molecular phenotype of Ewing’s family of tumors [Abstract]. 65(9 Supplement), 4633-4644.
Heidel JD, Hu-Lieskvoan S, Bartlett DW, Triche TJ, Davis ME (May 2005). Systemic Administration of siRNA Against EWS-FLI1 Using a Targeted, Non-Viral Formulation Inhibits Growth in a Disseminated Murine Model of Ewing's Sarcoma [Abstract]. 11(Supplement 1), S28-S29.
Hu S, H JD, B DW, K DB, D ME, T TJ (May 2005). Systemic targeted EWS-FLI1 siRNA abrogates growth of metastases in a murine Ewing’s tumor model [Abstract]. 65(9 Supplement), 1435-1436.
Midathada M, Safar A, Schaefer R, Viswamitra S, Kohli M (2005). Ocular melanoma versus ocular metastasis: a diagnostic dilemma. Clin Adv Hematol Oncol, 3(5), 425-7.
Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B (2005). Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA, 293(8), 970-8.
Kumar A, Soares H, Serdarevic F (2005). Totality of evidence: one of the keys to better oncology management. J Oncol Manag, 14(1), 12-4.
Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME (Dec 2004). Lack of interferon response in animals to naked siRNAs. Nat Biotechnol, 22(12), 1579-82.
Alikhan MA, Phooskooru V, Kohli M (2004). Re: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. [Letter to the editor]. J Natl Cancer Inst, 96(23), 1794; author reply 1794.
Christakis C, Vaklavas C, Kontos N, Chatzidimitriou C, Tzelepi K, Karanikas M, Christakis E (2005). Pelvic reconstruction of the retroperitoneum after abdominoperineal resection of the rectum using full-thickness skin grafts. Techniques in Coloproctology, 8 Suppl 1, s85-8.
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 351(15), 1513-20.
Weinschenker P, Soares HP, Clark O, Del Giglio A (2004). Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat, 87(3), 215-24.
Zhang J, Hu S, Schofield D, Sorensen P, Triche TJ (Sep 2004). Selective usage of D type cyclins by Ewing's tumors and rhabdomyosarcomas. Oncogene, 64(17), 6026-34.
Agarwal N, Klix MM, Burns CP (2004). Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance. [Letter to the editor]. Ann Intern Med, 141(1), 83-4.
Socinski MA, Zhang C, Herndon JE 2nd, Dillman RO, Clamon G, Vokes E, Akerley W, Crawford J, Perry MC, Seagren SL, Green MR (2004). Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol, 15(7), 1033-41.
Megale Costa LJ, Soares HP, Gaspar HA, Trujillo LG, Santi PX, Pereira RS, de Santana TL, Pinto FN, del Giglio A (2004). Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol, 27(3), 304-6.
Camphausen K, Brady KJ, Burgan WE, Cerra MA, Russell JS, Bull EE, Tofilon PJ (2004). Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Mol Cancer Ther, 3(4), 409-16.
Kohli M, Zent C, Hutchins LF, Safar M, Dotson P, Mehta P (2004). The academic hematology-oncology firm:a model for postgraduate cancer education. J Cancer Educ, 19(1), 45-9.
Samano ES, Goldenstein PT, Ribeiro Lde M, Lewin F, Filho ES, Soares HP, del Giglio A (2004). Praying correlates with higher quality of life: results from a survey on complementary/alternative medicine use among a group of Brazilian cancer patients. Sao Paulo Med J, 122(2), 60-3.
Lo T, van Der Schalie E, Werner T, Brun YV, Din N (2004). A temperature-sensitive mutation in the dnaE gene of Caulobacter crescentus that prevents initiation of DNA replication but not ongoing elongation of DNA. J Bacteriol, 186(4), 1205-12.
Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B, Radiation Therapy Oncology Group (2004). Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ, 328(7430), 22-4.
Stults BM, Dunson WA, Miller T (2004). Management of Hypertension in Diabetes Mellitus. Utah Diabetes Association Review.
Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, Tofilon PJ (2003). Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res, 63(21), 7377-83.
Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ (2003). Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res, 9(10 Pt 1), 3749-55.
Kohli M, Khan MA, Mehta P, Hutchins L (2003). Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management? [Letter to the editor]. J Clin Oncol, 21(12), 2445.
Katz BJ, Ward JH, Digre KB, Creel DJ, Mamalis N (2003). Persistent severe visual and electroretinographic abnormalities after intravenous Cisplatin therapy. J Neuroophthalmol, 23(2), 132-5.
Hussain I, Agarwal N (2003). DRESS syndrome associated with cephalosporin therapy [Web]. E-Letter in British Medical Journal. Available: https://goo.gl/NIq711.
Kohli M, Kaushal V, Mehta P (2003). Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost, 29(3), 301-8.
Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR (2003). Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer, 97(10), 2480-6.
Kohli M, Kaushal V, Spencer HJ, Mehta P (2003). Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urology, 61(4), 765-9.
Akerley W, Herndon J, Green M, et al (2003). Dose-Dense Weekly Paclitaxel and Pharmacologic Evaluation for Patients with Stage IIIB-IV Non-Small Cell Lung Cancer: A Phase II Trial of Cancer and Leukemia Group B (CALGB 9731/9765). Cancer, 97, 2480-6.
Kaushal V, Kohli M, Mehta P, Mehta JL (2003). Potential anticancer effects of statins: fact or fiction? Endothelium, 10(1), 49-58.
Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T (2002). A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer, 95(9), 2000-5.
Russell JS, Tofilon PJ (2002). Radiation-induced activation of nuclear factor-kappaB involves selective degradation of plasma membrane-associated I(kappa)B(alpha). Mol Biol Cell, 13(10), 3431-40.
Fonseca FL, Soares HP, Manhani AR, Bendit I, Novaes M, Zatta SM, Arias V, Pinhal MA, Weinschenker P, del Giglio A (2002). Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy. Clin Breast Cancer, 3(3), 201-5.
Gupta S (2002). Retrospective study on the effect of chronic ACE inhibitor therapy on inter-dialysis weight gain in patients on hemodialysis [Abstract]. Ren Fail, Jul;24(4), 461-6.
Kaushal V, Kohli M, Zangari M, Fink L, Mehta P (2002). Endothelial dysfunction in antiangiogenesis-associated thrombosis. [Letter to the editor]. J Clin Oncol, 20(13), 3042; author reply 3042-3.
Agarwal N, Cherascu B (2002). Concomitant acral necrosis and haemolytic uraemic syndrome following ingestion of quinine. J Postgrad Med, 48(3), 197-8.
Russell JS, Raju U, Gumin GJ, Lang FF, Wilson DR, Huet T, Tofilon PJ (2002). Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization. Cancer Res, 62(8), 2318-26.
Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002). A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer, 94(6), 1654-60.
Takahashi M, Chernin MI, Yamamoto O, Tonzetich J, Kinsey CG, Novak JF (2002). Transformation of MC3T3-E1 cells following stress and transfection with pSV2neo plasmid. Anticancer Res, 22(2A), 585-98.
Blackstock AW, Herndon JE 2nd, Paskett ED, Perry MC, Graziano SL, Muscato JJ, Kosty MP, Akerley WL, Holland J, Fleishman S, Green MR (2002). Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst, 94(4), 284-90.
Makarovskiy A, Siryaporn E, Hixon D, Akerley W (2002). Survival of Docetaxel-resistant Prostate Cancer Cells Depends on Phenotype Alterations and Continuity of Drug Exposure. Cell Mol Life Sci, 59, 1198-1211.
Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002). A Multiinstitutional, Concurrent Chemoradiation Trial of Strontium-89, Estramustine, and Vinblastine for Hormone Refractory Prostate Carcinoma Involving Bone. Cancer, 94(6), 1654-1660.
Blackstock A, Herndon J, Paskett E, Perry M, Graziano S, Muscato, Kosty M, Akerley W, Holland J, Fleishman S, Green M (2002). Outcomes Among African-American and Non African-American Patients with Advanced Non-Small Cell Lung Cancer: A Report from the CALGB. J Natl Cancer Inst, 94(4), 284-90.
Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T (2002). A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer, 95(9), 2000-5.
Kohli M, Fink LM, Spencer HJ, Zent CS (2002). Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis, 13(1), 1-5.
Pereira LP, Waisberg J, Andr EA, Zanoto A, Mendes Jnior JP, Soares HP (2002). Detection of Helicobacter pylori in gastric cancer. Arq Gastroenterol, 38(4), 240-6.
Agarwal N, Handa R, Acharya SK, Wali JP, Dinda AK, Aggarwal P (2001). A study of autoimmune markers in hepatitis C infection. Indian J Med Res, 113, 170-4.
Manhani AR, Manhani R, Soares HP, Bendit I, Lopes F, Nicoletti AG, Fonseca FL, Novaes M, Zatta SM, Arias V, Giralt S, del Giglio A (2001). CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy. Breast Cancer Res Treat, 66(3), 249-54.
Akerley W (2001). Recent developments in weekly paclitaxel therapy in lung cancer. Curr Oncol Rep, 3(2), 165-9.
Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, ODay SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB (2001). Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer, 84(2), 157-63.
Akerley W (2001). Recent Development in Weekly Paclitaxel Therapy of Lung Cancer. Curr Oncol Rep, 3(2), 165-169.
Gurevich I, Akerley W (2001). Treatment of the Jaundiced Patient with Breast Carcinoma. Cancer, 91(4), 660-663.
Wanebo H, Chougule P, Ready N, Safran H, Akerley W, Koness R, McRae R, Nigri P, Leone L, Kennedy T, Webber B (2001). Surgical Resection is Necessary to Maximize Tumor Control In Function Preserving, Aggressive Chemoradiation Protocols for Advanced Squamous Cancer of the Head and Neck (Stage III and IV). Ann Surg Oncol, 8, 644-50.
Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ (2001). Phase II Study of Docetaxel, Estramustine, and Low-dose Hydrocortisone in Men with Hormone-refractory Prostate Cancer: a final report of CALGB 9780. J Clin Oncol, 19(9), 2509-16.
Stults BM, Dunson WA, Young D (2001). Management of Hypertension in Diabetes Mellitus. Utah Diabetes Association Review.
del Giglio A, Soares HP, Caparroz C, Castro PC (2001). Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer, 89(11), 2301-8.
Wang H, Hu S, Zhang J (Jul 2000). Expression of T cell receptor Va gene families in intrathyroidal T cells of Chinese patients with Graves’ disease (in English)Expression of T cell receptor Va gene families in intrathyroidal T cells of Chinese patients with Graves’ disease (in English). Chin Med Sci J, 15(3), 175-9.
King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, Safran H (2000). p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer, 89(4), 769-73.
Kohli M, Schichman SA, Fink L, Zent CS (2000). Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. South Med J, 93(5), 469-71.
Akerley W 3rd (2000). Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule. Chest, 117(4 Suppl 1), 152S-155S.
Baraldi-Junkins CA, Beck AC, Rothstein G (2000). Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North Am, 14(1), 45-61, viii.
Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H (2000). Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol, 174(1), 57-9.
Dupuy D, Zagoria R, Akerley W, Mayo-Smith W, Kavanagh P, Safran H (2000). Percutaneous Radiofrequency Ablation of Malignancies in the Lung. Am J Roentgenol Radium Ther Nucl Med, 174(1), 57-9.
Akerley W (2000). Secondary Leukemia: Twice is a Coincidence? Cancer, 88(3), 497-9.
King T, Akerley W, Fan A, Walsh K, Mangray S, Chen M, Safran H (2000). P53 Mutations Do Not Predict Response to Paclitaxel for Metastatic Non-Small Cell Lung Cancer. Cancer, 89(4), 769-73.
Akerley W (2000). Paclitaxel in Advanced Non-small Cell Lung Cancer: An Alternative High-dose Weekly Schedule. Chest, 117:4 (suppl 1), 152-5.
Russell JS, Lang FF, Huet T, Janicot M, Chada S, Wilson DR, Tofilon PJ (1999). Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. Cancer Res, 59(20), 5239-44.
Sharma S, Dey AB, Agarwal N, Nagarkar KM, Gujral S (1999). Tuberculosis: a rare cause of splenic abscess. J Assoc Physicians India, 47(7), 740-1.
Chougule PB, Akhtar MS, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness J, Radie-Keane K, Wanebo H (1999). Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study. Semin Radiat Oncol, 9(2 Suppl 1), 58-63.
Akerley W, Choy H (1999). Single-agent paclitaxel and radiation for non-small cell lung cancer. Semin Radiat Oncol, 9(2 Suppl 1), 85-9.
Wanebo HJ, Chougule P, Ready N, Koness RJ, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H (1999). Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Semin Radiat Oncol, 9(2 Suppl 1), 77-84.
Akerley W and Choy H (1999). Single Agent Paclitaxel and Radiation for Non-Small Cell Lung Cancer. Semin Radiat Oncol, 9(2) suppl 1, 85-89.
Wanebo H, Chougule P, Ready N, Koness R, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H (1999). Preoperative Paclitaxel, Carboplatin and Radiation Therapy in Advanced Head and Neck Cancer. Semin Radiat Oncol, 9(2) suppl 1, 77-84.
Chougule P, Akhtar M, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness R, Radie-Kane K, and Wanebo H (1999). Chemoradiotherapy for Advanced Inoperable Head and Neck Cancer: A Phase II Study. Semin Radiat Oncol, 9(2) suppl 1, 58-63.
Glantz M, Kim L, Choy H, Akerley W (1999). Concurrent Chemotherapy and Radiotherapy in Patients with Brain Tumors. Oncology, 13(10) suppl 5, 78-82.
Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T (1998). Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol, 16(10), 3316-22.
Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF (1998). Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res, 4(8), 1931-6.
Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ (1998). High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol, 16(4), 1561-7.
Recht LD, Glantz MJ, Meitner P, Glantz L, Akerley W, Wahlberg L, Saris S, Cole BF (1998). Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). J Neurooncol, 36(3), 201-8.
Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L (1998). Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol, 16(1), 153-8.
Akerley W (1998). Oncology: Combined Modalilty Therapy in Non-Small Cell Lung Cancer. Disease Management Digest, 2(3), 14-15.
Clamon G, Herndon J, Akerley W, Green M (1998). Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. Lung Cancer, 19(1), 25-9.
Chougule P, Wanebo H, Akerley W, McRae R, Nigri P, Leone L, Safran H, Ready N, Koness RJ, Radie-Keane K, Cole B (1997). Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results. Semin Oncol, 24(6 Suppl 19), S19-57-S19-61.
Wanebo HJ, Chougule P, Akerley WL 3rd, Koness RJ, McRae R, Nigri P, Leone L, Ready N, Safran H, Webber B, Cole B (1997). Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. Am J Surg, 174(5), 518-22.
Akerley W, Sikov WM, Cummings F, Safran H, Strenger R, Marchant D (1997). Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Semin Oncol, 24(5 Suppl 17), S17-87-S17-90.
Akerley W, Choy H, Safran H, Sikov W, Rege V, Sambandam S, Wittels E (1997). Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol, 24(4 Suppl 12), S12-10-S12-13.
Safran H, King TP, Choy H, Hesketh PJ, Wolf B, Altenhein E, Sikov W, Rosmarin A, Akerley W, Radie-Keane K, Cicchetti G, Lopez F, Bland K, Wanebo HJ (1997). Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J Clin Oncol, 15(3), 901-7.
Choy H, Akerley W, Safran H, Graziano S (1997). Concurrent Weekly Paclitaxel and Radiation Therapy for Locally Advanced NSCLC. Lung Cancer, 18(S2), 152.
Choy H, King T, Akerley W, Safran H (1997). Paclitaxel and Concurrent Radiation for Lung, Pancreatic and Gastric Carcinomas: Significance of p53 Gene Mutations for Treatment Response. Semin Radiat Oncol, 7(3), s77-81.
Choy H, Akerley W, Devore R (1997). Paclitaxel in Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Advances in Oncology, 13(4), 17-24.
Makarovskiy A, Ackerley W, Wojcik W, Halpert G, Stein B, Carreiro M, Hixson D (1997). Application of Immunomagnetic Beads in Combination with RT-PCR for the Detection of Circulating Prostate Cancer Cells. J Clin Lab Anal, 11, 346-50.
Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L (1997). Phase I Trial of Outpatient Weekly Paclitaxel and Concurrent Radiation Therapy for Advanced Non-Small Cell Lung Cancer. Classic Papers and Current Comments, 2(1), 167-71.
Akerley W (1996). Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer. Semin Oncol, 23(6 Suppl 16), 55-8.
Choy H, Akerley W, Safran H, Graziano S, Chung C (1996). Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. Semin Oncol, 23(6 Suppl 16), 117-9.
Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH, Cole BF (1996). Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Semin Oncol, 23(6 Suppl 16), 128-35.
Akerley W 3rd, Glantz M, Choy H (1996). Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer. Semin Oncol, 23(5 Suppl 12), 14-8.
Choy H, Akerley W, Glantz M, Safran H, Graziano S, Chung C (1996). Concurrent Paclitaxel and Radiation Therapy for Solid Tumors. Cancer Control, 3(4), 310-318.
Glantz MJ, Cole BF, Friedberg MH, Lathi E, Choy H, Furie K, Akerley W, Wahlberg L, Lekos A, Louis S (1996). A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology, 46(4), 985-91.
Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW (1996). Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum, 39(2), 325-9.
Wu X, Ting JY, Markoe AM, Landy HJ, Fiedler JA, Russell J (1996). Stereotactic dose computation and plan optimization using the convolution theorem. I. Dose computation. Stereotact Funct Neurosurg, 66 Suppl 1, 302-8.
Glantz M, Choy H, Akerley W, Kearns C, Egorin M, Rhodes H, Cole B (1996). Weekly Paclitaxel With and Without Concurrent Radiation Therapy: Toxicity, Pharmacokinetics and Response. Semin Oncol, 23(6) Suppl 16, 128-135.
Clark J, Sikov W, Cummings F, Browne M, Akerley W, Wanebo H, Weitberg A, Kennedy T, Cole B, Bigley J, Beitz J, Darnowski J (1996). Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol, 122(9), 554-8.
Akerley W, Glantz M, Choy H (1996). Phase I Study of Weekly Outpatient Paclitaxel in Advanced and Metastatic Non-small Cell Lung Cancer. Semin Oncol, 23(5), Suppl 12, 14-18.
Glantz MJ, Choy H, Kearns CM, Akerley W, Egorin MJ (1995). Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Semin Oncol, 22(5 Suppl 12), 26-32.
Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, Akerley W, Marin L, Choy H (1995). Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer, 75(12), 2919-31.
Akerley W, Choy H (1995). Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. Lung Cancer, 12 Suppl 2, S107-15.
Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L (1994). Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol, 12(12), 2682-6.
Miller ME, Dores GM, Thorpe SL, Akerley WL (1994). Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb Res, 74(6), 577-94.
Akerley WL 3rd, Moritz TE, Ryan LS, Henderson WG, Zacharski LR (1993). Racial comparison of outcomes of male Department of Veterans Affairs patients with lung and colon cancer. Arch Intern Med, 153(14), 1681-8.
Posner M, Martin A, Slapak CA, Clark JW, Cummings FJ, Robert NJ, Sikov W, Akerley W (1992). A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma. Am J Clin Oncol, 15(3), 239-41.
Akerley WL 3rd, Guyre PM, Davis BH (1991). Neutrophil activation through high-affinity Fc gamma receptor using a monomeric antibody with unique properties. Blood, 77(3), 607-15.
Mann H, Ward JH, Samlowski WE (1990). Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations. Radiology, 176(1), 191-4.
Grunberg SM, Ehler E, McDermed JE, Akerley WL (1988). Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. J Natl Cancer Inst, 80(11), 864-8.
Grunberg SM, Akerley WL, Krailo MD, Johnson KB, Baker CR, Cariffe PA (1986). Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest, 4(5), 379-85.

Oncology Research Publications

Oncology Research Publications

Internal Medicine